

CROI 2024

Conference on Retroviruses
and Opportunistic Infections

March 3-6 | Denver, Colorado

PROGRAM GUIDE

CONTENTS

CROI Foundation2
International Antiviral Society—USA3
CROI 2024 Program Committee4
Scientific Program Committee4
Community Liaison Subcommittee7
External Reviewers8
Continuing Medical Education11
General Conference Information13
Overview13
Funding and Grant Support13
Affiliated and Proximate Activities.....	.13
Conference Badges.....	.14
Conference Etiquette14
COVID-19 Protocol14
Americans With Disabilities Act14
Emergency Services14
Technology and Connectivity15
WiFi Access at the Conference.....	.15
Conference App.....	.15
Website15
Live Streaming and On-Demand Webcasts.....	.15
Abstract Process18
Scholarship Awardee Information20
Conference Services22
Oral Sessions23
Poster Sessions, by Day66
Poster Sessions, by Category180
Index of Presenters184
Conference Schedule at a Glance	Foldout
Convention Center Map	Foldout

Version 2 | Last Updated February 21, 2024

© Copyright 2024 CROI Foundation/IAS—USA. All rights reserved.

ISBN #978-0-692-36902-9

CROI FOUNDATION

The CROI Foundation is a 501(c)(3) not-for-profit professional education organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Duties of the Board of Directors

- Oversee the long-term financial and administrative integrity of CROI
- Work closely with the CROI Scientific Program Committee (PC) and the Conference Manager (IAS-USA) to accomplish the mission of CROI
- Approve nominations and rotations for members of the CROI PC, the CROI PC Chair and Vice Chairs, and the Community Liaison Subcommittee (CLS)
- Ensure that the CROI PC is responsible for the scientific program content of CROI
- Enter and oversee the partnership agreement with the CROI Conference Manager (IAS-USA)
- Have the sole and absolute discretion to implement or veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC, CLS, or the CROI Conference Manager that would pose a substantial risk of preventing the Corporation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualifications

CROI Foundation Board Members

Constance A. Benson, MD

President

University of California San Diego
San Diego, CA, USA

Diane V. Havlir, MD

University of California San Francisco
San Francisco, CA, USA

John M. Coffin, PhD

Secretary-Treasurer

Tufts University
Boston, MA, USA

Sharon L. Hillier, PhD

University of Pittsburgh
Pittsburgh, PA, USA

Elaine J. Abrams, MD

ICAP at Columbia University
New York, NY, USA

James A. Hoxie, MD

University of Pennsylvania
Philadelphia, PA, USA

Susan P. Buchbinder, MD

San Francisco Department of
Public Health
San Francisco, CA, USA

Richard A. Koup, MD

Vaccine Research Center within NIAID
Bethesda, MD, USA

Nicolas Chomont, PhD

Université de Montréal—CHUM
Research Center
Montreal, Quebec, Canada

John W. Mellors, MD

University of Pittsburgh
Pittsburgh, PA, USA

Judith S. Currier, MD

University of California Los Angeles
Los Angeles, CA, USA

Landon Myer, MD

University of Cape Town
Cape Town, South Africa

Robert T. Schooley, MD

University of California San Diego
San Diego, CA, USA

INTERNATIONAL ANTIVIRAL SOCIETY—USA

The International Antiviral (formerly AIDS) Society—USA (IAS—USA) is a not-for-profit organization that serves as the Conference Organizer for the logistical planning and organization of CROI in partnership with the CROI Foundation and Program Committee. The mission of the IAS—USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access other educational and informational programs sponsored by the IAS—USA, please visit www.iasusa.org for:

- Live CME courses, CME webinars, and dialogues available for signup
- On-demand webcasts of CME courses and webinars
- *Topics in Antiviral Medicine™*, the free, open-access, online journal published by the IAS—USA
- *Going anti-Viral*, a podcast for clinicians
- Practice guidelines on the use of antiretroviral drugs and HIV drug resistance mutations



SCIENTIFIC PROGRAM COMMITTEE

The CROI Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, concurrent interactive sessions and symposia, and special sessions.



Landon Myer, MD, PhD

CROI 2024 Chair

University of Cape Town
Cape Town, South Africa



Nicolas Chomont, PhD

CROI 2024 Vice Chair
Université de Montréal
Montreal, Canada



Diane V. Havlir, MD

CROI 2024 Vice Chair
University of California
San Francisco, San
Francisco, CA, USA

Scientific Program Committee



Elaine J. Abrams, MD

Columbia University
New York, NY, USA



Susan P. Buchbinder, MD

San Francisco Department
of Public Health, San
Francisco, CA, USA



Katharine J. Bar, MD

University of Pennsylvania
Philadelphia, PA, USA



Connie L. Celum, MD, MPH

University of Washington
Seattle, WA, USA



**Ruanne V. Barnabas,
MBChB, PhD**

Massachusetts General
Hospital, Boston, MA, USA



Richard E. Chaisson, MD

The Johns Hopkins University
School of Medicine
Baltimore, MD, USA



Constance A. Benson, MD

University of California San
Diego, La Jolla, CA, USA



John M. Coffin, PhD

Tufts University
Boston, MA, USA



Elizabeth Connick, MD
University of Arizona
Tucson, AZ, USA



Peter W. Hunt, MD
University of California
San Francisco, San
Francisco, CA, USA



Judith S. Currier, MD
University of California
Los Angeles, Los Angeles,
CA, USA



Jennifer Jao, MD, MPH
Northwestern University
Chicago, IL, USA



Carlos del Rio, MD
Emory University
Atlanta, GA, USA



**Angela D. Kashuba,
PharmD**
University of North
Carolina at Chapel Hill
Chapel Hill, NC, USA



Wafaa El-Sadr, MD, MPH
Columbia University
New York, NY, USA



Frank Kirchhoff, PhD
Ulm University Medical
Center, Ulm, Germany



Joseph J. Eron, Jr., MD
University of North
Carolina at Chapel Hill
Chapel Hill, NC, USA



Richard A. Koup, MD
National Institute of Allergy
and Infectious Diseases
Bethesda, MD, USA




Monica Gandhi, MD, MPH
University of California
San Francisco, San
Francisco, CA, USA



Raphael J. Landovitz, MD
University of California
Los Angeles, Los Angeles,
CA, USA



Huldrych F. Günthard, MD
University Hospital Zurich
Zurich, Switzerland



Anna S. Lok, MD
University of Michigan
Ann Arbor, MI, USA



**Theodora
Hatzioannou, PhD**
The Rockefeller University
New York, NY, USA



John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, USA



Sharon L. Hillier, PhD
University of Pittsburgh
Pittsburgh, PA, USA



Jonathan Mermin, MD
Centers for Disease Control
and Prevention, Atlanta,
GA, USA



Ya-Chi Ho, MD, PhD
Yale University
New Haven, CT, USA



**Jean-Michel G. Molina,
MD, PhD**
University of Paris-Est
Paris, France



James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA, USA



Penny Moore, PhD
University of the
Witwatersrand
Johannesburg, South Africa



**Andrew Mujugira, PhD,
MPH, MBBS**
Infectious Diseases
Institute, Kampala, Uganda



Douglas D. Richman, MD
University of California San
Diego, La Jolla, CA, USA



Stuart J. D. Neil, PhD
King's College London
London, UK



Juergen K. Rockstroh, MD
University of Bonn, Bonn,
Germany



**LaRon E. Nelson, PhD,
RN, FNP**
Yale University, New
Haven, CT, USA



Robert T. Schooley, MD
University of California San
Diego, La Jolla, CA, USA



Afram A. Okoye, PhD
Oregon Health and
Sciences University
Portland, OR, USA



Annette Sohn, MD, PhD
TREAT Asia, amfAR
Bangkok, Thailand



Sari L. Reisner, ScD
Harvard Medical School
Boston, MA, USA



Serena S. Spudich, MD
Yale University, New
Haven, CT, USA



Peter Reiss, MD, PhD
Amsterdam Institute
for Global Health and
Development, Amsterdam,
Netherlands



David L. Thomas, MD
The Johns Hopkins University
School of Medicine
Baltimore, MD, USA

In Memoriam: Adaora Adimora, MD, MPH (1956 - 2024)



An exceptional physician, scientist, mentor, and advocate, Dr Adimora served on the Scientific Program Committee for CROI from 2017 to 2023. Her contributions and kindness will endure in our hearts and minds, and in the spirit of CROI.

Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates who volunteer to provide feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.



Dawn Averitt
The Well Project,
Women's Research
Initiative on HIV/AIDS
South Strafford, VT, USA



Jim Pickett
Jim Pickett Consulting
Chicago, IL, USA



Grace Kumwenda, MA
AIDS Vaccine Advocacy
Coalition, Blantyre,
Malawi



Ntando Yola
University of Cape Town
Cape Town, South Africa



**Udom
Likhitwonnawut, BS**
SEARCH, Bangkok
Thailand

EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following individuals, who, in addition to the scientific program committee members, served as volunteer external reviewers of abstract or scholarship submissions for CROI 2024.

K. Rivet Amico, PhD

University of Michigan, Ann Arbor,
MI, USA

Peter L. Anderson, PharmD

University of Colorado Anschutz
Medical Campus, Aurora, CO, USA

Moherndran Archary, PhD, MBChB

University of KwaZulu-Natal, Durban,
South Africa

Georg N. M. Behrens, MD, PhD

Medizinische Hochschule Hannover
Hannover, Germany

Marta Boffito, MD, PhD

Chelsea and Westminster Hospital
London, United Kingdom

Bruce J. Brew, MD, MBBS, DSc

St Vincent's Hospital, Sydney, Australia

Carol S. Camlin, MD, PhD

University of California San Francisco,
San Francisco, CA, USA

Corey Casper, MD, MPH

Access to Advanced Health Institute
Seattle, WA, USA

Ellen G. Chadwick, MD

Northwestern University, Chicago,
IL, USA

David B. Clifford, MD

Washington University in St Louis
St Louis, MO, USA

Kevin M. De Cock, MD, MBChB

Centers for Disease Control and
Prevention, Atlanta, GA, USA

Kelly E. Dooley, MD, PhD, MPH

Vanderbilt University, Nashville,
TN, USA

Kristine M. Erlandson, MD

University of Colorado Anschutz
Medical Campus, Aurora, CO, USA

David T. Evans, PhD

University of Wisconsin–Madison
Madison, WI, USA

Courtney V. Fletcher, PharmD

University of Nebraska Medical Center
Omaha, NE, USA

Patricia M. Flynn, MD

St Jude Children's Research Hospital
Memphis, TN, USA

Dana Gabuzda, MD

Dana–Farber Cancer Institute, Boston,
MA, USA

Gerardo Garcia-Lerma, PhD

Centers for Disease Control and
Prevention, Atlanta, GA, USA

Carlo Giaquinto, MD

University of Padova, Padova, Italy

Beatriz Grinsztejn, MD, PhD

Oswaldo Cruz Foundation - Fiocruz
Rio de Janeiro, Brazil

Jessica Haberer, MD

Massachusetts General Hospital
Boston, MA, USA

Renee Heffron, PhD, MPH

University of Alabama at Birmingham
Birmingham, AL, USA

Sybil Hosek, PhD

University of Illinois at Chicago,
Chicago, IL, USA

Jennifer F. Hoy, MBBS

Alfred Hospital, Melbourne, Australia

Grace John-Stewart, MD, PhD

University of Washington, Seattle,
WA, USA

Sarah B. Joseph, PhD

University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA

Dennis L. Kolson, MD, PhD

Hospital of the University of
Pennsylvania, Philadelphia, PA, USA

Susan E. Krown, MD

Memorial Sloan-Kettering Cancer
Center, Emeritus, New York, NY, USA

Mohammed Lamorde, MBBS, PhD

Bamrasnaradura Infectious Diseases
Institute, Bangkok, Thailand

Maud Lemoine, MD, PhD

Imperial College London, London, UK

Scott L. Letendre, MD

University of California San Diego
San Diego, CA, USA

Sharon R. Lewin, MBBS, PhD

University of Melbourne, Melbourne,
Australia

Hermione Lyall, MD

Imperial College London, London,
United Kingdom

Rebecca M. Lynch, PhD

George Washington University
Washington, DC, USA

Patrick Mallon, MBBS, PhD

University College Dublin, Dublin,
Ireland

Grace A. McComsey, MD

University Hospitals Cleveland Medical
Center, Cleveland, OH, USA

James A. McIntyre, MBChB

Anova Health Institute, Johannesburg,
South Africa

Graeme A. Meintjes, MD, PhD, MPH

University of Cape Town, Cape Town,
South Africa

Ronald T. Mitsuyasu, MD

University of California Los Angeles
Los Angeles, CA, USA

Victor Musiime, PhD, MBChB

Makerere University, Kampala, Uganda

Susanna Naggie, MD

Duke University, Durham, NC, USA

**Harriet Nuwagaba-Biribonwoha,
PhD, MBChB**

ICAP at Columbia University, New York,
NY, USA

Michael J. Peluso, MD

University of California San Francisco
San Francisco, CA, USA

Martina Penazzato, MD, PhD

World Health Organization, Geneva,
Switzerland

Robert Remien, PhD

New York State Psychiatric Institute,
New York, NY, USA

Michael S. Saag, MD

University of Alabama at Birmingham
Birmingham, AL, USA

Jorge L. Sánchez, MD, MPH

Universidad Nacional Mayor de San
Marcos, Lima, Peru

Kimberly K. Scarsi, PharmD

University of Nebraska Medical Center
Omaha, NE, USA

Hyman M. Scott, MD, MPH

San Francisco Department of Public
Health, San Francisco, CA, USA

Kenneth E. Sherman, MD, PhD

Massachusetts General Hospital
Boston, MA, USA

Euphemia Sibanda, PhD

Centre for Sexual Health & HIV/AIDS
Research, Harare, Zimbabwe

Izukanji Sikazwe, MPH

Center for Infectious Disease Research
Seattle, WA, USA

Viviana Simon, MD

Icahn School of Medicine at Mt Sinai
New York, NY, USA

Lynda Stranix-Chibanda, MBChB

University of Zimbabwe, Harare,
Zimbabwe

Susan Swindells, MBBS

University of Nebraska Medical Center
Omaha, NE, USA

Alexandra Trkola, PhD

University of Zurich, Zurich, Switzerland

Alice Tseng, PharmD

Toronto General Hospital, Toronto,
Canada

Heidi van Rooyen, PhD

Human Sciences Research Council,
Pretoria, South Africa

Carole L. Wallis, MD, PhD

Africa Health Research Institute
Mtubatuba, South Africa

Annemarie M. Wensing, MD, PhD

University Medical Center Utrecht
Utrecht, Netherlands

Alan Winston, MD

Imperial College London, London, UK

Robert Yarchoan, MD

National Cancer Institute, Bethesda,
MD, USA

EXTERNAL REVIEWERS WITH ADDITIONAL ROLES AT CROI

Todd T. Brown MD, PhD

The Johns Hopkins University,
Baltimore, MD, USA

Maria Buzón, PhD

Vall d'Hebron Research Institute,
Barcelona, Spain

Matthew J. Feinstein, MD

Northwestern University, Chicago,
IL, USA

Charles W. Flexner, MD

The Johns Hopkins University School of
Medicine, Baltimore, MD, USA

John Frater, MBBS, MBChB, PhD

University of Oxford, Oxford, UK

Priscilla Y. Hsue, MD

University of California San Francisco,
San Francisco, CA, USA

Annie Luetkemeyer, MD

University of California San Francisco,
San Francisco, CA, USA

Gert U. van Zyl MBChB, PhD

Stellenbosch University, Cape Town,
South Africa

Timothy J. Wilkin, MD, MPH

Weill Cornell Medicine, New York,
NY, USA

David L. Wyles, MD

Denver Health Medical Center, Denver,
CO, USA

Markella V. Zanni, MD

Massachusetts General Hospital,
Boston, MA, USA

COMMUNITY EDUCATOR SCHOLARSHIP REVIEWERS

Luciana Kamel, MA

Oswaldo Cruz Foundation - Fiocruz Rio de Janeiro, Brazil

Devan Nambiar, MSc

Gay Men's Sexual Health Alliance
Ontario, Canada

Bridgette Picou, LVN

The Well Project, Women's Research Initiative on HIV/AIDS
South Strafford, VT, USA

CONTINUING MEDICAL EDUCATION

Accreditation Statement

The International Antiviral Society (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



The IAS–USA designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

After participating in CROI 2024, participants will be able to do the following as they relate to research in HIV, hepatitis viruses, SARS-CoV-2, and mpox and their related conditions:

- Describe basic science research advances in the understanding of viral infections, their pathogenesis, and their complications
- List the most recent findings from clinical trials and the implications of these data for state-of-the-art treatment and prevention strategies
- Describe current epidemiologic data on the prevalence of infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public health program planning; and current advances in biobehavioral prevention

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections, such as COVID-19 and mpox.

CME Credit Information CME

Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for their participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, concurrent interactive sessions and symposia, and selected special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, certain special sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

ABIM MOC Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation

During the conference, links to the daily evaluations will be available on the CROI website. The overall evaluation with detailed instructions on how to claim credits will be provided after the conference. You will need the email address used to register for this conference and your confirmation number (on your badge) to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, overall evaluation, posttest assessment, and claim forms must be submitted by April 8, 2024. Once the final evaluation and posttest are submitted, your certificate will be available on your IAS–USA profile on the IAS–USA website.

To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate the time spent attending conference activities, including premeeting workshops, opening session lectures, plenary lectures, concurrent interactive sessions and symposia, and selected special sessions. For example, if you attended 2 plenary talks (8:30 to 9:30 AM) and a symposium (4:00 to 5:30 PM), you would have 2.5 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended.

A CME/ABIM MOC hour worksheet can be found on the CROI website.

Disclosure of Financial Relationships

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, the Scientific Leadership Board, Governance Board, and program planners) to disclose any financial relationships with ineligible companies (previously defined as "commercial interests") that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the delivery of the CME activity. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients."

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the slides prior to the presentation of educational content.

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

GENERAL CONFERENCE INFORMATION

Overview

CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Funding and Grant Support

CROI seeks grants from commercial companies, particularly from companies with competing products. These companies have no input or control over the selection of faculty, the content of the CME portions of the program, or the abstract review and selection processes. This support is used to cover some of the costs of the venue, audiovisual services, and other conference expenses. CROI 2024 received grant support commitments from the following:

Platinum

Gilead Sciences, Inc

Merck & Co., Inc.

ViiV Healthcare

Silver

Janssen Therapeutics

Bronze

Hologic

Theratechnologies, Inc.

Additional support received after the printing of this program guide will be announced during the Conference.

Affiliated and Proximate Activities

CROI promotes the meaningful and high-level interchange of scientific ideas to improve the treatment of HIV and AIDS and to one day see HIV and other viral infections, including hepatitis viruses, SARS-CoV-2, and mpox virus, eradicated. In keeping with this goal, certain organizations (eg, commercial companies and their agents, not-for-profit groups, research study groups, and government agencies) have been approved to host Affiliated or Proximate Activities occurring outside CROI session times. Affiliated or Proximate Activities are not sponsored, endorsed, or supported by the IAS–USA, the CROI foundation, or CROI 2024. An Affiliated or Proximate Activity is any activity, event, or meeting held at any time from 3 days before (Thursday, February 29) through 2 days after (Friday, March 8) CROI 2024 and targeted toward or including any registrants of CROI.

If an activity is found to have violated the Guidelines for Affiliated or Proximate Activities, the sponsoring organization, the supporting organization, or the organizer of the meeting may be prohibited from holding an Affiliated or Proximate Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and could negatively impact the registration and attendance of anyone attending an unapproved activity.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you think may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

Conference Badges

Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the meeting spaces without their CROI badge. THE CROI BADGE AND CONFIRMATION NUMBER MAY ONLY BE USED BY THE REGISTRANT AND CANNOT BE TRANSFERRED TO OR SHARED WITH OTHERS. USING ANOTHER INDIVIDUAL'S BADGE OR CONFIRMATION NUMBER TO GAIN ACCESS TO THE CONFERENCE VENUE, APP, OR OTHER RESOURCES IS STRICTLY PROHIBITED AND A VIOLATION OF CROI POLICIES.

DO NOT LOSE YOUR BADGE. Payment equivalent to the full registration fee will be required to replace a lost badge.

Conference Etiquette

Please ensure all mobile devices are turned off or set to SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees may not photograph posters, record parts of talks, or post data without the presenter's consent.

Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster halls.

COVID-19 Protocol

Although masking is not mandatory, we are mask-friendly and support anyone who wishes to wear a mask. Prior to your departure, we encourage you to take a COVID-19 test to ensure it is safe to travel and to follow CDC guidelines with regard to appropriate precautions and self-isolation.

A limited number of rapid antigen tests are available on a first-come, first-served basis at the Attendee Services desk in Lobby D, Meeting Room (Street) Level.

Americans With Disabilities Act

CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). Please visit the Attendee Services desk in Lobby D, Meeting Room (Street) Level, for information about accessibility services, including designated handicapped parking, seating for attendees with mobility needs, and listening devices for individuals who are hard of hearing.

Emergency Services

In the event of an emergency, please notify Colorado Convention Center Security immediately by dialing 200 on any beige House Phone or by calling **+1 (303) 228-8030**. CROI staff or any uniformed Colorado Convention Center personnel with a 2-way radio can also assist in an emergency. Colorado Convention Center requests that guests do not contact 911 directly, if at all possible.

The Convention Center First Aid Station is in Lobby E on the Street Level, near Guest Services.

TECHNOLOGY AND CONNECTIVITY

WiFi Access at the Conference

Complimentary WiFi access is provided at the Colorado Convention Center.

Network information is as follows:

Network Name: **CROI2024**

The WiFi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will help maximize the internet speeds for those devices actively in use. The password for each day of the conference is listed below and is case-sensitive.

Saturday password: **2024saturday**

Sunday password: **2024sunday**

Monday password: **2024monday**

Tuesday password: **2024tuesday**

Wednesday password: **2024wednesday**

If you are having a problem with WiFi access, please contact an IAS–USA staff member.

Conference App

To access the CROI Mobile App, use your reference number (on your name badge) and the email address you used to register for CROI. The CROI 2024 Mobile App has many features to enhance your conference experiences, including to:

- View abstracts and electronic posters
- Find information about speakers and other CROI attendees
- Create a personal calendar of the sessions you plan to attend
- Receive announcements with the latest changes to the CROI program

The Mobile App is compatible with iOS and Android devices.

Search “CROI 2024” in your mobile device App store, or scan the QR code for a direct link via the CROI website. Access is restricted to registered attendees. Your login information and password are provided with the registration materials.



Website

For additional information and to access electronic materials, please visit the CROI website at www.CROIconference.org.

Abstracts from CROI 2024 can be viewed and downloaded by registered attendees via the Abstract eBook or the searchable database. Abstracts and electronic posters from CROI 2014 to 2023 are publicly available at www.CROIconference.org/abstracts/search-abstracts/

Live Streaming and On-Demand Webcasts

Plenary lectures, concurrent interactive symposia, oral abstract sessions sessions, and themed discussions are streamed live and are available as on-demand webcasts within 24 hours of the end of the relevant session for registered attendees only.

Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.



Visit www.CROIconference.org/CROI-2024-resources for updated hotel information.

Denver Downtown Hotel Accommodations

- 1** Embassy Suites by Hilton Denver Downtown Convention Center
1420 Stout St, Denver, CO 80202 | (303) 592-1000
- 2** Hyatt Regency Denver at Colorado Convention Center
650 15th St, Denver, CO, 80202 | (303) 436-1234
- 3** Hampton Inn & Suites Denver/Downtown – Convention Center
550 15th St, Denver, CO 80202 | (303) 623-5900
- 4** Homewood Suites Denver/Downtown – Convention Center
550 15th St, Denver, CO 80202 | (303) 534-7800
- 5** Home2 Suites by Hilton Denver Convention Center
801 15th St, Denver, CO 80202 | (303) 759-1301
- 6** Tru by Hilton Denver Downtown Convention Center
801 15th St, Denver, CO 80202 | (303) 753-1201
- 7** The Slate Denver – Tapestry Collection by Hilton
1250 Welton St, Denver, CO 80204 | (303) 292-5000
- 8** Sonesta Denver Downtown
1450 Glenarm Pl, Denver, CO 80202 | (303) 573-1450
- 9** The Curtis Denver – A DoubleTree by Hilton Hotel
1405 Curtis Street, Denver, CO 80202 | (303) 571-0300
- 10** Hotel Indigo Denver Downtown – Union Station, an IHG Hotel
1801 Wewatta St, Denver, CO 80202 | (303) 623-4422
- 11** Grand Hyatt Denver
1750 Welton St, Denver, CO, 80202 | (303) 295-1234
- 12** Kimpton Hotel Monaco Denver
1717 Champa St, Denver, CO 80202 | (303) 296-1717
- 13** Hilton Denver City Center
1701 California St, Denver, CO 80202 | (303) 297-1300
- 14** Hyatt Centric Downtown Denver Hotel
1776 Champa St, Denver, CO 80202 | (303) 529-2340
- 15** Holiday Inn Express Denver Downtown
1715 Tremont Pl, Denver, CO, 80202 | (303) 296-0400
- 16** Warwick Denver
1776 Grant St, Denver, CO, 80203 | (303) 861-2000

ABSTRACT PROCESS

Abstract Content

Author names, institutions, titles, and abstracts in the CROI Program and Information Guide, Abstract eBook, Mobile App, and other materials are presented largely as submitted by the submitting author. The submitting author is responsible for ensuring that all coauthors have reviewed and approved the abstract before submission and for providing complete, including email addresses.

THE SUBMITTING AUTHOR MUST ENSURE THAT THE EMAIL ADDRESSES

OF ALL LISTED AUTHORS IN THEIR SUBMISSION ARE CORRECT for authors to receive important information regarding dispositions, presentation details, registration and housing information, and other CROI-related announcements.

Special Notes on Abstract Content

Tables and Figures

Each figure, table, or other graphic was reviewed in a blinded fashion by a 3-person panel. For reviews without unanimous consensus, the table, figure, or other graphic was assessed by an additional reviewer from the Scientific Program Committee. The inclusion of a figure, table, or other graphic must conform to the guidelines around length, size, complexity, and legibility. Elements that did not meet these guidelines were removed from consideration from the review process and, if the abstract was accepted, from inclusion in the eAbstract Book. For more information and examples, please visit <https://www.croiconference.org/common-reasons-for-removal-of-table-and-figure/>

People-First Language and the Use of Appropriate Terminology

CROI strongly advocates for the use of and strives to incorporate “people-first” language and acceptable terminology in all CROI-related written materials and presentations. All abstract authors and presenters should apply the following basic principles of appropriate language and terminology, including:

- Describe populations as “people, persons, or individuals with HIV” rather than “HIV-infected people, persons, or individuals.”
- Do not characterize people by their disease, infection, or condition; instead, use “people who inject drugs,” “individuals with cirrhosis,” or other similar constructs.
- Do not describe people enrolled in research studies or clinical trials as “subjects” or “patients.” Acceptable terms are research or clinical trial “participants” or “volunteers.”
- Ensure the correct use of the terms “sex” (refers to biologic sex at birth) and “gender” (refers to psychosocial or cultural identity). Appropriate corollary terms are “cisgender” (people whose gender matches their sex assigned at birth) or “transgender” (people whose gender does not match the sex assigned at birth).
- Do not use the term “sterilizing” when referring to HIV cure; it triggers a negative perception in many people due to historic sterilization campaigns and may discourage participation in research.

Presenting Author Responsibilities

The presenting author is responsible for presenting the abstract at the conference; poster presenters must be present at the poster during the entire assigned session. Submitting authors are responsible for ensuring that all coauthors have reviewed and approved the abstract contents before submission.

Embargo Policies and Social Media

All research presented at CROI 2024 is embargoed until the conclusion of the study's presentation at the conference or after presentation at a press conference. For example, if a study is presented from 2:15 PM to 2:23 PM, as part of a session that begins at 2:00 PM and ends at 3:00 PM, the embargo on that study lifts at 2:23 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented. If a study to be presented at CROI 2024 is included in an official CROI press conference that takes place before the scheduled presentation of the study, the embargo on that study lifts at the conclusion of the press conference panel in which the study is featured. No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo.

CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs), or social media (eg, X [formerly Twitter], Instagram, Facebook, etc). Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.

Abstract Review Process

Each abstract was assigned to approximately 10 reviewers selected for each abstract category based on their individual expertise.

Abstracts were reviewed for the quality and originality of the work and were scored numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were discussed. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission, as they must meet a high threshold of scientific merit).

For more information, including common reasons for abstract rejection, visit the Abstract Guidelines page of www.CROIconference.org

Statistics for Abstracts

Abstract and Presentation Statistics for CROI 2024

Description	Number	Total
General Abstracts Submitted	1682	
General Abstracts Accepted	966	
Late-breaking Abstracts Submitted	220	
Late-breaking Abstracts Accepted	101	
Total Abstracts Submitted		1902
Total Abstracts Accepted		1067
Oral Abstract Presentations	111	
Themed Discussion Presentations	54	
Poster Presentations	956	

Accepted Abstracts for Emerging Infections or Specific Populations

Description	Total
SARS-CoV-2	193
Mpox	33
Adolescents	137
Men who have sex with men (MSM)	220
People who inject drugs (PWID)	84
Transgender men or women	84
Women or girls	259

SCHOLARSHIP AWARDEE INFORMATION

CROI is committed to supporting new and early-career investigators, as well as community educators and international investigators working in resource-limited countries who would otherwise be unable to attend CROI. Through their applications and letters of recommendation, these awardees have shown they will greatly benefit from attending CROI. New Investigator and International Scholarship recipients are presenting authors on their respective abstracts and are labeled as such through the program.

Activities for New Investigator Scholarship Awardees

Scott M. Hammer Workshop for New Investigators and Trainees

Widely considered the most informative and comprehensive session at CROI, this workshop highlights advances in HIV and SARS-CoV-2 molecular virology and immunology; advances in HIV treatment strategies, biomedical prevention, and cure; and community perspectives. Scholarship awardees are required to attend the entire workshop.

Meet the Luminary Sessions

Small-group sessions provide the unique opportunity to meet and network with a leading scientific expert (eg, a named lecturer or plenary speaker at CROI) and to ask one-on-one questions in an intimate setting. Note: Sign-up in advance is required.

Poster Walks

Poster Walks promote a rich scientific discourse between scholarship awardees, poster presenters, and CROI Scientific Program Committee members as they discuss a curated list of presentations in basic science, clinical research, epidemiology, and public health. Each New Investigator Scholarship Awardee can attend a single Poster Walk session. Note: Sign-up in advance is required.

New Investigator Networking Area

Located in the Poster Hall (Poster Hall C-D, Exhibit Level), the New Investigator Networking Area provides a central meeting point and designated networking area for New Investigator Scholarship Awardees.

Activities for Community Educator Scholarship Awardees

Scott M. Hammer Workshop for New Investigators and Trainees

Scholarship awardees are required to attend the entire workshop. Please refer to the description above for further details.

Virtual Community Networking Breakfast Club

Coordinated by the CROI Community Liaisons and their global collaborators, these virtual meetings feature researchers and advocates discussing some of the most consequential science presented at CROI 2024. Open to CROI registrants and nonregistrants alike, these Zoom webinars will take place March 4, 5, and 6 from 7:00 AM MT to 8:00 AM MT.

Meet the Luminary Sessions

Small-group sessions for Community Educator Scholarship Awardees provide the unique opportunity to network with a leader in the field (eg, Community Educator mentor, or Program Committee member) and ask one-on-one questions in an small-group setting. Note: Sign-up in advance is required.

Poster Walks

Community Educator Scholarship Awardees can attend a single Poster Walk session. Please refer to the description above for further details. Note: Sign-up in advance is required.

Community Educator Scholarship Awardee Networking Area

A designated area in the Poster Hall (Poster Hall C-D, Exhibit Level) provides a central meeting point and designated networking area for Community Educator Scholarship Awardees and other HIV community representatives and advocates.

CONFERENCE SERVICES

Service	Location	Day	Hours
Attendee Services • Badge and Conference Materials Pickup • Housing Information • Registration Desk	Lobby D Meeting Room (Street) Level	Saturday Sunday Monday to Wednesday	3:00 PM – 6:00 PM 7:00 AM – 7:00 PM 7:30 AM – 6:00 PM
Bag and Coat Check	Lobby D Meeting Room (Street) Level	Saturday Sunday Monday to Wednesday	3:00 PM – 6:00 PM 7:00 AM – 9:00 PM 7:30 AM – 6:00 PM
Continental Breakfast	Bellco Lobby Meeting Room (Street) Level	Monday to Wednesday	7:30 AM – 8:30 AM
Media Center	Room 501/502 Meeting Room (Street) Level	Sunday Monday and Tuesday Wednesday	10:00 AM – 7:30 PM 8:00 AM – 6:00 PM 7:00 AM – 6:00 PM
IAS-USA Office	Room 603 Meeting Room (Street) Level	Saturday Sunday to Wednesday	3:00 PM – 6:00 PM 7:00 AM – 6:00 PM
Speaker Ready Room	Room 702/704/706 Meeting Room (Street) Level	Saturday Sunday to Wednesday	3:00 PM – 6:00 PM 6:00 AM – 6:00 PM
Personal Considerations and Lactation Room	Room 701 Meeting Room (Street) Level	Sunday to Wednesday	7:00 AM – 6:00 PM
New Investigator Networking Area	Poster Hall (Poster Hall C-D) Exhibit Level	Sunday Monday to Wednesday	8:00 AM – 6:00 PM 7:30 AM – 6:00 PM
Community Educator Networking Area	Poster Hall (Poster Hall C-D) Exhibit Level	Sunday Monday to Wednesday	8:00 AM – 6:00 PM 7:30 AM – 6:00 PM
Denver Visitors Information Booth	Lobby F Street Level	Sunday to Wednesday	10:00 AM – 4:00 PM
Convention Center First Aid Station	Lobby E (Guest Services) Street Level	Saturday Sunday Monday to Wednesday	3:00 PM – 6:00 PM 8:00 AM – 9:00 PM 7:30 AM – 5:30 PM
Convention Center Emergency Medical Services		Dial 200 on any beige house phone or call (303) 228-8030	Available 24/7

SUNDAY, MARCH 3, 2024

Workshop-01 | Scott M. Hammer Workshop for New Investigators and Trainees

8:30 AM - 12:40 PM • Mile High Ballroom 1-2-3

CME

Objective: At the completion of the session, participants will be able to:

- Attend CROI with an understanding of novel research in molecular virology, immunology, cure, and HIV in children and adolescents, as well as the important role of community in research design and implementation

Target Audience: This session is directed to new investigators and trainees (eg, postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for 1 to 3 years.

Conveners

Katharine J. Bar *University of Pennsylvania, Philadelphia, PA, USA*



Serena S. Spudich *Yale University, New Haven, CT, USA*

1 | 8:30 AM | Overview of the Scott M. Hammer Workshop for New Investigators and Trainees



8:33 AM | **The Evolving HIV Landscape: From the Unimaginable to the Imaginable Cure**
Adam Castillejo, *The London Patient, London, UK*



9:05 AM | **Navigating Presentations in Molecular Virology at CROI 2024**
Frank Kirchhoff, *Ulm University Medical Center, Ulm, Germany*



9:47 AM | **Navigating Presentations in SARS-CoV-2 and HIV Immunology at CROI 2024**
Elizabeth Connick, *University of Arizona, Tucson, AZ, USA*



10:19 AM | **Navigating Presentations in HIV Cure at CROI 2024**
Afram A. Okoye, *Oregon Health and Sciences University, Portland, OR, USA*

Sunday



10:51 AM | Navigating Presentations in HIV Prevention at CROI 2024

LaRon E. Nelson, Yale University, New Haven, CT, USA



11:33 AM | Navigating Presentations in Pediatric HIV at CROI 2024

Jennifer Jao, Northwestern University, Chicago, IL, USA



12:05 PM | From Early-Stage Investigator to Change Agent: Thoughts on Maximizing the Impact of Your Career

Jeanne M. Marrazzo, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Workshop-02 | Frontiers in Laboratory Technologies

1:30 PM - 3:30 PM • Four Seasons Ballroom 2-3

CME

Objective: At the completion of the session, participants will be able to:

- Describe state-of-the-art approaches for single-cell analyses, transcriptomics, and imaging, including strengths, limitations, and novel applications

Target Audience: This session is directed to early-stage investigators who are interested in understanding the impact of novel laboratory technologies.

Level of Knowledge: It is assumed that the participants are familiar with the basics of laboratory technologies in HIV virology, immunology, and vaccine science.

Conveners

Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, USA



Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany



2 | 1:30 PM | Cryoelectron Microscopy-Based Polyclonal Epitope Mapping (cryoEMPEM)

Gabriel Ozorowski, The Scripps Research Institute, La Jolla, CA, USA



3 | 2:00 PM | A Spotlight on HIV: Visualizing Post-Entry Events by Correlative Light and Electron Microscopy

Barbara Müller, Heidelberg University, Heidelberg, Germany



4 | 2:30 PM | Single-Virus Tracking: Capturing Fast, 3-Dimensional Viral Dynamics in Live Tissue Models

Kevin D. Welsher, Duke University, Durham, NC, USA



5 | 3:00 PM | Single-Cell Multi-Omics of HIV Cellular Reservoirs

Iain C. Clark, University of California Berkeley, Berkeley, CA, USA

Workshop-03 | Case-Based Workshop on the Liver and Its**Complications****1:30 PM - 3:30 PM • Mile High Ballroom 4****CME**

Objectives: At the completion of the session, participants will be able to:

- List risk factors and valid methods for detecting steatotic liver disease
- Describe the optimal approach to detect and treat hepatitis D virus infection
- Identify hepatocellular carcinoma screening indications and evidence-based interventions in persons with cirrhosis

Target Audience: This session is directed to clinicians and clinical researchers with an interest in hepatitis and liver disease.

Level of Knowledge: It is assumed that the participants are familiar with general clinical principles, physical findings, and diagnostic testing as they relate to liver disease.

Sunday

Conveners

David L. Wyles, *Denver Health Medical Center, Denver, CO, USA*



Annie Luetkemeyer, *University of California San Francisco, San Francisco, CA, USA*



6 | 1:30 PM | Steatotic Liver Disease in Persons Living With HIV

Jennifer C. Price, *University of California San Francisco, San Francisco, CA, USA*



7 | 2:05 PM | Hepatitis Delta: What to Know, What to Do?

Kathrin van Bremen, *University of Bonn, Bonn, Germany*



8 | 2:40 PM | Cirrhosis Management

Mazen Noureddin, *Houston Methodist Hospital, Houston, TX, USA*

Workshop-04 | Case-Based Workshop on Antiretroviral**Therapy: A Panel Discussion****1:30 PM - 3:30 PM • Mile High Ballroom 1-2-3****CME**

Objectives: At the completion of the session, participants will be able to:

- Describe the options for initial antiretroviral therapy (ART) for people with HIV
- Identify the challenges in managing ART during pregnancy
- Describe appropriate ART in persons with tuberculosis coinfection

Target Audience: This session is directed to clinicians treating persons with HIV.

Level of Knowledge: It is assumed that the participants are familiar with the basics of antiretroviral therapy.

Conveners

Claudia P. Cortes, University of Chile,
Santiago, Chile



Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA

9 | 1:30 PM | Overview of the Case-Based Workshop on Antiretroviral Therapy

Panel Discussion

Anchalee Avihingsanon,
HIV-NAT, Bangkok,
Thailand



Anton L. Pozniak,
Chelsea and Westminster Hospital, London, UK



Cissy M. Kityo, Joint Clinical Research Centre, Kampala, Uganda



Janine M. Trevillyan, Doherty Institute for Infection and Immunity, Melbourne, Australia

Workshop-05 | Clinical Trial Design and Analysis

1:30 PM - 3:30 PM • Four Seasons Ballroom 1

CME

Objectives: At the completion of the session, participants will be able to:

- Describe strategies for measuring user preferences for prevention and treatment tools
- Explain the goals and design of hybrid effectiveness implementation studies
- Describe rationale and strategies for stopping trials early, as well as potential pitfalls and cautions

Target Audience: This session is directed to investigators who are interested in unique clinical and epidemiologic trial design and interpretation.

Level of Knowledge: It is assumed that the participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies.

Conveners

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA



Richard E. Chaisson, The Johns Hopkins University School of Medicine, Baltimore, MD, USA



10 | 1:30 PM | Exploring Strategies to Measure and Understand Users' Preferences in HIV Prevention and Care
José A. Bauermeister, University of Pennsylvania, Philadelphia, PA, USA



11 | 2:05 PM | Hybrid Effectiveness Implementation Studies: Unrecognized Challenges and Emerging Directions
Elvin H. Geng, Washington University in St Louis, St Louis, MO, USA



12 | 2:40 PM | Stopping Clinical Trials Early: When and Why
Sally A. Hunsberger, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Opening-01 | Opening Session

5:00 PM - 7:00 PM • Bellco Theatre

CME

Session Hosts

Landon Myer, University of Cape Town,
Cape Town, South Africa



Diane V. Havlir, University of California San
Francisco, San Francisco, CA, USA

Richard A. Koup, National Institute of Allergy and
Infectious Diseases, Bethesda, MD, USA



Ntando Yola, University of Cape Town, Cape
Town, South Africa

Sunday

Welcome from the Chairs**Bernard Fields Lecture**

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard N. Fields, is given during the Opening Session by a basic scientist recognized for their important and relevant contributions to the field of virology and viral pathogenesis.

Introduction of the Bernard Fields Lecture**13 | Modern Vaccinology: A Legacy of HIV Research**

Barney S. Graham, Morehouse School of Medicine,
Atlanta, GA, USA

N'Galy-Mann Lecture

The N'Galy-Mann Lecture recognizes an HIV/AIDS researcher for their important and relevant work in the fields of epidemiology or clinical research. The Lecture is named in honor of Drs Bosenge N'Galy and Jonathan Mann for their crucial, pioneering work in HIV science in Africa.

Introduction of the N'Galy-Mann Lecture**14 | Reflections on Ending Pediatric HIV: Back to Basics,
Confront the Unexpected, Challenge Assumptions**

Dorothy Mbori-Ngacha, United Nations Children's Fund
(Former), Nairobi, Kenya

Martin Delaney Presentation

The Martin Delaney Presentation, named in honor of the exceptional advocacy work of Martin Delaney, recognizes the important role of community advocacy and engagement in research.

Introduction of the Martin Delaney Presentation**15 | Unveiling the Power of Uganda's LGBTIQ Advocacy
in Shaping HIV Response and Health Care Access**

Frank Mugisha, Sexual Minorities Uganda (SMUG),
Kampala, Uganda

Opening Reception

(Poster Hall C-D) Exhibit Level

MONDAY, MARCH 4, 2024

Plenary-01 | Monday Plenary Session

8:30 AM - 9:30 AM • Bellco Theatre

CME

Session Hosts

Elizabeth Connick, University of Arizona,
Tucson, AZ, USA



Ruanne V. Barnabas, Massachusetts General Hospital, Boston, MA, USA

CROI Program Committee Chair Welcome to Monday

Landon Myer, University of Cape Town, Cape Town, South Africa

16 | What's New in HIV Vaccines: Vaccine-Induced Immune Responses

Juliana M. McElrath, Fred Hutchinson Cancer Center, Seattle, WA, USA

17 | Shall We Reach Human Papillomavirus Elimination in the Face of Inequity?


Nelly R. Mugo, Kenya Medical Research Institute, Nairobi, Kenya

Oral Abstract Session-01 | HIV Immunology and Vaccines

10:00 AM - 12:00 PM • Four Seasons Ballroom 1

Moderators

Cara C. Wilson, University of Colorado Anschutz Medical Campus, Aurora, CO, USA



Guido Ferrari, Duke University, Durham, NC, USA

Introductions (Part 1)

100 Safety Profile and Immunogenicity of a Phase I Clinical Trial
10:05 AM Using Germline-Targeting Trimer GT1.1

NIS **Karlijn van der Straten**, Tom Caniels, Emma Reiss, Annelou L. van der Veen, Katrina Millard, David C. Montefiori, Georgia D. Tomaras, Dagna Laufer, Vincent Philiponis, Michelle J. Klouwens, Marit van Gils, Rogier W. Sanders, David Diemert, Godelieve J. de Bree, Marina Caskey

101 Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses
10:13 AM

Kristen A. Rodrigues, **Y. Jason Zhang**, Aereas Aung, Duncan Morgan, Laura Maiorino, Parisa Yousefpour, Justin Gregory, Parastoo Amlashi, Maureen Buckley, J. Christopher Love, Darrell Irvine

102 **Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity**

10:21 AM

Peter Rusert, Chloé Pasin, Merle Schanz, Borys Pedenko, Daniel Schmidt, Irene A. Abela, Nikolas Friedrich, Cyrille Niklaus, Michèle Sickmann, Jacqueline Weber, Gregory Effantin, Winfried Weissenhorn, Huldrych F. Günthard, Roger Kouyos, **Alexandra Trkola**

10310:29 AM **CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques**

Daniel J. Morris, Hui Li, Jinery Lora, Kirsten Sowers, Christian Martella, Yingying Li, Barton F. Haynes, Tongqing Zhou, Peter D. Kwong, George M. Shaw

Questions and Answers (Part 1)**Introductions (Part 2)****104** **MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques**

11:00 AM

Philippe Rasclé, Rhianna Jones, Griffin Woolley, Kyle Kroll, Karen Terry, Esther Lee, Stephanie Jost, Keith Reeves

105 **[¹⁸F]F-AraG PET Imaging Reveals Unique Tissue T-Cell Activation Patterns Across HIV Infection States**

11:08 AM

Timothy J. Henrich, Robert Flavell, Michael J. Peluso, Kofi Asare, Maya Aslam, Emily Fehrman, Meghann C. Williams, Viva Tai, Rebecca Hoh, Youngho Seo, Jelena Levi, Steven G. Deeks, Henry VanBrocklin

106 **Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI**

11:16 AM

LB **Preethi Krishnan**, Ana Gabriela Pires Dos Santos, Harsh Sharthiya, Rakesh L. Tripathi, Thomas J. Reisch, Tanaya Vaidya, Fei Zhou, Moti Ramgopal, Meri Oliva, Aparna Vasanthakumar, Daniel E. Cohen, Jean-Pierre Routy, Patrick K. Dorr

107 **Live Single-Cycle SARS-CoV-2 Vaccine Elicits High Protection and Sterilizing Immunity**

11:24 AM

LB **Fabian Otte**, David Hauser, Martin J. Lett, Jacob Schoen, Enja T. Kipfer, Donata Hoffmann, Nico J. Halwe, Angele Breithaupt, Lorenz Ulrich, Tobias Britzke, Lorena Urda, Christian Mittelholzer, Martin Beer, Thomas Klimkait

Questions and Answers (Part 2)**Oral Abstract Session-02 | Neuropathogenesis of HIV****10:00 AM - 12:00 PM • Four Seasons Ballroom 2-3****Moderators**

Shibani S. Mukerji, Massachusetts General Hospital, Boston, MA, USA

Andrea Calcagno, University of Turin, Turin, Italy

**Introductions (Part 1)**

109 Assessing the Contribution of Glial Activation to Cognitive Control and Declarative Memory in PWH

10:05 AM **Leah H. Rubin**, Pauline Maki, Yong Du, Shannon Eileen Sweeney, Riley O'Toole, Raha M. Dastgheyb, Eran F. Shorer, Asante Kamkwala, Hannah Lee, Joan Severson, Il Minn, Katrina A. Wugalter, Arnold Bakker, Martin Pomper, Jennifer M. Coughlin

110 Associations Between Depressive Symptom Severity and Incident Stroke Among People With HIV

10:13 AM **Jimmy Ma**, Robin M. Nance, David Tirschwell, Stephanie A. Ruderman, Lydia N. Drumright, Maile Karris, Lyndsey S. Mixson, Joseph Zunt, Felicia C. Chow, Barbara M. Gripshover, Emily Ho, Richard D. Moore, Joseph A. Delaney, Heidi M. Crane, for the Center for AIDS Research Network of Integrated Clinical Systems

111 Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection

NIS **Meg Wilson**, Shady Abohashem, Ahmed A. Tawakol, Priscilla Y. Hsue, Felicia C. Chow

112 Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation

10:29 AM **Laura P. Kincer**, Sarah B. Joseph, Jessica R. Keys, Natalie M. Bowman, Chris Evans, Alyssa Vecchio, Serena Spudich, Magnus Gisslén, Prema Menezes, Frank Maldarelli, Robert Gorelick, Joseph J. Eron, Richard W. Price, Ronald Swanstrom

Questions and Answers (Part 1)**Introductions (Part 2)****113 HIV Transcription Persists in the Brain of People With HIV and Viral Suppression**

11:00 AM **Janna Jamal Eddine**, Thomas A. Angelovich, Jingling Zhou, Sarah J. Byrnes, Carolin Tumpach, Nadia Saraya, Emily Chalmers, Stephanie Marinis, Paul R. Gorry, Jacob D. Estes, Bruce J. Brew, Sharon R. Lewin, Sushama Telwatte, Michael Roche, **Melissa J. Churchill**


114 Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH

11:08 AM **Meng Wang**, Jennifer Yoon, Hailey Reisert, Bibhuprasad Das, Jennifer Chiarella, John W. Mellors, Alina P. Pang, Joshua C. Cyktor, Margaret Fikrig, Elias K. Halvas, Yuval Kluger, Serena Spudich, Michael J. Corley, **Shelli Farhadian**

108 Mini-Lecture on Neuropathogenesis of HIV

Sharon R. Lewin

Questions and Answers (Part 2)

Oral Abstract Session-03 | Clinical Trials of Novel**Antiretroviral Therapies****10:00 AM - 12:00 PM • Mile High Ballroom 1-2-3****Moderators****Aadia I. Rana, University of Alabama at Birmingham, Birmingham, AL, USA****Jose R. Arribas, La Paz University Hospital, Madrid, Spain****Introductions (Part 1)**

- 115 Single Dose Administration of MK-8527, a Novel nRTI, in Adults With HIV-1**
10:05 AM

Russ P. Carstens, Yash Kapoor, Ryan Vargo, Arinjita Bhattacharyya, Graigory Garrett, Jean-Francois Denef, Kemira Naidoo, Liliana Pretescu, Richard Kaplan, Mohammed Rassool, Johannes Lombaard, Randolph P. Matthews, S. Aubrey Stoch, Marian Iwamoto, Gillian Gillespie

- 116 Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral INSTI**
10:13 AM

Carl J. Fichtenbaum, Mezgebe Berhe, Jose Bordon, Jacob P. Lalezari, Godson Oguchi, Gary Sinclair, Furong Wang, Brie Falkard, Haeyoung Zhang, Eva Mortensen, Jared Baeten, Moti Ramgopal

- 117 VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive: Phase IIa BANNER Efficacy Data**
10:21 AM

Peter Leone, Alejandro Ferro, Sergio Lupo, Joseph McGowan, Paul Benson, Marisa Sanchez, Stefan Schneider, Paul Wannamaker, Beta Win, Judah Abberbock, Viviana Wilches, Margaret Gartland, Max Lataillade, **Jan Losos**

- 118 A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236**
10:29 AM

Athe Tsibris, Yu E. Zheng, Edmund Capparelli, Katherine Rodriguez, Randall Tressler, Antoine Deslandes, Katherine Shin, Philip Marzinek, Lucio Gama, Baiba Berzins, Chanelle Wimbish, Chih-Jen Wei, Gary Nabel, Daniel R. Kuritzkes, Pablo Tebas

Questions and Answers (Part 1)**Introductions (Part 2)**

- 119 Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial**
11:00 AM

Babafemi Taiwo, Yu E. Zheng, Katherine Rodriguez, Leah Burke, Jackie Reeves, Paul Wannamaker, Lucio Gama, Christos Petropoulos, Kimberly K. Scarsi, Pablo Belaunzarán-Zamudio, Ronald D'Amico, Katharine J. Bar, Pablo Tebas, for the ACTG A5357 Team

- 120 Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab**
11:08 AM

Joseph J. Eron, Paul P. Cook, Megha Mehrotra, Hailin Huang, Marina Caskey, Gordon Crofoot, Edwin DeJesus, Linda Gorgos, Laurie VanderVeen, Olayemi O. Osiyemi, Cynthia Brinson, Sean E. Collins

Monday

121 Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies

11:16 AM

LB

Boris D. Juelg, Victoria E. Walker-Sperling, Kshitij Wagh, Kathryn Stephenson, Jinyan Liu, Malika A. Boudries, Roberto C. Arduino, Lucio Gama, Elena Giorgi, Richard A. Koup, Michael S. Seaman, Charlotte-Paige M. Rolle, Edwin DeJesus, Bette Korber, Dan H. Barouch

122 Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results

11:24 AM

LB

Cissy M. Kityo, Ivan K. Mambule, Simiso Sokhela, Reena Shah, Caroline Otike, Joseph Musaazi, Kimton Opiyo, Fiona Cresswell, Charity Wambui, Gilbert Ategeka, Josphat Kosgei, Logashvari Naidoo, Fafa A. Boateng, Nicholas Paton

Questions and Answers (Part 2)**Oral Abstract Session-04 | Game Changers in Prevention of HIV and Sexually Transmitted Infections**

10:00 AM - 12:00 PM • Mile High Ballroom 4

Moderators

Ken Ho, University of Pittsburgh,
Pittsburgh, PA, USA



Sharon Mannheimer, Harlem Hospital Center,
New York, NY, USA

**Introductions (Part 1)****123 Phase I Safety, Tolerability, and Pharmacokinetics of Tenovir Alafenamide Implants in African Women**

10:05 AM

Tanuja N. Gengiah, Quarraisha Abdool Karim, Lara Lewis, Ishana Harkoo, Leila E. Mansoor, Johara Khan, Zainab Kharva, Nqobile Myeni, Natasha Samsunder, Marc M. Baum, John A. Moss, Catherine Hankins, Bruno Pozzetto, James F. Rooney, Salim S. Abdoool Karim

124 Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP

10:13 AM

Jean-Michel G. Molina, Béatrice Berçot, Lambert Assoumou, Michele Algarte-Genin, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Cecile Bebear, Nicolas Dupin, Jean-Paul Viard, Juliette Pavie, Claudine Duvivier, Jade Ghosn, Dominique Costagliola

125 Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension

10:21 AM

Annie Luetkemeyer, Deborah Donnell, Stephanie Cohen, Julia C. Dombrowski, Cole Grabow, Clare E. Brown, Chase Cannon, Eric Vittinghoff, Hyman Scott, Edwin Charlebois, Susan P. Buchbinder, Diane Havlir, Olusegun Soge, Connie Celum, for DoxyPEP Study Team

126 Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation

10:29 AM

LB

Hyman Scott, Jorge Roman, Matthew A. Spinelli, Jason Bena, Thiago S. Torres, Susan P. Buchbinder

Questions and Answers (Part 1)**Introductions (Part 2)**

- 127** Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco
11:00 AM **Madeline Sankaran**, David V. Glidden, Robert P. Kohn, Courtney Liebi, Thiago S. Torres, Susan P. Buchbinder, Annie Luetkemeyer, Monica Gandhi, Diane Havlir, Janet Q. Nguyen, Hyman Scott, Jorge Roman, Oliver Bacon, Trang Q. Nguyen, Stephanie E. Cohen

- 128** Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083
11:08 AM **Raphael J. Landovitz**, Emily Voldal, Brett Hanscom, Susan H. Eshleman, Estelle Piwowar-Manning, Philip Sullivan, Marybeth McCauley, Lydia Soto-Torres, James F. Rooney, Alex R. Rinehart, Myron S. Cohen, Mina Hosseiniipour, Sinead Delany-Moretlwe, Beatriz Grinsztejn, for the HPTN 083 study team

- 129** Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV
11:16 AM **Gillian Gillespie**, Russ P. Carstens, Xiaowei Zang, Ryan Vargo, Yash Kapoor, Arinjita Bhattacharyya, Jean-Francois Denef, Tom Reynders, Frédéric Vanhoutte, Sylvie Rottey, Randolph P. Matthews, S. Aubrey Stoch, Marian Iwamoto

- 130** Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval
11:24 AM **Kelong Han**, Ronald D'Amico, Jörg Sievers, Darin Brimhall, Brian Spears, Dale Taylor, David Dorey, Paul Benn, Lisa Morgan, Randa Hareedy, Gilda Bontempo, Max Lataillade, William Spreen

- 131** Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083
11:32 AM **LB** **Meredith Clement**, Brett Hanscom, Daniel Haines, Jose A. Bazan, Nuntisa Chotirosniramit, Sharon Mannheimer, Kenneth H. Mayer, Mayara Secco Torres da Silva, Lydia Soto-Torres, Alex R. Rinehart, James F. Rooney, Marybeth McCauley, Beatriz Grinsztejn, Raphael J. Landovitz, for the HPTN 083 Study Team

Questions and Answers (Part 2)

Themed Discussion-01 | Viral Rebound 1:30 PM - 2:30 PM • Four Seasons Ballroom 2-3

Themed Discussion Leader

Javier Martinez-Picado, IrsiCaixa Institute for AIDS Research, Badalona, Spain



Session Overview

- 484** Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment
1:35 PM **NIS** **Tongcui Ma**, Ashley F. George, Reuben Thomas, Min-Gyoong Shin, Mauricio Montano, Satish K. Pillai, Katherine S. Pollard, Rajesh T. Gandhi, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Ole S. Søgaard, Martin Tolstrup, Warner C. Greene, Nadia R. Roan

- 482** **The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound**
1:40 PM **NIS**
Mauro A. Garcia, Junlin Zhuo, Joseph Varriale, Anna Farrell-Sherman, Jun Lai, Anthony Abeyta-Lopez, Natalie F. McMyn, Rebecca Hoh, Michael J. Peluso, Francesco R. Simonetti, Steven G. Deeks, Lillian Cohn, Robert F. Siliciano, Janet M. Siliciano

- 487** **Intact HIV Reservoir Levels Are Stable After Short-Term ART Interruption**
1:45 PM **NIS**
Prerana Shrestha, Autumn Kittilson, Meghan Melberg, Evgenia Aga, Ronald J. Bosch, Jintanat Ananworanich, Robert Coombs, John W. Mellors, Alan Landay, Bernard Macatangay, Steven G. Deeks, Rajesh T. Gandhi, Davey M. Smith, Jonathan Z. Li, for the AIDS Clinical Trials Group A5345 Study Team

- 485** **Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption**
1:50 PM **NIS**
Maegan R. Manning, Jana Blazkova, Jesse S. Justement, Victoria Shi, Brooke D. Kennedy, M. A. Rai, Catherine A. Seamon, Kathleen R. Gittens, Michael C. Sneller, Susan Moir, Tae-Wook Chun

- 486** **Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control**
1:55 PM **NIS**
Leah Carrere, Miriam Rosás-Umbert, Benjamin Bone, Giacomo S. Frattari, Isabelle Roseto, Xiaodong Lian, Martin Tolstrup, Ce Gao, Mariane H. Schleimann, Xu G. Yu, Jesper D. Gunst, Mathias Licherfeld, Ole S. Søgaard

Discussion with Audience Questions and Answers

Themed Discussion-02 | Is the Weight Over: GLP-1 Receptor Agonists Are Here

1:30 PM - 2:30 PM • Mile High Ballroom 1-2-3

Themed Discussion Leader

Todd T. Brown, *The Johns Hopkins University, Baltimore, MD, USA*



Session Overview

- 797** **Impact of Semaglutide on Weight Change Among People With HIV: A Stratified Analysis by Baseline BMI**
1:35 PM
Lara Haidar, **Heidi M. Crane**, Robin M. Nance, Allison R. Webel, Geetanjali Chander, Bridget Whitney, Amanda Willig, Lyndsey S. Mixson, Alekhya Lavu, Laila Aboulatta, Mindy Dai, Andrew Hahn, Edward Cachay, Lydia N. Drumright, Sherif Eltonsy

- 798** **Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy**
1:40 PM
Allison Ross Eckard, Qian Wu, Abdus Sattar, Nicholas Funderburg, Kate Ailstock, Danielle Labbato, Grace A. McComsey

- 799** **Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study**
1:45 PM **NIS**
Grace L. Ditzengerger, Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Raja Muthupillai, Pablo Belaunzaran-Zamudio, Todd T. Brown, Kathleen Corey, Alan Landay, Anchalee Avihingsanon, Fred R. Sattler, Kristine M. Erlandson

Discussion with Audience Questions and Answers

Themed Discussion-03 | PEP Prevention Toolbox: Do We Know How to Use It?

1:30 PM - 2:30 PM • Four Seasons Ballroom 1

Themed Discussion Leader

Sigal Yawetz, Brigham and Women's Hospital,
Boston, MA, USA



Session Overview

1131 HIV Post-Exposure Prophylaxis Prescription Trends: United States, 2013-2022
1:35 PM

Mary R. Tanner, Wei Wei, Weiming Zhu, Ya-Lin A. Huang, Jesse G. O'Shea, Athena Kourtis, Karen W. Hoover

1134 BIC/FTC/TAF as HIV PEP Was Well-Tolerated With High Adherence and No Seroconversions
1:40 PM

Darrell H. S. Tan, Reva Persaud, Attia Qamar, Isaac I. Bogoch, Arlene Chan, Allison Chris, Karla Fisher, Richard T. Lester, John Maxwell, James Murray, Hong Qian, Hubert Wong

1130 A Matter of Time: Factors Associated With Delayed nPEP Initiation
1:45 PM

NIS **Nicholas Brian Bana**, Massimo Puoti, Chiara Baiguera, Alessandro Raimondi, Leonardo Rezzonico, Francesco Peracchi, Cristina Moioli, Leonardo Chianura, Giovanna Travi, Carloandrea Orcese, Fulvio Crippa, Carlotta Rogati, Marta Vecchi, Marco Merli, Roberto Rossotti

1133 PrEP Following PEP: An Effective HIV Risk-Reduction Strategy
1:50 PM **Gary Whitlock**, Courtney Taylor, Lucy Turner, Holly Thompson

Discussion with Audience Questions and Answers

Themed Discussion-04 | Hazards Ahead: The Intersection of HIV and Substance Use

1:30 PM - 2:30 PM • Mile High Ballroom 4

Themed Discussion Leader

Steffanie A. Strathdee, University of California San Diego, San Diego, CA, USA



Session Overview

999 Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021
1:35 PM

NIS **Michael P. Barry**, Benjamin Meana, Sara N. Glick, David Katz, Travis H. Sanchez, Matthew Golden, Steven M. Goodreau

1009 Changes in HIV PrEP Awareness and Use Among PWID in 19 US Cities, 2018 and 2022
1:40 PM

Johanna Chapin-Bardales, Dita Broz, **Patrick Eustaquio**, Jonathan Feelemyer, Teresa Finlayson, Savannah Harris, Cyprian Wejnert, for the NHBS Study Group

Monday

995 Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019

Stephanie Shiao, Fabrizio Drago, Kylie Getz, Greta Bushnell, Hillary Samples, Alexis Bender, Laura Bennett, Perry N. Halkitis, Tobias Gerhard, Jason A. Roy, Silvia S. Martins, Michael T. Yin, Stephen Crystal

1001 Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis

Amanda P. Miller, Rhoda K. Wanyenze, Rose Naigino, Michael Ediau, Seth C. Kalichman, Nicolas A. Menzies, Mose H. Bateganya, Susan M. Kiene

1003 Associations of Alcohol Consumption With Long-Term Mortality of ART-Naive Persons Seeking HIV Care

Daniel Fuster, Paola Zuluaga, Enric Abelli-Deulofeu, Laura Bermejo, Santiago Moreno, Lucio J. García-Fraile, Jose Antonio Iribarren, Cristina Moreno, Ines Suarez-Garcia, David Vinuesa, Vicente Estrada, Julian Olalla-Sierra, Juan Macias, Inma Jarrin, Robert Muga

Discussion with Audience Questions and Answers**Interactive Symposium-01 | The HIV Vaccine Journey: Don't Stop Believin'**

4:00 PM - 5:30 PM • Four Seasons Ballroom 2-3

CME

Objectives: At the completion of the session, participants will be able to:

- Describe the relationship between plasma virus neutralization after passive antibody administration and protection from HIV infection and how this establishes a goal for vaccine-induced plasma virus neutralization
- List different germline targeting HIV vaccine strategies and their design differences
- Describe at least 2 novel vaccine strategies that have increased immune responses in preclinical vaccine testing

Target Audience: This session is directed to virologists, immunologists, clinicians, and all stakeholders interested in the latest information on HIV vaccine progress.

Level of Knowledge: It is assumed that the participants are familiar with the basic elements of HIV biology, protein structure, and how the immune system responds to vaccination.

Conveners

Georgia D. Tomaras, Duke University,
Durham, NC, USA



Leonidas Stamatatos, Fred Hutchison Cancer Center, Seattle, WA, USA



18 | 4:00 PM | Neutralizing Antibody Protection: Where Do We Go From Here?
Yunda Huang, Fred Hutchison Cancer Center, Seattle, WA, USA



19 | 4:20 PM | Germline Targeting Strategies to Get On the Road Again

Rogier W. Sanders, Academic Medical Center, Amsterdam, Netherlands



20 | 4:40 PM | Novel Immunization Strategies to Move on Down the Road

Darrell Irvine, Massachusetts Institute of Technology, Cambridge, MA, USA

5:00 PM | Audience Questions and Answers

Interactive Symposium-02 | Living Into Young Adulthood With Perinatal HIV

4:00 PM - 5:30 PM • Four Seasons Ballroom 1

CME

Objectives: At the completion of the session, participants will be able to:

- Describe the epidemiology of the growing cohorts of young adults who have grown up living with HIV
- Identify health and social challenges young adults with perinatally-acquired HIV are facing in their HIV care and transition into adult life, including the burden of mental health disorders and social inequities that drive poorer health outcomes in ways that differ from those without HIV
- Explain how life-long HIV and antiretroviral therapy exposures impact inflammation and associated cardiometabolic complications

Target Audience: This session is directed to clinicians, epidemiologists, advocates, and others involved in the care and study of adolescents and young adults with HIV.

Level of Knowledge: It is assumed that the participants will be familiar with pediatric and adolescent HIV clinical management and with the long-term impacts of HIV and antiretroviral therapy on physical and mental health.

Conveners

Allison L. Agwu, The Johns Hopkins University School of Medicine, Baltimore, MD, USA



Victor Reyes, Howard University, Washington, DC, USA



21 | 4:00 PM | Epidemiology of Perinatally-Acquired HIV Among Adolescents and Young Adults

Mutsawashe F. Bwakura-Dangarembizi, University of Zimbabwe, Harare, Zimbabwe



22 | 4:20 PM | Historic Evolution of HIV and Mental Well-Being Among Adults Living With Perinatally-Acquired HIV

Ezer Kang, Howard University, Washington, DC, USA



23 | 4:40 PM | Cardiometabolic Risks and Complications: Adolescents and Young Adults With Perinatally-Acquired HIV

Sahera Dirajlal-Fargo, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA

5:00 PM | Audience Questions and Answers

Monday

Interactive Symposium-03 | The Return of Syphilis

4:00 PM - 5:30 PM • Mile High Ballroom 1-2-3

CME**Objectives:** At the completion of the session, participants will be able to:

- List the current limitations, challenges, and prospects for syphilis testing
- Describe the current global epidemic of syphilis in pregnant people and the challenges with eradicating congenital syphilis
- Describe diagnostic and treatment challenges in the management of syphilis

Target Audience: This session is directed to physicians, laboratory scientists, and epidemiologists who have an interest in sexually-transmitted infections and syphilis in particular.**Level of Knowledge:** It is assumed that the participants are familiar with syphilis etiology and the current epidemic of syphilis.**Conveners****Jodie A. Dionne**, *University of Alabama at Birmingham, Birmingham, AL, USA***Alex de Voux**, *University of Cape Town, Cape Town, South Africa***24 | 4:00 PM | Why Can't We Do Better at Diagnosing Syphilis?****Ina Park**, *University of California San Francisco, San Francisco, CA, USA***25 | 4:20 PM | The Burgeoning Epidemic of Congenital Syphilis****Angelica Espinosa Miranda**, *Ministry of Health, Brasilia, Brazil***26 | 4:40 PM | Syphilis Management Conundrums****Khalil G. Ghanem**, *The Johns Hopkins University School of Medicine, Baltimore, MD, USA***5:00 PM | Audience Questions and Answers****Oral Abstract Session-05 | COVID-19: Epidemiologic and Clinical Insights**

4:00 PM - 5:30 PM • Mile High Ballroom 4

Moderators**Jonathan Z. Li**, *Brigham and Women's Hospital, Boston, MA, USA***Barry S. Zingman**, *Montefiore Medical Center, Bronx, NY, USA*

Introductions (Part 1)

- 132** **COVID-19 Incidence and Severity in Persons With Reinfection vs Post-Vaccination Breakthrough Infection**
4:05 PM **Adeel A. Butt**, Peng Yan, Obaid S. Shaikh
- 133** **mRNA Vaccine Versus Hybrid Immunity Against COVID-19 Among People With HIV During Omicron Wave**
4:13 PM **Asa Tapley**, Aaron Hudson, Bo Zhang, Jessica Andriesen, Leigh H. Fisher, Craig A. Magaret, Margaret Yacovone, Peter B. Gilbert, Corey Larry, Glenda Gray, Sufia Dadabhai, Philip Kotze, Yunda Huang, Nigel Garrett, for the CoVPN 3008 Ubuntu Study Team
- 134** **SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency**
4:21 PM **Yijia Li**, Manish C. Choudhary, James Regan, Julie Boucau, Anusha Nathan, Tessa Speidel, May Y. Liew, Gregory E. Edelstein, Michael S. Seaman, Gaurav D. Gaiha, Mark J. Siedner, Amy K. Barczak, Jacob E. Lemieux, Jonathan Z. Li, for the POSITIVES Study Team
- 135** **Analysis of Emergent SARS-CoV-2 Antiviral Resistance and Its Association With Virologic Rebound**
4:29 PM **NIS Trevor J. Tamura**, Fizah Yousuf, Manish C. Choudhary, Rinki Deo, Anadela Navarrete Gomez, Gregory E. Edelstein, Julie Boucau, Dessie Tien, Tammy D. Vyas, Robert W. Shafer, Mark J. Siedner, Amy K. Barczak, Jacob E. Lemieux, Jonathan Z. Li, for the POSITIVES Study Team

**Questions and Answers (Part 1)
Introductions (Part 2)**

- 136** **Molnupiravir Does Not Increase 3CLpro Resistance Mutations When Co-Administered With Nirmatrelvir/r**
5:00 PM **Shuntai Zhou**, Nathan Long, Kyle Rosenke, Michael A. Jarvis, Heinz Feldmann, Ronald Swanstrom
- 137** **Mini-Lecture: Progress in Understanding the Mechanisms of Long COVID**
5:08 PM **Annukka A. R. Antar**
- 138** **Multimodal Assessment of Antigen Persistence in the Post-Acute Phase of SARS-CoV-2 Infection**
5:18 PM **Michael J. Peluso**, Sarah Goldberg, Zoe Swank, Brian H. Lafranchi, Scott Lu, Thomas Dalhuisen, Badri Viswanathan, Ma Somsouk, J. D. Kelly, Steven G. Deeks, Zoltan Laszik, David Walt, Jeffrey Martin, Timothy J. Henrich, for the LIINC Study Team

Questions and Answers (Part 2)

Monday

TUESDAY, MARCH 5, 2024

Plenary-02 | Tuesday Plenary Session**8:30 AM - 9:30 AM • Bellco Theatre****CME****Session Hosts****Stuart J. D. Neil**, *King's College London, London, UK***Constance A. Benson**, *University of California San Diego, La Jolla, CA, USA***CROI Program Committee Chair Welcome to Tuesday****Nicolas Chomont**, *Université de Montréal, Montreal, Canada***27 | HIV Assembly, Maturation Inhibitors, and Drug Resistance****Eric O. Freed**, *National Cancer Institute, Frederick, MD, USA***28 | Accelerating Tuberculosis Elimination: Short-Course Prevention and Treatment****Vidya Mave**, *Center for Infectious Diseases in India, Pune, India***Oral Abstract Session-06 | Virus at the Wheel: Regulation of Replication and Immunity****10:00 AM - 12:00 PM • Four Seasons Ballroom 2-3****Moderators****Juwon Park**, *University of Hawaii at Manoa, Honolulu, HI, USA***Eric M. Poeschla**, *University of Colorado Anschutz Medical Campus, Aurora, CO, USA***Introductions (Part 1)****139 HIV-1 Transcription Start Sites Usage and Its Impact on Unspliced RNA Functions In Vivo****Saiful Islam**, Zetao Cheng, Olga Nikolaitchik, Robert Gorelick, Vinay K. Pathak, Frank Maldarelli, Wei-Shau Hu**140 Investigation of the Functional Role of DDX42 in HIV-1 Viral RNA Splicing****Xiao Lei**, Ann Emery, Peng Zhang, Arjun Kanjarpante, Ronald Swanstrom, Paul D. Bieniasz

- 141** **Structural Basis of Translation Inhibition by MERS-CoV Nsp1 Reveals a Conserved Mechanism for β-CoVs**
 10:21 AM **Michael Vetick**, Swapnil Devarkar, Shravani Balaji, Ivan Lomakin, Yong Xiong

- 142** **"Traitor"-Virus-Guided Discovery of Novel Antiviral Factors**
 10:29 AM **Caterina Prelli Bozzo**, Alexandre Laliberté, Aurora De Luna, Chiara Pastorio, Meta Volcic, Alexander Graf, Stefan Krebs, Helmut Blum, Konstantin M. Sparrer, Frank Kirchhoff

Questions and Answers (Part 1)
Introductions (Part 2)

- 143** **Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV**
 11:00 AM **NIS** **Samuel R. Schnittman**, Rebecca Abelman, Gabriele B. Beck-Engeser, Noah Aquino, Gabrielle C. Ambayec, Carl Grunfeld, Edward Cachay, Joseph J. Eron, Michael S. Saag, Robin M. Nance, Joseph A. Delaney, Heidi M. Crane, Adam Olshen, Peter W. Hunt, for the CFAR Network of Integrated Clinical Systems (CNICS) Network

- 144** **HIV-1 Soluble gp120 Is Associated With Immune Dysfunction in Individuals on Antiretroviral Therapy**
 11:08 AM **NIS** **Mehdi Benlarbi**, Jonathan Richard, Carl Chartrand-Lefebvre, Marc Messier-Peet, Andrew Clark, Walther Mothes, Daniel E. Kaufmann, Frank Maldarelli, Nicolas Chomont, Cécile Tremblay, Ralf Duerr, Marzena Pazgier, Madeleine Durand, Andrés Finzi, for the Canadian HIV and Aging Cohort Study

- 145** **Rapid Emergence and Adaptive Evolution of SARS-CoV-2 Variants in Advanced HIV Infection**
 11:16 AM **LB** **Sung Hee Ko**, Pierce Radecki, Frida Belinky, Jinal Bhiman, Susan Meiring, Jackie Kleynhans, Daniel Amoako, Margaret Lucas, Vanessa Guerra, Tatsiana Bylund, Nicole Wolter, Stefano Tempia, Anne von Gottberg, Cheryl Cohen, Eli Boritz

- 146** **Temperature-Dependent SARS-CoV-2 Spike-ACE2 Interaction Is Associated With Viral Transmission**
 11:24 AM **LB** **Mehdi Benlarbi**, Shilei Ding, Étienne Bélanger, Alexandra Tauzin, Halima Medjahed, Raphaël Poujol, Omar El-Ferri, Yuxia Bo, Julie Hussin, Judith Fafard, Marzena Pazgier, Inès Levade, Cameron Abrams, Marceline Côté, **Andrés Finzi**

- 147** **IFNa2 Autoantibodies Post-SARS-CoV-2 Wave 1 in India Are Associated With Lower Omicron Symptomology**
 11:32 AM **LB** **Enrico Bravo**, Marianne Perera, Vasista Adiga, Nirutha Chetan, Asma Ahmed, Hima Bindu, Katie Doores, Adrian Hayday, Annapurna Vyakarnam, Stuart J. Neil

Questions and Answers (Part 2)

Tuesday

Oral Abstract Session-07 | Combating Complications of HIV

10:00 AM - 12:00 PM • Mile High Ballroom 1-2-3

Moderators**Mosepele Mosepele**, University of Botswana,
Gaborone, Botswana**Celestine Wanjalla**, Vanderbilt University,
Nashville, TN, USA**Introductions (Part 1)**

- 148 Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial**
10:05 AM

Lily D. Yan, Vanessa Rouzier, Rodney Sufra, Colette Guiteau, Mirline Jean, Fabyola Preval, Joseph Inddy, Pierre Obed Fleurijean, Alexandra Apollon, Nour Mourra, Myung Hee Lee, Suzanne Oparil, Marie Deschamps, Jean W. Pape, Margaret McNairy

- 149 A Nurse-Led Strategy Improves Blood Pressure and Cholesterol in People With HIV: The EXTRA-CVD Trial**
10:13 AM

Chris T. Longenecker, Kelley A. Jones, Corrilynn O. Hileman, Nwora Lance Okeke, Barbara M. Gripshover, Angela Aifah, Gerald S. Bloomfield, Charles Muiruri, Valerie A. Smith, Rajesh Vedanthan, Allison R. Weibel, Hayden B. Bosworth

- 150 Community Health Worker-Facilitated Telehealth for Severe Hypertension Care in Kenya and Uganda**
10:21 AM

Matt Hickey, Asiphas Owaraganise, Sabina Ogachi, Norton M. Sang, Erick Wafula Mugoma, James Ayieko, Jane Kabami, Gabriel Chamie, Elijah Kakande, Maya L. Petersen, Laura B. Balzer, Diane Havlir, Moses R. Kamya

- 151 Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE**
10:29 AM

Márton Kolossváry, Samuel R. Schnittman, Markella Zanni, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Gerald S. Bloomfield, Judith S. Currier, Marissa Diggs, Chris deFilippi, Sara McCallum, Michael T. Lu, Heather J. Ribaudo, Pamela S. Douglas, Steven Grinspoon

Questions and Answers (Part 1)**Introductions (Part 2)**

- 152 Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE**
11:00 AM

Kristine M. Erlandson, Triin Umbleja, Heather J. Ribaudo, Jennifer A. Schrack, Edgar T. Overton, Carl J. Fichtenbaum, Kathleen V. Fitch, Kenneth Wood, Markella Zanni, Gerald S. Bloomfield, Pamela S. Douglas, Steven Grinspoon, Todd T. Brown

- 153 Lung Function, HIV, and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort**
11:08 AM

Sarath Raju, Jacquie Astemborski, Jing Sun, Meredith C. McCormack, Greg Kirk

154 Prostate Cancer Characteristics and Outcomes for Veterans With HIV in the Antiretroviral Era

11:16 AM
Keith Sigel, Lesley S. Park, Amy C. Justice, Michael Leapman, Janet Tate, for the VACS Study Group

155 InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change

11:24 AM
NIS
LB
Rebecca Abelman, Yifei Ma, Cyra C. Mehta, Qian Yang, James Brock, Maria L. Alcaide, Anjali Sharma, Michelle Floris-Moore, Elizabeth F. Topper, Kathleen Weber, Seble Kassaye, Deborah Gustafson, Cecile D. Lahiri, Phyllis Tien

Questions and Answers (Part 2)**Oral Abstract Session-08 | Hepatitis and Tuberculosis**

10:00 AM - 12:00 PM • Four Seasons Ballroom 1

Moderators

Karine Lacombe, Sorbonne Université, Paris, France



Jyoti S. Mathad, Weill Cornell Medicine, New York, NY, USA

Introductions (Part 1)**156 Simultaneous Initiation in ART-Naive PWH of DTG-Based ART & 3HP Maintains Efficacious DTG Levels**

10:05 AM
Ethel D. Weld, Belén Perez Solans, Isadora Salles, Bareng Aletta Nonyane, M Sebe, Trevor Beattie, Manasa Mapendere, Tanya Nielson, Jayajothi Moodley, Violet Chihota, Rada Savic, Kelly Dooley, Richard Chaisson, Gavin Churchyard, for the UNITAID IMPAACT4TB Consortium

157 Early Bactericidal Activity of the Alpibectir-Ethionamide (AlpE) Combination Against Tuberculosis

10:13 AM
Jeantelle Du Preez, Caryn Upton, Laurynas Mockeliunas, Michel Pieren, Ulrika Simonsson, Andreas H. Diacon, Glenn E. Dale, Pierre Delique, Lisa Husband, Simon Tiberi, Sophie Penman, Thabo Mabuka, Mandi Nieuwenhuys, Anteneh Yalew, Veronique de Jager

158 NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology

10:21 AM
Jordan E. Lake, Daniela S. Allende, Oscar W. Cummings, **Jennifer C. Price**, Susanna Naggie, Eduardo Vilar-Gomez, Samer Gawrieh, Alice L. Sternberg, Sonya Heath, Richard Sterling, Rohit Loomba, Mark Sulkowski, Laura Wilson, Naga Chalasani, David Kleiner

159 Semaglutide Reduces Metabolic-Associated Steatotic Liver Disease in People With HIV: The SLIM LIVER

10:29 AM
Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Raja Muthupillai, Karin Klingman, Christina Vernon, Carl J. Fichtenbaum, Sonya Heath, Hugo Perazzo, Kathleen Corey, Todd T. Brown, Alan Landay, Fred R. Sattler, Kristine M. Erlandson

Questions and Answers (Part 1)**Introductions (Part 2)**

Tuesday

160 Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore

11:00 AM **Eshan U. Patel**, Becky Genberg, Bryan Lau, Jacqueline E. Rudolph, Jacquie Astemborski, Rachel E. Gicquelais, Danielle German, David D. Celentano, David Vlahov, Steffanie Strathdee, Greg Kirk, David Thomas, Shruti H. Mehta

161 Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation

11:08 AM **Usman Arshad**, Henry Pertinez, Joanne Sharp, Joanne Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Andrew B. Dwyer, Catherine Unsworth, Alison C. Savage, James J. Hobson, Lee Tatham, David Thomas, Paul Curley, Steve Rannard, Andrew Owen

162 Intrahepatic HDV Activity Is Fueled by Integrated HBV DNA-Derived HBs Independently From cccDNA Size

11:16 AM **NIS** **Stefano D'Anna**, Lorenzo Piermatteo, Elisabetta Teti, Andrea Di Lorenzo, Giuseppina Brancaccio, Umberto Cillo, Alessandro Vitale, Leonardo Baiocchi, Antonella Olivero, Giovanni Battista Gaeta, L. Sarmati, Mario Rizzetto, Gian Paolo Caviglia, Valentina Svicher, Romina Salpini

163 A 4-Month Regimen of Quabolepistat, Delamanid, and Bedaquiline for Pulmonary TB: Interim Results

11:24 AM **LB** **Rodney Dawson**, Andreas H. Diacon, **Simbarashe Takuva**, Yongge Liu, Bo Zheng, Vatsala Karwe, Tomohiro Sasaki, Jeffrey Hafkin

164 Provisional Results From a 3-Month Clofazimine/Rifapentine-Containing Regimen for Drug-Sensitive TB

11:32 AM **LB** **John Metcalfe**, Isabelle Weir, Kimberly K. Scarsi, Samuel Pierre, Austin Van Grack, Cecilia Kanyama, Maxwell Yohane, Wadzanai Samaneka, Neetal Nevrekar, Jorge Leon-Cruz, Alberto Mendoza-Ticona, Melanie Goth, Richard E. Chaisson, for the ACTG A5362 CLO-FAST Study Team

Questions and Answers (Part 2)**Oral Abstract Session-09 | Leaning Into the Success of Biomedical HIV Prevention****10:00 AM - 12:00 PM • Mile High Ballroom 4****Moderators**

Nomathemba Chandiwana, University of the Witwatersrand, Johannesburg, South Africa



Meredith Clement, Louisiana State University, New Orleans, LA, USA

Introductions (Part 1)**165 Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012-2021**

10:05 AM **Patrick S. Sullivan**, Stephanie Dubose, Kamaria Brisco, Gordon Le, Marta Juhasz

166 HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis

10:13 AM **Nicholas A. Medland**, Hamish McManus, Benjamin Bavinton, Michael Traeger, Doug Fraser, Andrew Grulich, Mark Stoope, Skye McGregor, Jonathan King, Dash Heath-Paynter, Rebecca Guy

167 High PrEP Uptake and Adherence Measured Objectively Among Young African Women in the INSIGHT Cohort

10:21 AM **Brenda G. Mirembe**, Meighan Krows, Zinhle Zwane, Elizabeth Bukusi, Ravindre Panchia, Cheryl Louw, Noluthanda Mwelase, Pearl Selepe, Melissa Senne, Logashvari Naidoo, Rachel Kawalzaira, Margaret Kasaro, Monica Gandhi, Renee Heffron, Connie Celum

168 Safety of Dapivirine Vaginal Ring and Oral PrEP for HIV Prevention in the Second Trimester

10:29 AM **Felix Mhlanga**, Katherine E. Bunge, Lee Fairlie, Clemensia Nakabiito, Luis Gadama, Nyaradzo Mgodi, Ashley J. Mayo, Catherine A. Chappell, Jeanna Piper, Nahida Chakhtoura, Daniel W. Szydlo, Barbra Richardson, Sharon L. Hillier

Questions and Answers (Part 1)**Introductions (Part 2)****169 Phone Calls for PrEP Persistence in Kenyan Women in Postabortal Care: A Cluster Randomized Trial**

11:00 AM **Renee Heffron**, Lydia Etyang, Bernard Nyerere, Inviolata Wanyama, Yasaman Zia, Torin T. Schaafsma, Katherine K. Thomas, Margaret Mwangi, Lavender A. June, Felix Mogaka, Catherine Kiptinness, Michael Kamiru, Kenneth Ngure, Elizabeth Bukusi, Nelly R. Mugo

170 Adherence Benchmarks for TFV-DP in DBS and PBMCs for African Women Using FTC/TDF PrEP

11:08 AM **Kenneth K. Mugwanya**, Nelly R. Mugo, Deborah Donnell, Matilda Saina, Clare E. Brown, Torin T. Schaafsma, David Chege, Elena A. Rechkina, Bhavna Chohan, Sarah Mbaire, Elex Hill, Kenneth Ngure, Lane Bushman, Jared Baeten, Peter L. Anderson, for the Women Benchmark Study Team

171 HIV Incidence in the INSIGHT Cohort of African Women: Recency Testing and Prospective Follow-Up

11:16 AM **Deborah Donnell**, **Irene Mukui**, Brenda G. Mirembe, Sue Peacock, Harriet Nuwagaba-Biribonwoha, Sinead Delany-Moretlwe, Katherine Gill, Pippa MacDonald, Philip Kotze, Alastair van Heerden, Remco Peters, Manjeetha Jaggernath, Phillip du Preez, Renee Heffron, Connie Celum

172 Randomized Trial of SEARCH Dynamic Choice HIV Prevention Including Injectable Cabotegravir (CAB-LA)

11:24 AM **LB Moses R. Kamya**, Laura B. Balzer, James Ayieko, Jane Kabami, Elijah Kakande, Gabriel Chamie, Nicole Sutter, Helen Sunday, John Schrom, Melanie Bacon, Catherine A. Koss, Alex R. Rinehart, Maya L. Petersen, Diane Havlir, for the SEARCH Consortium

Questions and Answers (Part 2)**Themed Discussion-05 | Persistent Immune Activation and Inflammation During Antiretroviral Therapy**

1:30 PM - 2:30 PM • Four Seasons Ballroom 1

Themed Discussion Leader

Frank Maldarelli, National Cancer Institute, Frederick, MD, USA



Tuesday

Introductions (Part 1)

348 **Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era**

1:35 PM

NIS

Violeta Lara Aguilar, Manuel Llamas-Adán, Oscar Brochado-Kith, Celia Crespo-Bermejo, Sergio Grande-García, Sonia Arca-Lafuente, Ignacio De los Santos, María Carmen Prado, Mario Alía, Coral Sainz-Pinós, Amanda Fernández-Rodíguez, Luz Martín-Carbonero, Ricardo Madrid, Verónica Briz

349 **Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART**

1:40 PM

NIS

Enrico Richter, Theresa Bechtel, Antonia Büning, Marek Korencak, Trevor A. Crowell, Heiko Jessen, Juergen K. Rockstroh, Stefan Esser, Christoph Boesecke, Hendrik Streeck

350 **CARD8 Activation in Myeloid Cells as a Driver of Inflammation in HIV Infection**

1:45 PM

NIS

Marilia R. Pinzone, Liang Shan

351 **Increased Immune Activation Following Acute Sleep Deprivation in People With HIV on ART**

1:50 PM

Priya V. Borker, Benjamin Morris, Jennifer Roscher, Steven Swanger, Sanjay R. Patel, **Bernard J. C. Macatangay**

352 **Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques**

1:55 PM

Xiaosheng Liu, Tingxia Lv, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li

Discussion with Audience Questions and Answers**Themed Discussion-06 | Hypertension and HIV: Pregnancy, Postpartum, and Beyond**

1:30 PM - 2:30 PM • Mile High Ballroom 1-2-3

Themed Discussion Leader

Elizabeth M. Stringer, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

**Session Overview**

913 **Maternal HIV Is Associated With Lower Risk of Preeclampsia Among Zambian Women**

1:35 PM

NIS

Katelyn J. Rittenhouse, Margaret Kasaro, M. Bridget Spelke, Yuri Sebastiao, Humphrey Mwape, Kenneth Chanda, Nelly Mandona, Bellington Vwalika, Jeffrey S. Stringer

910 **Hypertension in Pregnant Persons by HIV Status and by DTG vs EFV Use in Botswana**

1:40 PM

Denise L. Jacobson, Modiegi Diseko, Judith Mabuta, Ellen Caniglia, Kathleen M. Powis, Lynn Yee, Joseph M. Makhema, Shahin Lockman, Roger Shapiro, Rebecca Zash

- 916** **Association of HIV and Dolutegravir With Changes in Blood Pressure During Pregnancy and Postpartum**
1:45 PM Landon Myer, Elaine J. Abrams, Mustafa Shuaib, Hlengiwe P. Madlala, Sandisiwe Matyseni, Phindi Zwane, Allison Zerbe, Justine Legbedze, Elton Mukonda, **Jennifer Jao**

- 912** **Pregnancy History Affects Age-Related Comorbidity Burden in US Women With and Without HIV**
1:50 PM **Lauren F. Collins**, Cyra C. Mehta, Ava Cox, Qian Yang, Tina Tisdale, Martina Badell, Igbo Ofotokun, Daniel Westreich, Adaora Adimora, Seble Kassaye, Elizabeth F. Topper, Deborah Konkle-Parker, Aadia Rana, Maria L. Alcaide, Anandi N. Sheth

- 918** **DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure**
1:55 PM **NIS Thokozi R. Malaba**, Sylvia Nassiwa, Nengjie He, Helen Reynolds, Jim Read, Lucy Read, Catherine Orrell, Angela Colbers, Catriona Waitt, Mohammed Lamorde, Saye Khoo, Duolao Wang, Landon Myer, for the DolPHIN-2 Study Group

Discussion with Audience Questions and Answers

Themed Discussion-07 | Anal Cancer Screening and Pathogenesis

1:30 PM - 2:30 PM • Four Seasons Ballroom 2-3

Themed Discussion Leader

Timothy J. Wilkin, Weill Cornell Medicine, New York, NY, USA



Session Overview

- 760** **Evaluation of the Performance of Different High-Resolution Anoscopy Triage Strategies in MSM LWH**
1:35 PM **Eugenio Nelson Cavallari**, Federica Alessi, Chiara Eberspacher, Marco Ridolfi, Ilyass El Abboubi, Alessandra Latini, Angelina Pernazza, Daniela Bosco, Domenico Mascagni, Claudio Maria Mastroianni, Gabriella D'Ettorre

- 761** **Anal Self-Sampling Is Suitable for Anal Cancer Screening Among Men Who Have Sex With Men in Togo**
1:40 PM Valentine M. Ferré, Arnold Sadio, Romane Guilbaud, Meryem Zaidi, Mawussé K. Attiso, Mounerou Salou, Laurent Abramowitz, Mélanie Bertine, Amivi P. Amenyah-Ehlan, Ephram Mensah, Claver Anoumou Dagnra, Jade Ghosn, Diane Descamps, Didier Kouamvi Ekouevi, **Charlotte Charpentier**

- 759** **Clinical Predictors and Outcomes of Anal Cancer for People With HIV in an Inception Cohort**
1:45 PM **Edward Cachay**, Tari Gilbert, Huifang Qin, Christopher Mathews

- 762** **Long-Term ART Is Not Associated With Reduced Anogenital Cancer Risk: A Case-Cohort Study**
1:50 PM **NIS Maanasa Mendu**, Taolo Ntloedibe, Memory Bvchora-Nsingi, Sebathu Chiyapo, Kutlo Manyake, Isaac Nkele, Rebecca Luckett, Tendani Gaolathe, Joseph M. Makhema, Peter Vuylsteke, Shahin Lockman, Scott Dryden-Peterson

Discussion with Audience Questions and Answers

Tuesday

Themed Discussion-08 | Violence, Displacement, and HIV

1:30 PM - 2:30 PM • Mile High Ballroom 4

Themed Discussion Leader

Mesfin T. Tessema, *International Rescue Committee, New York, NY, USA*

**Session Overview**

1205 **Impact of Natural Disasters on HIV Risks and Viral Suppression in Ugandan Fishing Village**
1:35 PM

Hadijja Nakawooya, Victor Ssempejja, Anthony Ndyanabo, Fred Nalugoda, Maria J. Wawer, David Serwadda, Ronald H. Gray, Joseph Kagaayi, Steven J. Reynolds, Tom Lutalo, Godfrey Kigozi, Ping T. Yeh, Larry W. Chang, Mary Kate Grabowski, Robert Ssekubugu

1221 **The Need to Address Violence for PrEP Uptake Among Adolescent Girls and Young Women in South Africa**
1:40 PM

Courtney P. Bonner, Felicia A. Browne, Jacequeline W. Ndirangu, Alexandra M. Minnis, Ilene Speizer, Laura Nyblade, Khatija Ahmed, Tracy Kline, Wendee M. Wechsberg

1206 **Prevalence of HIV and Viral Load Suppression Among Refugees in Uganda, October to December 2021**
1:45 PM

Samuel Biraro, Shannon M. Farley, Joshua Musinguzi, Wilford Kirungi, David Okimait, Veronicah Mugisha, Ronald Nyakoojo, Sam Sendagala, Herbert Kiyingi, Jennifer Nel, Lisa Nelson, Brittany Gianetti, Christine West, David Hoos, Wafaa El-Sadr

1226 **Violence and HIV Sexual Risk Behaviours Among Adolescent Girls and Young Women: Eswatini Experience**
1:50 PM

NIS

Siphiwe M. Shongwe-Gama, Cebisile Ngcamphalala, Mabutho C. Mamba, Harrison Kamiru, Poppy M. Sithole, Bonisile Nhlabatsi, Choice Ginindza, Michelle Li, Kaye Seya Marie, Francis B. Annor, Luara Chiang, Ruben Sahabo

Discussion with Audience Questions and Answers**Interactive Symposium-04 | Not Just a Pretty Shape: HIV Assembly to Disassembly**

4:00 PM - 5:30 PM • Four Seasons Ballroom 1

CME

Objectives: At the completion of the session, participants will be able to:

- Identify the properties of the HIV-1 genome that promote selective incorporation into assembling virus particles
- Describe how the viral Gag protein coordinates assembly and structural rearrangements to form a mature capsid lattice
- List the steps the mature capsid lattice follows upon release in the new target cells to regulate nuclear import and evasion of intrinsic immunity

Target Audience: This session is directed to trainee and senior scientists, clinicians, and others with a general interest in virology.

Level of Knowledge: It is assumed that the participants are familiar with the basics of the HIV-1 replication cycle and cell tropism.

Conveners

Owen Pernillo, University of Utah, Salt Lake City, UT, USA



Melissa Kane, University of Pittsburgh, Pittsburgh, PA, USA




29 | 4:00 PM | HIV-1 Genome Packaging During Virion Assembly: Selecting the Right RNA

Wei-Shau Hu, National Cancer Institute, Frederick, MD, USA



30 | 4:20 PM | Virion Maturation: Folding Into the Right Shape

Mamuka Kvaratskhelia, University of Colorado, Aurora, CO, USA



31 | 4:40 PM | Virion Disassembly: Keeping it Together Until the Right Moment

Gregory Towers, University College London, London, UK

5:00 PM | Audience Questions and Answers

Interactive Symposium-05 | New Frontiers in Hepatitis B

4:00 PM - 6:00 PM • Mile High Ballroom 4

CME

Tuesday

Objectives: At the completion of the session, participants will be able to:

- Describe the treatment, prophylaxis, and public health impact of hepatitis B in sub-Saharan Africa
- Summarize the current understanding of novel hepatitis B biomarkers and their use in disease staging and therapeutic management
- Identify host mechanisms responsible for control of hepatitis B and treatment modalities that seek to enhance these mechanisms to facilitate viral suppression
- Describe the international management of hepatitis B

Target Audience: This session is directed to epidemiologists, clinicians, immunologists, virologists, and public health officials who are interested in hepatitis B and similar infectious diseases.

Level of Knowledge: It is assumed that the participants are familiar with fundamental principles of epidemiology, microbiology, immunology, and clinical medicine as related to viral hepatitis.

Conveners

Gilles Wandeler, University of Bern, Bern, Switzerland



Gail Matthews, Kirby Institute, Sydney, Australia



32 | 4:00 PM | Novel Markers of Hepatitis B: Clinical Utility for New Treatment Strategies

Fabien Zoulim, L'Université Claude Bernard Lyon 1, Lyon, France



33 | 4:25 PM | Advances in HBV Immunotherapy: The Beginning of the End?

Adam Gehring, University of Toronto, Toronto, Canada



34 | 4:50 PM | How New WHO Guidance Might Transform Hepatitis B in Sub-Saharan Africa

Olufunmilayo Lesi, World Health Organization, Geneva, Switzerland

5:10 PM | International Perspectives on Hepatitis B: Panel Discussion



**Anna S. Lok,
University of Michigan,
Ann Arbor, MI, USA**



**Beatriz Grinsztejn,
Oswaldo Cruz Foundation - Fiocruz, Rio de Janeiro, Brazil**



**Fabien Zoulim,
L'Université Claude Bernard Lyon 1, Lyon, France**



Olufunmilayo Lesi, World Health Organization, Geneva, Switzerland



**Chien-Ching Hung,
National Taiwan University Hospital, Taipei, Taiwan**

**Lived Experience:
Wes Spurr, Denver, CO, USA**

Interactive Symposium-06 | Roundtable on DoxyPEP: Ready or Not...

4:00 PM - 5:30 PM • Mile High Ballroom 1-2-3

CME

Objectives: At the completion of the session, participants will be able to:


- Describe findings about efficacy, adherence, and acceptability of doxyPEP in trials among men who have sex with men, transgender women, and cisgender women
- Explain the concerns and available data about antimicrobial resistance in STIs and bystander bacteria
- Describe doxyPEP guidelines, early implementation approaches, and uptake

Target Audience: This session is directed to clinicians, program managers, and community members interested in doxycycline postexposure prophylaxis (doxyPEP) for sexually transmitted infection (STI) prevention.

Level of Knowledge: It is assumed that the participants are familiar with the concept of doxycycline for STI prevention.

Conveners

Kenneth Ngure, *Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya*



Michael Traeger, *Burnet Institute, Melbourne, VIC, Australia*



35 | 4:00 PM | Introduction to DoxyPEP: Understanding the Issues

Chase A. Cannon, *University of Washington, Seattle, WA, USA*



36 | 4:20 PM | DoxyPEP: Should We Worry About Antimicrobial Resistance?

Beatrice B. S. L. Bercot, *St Louis Hospital, Paris, France*



37 | 4:40 PM | Implementation of DoxyPEP: Challenges and Opportunities

Stephanie E. Cohen, *San Francisco Department of Public Health, San Francisco, CA, USA*

5:00 PM | Audience Questions and Answers

Interactive Symposium-07 | Impact on HIV Care and Services Among Refugees, Displaced Persons, and Marginalized Populations

4:00 PM - 5:30 PM • Four Seasons Ballroom 2-3

CME

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of displacement around the world, including major causes of displacement
- List the health challenges faced by refugees, displaced persons, and marginalized populations
- Identify successful models for responding to the health needs of refugees, displaced persons, and marginalized populations

Target Audience: This session is directed to researchers, policymakers, program managers, community representatives, trainees, and students who are interested in HIV care and services among refugees, displaced persons, and marginalized populations.

Level of Knowledge: It is assumed that participants are familiar with basic information regarding the current crisis faced by refugees, displaced persons, and marginalized populations around the world.

Conveners

Wafaa El-Sadr, *Columbia University, New York, NY, USA*



Carlos del Rio, *Emory University, Atlanta, GA, USA*

Tuesday



38 | 4:00 PM | Overview of the Global Displacement Crisis

Mesfin T. Tessema, *International Rescue Committee, New York, NY, USA*

4:10 PM | Panelist Reflections on the Global Displacement Crisis



4:15 PM | Meeting the Needs of People Affected by HIV From Ukraine **Milosz Parczewski**, *Pomeranian Medical University, Szczecin, Poland*



4:20 PM | Protracted Consequences of Displacement: A Perspective From Latin America

Omar M. Sued, *Pan American Health Organization, Washington, DC, USA*



4:25 PM | Lived Experience From Ukraine

Yana Panfilova, *Teenergizer, Kyiv, Ukraine*

4:30 PM | Roundtable Discussion

WEDNESDAY, MARCH 6, 2024

Plenary-03 | Wednesday Plenary Session

8:30 AM - 9:30 AM • Bellco Theatre

CME

Session Hosts

Joseph J. Eron, Jr., University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA



Jonathan Mermin, Centers for Disease Control
and Prevention, Atlanta, GA, USA

CROI Program Committee Chair Welcome to Wednesday

Diane V. Havlir, University of California San Francisco, San Francisco, CA, USA

39 | The End of Oral? How Long-Acting Formulations Are Changing the Management of Infectious Diseases

Charles W. Flexner, The Johns Hopkins University,
Baltimore, MD, USA

40 | Diagnostics 4.0: The Future of Diagnostics for HIV and Related Infections

Nitika P. Pai, McGill University, Montreal, Canada

Oral Abstract Session-10 | HIV Reservoir and Cure Strategies

10:00 AM - 12:00 PM • Mile High Ballroom 1-2-3

Moderators

Joel N. Blankson, The Johns Hopkins University,
Baltimore, MD, USA



Nancie M. Archin, University of North Carolina
at Chapel Hill, Chapel Hill, NC, USA

Introductions (Part 1)**173 Selection of Epigenetically-Privileged HIV-1 Proviruses During Treatment With Panobinostat and IFN α**

10:05 AM
NIS **Marie Armani-Tourret**, Ciputra Adijaya Hartana, Isabelle Roseto, Leah Carrere, Amy Sbrolla, Katrina Shea, Theresa Flynn, Liliana Vela, Alexander Hochroth, Frederic D. Bushman, Rajesh T. Gandhi, Ce Gao, Xu G. Yu, Daniel R. Kuritzkes, Mathias Lichterfeld

174 Role of Cytoskeleton and Adhesion in a Rare Subset of HIV-Infected Cells That Resist CTL

10:13 AM
NIS **Louise Leyre**, Farah Mustapha, Alberto Herrera, Paul Zumbo, Micheal Galiano, Jared Weiler, Doron Betel, Morgan Huse, R. Brad Jones

175 Sex-Specific Innate Immune Selection in Vertical HIV**Transmission and cART-Free Aviraemia in Males****LB**

Nomonde Bengu, **Gabriela Z. L. Cromhout**, Emily Adland, Katya Govender, Nicholas Herbert, Nicola Cotugno, Paolo Palma, Maria C. Puertas, Thumbi Ndung'u, Edmund Capparelli, Mathias Licherfeld, Javier Martinez-Picado, John Kappes, Moherndran Archary, Philip J. Goulder

176 Sex-Based Differences in HIV-1 Reservoir Profile in Individuals With Long-Term ART Suppression**NIS**

Toong Seng Tan, Alexander Hochroth, Leah Carrere, Sruthi Kalavacherla, Liliana Vela, Ce Gao, Rowena Johnston, Steven G. Deeks, Seble Kassaye, Phyllis Tien, Michael J. Peluso, Jeffrey Jacobson, Mary Carrington, Mathias Licherfeld, Xu G. Yu

Questions and Answers (Part 1)**Introductions (Part 2)****177 AAV-Expressed HIV IgG Biologics Enable Durable ART-Free Viral Control in Infant Macaques**

11:00 AM

LB

Daniel O'Hagan, Tracy Ordonez, Lucas Costa, Shilpi Pandey, Siddhartha Shandilya, Jeremy Smedley, Diogo M. Magnani, Deborah Persaud, Ann Chahroudi, Matthew R. Gardner, Michael D. Alpert, Ann J. Hessell, Michael Farzan, Nancy L. Haigwood, **Mauricio A. Martins**

178 Broadly Neutralizing Antibody-Secreting T-Cells and CAR-Ts Potently Suppress In Vivo HIV Infection

11:08 AM

Hang Su, Jenny Zheng, Scott Garforth, Kim Anthony-Gonda, Rimas J. Orentas, Boro Dropulic, Steven Almo, Harris Goldstein

179 Autologous Neutralizing Antibodies Contribute to Virus Control in a Subset of PWH Treated With bNAbs

11:16 AM

Francesco E. Marino, Maxime Bellefroid, Ryan Krause, Marie Armani-Tourret, Suvidip Mallick, Emmanouil Papasavvas, Matthew Fair, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Mathias Licherfeld, **Katharine J. Bar**

180 A T Cell-Targeting mRNA SIV Vaccine Extends Time to Rebound and Enhances Post-ART Viral Control

11:24 AM

Robert W. Omange, **Benjamin Varco-Merth**, Omo Fadeyi, William Goodwin, Alejandra Marenco, Derick Duell, Jeremy Smedley, Michael Axthelm, Brandon Keele, Jeffrey Lifson, Janina Gergen, Susanne Rauch, Benjamin Petsch, Louis Picker, Afam A. Okoye

181 IL-15/IL-15RA Cytokine Therapy Enhances Control of Viral Rebound in SIV-Infected Macaques

11:32 AM

LB

Sakthivel Govindaraj, Hemalatha Babu, Syed Ali, Sheikh A. Rahman, Susan P. Ribeiro, Jeffrey A. Tomalka, Ashish A. Sharma, Rafick P. Sekaly, Francois J. Villinger, Rama R. Amara, **Vijayakumar Velu**

Questions and Answers (Part 2)

Oral Abstract Session-11 | HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents 10:00 AM - 12:00 PM • Four Seasons Ballroom 1

Moderators

Moherndran Archary, University of KwaZulu-Natal, Durban, South Africa



Grace John-Stewart, University of Washington, Seattle, WA, USA

Introductions (Part 1)

- 182** **High Rates of Viral Suppression in Pregnancy Drop Postpartum in South African Women on TLD**

10:05 AM

Elaine J. Abrams, Jennifer Jao, Elton Mukonda, Hlengiwe Madlala, Phindi Zwane, Jack Hu, Allison Zerbe, Justine Legbedze, Landon Myer

- 183** **Hypertension in a Randomized Trial of DTG vs EFV-Based ART in Pregnant and Postpartum Women**

10:13 AM

Risa Hoffman, Sean Brummel, Mauricio Pinilla, Lameck Chinula, Grace Malonga, Sherika Hanley, Lynda Stranix-Chibanda, Elizabeth S. Machado, Shilpa Naik, Katie McCarthy, Chelsea Krotje, Patrick Jean-Philippe, Paul E. Sax, Judith S. Currier, Shahin Lockman

- 184** **ART-Free HIV-1 Remission in Very Early Treated Children: Results From IMPAACT P1115**

10:21 AM

LB

Deborah Persaud, Anne Coletti, Bryan S. Nelson, Jennifer Jao, Edmund Capparelli, Diane Costello, Camlin Tierney, Adeodata R. Kekitiinwa, Teowler Nemadzira, Boniface N. Njau, Jack Moye, Patrick Jean-Philippe, Yvonne Bryson, Ellen G. Chadwick, for the IMPAACT P1115 Study Team

- 185** **GIVE MOVE: Randomized Trial on Genotype-Informed Management of Viremia in Children and Adolescents**

10:29 AM

NIS

Jennifer A. Brown, Isaac K. Ringera, Ezekiel Luoga, Buoang Mothobi, Brenda Simba, Kasasi Mayogu, Mosa Molapo Hlasoa, Buntshi P. Kayembe, Josephine Muhairwe, Thomas Klimkait, Tracy R. Glass, Maja Weisser, Niklaus D. Labhardt, for the GIVE MOVE Research Group

Questions and Answers (Part 1)

Introductions (Part 2)

- 186** **ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART**

11:00 AM

LB

Hilda A. Mujuru, Ellen M. White, Adeodata R. Kekitiinwa, Abbas Lugemwa, Cissy Kityo, Philippa Musoke, Tim R. Cressey, Ebrahim Variava, Avy Violari, Moherndran Archary, Mark F. Cotton, Thanyawee Puthanakit, Pablo Rojo, Anna Turkova, for the ODYSSEY Trial Team

- 187** **Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi**

11:08 AM

LB

George Bello, Sherri Pals, Barbara Bighignoli, Alinune Kabaghe, Jonathan Mkungudza, Loise Panje, Elliot Raizes, Elizabeth Kampira, Dumbani Kayira, Bilaal W. Matola, Stephanie Hackett, Duping Zheng, Bianca Alvarez, Nellie Wadonda-Kabondo, for the HIV Drug Resistance Surveillance Team

Wednesday

188 **Long-Acting Cabotegravir Plus Rilpivirine In Adolescents With HIV: Week 24 IMPAACT 2017(MOCHA) Study**

11:16 AM **Aditya Gaur**, Edmund Capparelli, Kristin Baltrusaitis, Mark Marzinke, Conn M. Harrington, Cindy McCoig, Herta Crauwels, Ellen Townley, Jack Moye, Sarah Buisson, Avy Violari, Pradthana Ounchanum, Chelsea Krotje, Carolyn Bolton, for the IMPAACT 2017 Team

189 **SEARCH: Youth Intervention Impact on Symptoms of Depression in East African Youth Living With HIV**

11:24 AM **Florence Mwangwa**, James Peng, Laura B. Balzer, James Ayieko, Janice Litunya, Jason Johnson-Peretz, Douglas Black, Janet Nakigudde, Elizabeth Bukusi, Moses R. Kamya, Theodore Ruel, Diane Havlir, Carol S. Camlin

190 **Role of Community-Level Factors in Declines in HIV Incidence and Prevalence Among Rakai Adolescents**

11:32 AM **Stephanie A. Grilo**, Julia Thompson, Ivy S. Chen, Fred Nalugoda, Tom Lutalo, Ying Wei, Esther Spindler, Susie Hoffman, Philip Kreniske, David Serwadda, Mary Kate Grabowski, Maria J. Wawer, Fred M. Ssewamala, Larry W. Chang, **John S. Santelli**

Questions and Answers (Part 2)

Oral Abstract Session-12 | Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19
10:00 AM - 12:00 PM • Mile High Ballroom 4

Moderators

Euphemia Sibanda, Centre for Sexual Health & HIV/AIDS Research, Harare, Zimbabwe



Aaron J. Siegler, Emory University, Atlanta, GA, USA

Introductions (Part 1)**191** **Investigation of HIV Transmission Associated With Receipt of Vampire Facials: New Mexico, 2018-2023**

10:05 AM LB **Anna M. Behar**, Mika N. Gehre, Liana Atallah, Tegan Clarke, Ana-Alicia Leonso, Francella Jojola, HaoQiang Zheng, Hongwei Jia, Sheryl Lyss, William M. Switzer, Scott P. Grytdal, Miranda Durham, N. Mariam Salas, Marla Sievers, Chad Smelser

192 **Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States**

10:13 AM **André Dailey**, Zanetta Gant Sumner, Anna Satcher Johnson, Juliet A. Morales, Sue Reynolds

193 **Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021**

10:21 AM **Sonia Singh**, Xiaohong Hu, Kristen L. Hess, Kashif Iqbal

194 **Quantifying HIV-1 Transmission Between People Who Inject Drugs and Other Populations in Kenya**

10:29 AM NIS **Hanley Kingston**, Bhavna Chohan, George Nduva, Loice Mbogo, Aliza Monroe-Wise, Betsy Sambai, Brandon Guthrie, Sarah Masyuko, David Bukusi, John Scott, Carey Farquhar, Josh Herbeck

Questions and Answers (Part 1)**Introductions (Part 2)**

- 195 Demographics Are Crucial to Interpret 95-95-95 Targets in African Populations With High ART Coverage**

11:00 AM **Andrea Brizzi**, Joseph Kagaayi, Robert Ssekubugu, Alexandra Blenkinsop, Mélodie Monod, Gertrude Nakigozi, Larry W. Chang, Thomas C. Quinn, Fred Nalugoda, Godfrey Kigozi, Ronald M. Galiwango, Oliver Laeyendecker, Mary Kate Grabowski, Steven J. Reynolds, Oliver Ratmann

- 196 High Prevalence of Advanced HIV Disease in Sub-Saharan Africa: An Analysis of 11 Household Surveys**

11:08 AM **Dominik Stelzle**, Ajay Rangaraj, Joseph N. Jarvis, Nirina H. Razakaso, Daniel Low-Beer, Meg Doherty, Nathan Ford, Shona Dalal

- 197 Low-Level Viremia Trends Among Persons With HIV: A 5-Country Analysis From 10 PHIA Surveys**

11:16 AM **Jessica E. Justman**, Giles A. Reid, Shannon M. Farley, Helen Chun, Hetal Patel, Kyle Milligan, Harriet Nuwagaba-Biribonwoha, Felix Ndagije, Nzali G. Kancheya, Wilford Kirungi, Owen Mugurungi, Rejoice Nkambule, Rose K. Nyirenda, Tapiwa Tarumbiswa, Wafaa El-Sadr

- 198 A New 2023-2024 Mpox Outbreak in Brazil: Lessons From a Reemerging Neglected Disease**

LB Mayara Secco Torres da Silva, Carolina Coutinho, Thiago S. Torres, Amanda Echeverría-Guevara, Matheus O. Bastos, Pedro S. Martins, Maira B. Mesquita, Estevao P. Nunes, Ronaldo Moreira, Eduardo M. Peixoto, Edson E. Silva, Sandra Wagner-Cardoso, Valdilea Veloso, Beatriz Grinsztejn, for the INI-Fiocruz Mpox Study Group

- 199 Vaccine Effectiveness Against COVID-19 In-Hospital Mortality by HIV Status Across SARS-CoV-2 Variants**

LB Seth Inzaule, Ronaldo Silva, Nathan Ford, Soe Soe Thwin, Jassat Waasila, Meg Doherty, Janet Diaz, Silvia Bertagnolio

Questions and Answers (Part 2)

Oral Abstract Session-13 | Strengthening Testing, Treatment, and Prevention of HIV and STIs

10:00 AM - 12:00 PM • Four Seasons Ballroom 2-3

Moderators

Harriet Nuwagaba-Biribonwoha, ICAP at Columbia University, New York, NY, USA



Adetokunbo B. O. Oyeledun, Centre for Integrated Health Programs, Abuja, Nigeria

Introductions (Part 1)

- 200 Together TakeMeHome: Launch of a National HIV Self-Test Distribution Program, March-December 2023**

LB Kevin P. Delaney, Travis H. Sanchez, Robin Macgowan, Ruth Dana, Lucinda Ackah-Toffey, Jen Hecht, Emily Lilo, Avery Smithson, Revae S. Downey, Jessica Keralis, Emily Pingel, Natalie O. Cramer, Patrick S. Sullivan, Athena Kourtis, for the Together TakeMeHome Program Team

201 **Incidence of Health Facility Switching and HIV Viral Rebound in Uganda: A Population-Based Study**

10:13 AM

NIS

Joseph G. Rosen, Anthony Ndyanabo, Ronald M. Galiwango, Robert Ssekubugu, Katherine Rucinski, Gertrude Nakigozi, Fred Nalugoda, Godfrey Kigozi, Thomas C. Quinn, Larry W. Chang, Caitlin E. Kennedy, Steven J. Reynolds, Joseph Kagaayi, Mary Kate Grabowski, for the Rakai Health Sciences Program

203 **Improving Posthospital Outcomes in People With HIV: A Multicenter Randomized Trial in Tanzania**

10:21 AM

Robert Peck, Benson Issarow, Godfrey Kisigo, Elialilia Okello, Severin A. Kabakama, Thomas Rutachunzibwa, Sean Murphy, Heiner Grosskurth, Lisa Rosen-Metsch, Daniel Fitzgerald, Philip Ayieko, Myung Hee Lee, Saidi Kapiga

202 **Lakeside Combined HIV and Schistosomiasis Services in Malawian Fishermen: A Cluster Randomized Trial**

10:29 AM

Augustine T. Choko, Kathryn L. Dovel, Sekeleghe A. Kayuni, Donaldson Conserve, Anthony Butterworth, Amaya Bustinduy, J. Russel Stothard, Wala Kamchedzera, Madalo Mukoka-Thindwa, James Jafali, Peter MacPherson, Katherine Fielding, Nicola Desmond, Elizabeth L. Corbett

Questions and Answers (Part 1)**Introductions (Part 2)****204** **What Are the Outcomes for Established Clients Enrolled in DSD During the First 3 Years on ART?**

11:00 AM

Amy N. Huber, Lise Jamieson, Musa Manganye, Lufuno Malala, Thato Chidarikire, Matthew P. Fox, Sydney Rosen, Sophie Pascoe

205 **Opt-Out HIV Testing in Emergency Departments Successfully Addresses Key Gaps in Testing**

11:08 AM

Lisa Hamzah, Kathryn Childs, Ian S. Cormack, Olubanke Davies, Roddy Font, Lewis Haddow, Elizabeth Hamlyn, Kathryn Harrop, Rachel Hill-Tout, Steven Kegg, Isha Lovatt, Larissa Mulka, Melanie Rosenvinge, Lucy Wood, for the South London HIV ED Opt Out Testing Group

206 **Few Discordant HIV Ag/Ab and RNA Test Results Among Persons in a National Cohort of PrEP Users**

11:16 AM

LB

Weiming Zhu, Ya-Lin A. Huang, Kevin P. Delaney, Rupa Patel, Athena Kourtis, Karen W. Hoover

207 **Missed Opportunities to Prevent Congenital Syphilis in Antenatal PrEP Services in South Africa**

11:24 AM

LB

Dvora L. Joseph Davey, Aurelie Nelson, Kalisha Bheemraj, Alex de Voux, Rufaro Mvududu, Lisa Frigati, Landon Myer

Questions and Answers (Part 2)

Oral Abstract Session-14 | Special Session: Clinical Late-Breaking Oral Abstracts

12:15 PM - 1:30 PM • Mile High Ballroom 1-2-3

Moderators

Constance A. Benson, University of California San Diego, La Jolla, CA, USA



Peter Reiss, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands

Introductions

- 208 Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study**

LB

Amy Colson, Gordon Crofoot, Peter J. Ruane, Moti Ramgopal, Alexandra W. Dretler, Ronald G. Nahass, Gary Sinclair, Mezgebe Berhe, Chris Deaton, Angela S. Liu, Eva Mortensen, Martin S. Rhee, Elizabeth G. Rhee, Jared Baeten, Joseph J. Eron

- 209 HepB-CpG Vaccine Is Superior to HepB-alum in People With HIV and Prior Vaccine Nonresponse: A5379**

LB

Kristen Marks, Minhee Kang, Triin Umbleja, Andrea Cox, Karen J. Vigil, Ngan T. Ta, Ayotunde Omoz-Oarhe, Jennifer Price, Josphat Kosgei, Leolin Katsidzira, Hugo Perazzo, Kevin Knowles, Beverly L. Alston-Smith, Kenneth E. Sherman, for the ACTG 5379 (BEe-HIVe) Study Team

- 210 Efficacy, Safety, and Immunogenicity of H56:IC31 Vaccine for Prevention of Recurrent TB**

LB

Alvaro Borges, Marisa Russel, Dereck Tait, Elana van Brakel, Andrea Cabibbe, Daniela Cirillo, Elisa Nemes, Thomas Scriba, Gavin Churchyard, Rodney Dawson, Isa Sabi, Andreas H. Diacon, Rasmus Mortensen, Mark Hatherill, for the POR TB Consortium

- 211 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis on Rifampicin at Week 24**

LB

Anushka Naidoo, Kogieleum Naidoo, Marothi P. Letsoalo, Hylke Waalewijn, Gillian Dorse, Rubeshan Perumal, Mahomed-Yunus S. Moosa, Emmanuella C. Osuala, Resha Boodhram, Dennis Israelski, Paolo Denti, James F. Rooney, Kelly Dooley, for the INSIGHT Trial Team

- 212 Long-Acting Injectable CAB/RPV Is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359**

LB

Aadia I. Rana, Yajing Bao, Lu Zheng, Sara Sieczkarski, Jordan E. Lake, Carl J. Fichtenbaum, Tia Morton, Lawrence Fox, Paul Wannamaker, Jose R. Castillo-Mancilla, Kati Vandermeulen, Chanelle Wimbish, Karen T. Tashima, Raphael J. Landovitz, for the ACTG A5359 Team

Questions and Answers

Wednesday

Themed Discussion-09 | Mucosal Immunity to HIV

1:30 PM - 2:30 PM • Four Seasons Ballroom 1

Themed Discussion Leader**Barbara L. Shacklett**, University of California Davis, Davis, CA, USA**Session Overview**

- 431** **A Novel Non-Invasive Approach to Sample Female Genital Tract Immune Cell Populations**
1:35 PM

M. Quinn Peters, Eva Domenjo-Vila, Melanie Gasper, Smritee Dabee, Blair Armistead, Christopher Whidbey, Heather Jaspan, Martin Prlic, Whitney E. Harrington

- 432** **Identification of Innate Lymphoid Cell Subsets in the Human Female Genital Tract That Respond to HIV**
1:40 PM

NIS **Alexandra E. Werner**, Laura Moreno de Lara, Francisco J. Carrillo-Salinas, Anna Borchers, Siddharth Parthasarathy, Marta Rodriguez-Garcia

- 433** **The Cervicovaginal Neutrophil Protein CRISP3 Is a Correlate of HIV Protection**
1:45 PM

Christina Farr, Laura Noël-Romas, Michelle Perner, Marina Costa-Fujushima, Sausan Azzam, Marlon De Leon, Stefanie Avril, Vanessa Polquin, Alicia R. Berard, Lyle McKinnon, Thomas Murooka, Sharon L. Hillier, Zvavahera Chirenje, Jeanne Marrazzo, **Adam Burgener**

- 434** **CD101 Variants Are Associated With Lower Levels of Genital HIV-Inhibiting and Tissue Repair Factors**
1:50 PM

Sarah C. Vick, Corinne M. Mar, Bhavna Chohan, Katherine K. Thomas, James W. MacDonald, Theo K. Bammler, Kenneth Ngure, Nelly R. Mugo, Jennifer M. Lund, Jairam Lingappa

- 435** **Synergistic Effects of HIV, HPV, and Polyomaviruses on Interferon Response in Male Anal Mucosa**
1:55 PM

NIS **Matteo Fracella**, Sara Passerini, Letizia Santinelli, Leonardo Sorrentino, Luca Maddaloni, Ginevra Bugani, Eugenio Nelson Cavallari, Alessandra Pierangeli, Guido Antonelli, Claudio Maria Mastroianni, Gabriella D'Ettorre, Valeria Pietropaolo, Carolina Scagnolari

Discussion with Audience Questions and Answers**Themed Discussion-10 | Strategies for an HIV Cure**

1:30 PM - 2:30 PM • Four Seasons Ballroom 2-3

Themed Discussion Leader**Susana Valente**, The Scripps Research Institute, La Jolla, CA, USA**Session Overview**

524	Potent HIV Latency Reversal by Lipid Nanoparticles Encapsulating HIV Tat mRNA
1:35 PM	Bridget M. Fisher , Paula M. Cevala, Stanislav Kan, Abdalla Ali, Abigail Tan, Rory Shepherd, Youry Kim, Marvin Holz, Damian Purcell, Frank Caruso, Sharon R. Lewin, Michael Roche
523	CD4-Targeted mRNA Delivery of Tat Reverses HIV-1 Latency
1:40 PM	Edward Kreider , Vincent H. Wu, Jayme M. Nordin, Francesco Pennino, Amie Albertus, Tyler Papp, Obinna Uzosike, Khumoekae Richard, Carol Cheney, Karam Mounzer, Hamideh Parhiz, Michael R. Betts, Daniel T. Claiborne, Drew Weissman, Luis J. Montaner
525	Nanoparticle Delivery of Tat Synergizes With Latency Reversal Agents to Express HIV Antigen
1:45 PM	Shane D. Falcinelli , Samuel L. Raines, Jackson Peterson, Ellen Van Gulck, Jennifer Kirchherr, Isabel Najera, Jerel Vega, Daniel Boden, Nancie M. Archin, David M. Margolis
521	Ruxolitinib-Mediated HIV-1 Reservoir Decay in A5336 Phase IIa Trial
1:50 PM	Monica D. Reece , Vincent Marconi, Zhan Zhang, Susan P. Ribeiro, Rafick P. Sekaly, Deanna A. Kulpa, Christina Gavegnano
522	Short-Term BCL-2 Inhibition at ART Initiation Transiently Reduces SIV Reservoir in Rhesus Macaques
1:55 PM	Tomas Raul Wiche Salinas , Justin L. Harper, Kevin Nguyen, James Auger, Laurence Raymond Marchand, Mackenzie Cottrell, Jason Brenchley, Jeffrey Lifson, Brandon Keele, Andrew Badley, Guido Silvestri, Deanna A. Kulpa, Mirko Paiardini
Discussion with Audience Questions and Answers	
Themed Discussion-11 Dolutegravir Resistance in Resource-Limited Settings 1:30 PM - 2:30 PM • Mile High Ballroom 1-2-3	
<p>Themed Discussion Leader Gert U. van Zyl, Stellenbosch University, Cape Town, South Africa</p>	
	
<p>Session Overview</p>	
676	Viremia and Drug Resistance 2 Years After Routine Switching to Dolutegravir-Based First-Line ART
1:35 PM	Veronika Whitesell Skrivankova, Jacqueline Huwa, Guy Muula, Geldert D. Chiwaya, Esau Banda, Shameem Buleya, Belinda Chihota, Joseph Chintedza, Carolyn Bolton, Thokozani Kalua, Roger Kouyos, Gilles Wandeler, Matthias Egger, Richard J. Lessells
677	DTG Resistance in Patients with Previous ARV Experience and Viremia in Kenya Receiving DTG-Based ART
1:40 PM	Leonard Kingwara , Vera M. Onwonga, Rukia S. Madada, Peter Lokamar, John N. Kiiru, James Wagude, Barbara Mambo, Caroline Mwangi, Rose Wafula, Kerri Penrose, Urvi M. Parikh, Bhavna Chohan

- 678** **Emerging Dolutegravir Resistance in Lesotho**
 1:45 PM Nadine Tschumi, Blaise Lukau, Lipontšo Motaboli, Katleho Tlali, Mpho Kao, Mathebe Kopo, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka, Karoline Leuzinger, Jennifer A. Brown, **Niklaus D. Labhardt**

- 679** **Resistance to Second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant**
 1:50 PM Jannette A. Juárez-González, Emiliano Ivan Sanchez Cruz, Luis A. Angulo-Medina, Roberto A. Rodriguez-Díaz, Elsa Y. Vidal-Laurencio, Sofía Sierra Vásquez, **Luis Enrique Soto Ramírez**

- 680** **Virologic Outcomes With Tenovovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure**
 1:55 PM Ying Zhao, Jacqueline Voget, Isaac Singini, Zaayid Omar, Vanessa Mudaly, Andrew Boulle, Gary Maartens, Graeme A. Meintjes

Discussion with Audience Questions and Answers

Themed Discussion-12 | Novel Interventions in HIV Programming

1:30 PM - 2:30 PM • Mile High Ballroom 4

Themed Discussion Leader

Angeli Achrekar, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland



Session Overview

- 1250** **Automated Condom Distribution for HIV Prevention: Mwanza, Tanzania, 2021-2023**
 1:35 PM **Aafke Kinemo**, Julie Franks, Emmanuel Mihayo, Macdonald Mahiti, Joyce Thomas, Oreste Munishi, Omari Msomi, John Kahemele, Kokuhumbya Kazaura, Nyagonde Nyagonde, Mbaraka Amuri, Haruka Maruyama

- 1251** **Cost-Effectiveness of an Agricultural Intervention Among Adults With HIV and Their Children in Kenya**
 1:40 PM **Assurah W. Elly**, Elly Weke, Pauline Wekesa, Rachel Burger, Lila Sheira, Mocello Adrienne, Edward Frongillo, Lisa Butler, Sheri Weiser, Craig Cohen, Jim Kahn, Elizabeth Bukusi, Starley Shade

- 1253** **Persistence on Contraception and PrEP in Hair Salons in South Africa**
 1:45 PM **Ingrid V. Bassett**, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile M. Ngcobo, Shruti Sagar, Jana Jarolimova, Dani Zions, Christina Psaros, Nduduzo Dube, Robert A. Parker

- 1255** **Availability of Onsite Substance Use Disorder Services in HIV Facilities by Urbanicity in the US**
 1:50 PM **Kashif Iqbal**, Preetam A. Cholli, Yunfeng Tie, Stacy Crim, Jesse G. O'Shea, John Weiser, Sharoda Dasgupta

Discussion with Audience Questions and Answers

Interactive Symposium-08 | Innovations in Intervention:**Toward an HIV Cure****4:00 PM - 5:30 PM • Four Seasons Ballroom 1****CME****Objectives:** At the completion of the session, participants will be able to:

- Describe how nonnucleoside reverse transcriptase inhibitor (NNRTI)-induced protease activity can activate inflammasome and eliminate HIV-infected cells
- Summarize how single-cell transcriptomic analysis from clinical samples identifies potential therapeutic targets
- Explain how structural understanding of HIV envelope protein conformation can lead to therapeutic strategies

Target Audience: This session is directed to clinicians, researchers, and trainees interested in novel strategies for HIV cure.**Level of Knowledge:** It is assumed that the participants are familiar with the basic understanding of how HIV persists during antiretroviral therapy.**Conveners****Alberto Bosque**, *George Washington University, Washington, DC, USA***María Buzón**, *Vall d'Hebron Research Institute, Barcelona, Spain*

41 | 4:00 PM | From Mechanisms to Therapeutics: Eliminating HIV-Infected Cells by the CARD8 Inflammasome

Liang Shan, *Washington University in St Louis, St Louis, MO, USA*

42 | 4:15 PM | From Mechanisms to Therapeutics: TACK Molecules Kill HIV-Infected Cells Through Inflammasome Activation

Tracy L. Diamond, *Merck & Co., Inc., Rahway, NJ, USA*

43 | 4:30 PM | From Transcriptomics to Therapeutics: A Host Restriction Factor That Targets HIV Expression

Rasmi Thomas, *Walter Reed Army Institute of Research, Silver Spring, MD, USA*

44 | 4:45 PM | From Structure to Therapeutics: Small CD4 Mimetics 'Open-Up' Env and Sensitize HIV-1-Infected Cells

Andrés Finzi, *Université de Montréal, Montreal, Canada***5:00 PM | Audience Questions and Answers**

Wednesday

Interactive Symposium-09 | Follow Your Heart: Managing Cardiovascular Disease Risk in HIV

4:00 PM - 5:30 PM • Mile High Ballroom 4

CME

Objectives: At the completion of the session, participants will be able to:

- Summarize the findings from the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) Trial and the implications for clinical practice
- Identify the potential mechanisms underlying excess cardiovascular risk in people with HIV
- Discuss challenges to the implementation of cardiovascular risk reduction in different clinical settings globally

Target Audience: This session is directed to clinicians and researchers involved in cardiovascular disease prevention and treatment for people with HIV.

Level of Knowledge: It is assumed that the participants are familiar with research on cardiovascular and metabolic complications of HIV infection.

Conveners

Matthew J. Feinstein, Northwestern University,
Chicago, IL, USA



Franck Boccaro, Sorbonne Universite, Paris,
France



4:00 PM | Overview of the REPRIEVE Trial

Steven K. Grinspoon, Massachusetts General Hospital, Boston,
MA, USA



45 | 4:05 PM | Sex Differences in Atherosclerotic CVD Risks and Mechanisms: Insights From REPRIEVE

Markella V. Zanni, Massachusetts General Hospital, Boston, MA, USA



46 | 4:25 PM | Immunomodulation and Cardiovascular Disease: Lessons Learned From HIV

Priscilla Y. Hsue, University of California San Francisco, San Francisco, CA, USA



47 | 4:45 PM | Implications for Implementing CVD Risk Prevention Strategies for Low- and Middle-Income Countries

Mpiko Ntsekhe, University of Cape Town, Cape Town, South Africa

5:05 PM | Panel Discussion

Interactive Symposium-10 | Promise and Pitfalls of Biomedical Prevention: Beyond Phase III

4:00 PM - 5:30 PM • Four Seasons Ballroom 2-3

CME

Objectives: At the completion of the session, participants will be able to:

- List the challenges and opportunities in clinical implementation of long-acting injectable cabotegravir
- Describe reasons randomized phase III efficacy studies may not fully reflect the potential for benefit of an HIV prevention product
- Identify and debunk common misconceptions about on-demand, event-driven, or 2-1-1 preexposure prophylaxis (PrEP)

Target Audience: This session is directed to clinicians, researchers, and others who are interested in biomedical HIV prevention.

Level of Knowledge: It is assumed that the participants are familiar with the phase III efficacy and safety trials of current HIV biomedical prevention products.

Conveners

Linda-Gail Bekker, *Desmond Tutu HIV Foundation, Cape Town, South Africa*



Bruno Spire, *Institut National de la Santé et de la Recherche Médicale, Marseille, France*



48 | 4:00 PM | Why Is Cabotegravir Rollout So Slow?

Rupa R. Patel, *Centers for Disease Control and Prevention, Atlanta, GA, USA*



49 | 4:20 PM | The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III

Leila E. Mansoor, *Centre for the AIDS Programme of Research in South Africa, Durban, South Africa*



50 | 4:40 PM | Challenging the Dogma of Event-Driven PrEP

Jenell Stewart, *Hennepin Healthcare Research Institute, Minneapolis, MN, USA*

5:00 PM | Audience Questions and Answers

Wednesday

POSTER SESSIONS BY DAY

MONDAY, MARCH 4, 2024

Poster Session-B1 | Correlates of HIV Transmission and Control

2:30 PM - 4:00 PM • Poster Hall C-D

- 315 A Quiescent NK Cell Phenotype With Gut Homing Potential in HIV-1 Exposed Seronegative Individuals**

Kawthar Machmach Leggat, Kombo F. N'guessan, Isabella Swafford, Leigh-Anne Eller, Shelly J. Krebs, Merlin L. Robb, Julie Ake, Sandhya Vasan, Dominic Paquin-Proulx

- 316 Mucosal-Homing Invariant NKT Cells Are Elevated in HIV-Exposed Seroconverters Prior to Infection**

Kombo F. N'guessan, **Kawthar Machmach Leggat**, Isabella Swafford, Leigh-Anne Eller, Shelly J. Krebs, Julie Ake, Sandhya Vasan, Merlin L. Robb, Dominic Paquin-Proulx, for the RV217 Study Group

- 317 Mobility of Transmitted/Founder HIV-1 Variants in Human Cervicovaginal Mucus**

Matrona M. Akiso, Marianne Mureithi, Sarah Joseph, Ann M. Carias, Omu Anzala, Thomas Hope

- 318 IL7RA rs10491434 Polymorphism Is Related to Spontaneous HIV Infection Control: A Retrospective Study**

Daniel Sepúlveda-Crespo, María A. Jiménez-Sousa, Amanda Fernández-Rodíguez, María A. Muñoz-Fernández, José L. Jiménez, Jorge del Romero, Sergio Reus Bañuls, Helem Vilchez, **Beatriz Mothe**, Isidoro Martínez, José M. Benito, Norma Rallón, Salvador Resino

- 319 Genetic Variants Associated to HIV Control Are Associated With NK Cell Markers and Response to CMV**

Suzanne Ruijten, Jessica dos Santos, Albert L. Groenendijk, Marc Blaauw, Louise E. van Ekeren, Wilhelm A. Vos, Nadira Vadaq, Victoria Rios-Vazquez, Leo Joosten, Casper Rokx, Annelies Verbon, Mihai Netea, Vasiliki Matzaraki, Andre J. van der Ven, for 2000HIV

Poster Session-B2 | HIV Immunopathogenesis

2:30 PM - 4:00 PM • Poster Hall C-D

- 320 Plasma Proteome Signature of Immune Inhibition Is Associated With CMV Coinfection in People With HIV**

Michael L. Freeman, Gordon Honerkamp Smith, Patricia K. Riggs, Scott L. Letendre, Peter W. Hunt, Sara Gianella Weibel

- 321 B-Cells Augment HIV-1 Expression in Secondary Lymphoid Tissue**

Matthew Ollerton, Joy Folkvord, Cecilia Shikuma, Fredrick Yost, David Parry, Magali Porrachia, Davey Smith, Sara Gianella, Elizabeth Connick

322

Herpesviruses Reactivation and Associated Systemic Inflammation During Initiating ART, Rakai-Uganda

Victor Ssempijja, Viviane Callier, Martha Nason, Aggrey Anok, Andrea Lisco, Andrew Redd, Thomas C. Quinn, Adam Rupert, Stephen Tomusange, Taddeo Kityamuweesi, Paul Bbuule, Irini Sereti, Steven J. Reynolds

323

HIV-1 Coinfection Skews iNKT Cells Toward Anergy and Exhaustion in People With Hepatitis C

Danielle R. Nettere, Grant Williams, Joy Pickeral, Scott White, Cliburn Chan, Guido Ferrari, Susanna Naggie

324

Low SKAP1 Levels Indicate a Potential New Mechanism in HIV Immunological Non-Responders

Wilhelm A. J. W. Vos, Jiang Xun, Jessica D. Santos, Albert L. Groenendijk, Marc Blaauw, Louise E. van Ekeren, Nadira Vadaq, Vasiliki Matzaraki, Mike van der Kolk, Willem L. Blok, Janneke E. Stalenhoef, Jan van Lunzen, Yang Li, Cheng-Jian Xu, Andre J. van der Ven

325

Disruption of Intestinal Germinal Centers During HIV Infection

Francesca Cossarini, Azra Krek, Pablo Canales-Herrerias, Michael Tankelevich, Benjamin K. Chen, Judith A. Aberg, Francesca Petralia, Alexandros D. Polydorides, Saurabh Mehandru

326

Persons With Residual Viremia on ART Have Higher Frequencies of Myeloid-Derived Suppressor Cells

Patrick Mehta, Evgenia Aga, Ronald J. Bosch, Hanna Mar, Deborah K. McMahon, Rajesh T. Gandhi, Joseph J. Eron, John W. Mellors, Charles R. Rinaldo, Bernard Macatangay, for the ACTG A5321 Team

327

Persistent HIV-1 Plasma Viremia in Patients on Therapy Caused by Macrophage-Tropic Lineage

Matthew Moeser, Nathan Long, Abbas Mohammadi, Behzad Etemad, Jonathan Z. Li, Ann M. Dennis, Claire Farel, David Wohl, Mackenzie Cottrell, Joseph J. Eron, Julie A. Nelson, Meredith Clement, Tat Yau, Shuntai Zhou, Sarah B. Joseph

328

Variable HIV-1 C Env Characteristics Associated With Predicted bNAb Resistance in Botswana

Natasha O. Moraka, Wonderful T. Choga, Marea Pema, Irene Gobe, Margaret Mokomane, Ontlametse T. Bareng, Lynnette Bhebhe, Molly Pretorius Holme, Terence Mohammed, Catherine K. Koophethile, Joseph M. Makhema, Roger Shapiro, Shahin Lockman, Sikhulile Moyo, Simani Gaseitiswe

Poster Session-C1 | HIV Neutralizing Antibodies

2:30 PM - 4:00 PM • Poster Hall C-D

367

HIV Rapid Intra-Host Evolution Allows Evasion From VRC01 Infusion via Positive Selection

Frida Belinky, Sung Hee Ko, Pierce Radecki, Vanessa Guerra, Emily Coates, Pamela Costner, Julie Ledgerwood, John R. Mascola, Eli Boritz

368**NIS****A Rare Molecular Signature in HIV-1 Env V1 Associates With bNAb Evolution**

Maria C. Hesselman, Marius Zeeb, Peter Rusert, Jennifer Mamrosh, Samuel Kariuki, Hugh Murrell, Nonhlanhla N. Mkhize, Kshitij Waghray, Penny Moore, Carolyn Williamson, Huldrych F. Günthard, Roger Kouyos, Alexandra Trkola

369**LB****Potent Cross-Reactive HIV-1 Neutralization in Fusion Peptide-Primed SHIV-Infected Macaques**

Hua Wang, Cheng Cheng, James L. Dal Santo, Chen-Hsiang Shen, Tatsiana Bylund, Amy R. Henry, Colin A. Howe, Juyun Hwang, Nicholas C. Morano, Daniel J. Morris, Sergei Pletnev, Ryan S. Roark, Tongqing Zhou, Theodore C. Pierson, Peter D. Kwong

370**LB****Maturation Pathway of Rhesus V3-Glycan Broadly Neutralizing Antibody Lineage**

Mitchell Martin, Tyler Evangelous, Madison Berry, Bhavna Hora, Chuangcang Jiang, Katayoun Mansouri, Robert J. Edwards, Hui Li, George M. Shaw, Priyamvada Acharya, Kevin O. Saunders, Kevin Wiehe, Barton F. Haynes, Wilton Williams

371**NIS****An Efficient Envelope Genotypic Assay to Identify bNAb Susceptibility in Infants with HIV**

Kayla E. Delaney, Mary F. Kearney, Phillip A. Bester, Nicola Coetze, Susan Engelbrecht, Carlo Giaquinto, Paolo Rossi, Shaun L. Barnabas, Moira Spyer, Mathias Lichtenfeld, Alfredo Tagarro, Carl Lombard, Mark F. Cotton, Gert U. van Zyl, for the EPICAL Consortium

372**NIS****MHRP.01, an MPER Targeting bNAb, Enables Further Definition of the 4E10-Class of bNAbs**

Juhi Arora, Paul Thomas, Gina Donofrio, Rajeshwer S. Sankhala, Nicole Doria-Rose, Chaim A. Schramm, Vincent Dussupt, Lauren Smith, Letzibeth Mendez-Rivera, Lindsay Wieczorek, Sandhya Vasan, Julie Ake, Merlin L. Robb, M. Gordon Joyce, Shelly J. Krebs

373***Mycobacterium tuberculosis* Infection Dampens the HIV-1 Antibody Response**

Marius Zeeb, Chloé Pasin, Irene A. Abela, Katharina Kusejko, Sonja Hartnack, Julia Notter, Hansjakob Furrer, Matthias Hoffmann, Hans Hirsch, Alexandra Calmy, Enos Bernasconi, Huldrych F. Günthard, Roger Kouyos, Alexandra Trkola, Johannes Nemeth

374**Temsavir Treatment Enhances bNAb Recognition and Subsequent Clearance of HIV-1–Infected Cells**

Robert Ferris, Cristin Galardi, James Schawalder, Richard Dunham, Heather Madsen, **Hangfei Qi**

375**AAV-1, -8, and -9 Seroprevalence in Healthy Donors and People Living With HIV in Sub-Saharan Africa**

Giselle Lopez Fernandez, Daniel O'Hagan, Siddhartha Shandilya, Dorinda Mukura, Tinashe Chidemo, Alfred Kateta, Rodney Goreraza, Mookho Malahleha, Zoe Moodie, Mauricio A. Martins

376 Machine Learning-Guided Generation of a Combination of Broadly Neutralizing Sarbecovirus Antibodies

Grace Marden, Kimberly Schmitt, Hongru Li, Alex Ramos, Eric Carlin, Nadine Shaban, Geetika Sharma, Monica Menzenski, Anne Jecrois, Gevorg Grigoryan, Adam Root, Heather Van Epps, Kristen Hopson, Daria Hazuda, Francesco Borriello

Poster Session-C2 | HIV Vaccines

2:30 PM - 4:00 PM • Poster Hall C-D

377 Safety and Immunogenicity of Month 30 Boost of ALVAC+gp120/MF59 Preventive HIV Vaccines

Vimla Naicker, Fatima Laher, Kelly Seaton, Stephen C. De Rosa, Lynn Morris, Nonhlanhla N. Mkhize, Linda-Gail Bekker, Mookho Malahleha, Kathy T. Mngadi, Jack R. Heptinstall, David C. Montefiori, Juliana McElrath, Georgia D. Tomaras, Zoe Moodie, for the HVTN 100 Study Team

378 Adenosine Deaminase-1 Enhances HIV-Specific Responses to a HIV Trimeric Envelope DNA Vaccine

Gina Cusimano, David Joyner, Emily Konopka, Roshell Muir, Gabriela Canziani, Philip Barnette, Iván del Moral-Sánchez, Tom Bijl, Jonne Snitselaar, Kyra Woloszczuk, Irwin M. Chaiken, Ann J. Hessell, Rogier W. Sanders, Elias K. Haddad, Michele A. Kutzler

379 NIS Sex-Based Differences in Antibody Responses Induced by a Native-Like HIV-1 Envelope Trimer Vaccine

Emma Reiss, **Karlijn van der Straten**, Marinus Liesdek, Annelou L. van der Veen, Marloes Grobben, Hongmei Gao, Kelli Greene, David C. Montefiori, Maarten Soeters, Michelle J. Klouwens, Jan M. Prins, Marit van Gils, Rogier W. Sanders, Godelieve J. de Bree

380 LB IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in HVTN 108

Song Young Oh, Haleigh Conley, Nigel Garrett, One Dintwe, Guido Ferrari, Georgia D. Tomaras, Dan Geraghty, Cliburn Chan, Justin Pollara, for the HVTN 108 Study Team

381 Developing Novel HIV-1 Env Proteins That Efficiently Engage the Unmutated Forms of VRC01-Class Abs

Parul Agrawal, Junli Feng, Arineh Khechaduri, Kelsey R. Salladay, Latha S. Kallur, Madison M. Means, Matthew D. Gray, Leonidas Stamatatos

382 Enhancing HIV Vaccine Efficacy via Langerhans Cell-Targeted Env Trimers

Adele Hammoudi, Mathieu Surenaud, Florence Picard, Jade Legros, Emma Sicherre, Borys Pedenko, Christiane Moog, Winfried Weissenhorn, Mireille Centlivre, Véronique Godot, Yves Levy, **Sylvain Cardinaud**

383 LB Mucosal HIV Vaccine Targeting Host Epithelial Stem Cells for Long-Term Immunity

Robert White, Vida Hodara, Patrice Frost, Pamela A. Kozlowski, Francois J. Villinger, **Marie-Claire Gauduin**

384**NIS****Naive B-Cells From Unvaccinated Rhesus Macaques Cross-React With HIV gp140 Protein****Michelle Premazzi Papa**, Andrew Wilson, Rosemarie Mason, Jennifer A. Manuzak, Nichole R. Klatt, Rebecca M. Lynch**Poster Session-C3 | COVID-19 Vaccines****2:30 PM - 4:00 PM • Poster Hall C-D****385****Complement Activation as a Mechanism of Protection by SARS-CoV-2 mRNA Vaccines in Men With HIV-1****Dylan J. Tuttle**, Nicolas Sluis-Cremer, Robbie B. Mailliard, Charles R. Rinaldo, Ernesto T. Marques**386****WITHDRAWN****387****Sarbecovirus Ferritin Nanoparticle Vaccines as Protein or mRNA-LNP Elicit Broad Immunogenicity****M. Gordon Joyce**, Sandra V. Mayer, Philip Davidson, Paul Thomas, Daniel C. Douek, Monica Wu, Nicholas Clark, Amita Vaidya, William Warren, Natalie Anosova, Valerie Lecouturier, Sandhya Vasan, Nelson L. Michael, Natalie Collins, for Sarbecovirus Ferritin Nanoparticle Study Group**388****NIS****Immune Responses to an Original/BA.4-5 Bivalent Booster of SARS-CoV-2 mRNA Vaccine in PWH on ART****Matteo Augello**, Valeria Bono, Roberta Rovito, Alessandro Tavelli, Camilla Tincati, Alessandra Vergori, Anna Maria Azzini, Elda Righi, Andrea Antinori, Evelina Tacconelli, Antonella d'Arminio Monforte, Giulia Marchetti, for the VaxICONA-ORCHESTRA Study Group**389****NIS****Immune Response to SARS-CoV-2 Omicron Breakthrough is a Recall of Vaccine-Induced Memory****Jernej Pusnik**, Jasmin Zorn, Werner O. Monzon Posadas, Kathrin Peters, Emmanuil Osypchuk, Sabine Blaschke, Hendrik Streeck**390****NIS****Long-Term Immunodominant Profile of SARS-CoV-2 T-Cell Responses in Hybrid Immunity****Raúl Pérez-Caballero**, Laia Bernad, Athina Kilpeläinen, Oscar Blanch-Lombarte, Luis Romero, Ruth Peña, Gabriel F. Rodríguez-Lozano, Josep Maria Manresa-Dominguez, Bonaventura Clotet, Alex Olvera, Christian Brander, Eva María Martínez Cáceres, Concepción Violán, Pere Torán-Monserrat, Julia G. Prado**391****NIS****Bivalent mRNA COVID Vaccines Elicit Predominantly Cross-Reactive CD4+ T-Cell Clonotypes****Joel Sop**, Arbor G. Dykema, Caroline C. Traut, Christie R. Basseth, Annukka A. Antar, Kellie N. Smith, Joel N. Blankson

392

Spike-V987H Vaccination Protects Animal Models From SARS-CoV-2-Induced Severe Disease

NIS

Carlos Ávila Nieto, Julia Vergara-Alert, Pep Amengual-Rigo, Erola Ainsua Enrich, Edwards Pradenas, Jordi Rodon, Victor Urrea, Ester Ballana, Nuria Izquierdo-Useros, Alfonso Valencia, Julià Blanco, Victor Guallar, Bonaventura Clotet, Joaquim Segalés, Jorge Carrillo

393

Prior COVID-19 Alters Antibody Function in ART-Suppressed PWH Receiving SARS-CoV-2 Vaccination

Livio Azzoni, Ian Tietjen, Qin Liu, Shalini Singh, Mansi Purwar, Matthew Fair, Paridhima Sharma, Leila B. Giron, Jianyi Ding, Linden Lalley-Chareczko, Emily Hiserodt, Karam Mounzer, David B. Weiner, Mohamed Abdel-Mohsen, Luis J. Montaner

394

Distinct Absence of Post-Boost S-IgG Surge in Sub-Saharan African COVID-19 Vaccine Responses

Jennifer Serwanga, Violet Ankunda, Joseph S. Katende, Jackson Semenza, Gerald K. Oluka, Claire Baine, Pontiano Kaleebu

395

Disparities in Anti-SARS-CoV-2 Reactivity According to Vaccines in the Era of Omicron in Cameroon

NIS

Ezechiel Ngoufack Jagni Semengue, Joseph Fokam, Desire Takou, Collins Ambe Chenwi, Grace Beloumou, Alex Durand NKA, Aurelie Minelle Ngueko Kengni, Sandrine Djupsa, Alexis Ndjolo, Carlo Federico Perno, Vittorio Colizzi

396

Uptake of 3+ COVID-19 Vaccine Doses Among People Living With HIV in Ontario, Canada

NIS

Cassandra Freitas, Catharine Chambers, Curtis L. Cooper, Abigail E. Kroch, Sarah A. Buchan, Claire E. Kendall, Jeffrey C. Kwong, Lawrence Mbuagbaw, Nasheed Moqueet, Ann N. Burchell, for the CHESS Study Team

397

COVID-19 Breakthrough Infections Among People With and Without HIV: A Statewide Cohort Analysis

Xueying Yang, Jiajia Zhang, Ziang Liu, Shujie Chen, Bankole Olatosi, Gregory A. Poland, Sharon Weissman, Xiaoming Li

398

Effectiveness and Safety of SARS-CoV-2 mRNA Vaccines in Children: A Population-Based Study in Madrid

LB

Miguel Hernán, Alejandro Alvaro-Meca, María J. Calvo-Alcántara, María Luisa Navarro, José T. Ramos, José C. Estévez, Miguel Basanta, Sergio Ruiz, Ángel L. Mataix, Lourdes Cosano, Aura P. Silva, Pilar Salas, Jose R. Arribas, José M. Molero, **Juan Berenguer**

399

Heterologous mRNA-1273 Boost After Ad26.Cov2.S Prime in Health Workers in South Africa: SHERPA Trial

LB

Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidihwi Takalani, Kate Anteyi, Kubashni Woeber, Ishen Seocharan, Jackline Odhiambo, Penny Moore, Wendy Burgers, Brett Leav, Linda-Gail Bekker, Glenda Gray, Ameena Goga, for the SHERPA Study Group

Poster Session-D4 | Viral Rebound

2:30 PM - 4:00 PM • Poster Hall C-D

482**NIS****The Fraction of HIV Reservoir Variants Neutralized by Autologous IgG Correlates With Time to Rebound**

Mauro A. Garcia, Junlin Zhuo, Joseph Varriale, Anna Farrell-Sherman, Jun Lai, Anthony Abeyta-Lopez, Natalie F. McMyn, Rebecca Hoh, Michael J. Peluso, Francesco R. Simonetti, Steven G. Deeks, Lillian Cohn, Robert F. Siliciano, Janet M. Siliciano

483**LB****Plasma Correlates of Rebound After Discontinuation of ART in Persons Living With HIV-1 (PLWH)**

Malika A. Boudries, Dan H. Barouch, Boris D. Juelg, Victoria E. Walker-Sperling

484**NIS****Common T-Cell Features Predicting Time to Rebound in Interventional and Non-Interventional Treatment**

Tongcui Ma, Ashley F. George, Reuben Thomas, Min-Gyoung Shin, Mauricio Montano, Satish K. Pillai, Katherine S. Pollard, Rajesh T. Gandhi, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Ole S. Søgaard, Martin Tolstrup, Warner C. Greene, Nadia R. Roan

485**NIS****Dynamics of the Intact HIV Reservoir During ART Following Analytical Treatment Interruption**

Maegan R. Manning, Jana Blazkova, Jesse S. Justement, Victoria Shi, Brooke D. Kennedy, M. A. Rai, Catherine A. Seamon, Kathleen R. Gittens, Michael C. Sneller, Susan Moir, Tae-Wook Chun

486**NIS****Immune Responses and HIV Reservoir Evolution From Pre-ART to 5 Years Into Post-Treatment Control**

Leah Carrere, Miriam Rosás-Umbert, Benjamin Bone, Giacomo S. Frattari, Isabelle Roseto, Xiaodong Lian, Martin Tolstrup, Ce Gao, Mariane H. Schleimann, Xu G. Yu, Jesper D. Gunst, Mathias Licherfeld, Ole S. Søgaard

487**NIS****Intact HIV Reservoir Levels Are Stable After Short-Term ART Interruption**

Prerana Shrestha, Autumn Kittilson, Meghan Melberg, Evgenia Aga, Ronald J. Bosch, Jintanat Ananworanich, Robert Coombs, John W. Mellors, Alan Landay, Bernard Macatangay, Steven G. Deeks, Rajesh T. Gandhi, Davey M. Smith, Jonathan Z. Li, for the AIDS Clinical Trials Group A5345 Study Team

Poster Session-D5 | HIV Reservoirs in Cells and Tissues

2:30 PM - 4:00 PM • Poster Hall C-D

488**NIS****Clonal Expansion and Driving Forces of HIV-1 Persistence in Anatomic Compartments**

Annemarie Glassey, Wenjie Wang, Lindsey Adams, Mary-Elizabeth Zipparo, Robert Gorelick, Stephen Hewitt, Sharika Rajan, Kathryn Lurain, Ramya Ramaswami, Chuen-Yen Lau, Xiaolin Wu, Sean Patro, Thuy Nguyen, Frank Maldarelli

- 489** **Impact of BACH2 on the Formation of HIV Latent Reservoirs in Humanized Mouse Model**
NIS **Hongbo Gao, Liang Shan**
- 490** **Tissue-Resident TCR Repertoires Linked to HIV Persistence**
Antoine Chaillon, Alan Wells, Ravi Goyal, Nadia R. Roan, Angela Jones, Karen Beeri, Simon Mallal, Celestine Wanjalla, Magali Porrachia, Gemma Caballero, Pinyi Du, Caroline Ignacio, Davey M. Smith, **Sara Gianella Weibel**
- 491** **Single-Cell Multiomics Reveals Trafficking and Enrichment of HIV RNA+ CD4+ T-Cells in Gut Th17**
NIS **Michelle E. Wong, Jack Collora, Timothy Davenport, Oluwabunmi Olaloye, Kenneth Lynn, Emmanouil Papasavvas, Pablo Tebas, Ricardo Morgernstern, Karam Mounzer, Liza Konnikova, Luis J. Montaner, Ya-Chi Ho**
- 492** **Intact Proviruses From Lymph Nodes Are a Preferential Source of Viral Rebound in SHIV-Infected NHP**
NIS **César A. Trifone, Corentin Richard, Amélie Pagliuzza, Christine Fennessey, Brandon Keele, Jacob D. Estes, Natasha Clark, Sanath Janaka, Andrés Finzi, David T. Evans, Nicolas Chomont**
- 493** **Minimally Invasive Autopsy Confirms HIV Persistence in Multiple Compartments Despite Prolonged cART**
Adriaan Basson, Nadia Sabet, Tanvier Omar, Melanie Moodie, Monique Nijhuis, Annemarie M. Wensing, Caroline T. Tiemessen, Francois Venter, Ebrahim Variava, Neil Martinson, **Maria A. Papathanasopoulos**
- 494** **The Extended Survival of Infected Brain Myeloid Cells Contributes to HIV Persistence During ART**
NIS **Yuyang Tang, Antoine Chaillon, Sara Gianella Weibel, Gabriela D. Prates, Xiaoyi Li, Brendon L. Brown, Eduardo de la Parra Polina, Magali Porrachia, Caroline Ignacio, Brendon Woodworth, Davey M. Smith, David M. Margolis, Guochun Jiang**
- 495** **HIV Infection and Reactivation Heterogeneity in Tonsillar and Intestinal Models of HIV Persistence**
NIS **Ana Gallego Cortes, Nerea Sanchez Gaona, Cristina Mancebo Perez, Joan Rey Cano, Oriol Ruiz i Isant, Stefania Landolfi, Felix Pumarola, Nuria Ortiz, Ines Llano, Julia G. Prado, Enrique Martín Gayo, Vicenç Falcó, Meritxell Genescà, María Buzón**
- 496** **Development of a Single-Cell Multiomic Assay to Phenotype SIV/SHIV Infected Rhesus Macaque Cells**
Jayme M. L. Nordin, Vincent H. Wu, M. Betina Pampena, Michael R. Betts
- 497** **Pure CD32+CD4+ Cells Are Cytotoxic Memory CD4+ T-Lymphocytes Highly Enriched for HIV-1 DNA**
NIS **Philipp Adams, Ben Berkhout, Alexander Pasternak**
- 498** **Persistence of HIV-RNA in Autopsy Tissue Samples From Persons With HIV With Suppressed Viral Loads**
Hiromi Imamichi, Ven Natarajan, Francesca Scrimieri, Mindy Smith, Yunden Badralmaa, Marjorie Bosche, Jack Hensien, Thomas Buerkert, Weizhong Chang, Brad Sherman, Kanal Singh, H. Clifford Lane

499**NIS****Gut Microbiome Associations With Intestinal HIV Persistence in ART-Suppressed Pediatric Macaques**

Nicole Soo, Alexander Grier, Veronica Obregon-Perko, Zain Gohar Siddiqi, Gloria Mensah, Bhrugu Yagnik, Diane G. Carnathan, Julia T. Ngo, Rama R. Amara, Genevieve G. Fouda, Guido Silvestri, Sallie Permar, Ann Chahroudi, **Ria Goswami**

500**NIS****Decreased Frequency of Colon-Resident Memory T-Cells Is Associated With HIV-1 Persistence on ART**

Camille Vellas, Nived Collercandy, Manon Nayrac, Mary Requena, Justine Latour, Nicolas Jeanne, Karl Barange, Laurent Alric, Guillaume Martin-Blondel, Jacques Izopet, Pierre Delobel

501**NIS****Monocytes/Macrophages Contribute Only Marginally to the Gut Reservoir of HIV-1 on ART**

Camille Vellas, Mary Requena, Manon Nayrac, Karl Barange, Laurent Alric, Guillaume Martin-Blondel, Jacques Izopet, Pierre Delobel

502**Non-Invasive Imaging Identifies Elevated Metabolic Activity in Lymphoid Tissue During Long-Term ART**

Chuen-Yen Lau, Jessica Earhart, Danielle Konlian, Ariana Savramis, Thuy Nguyen, Corina Millo, Avindra Nath, Robert Gorelick, Ana Ortega-Villa, Michael Kassin, Elliott Levy, Brad Wood, Dima Hammoud, Frank Maldarelli, for the NIH Biopsy and Treatment Interruption Team

Poster Session-D6 | Immune Pressure on HIV Reservoirs

2:30 PM - 4:00 PM • Poster Hall C-D

503**NIS****Inducible, Infectious HIV-1 Resistance to Autologous Neutralizing Antibodies After Long-Term ART**

Natalie F. McMyn, Joseph Varriale, Hanna Wu, Janet M. Siliciano, Robert F. Siliciano

504**NIS****Immune Selection of HIV-1 Reservoir Cells After Early ART Initiation**

Weiwei Sun, Gregory Gladkov, Ce Gao, Leah Carrere, Isabelle Roseto, Elizabeth Parsons, Carmen Gasca Capote, John Frater, Sarah Fidler, Xu G. Yu, Mathias Lichterfeld

505**NIS****Identification and Targeting of Metabolic Profiles in CTL-Resistant, HIV-Infected CD4+ T-Cells**

Alberto Herrera, Louise Leyre, Jared Weiler, Paul Zumbo, Doron Betel, R. Brad Jones

506**Immune Profile During ATI in AELIX-002 HTI Vaccine Trial and Its Role in Post-Intervention Control**

Cristina Peligero-Cruz, Lucía Bailón, Samandhy Cedeño, Tuixent Escribà, Yovaninna Alarcón-Soto, Analía López, Edwards Pradenas, Anna Pons-Grifols, Anuska Llano, Devi SenGupta, Ian McGowan, Jose Molto, Christian Brander, **Beatriz Mothe**, for the AELIX-002 Study Team

507 IL-1 β Blockade in PWH on ART Enhanced Host Antiviral Responses and Cytotoxic Effector Functions

Sulgi A. Lee, Ashish A. Sharma, Naseem Sadek, Danny Li, Ashok K. Dwivedi, Rachel L. Rutishauser, Steven G. Deeks, Rafick P. Sekaly, Priscilla Y. Hsue, **Jeffrey A. Tomalka**

508 Elevated Plasma IL-10 and Type I Interferon Predict Faster HIV Reservoir Decay in Acute Treated HIV

Lei Shi, Junzhe Shao, Sannidhi Sarvadhavabhatla, Maria Sophia B. Donaire, **Alton Barbehenn**, Rebecca Hoh, Gregory M. Laird, Frederick Hecht, Christopher Pilcher, Timothy J. Henrich, Jingshen Wang, Jeffrey A. Tomalka, Rafick P. Sekaly, Steven G. Deeks, Sulgi A. Lee

509 Labelled High Affinity TCRs for Detection of HIV Epitopes on Infected Cells: How Low Can We Go?

Zoe Wallace, Jonathan Chamberlain, Esra Guc, Praveen K. Singh, Lucy Dorrell

510 HIV T-Cell Immunity Predicts Intact Proviral DNA Decline in People Treated During Acute Infection

Pien M. van Paassen, Alexander O. Pasternak, Ninée V. Buchholtz, Karel A. van Dort, Michelle J. Klouwens, Liffert Vogt, Casper Rokx, Tokameh Mahmoudi, Cynthia Lungu, Jori Symons, Monique Nijhuis, Jan M. Prins, Neeltje Kootstra, Godelieve J. de Bree

511 Lower ADCC After 26 Weeks of PEG-IFN- α 2b and 2 bNAbs in Otherwise Suppressed HIV-1+

Emmanouil Papasavvas, Jessicamarie Morris, Brian N. Ross, Matthew Fair, Livio Azzoni, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Luis J. Montaner

512 Slope of Neutralization Curve is Best Predictor of Viral Decay Response to 3BNC117 at ART Initiation

Jesper D. Gunst, Henrik Størvring, Marie H. Pahus, Ole S. Søgaard

Poster Session-E1 | Systemic Factors in NeuroHIV

2:30 PM - 4:00 PM • Poster Hall C-D

544 Associations Between Nadir CD4+ and Subsequent Immune Measures With Long-Term Cognitive Function

Frank Palella, Janeway Granche, Douglas W. Kitch, Katherine Tassiopoulos, Susan L. Koletar

545 Predictors of CD4/CD8 T-Cell Inversion After 96 Weeks of ART Initiated During Acute HIV

Robert Paul, Kyu Cho, Carlo P. Sacdalan, Ferron F. Ocampo, Phillip Chan, Lydie Trautmann, Julie Ake, Somchai Sriplienchan, Nathornson Poltubtim, Jacob Bolzenius, Sandhya Vasan, Napapon Sailasuta, Kilian Pohl, Serena Spudich, for the RV254/SEARCH 010 Study Team

546 Assessing Blood-Based Biomarkers as Predictors of Cognitive Decline in PWH: ACTG A5322 (HAILO)

Shibani S. Mukerji, Petra Bachanova, Linzy V. Rosen, Hemi Park, Rommi Kashlan, Pia Kivisäkk, Felicia C. Chow, Kunling Wu, Raha M. Dastgheyb, Leah H. Rubin, Katherine Tassiopoulos, Robert A. Parker, Emily P. Hyle

547 CD4+ Count Predicts Longitudinal Trajectories of Central Executive Network Connectivity in PLWH

Joshua M. Schrock, Yufen Chen, Casey Armstrong, Robin Nusslock, Ann Ragin

548 Inflammation and Cognition Associations in Young Adults With Perinatal HIV Exposure and/or Infection

Megan S. McHenry, Yanling Huo, Paige L. Williams, Kunjal Patel, Wei Li, **Alka Khaitan**, Sharon Nichols, for the Pediatric HIV/AIDS Cohort Study (PHACS) Network

549 Pro-Inflammatory Glycomic Dysregulations Define HIV-Associated Neurocognitive Impairments

Leila B. Giron, Janeway Granche, Frank Palella, Katherine Tassiopoulos, Mohamed Abdel-Mohsen

550 Immune Checkpoints in the Central Nervous System and HIV-Associated Neurocognitive Disorder

Wei Li, Fahim Syed, Xiang Gao, **Qigui Yu**

551 Immune Checkpoint Signatures Associated With Impaired Cognition in People Living With HIV

Ana Joy Lozano, Christian Francisco, Marissa Alejandria, Glen Chew, Chathura Siriwardhana, Nina Gloriani, Louie Mar Gangcuangco, Robert Paul, Cecilia Shikuma, Lishomwa Ndhlovu

Poster Session-E2 | Novel Treatment Strategies and ART Effects in NeuroHIV

2:30 PM - 4:00 PM • Poster Hall C-D

552 No Neurocognitive Benefit of Tesamorelin Immediate vs Delayed Treatment in Virally Suppressed PWH

LB Ronald J. Ellis, Florin Vaida, Keren Hu, Michael Dube, Brook Henry, Felicia C. Chow, Lee Daniel, Fred R. Sattler

553 Changes in Cognition, Mood, and Sleep Following EFV-DTG Switch in South Africa: The CONNECT Study

Sam Nightingale, Anna J. Dreyer, Kevin Thomas, Gert U. van Zyl, Eric Decloedt, Pieter Naude, Catherine Orrell, Phumla Sinxadi, Alan Winston, Saye Khoo, John Joska

554 Antiretroviral Regimens Are Associated With Cognitive Function in People With HIV

NIS Luis Parra-Rodriguez, Jane A. O'Halloran, Yuezhe Wang, Wei Jin, Lang Lang, Raha M. Dastgheyb, Donald Franklin, Ronald J. Ellis, Scott L. Letendre, Qing Ma, Yanxun Xu, Leah H. Rubin

555 Phenotyping Risk of Polypharmacy and Cognitive Impairment in ACTG A5322: "HAILO"

Robert Paul, Kristine M. Erlandson, Kunling Wu, Scott L. Letendre, Jacob Bolzenius, Katherine Tassiopoulos, Kyu Cho, Qing Ma, Ronald J. Ellis, Priya Kosana, Julie Mannarino, Shellie Farhadian, for the ACTG A5322 Study Team

556 Pharmacogenetics of Early Neuropsychiatric Adverse Events After Switching to DTG in Second-Line ART

Ying Zhao, Gary Maartens, Rulan Griesel, Graeme A. Meintjes, Phumla Sinxadi

557 Long-Acting Dolutegravir Formulation Reduces Fetal Drug Exposure

Emma G. Foster, Brady Sillman, Yutong Liu, Micah Summerlin, Vikas Kumar, Balasrinivasa R. Sajja, Adam R. Cassidy, Benson Edagwa, Howard E. Gendelman, Aditya N. Bade

558 A New Measure of ART Activity in CSF and Association With Persistence and Cognitive Function

Sean N. Avedissian, Caitlyn McCarthy, Ronald J. Bosch, Ying Mu, Serena Spudich, Leah H. Rubin, Lee Winchester, Timothy Mykris, Jonathan A. Weinhold, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Rajesh T. Gandhi, Deborah K. McMahon, Courtney V. Fletcher

Poster Session-E3 | Pathogenesis of Central Nervous System Post-Acute Sequelae of COVID-19

2:30 PM - 4:00 PM • Poster Hall C-D

559 The Association Between Prior SARS-CoV-2 Infection and Incidence of Stroke

Naveed Akhtar, Hiam Chemaitelly, Saadat Kamran, Abdul-Badi Abou-Samra, Laith J. Abu-Raddad, **Adeel A. Butt**

560 Focal Cerebral Hypoperfusion in Individuals With Cognitive Impairment After COVID-19

NIS Lindsay S. McAlpine, Allison Nelson, Jennifer Chiarella, Robert Fulbright, Shelli Farhadian, Maolin Qiu, Todd Constable, Serena Spudich

561 CSF Biomarker Evidence of Synaptic Dysfunction in Acute, but Not Post-Acute COVID-19

Arvid Edén, Johanna Nilsson, Anna Grahn, Nelly Kanberg, Erika Stenroft, Daniel Bremell, Aylin Yilmaz, Marie Studahl, Staffan Nilsson, Michael Schöll, Iris Bosch, Kaj Blennow, Ann Brinkmalm, Henrik Zetterberg, Magnus Gisslén

562 SARS-CoV-2 Nucleocapsid Antigen is Not Detected in the CSF During Long COVID

Shelli Farhadian, Allison Grubman, Lindsay S. McAlpine, Bibhuprasad Das, Jennifer Chiarella, Benjamin Orlinick, Hailey Reisert, Allison Nelson, Priya Kosana, Meenakshi Khare, Serena Spudich

563 Gut Microbiome Dysbiosis and Lower Abundance of Butyrate Producing Bacteria in Neurologic PASC

Lawrence Purpura, Lingsheng Wen, Heekuk Park, Ga Young Seo, Jayesh Shah, Amanda Castillo, Anne-Catrin Uhlemann, Michael T. Yin

Poster Session-F1 | Understanding Drug-Drug Interactions and Sanctuary Site Pharmacology
2:30 PM - 4:00 PM • Poster Hall C-D

604 Implementation of an Online Drug-Drug Interaction Screener for STRIVE Ensitrelvir Trial for COVID

Josh Havens, Nayon Kang, Lucy Chung, Courtney V. Fletcher, Page Crew, Jacquie Nordwall, Birgit Grund, Marcelo Losso, Shikha Vasudeva, Adit Ginde, Jason Baker, for the INSIGHT STRIVE Ensitrelvir Study Group

605 Evidence for Safe Use of Doravirine With Hormonal Contraceptives in African Women Living With HIV

Rena Patel, Nkosi Ndlove, La-Donna Kapa, Garoma Basha, Ché K. Moshesh, Nashon Yongo, Krishnaveni Reddy, Nompuemelelo Sigcu, Nazneen Cassim, Shukri A. Hassan, David W. Erikson, Kimberly K. Scarsi, Thesla Palanee-Phillips, for the EPIC Study Team

606 Pharmacogenetics of Dolutegravir During Rifapentine/Isoniazid Treatment of Latent TB in ACTG A5372

Nia Covington, Annie Luetkemeyer, Marjorie Imperial, Rodney Dawson, Yoninah Cramer, Sue Rosenkranz, Susan Swindells, Irina Gelmanova, Anchalee Avihingsanon, Roberto C. Arduino, Wadzanai Samaneka, Kelly Dooley, Rada Savic, Anthony Podany, David W. Haas

607 Population Pharmacokinetic Approaches to Standardize Antiviral Exposure in the Cerebrospinal Fluid

Sean N. Avedissian, Ying Mu, Caitlyn McCarthy, Ronald J. Bosch, Serena Spudich, Rajesh T. Gandhi, Deborah K. McMahon, Joseph J. Eron, John W. Mellors, Courtney V. Fletcher

608 Antiretroviral Concentrations in Post-Mortem Tissues: Preliminary Results From the Last Gift Program

Micol Ferrara, Amedeo De Nicolò, Alessandra Manca, Elisa De Vivo, Sara Soloperto, Davey M. Smith, Antoine Chaillon, Magali Porrachia, Niamh Higgins, Antonio D'Avolio, Stefano Bonora, Sara Gianella Weibel

Poster Session-G1 | Treatment With Currently Available Long-Acting Antiretroviral Therapy

2:30 PM - 4:00 PM • Poster Hall C-D

620 Gendered Inclusion in Studies Evaluating Injectable HIV Treatment and PrEP: A Scoping Review

Alexa L. Elias, Isabelle Whelan, Melanie Smuk, Nuala A. Pepper, Nishat Halim, Vanessa Apea, **Chloe M. Orkin**

621 Implementing LA Cabotegravir (CAB) +Rilpivirine (RPV) Therapy in 6 UK Clinics & in the Community: ILANA

Chloe M. Orkin, Joanne S. Haviland, Yuk L. Wong, Sara Paparini, Bakita Kasadha, Rosalie Hayes, Julie Fox, Ruth Byrne, Amanda Clarke, Emily Clarke, Tristan J. Barber, Vanessa Apea, for the ILANA Study Group

- 622 Acceptability of Long-Acting Cabotegravir & Rilpivirine in a Large Urban Ambulatory HIV Clinic**
Casey M. Luc, Blake Max, Sarah Perez, Kara Herrera, Mark Dworkin
- 623 Real-World Effectiveness of Cabotegravir + Rilpivirine vs Standard of Care Oral Regimens in the US**
Ricky K. Hsu, Michael Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Brooke Levis, Gregory P. Fusco
- 624 Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine**
Lucas Hill, Jeffrey Yin, Nimish Patel, Kari Abulhosn, Elvia Suarez, Afsana Karim, Laura Bamford
- 625 Real-World Utilization of Cabotegravir + Rilpivirine in the US: Data From Trio Health Cohort**
Joseph J. Eron, Supriya Sarkar, Andrew J. Frick, Gayathri Sridhar, Leigh Ragone, Karam Mounzer, Steven Santiago, Jean Van Wyk, Richard A. Elion, Vani Vannappagari
- 626 Real-World Virologic Outcomes of Cabotegravir/Rilpivirine in Patients With Elevated Body Mass Index**
Christina Maguire, Eric Farmer, Emily Huesgen, Kaitlyn Rueve, Marisa Brizzi, Amanda Binkley, Bernice Kear, Pallavi Chary, Helen Koenig, Peter Sung, Emily Hiserodt, Karam Mounzer, Danielle Rocha, Adrian Altieri, William R. Short
- 627 HIV-1 RNA Blips and Low-Level Viral Replication: SOLAR (CAB+RPV LA vs BIC/FTC/TAF)**
Christine Latham, Rimgaile Urbaityte, Kenneth Sutton, William Spreen, Ronald D'Amico
- 628 24-Week Viral Suppression in Patients Starting Long-Acting CAB/RPV Without HIV Viral Suppression**
Matt Hickey, Janet Grochowski, Francis Mayorga-Munoz, Elizabeth Imbert, John D. Szumowski, Jon Oskarsson, Mary Shiels, Samantha Dilworth, Ayesha Appa, Diane Havlir, Monica Gandhi, Katerina Christopoulos
- 629 Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial**
Monica Gandhi, Lucas Hill, Janet Grochowski, Alexander Nelson, Katerina Christopoulos, Diane Havlir, Catherine A. Koss, Francis Mayorga-Munoz, Jon Oskarsson, John D. Szumowski, Ann Avery, Laura Bamford, Jillian Baron, William R. Short, Corrilynn O. Hileman
- 630 Lenacapavir Efficacy in CAPILLA Patients With No Fully Active Agents in Optimized Background Regimen**
Onyema Ogbuagu, Winai Ratanasawan, Anchalee Avihingsanon, Ploenchai Chetchotisakd, Andrew Wiznia, Kimberly Workowski, Chien-Ching Hung, Jason Brunetta, Benoit Trottier, Mohammed Rassool, Hui Wang, Nicolas Margot, Hadas Dvory-Sobol, Martin S. Rhee, **Sorana Segal-Maurer**
- 631 Intramuscular Injection vs Intravenous Infusion of Ibalizumab for HTE PWH: The Results of TMB-302**
Kaitlin R. Anstett, R. Brandon Cash, **Anthony Mills**, Mezgebe Berhe, Edwin DeJesus

Poster Session-G4 | Rollout of Integrase Strand Transfer Inhibitors in Low- and Middle-Income Countries
2:30 PM - 4:00 PM • Poster Hall C-D

649 48-Week Outcomes After Programmatic Transition to Dolutegravir in South Africa

Suzanne McCluskey, Gugulethu Shazi, Njabulo Dayi, Ashley Stuckwisch, Taing N. Aung, Bethany Hett-Gauthier, Vincent Marconi, Mahomed-Yunus S. Moosa, Winnie Muyindike, Deenan Pillay, Ravindra K. Gupta, Mark J. Siedner

649 Uptake of Rapid and Early ART Initiation in Latin America and the Caribbean and Associated Factors

Yanink Caro-Vega, Anna K. Person, Bryan E. Shepherd, Rodrigo Ville, Serena Koenig, Carina Cesar, Claudia P. Cortes, Beatriz Grinsztejn, Eduardo Gotuzzo, **Brenda E. Crabtree-Ramírez**

650 Bictegravir as Universal Initial Antiretroviral Therapy: A National Target Trial Emulation Study

Isaac Núñez, Yanink Caro-Vega, Conor MacDonald, Juan L. Mosqueda, **Alicia Piñeirúa-Menéndez**, Anthony Matthews

651 HIV Detectable Low-Level Viremia Suggests a Revised Threshold for Viral Suppression in Cameroon

Alex Durand Nka, Joseph Fokam, Collins Ambe Chenwi, Efakaki Gabisa Jeremiah, Yagai Bouba, Serge Clotaire Billong, Anne-Cecile Z.-K. Bissek, Hamsatou Hadja, Carlo Federico Perno, Samuel Martin Sosso, Alexis Ndjolo

652 Increased Viral Suppression With Adherence Counseling Incorporating a Point-of-Care Urine TFV Test

Leonard T. Bikinesi, Matthew A. Spinelli, Ntombizodwa M. Nyoni, Jesaya Hifindwako, Assegid Mengistu, Jacques Kamangu, Gram Mutandi, Daniella Mouton, Fekir Negussie, Rachel S. Beard, Monica Gandhi, Steven Y. Hong

Poster Session-H2 | Resistance to Specific Drugs: Lenacapavir, Tecovirimat, Dolutegravir and Cabotegravir/Rilpivirene
2:30 PM - 4:00 PM • Poster Hall C-D

681 Phenotypic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates

Sally Demirdjian, Vidula Naik, Nicolas Margot, Brie Falkard, Christian Callebaut

682 Rapid Selection of HIV-2 Capsid Mutations After Failure of a Lenacapavir-Containing Regimen

Mélanie Bertine, Gilles Peytavin, Thibault Saint-Joannis, Antoine Bachelard, Pierre de Truchis, Sylvie Lariven, Philippe Morlat, Cécile Pouderoux, Naomi Sayre, Roland Tubiana, Nadia Valin, Charlotte Charpentier, Diane Descamps, Jade Ghosn, **Quentin Le Hingrat**

683**Role of Dolutegravir in the Emergence of the S147G Integrase Resistance Mutation**

Marc Wirden, **Basma Abdi**, Sidonie Lambert-Niclot, Marie-Laure Chaix, Anne de Monte, Brigitte Montes, Coralie Pallier, Pantxika Bellecave, Magali Bouvier-Alias, Stephanie Raymond, Sabine Yerly, Charlotte Charpentier, Vincent Calvez, Anne-Genevieve Marcellin, for the French ANRS MIE Resistance Study Group

684**HIV-1 Resistance Mutations to Integrase Inhibitors Impair Both Integration and Reverse Transcription**

Pauline Ratouit, Vincent Guiraud, Isabelle Malet, Cathia Soulie, Jérôme Denis, Ronan Legrand, Elisa Teyssou, Anne-Genevieve Marcellin, **Vincent Calvez**

685**High-Level Resistance to Integrase Inhibitors Conferred by Mutations Outside Integrase**

Yuta Hikichi, Sherimay D. Ablan, Erin Clark, **Eric O. Freed**

686

LB

Virologic Failure With Cabotegravir-Rilpivirine Injections: A Single-Site Experience

Shivanjali Shankaran, Laura Hernandez-Guarin, Neel Jhobalia, Beverly Sha, **Mariam Aziz**

Poster Session-I1 | Elimination of Hepatitis C**2:30 PM - 4:00 PM • Poster Hall C-D****696**

LB

A Phase II Trial of 4 Weeks of Glecacrevir/Pibrentasvir for Early Hepatitis C Virus: ACTG A5380

Arthur Kim, Minhee Kang, Triin Umbleja, Estevao P. Nunes, Kristen Marks, Chanelle Wimbish, Daniel S. Fierer, Annie Luetkemeyer, Dimas Kleimann, Sunil Suhas Solomon, Leonard Sowah, Beverly L. Alston-Smith, David L. Wyles, Susanna Naggie, for the A5380 Study Team

697

LB

Precision Randomized Trial of Hepatitis C Treatment Adherence Support Among 3000 PWID in India

Shruti H. Mehta, Allison M. McFall, Mihili P. Gunaratne, Aylur K Srikrishnan, Jiban J. Baishya, Ashwini Kedar, Amrose Pradeep, Jayseelan Boobalan, Bryan Lau, Stephan Ehrhardt, David Thomas, Muniratnam S. Kumar, Gregory M. Lucas, Sunil Suhas Solomon

698**Prevalence and Risk Factors for Hepatitis C Viremia in People With HIV in the US During the DAA Era**

Jimmy Ma, Robin M. Nance, Edward Cachay, Stephanie A. Ruderman, Lydia N. Drumright, Rob Fredericksen, Oluwaseun Falade-Nwulia, Geetanjali Chander, Christopher Hurt, George A. Yendewa, April Pettit, Richard D. Moore, Mari Kitahata, H. Nina Kim, for the Center for AIDS Research Network of Integrated Clinical Systems

699

NIS

Elimination of HCV Among People With HIV in Australia

Joanne Carson, Marianne Martinello, Samira Hosseini-Hooshyar, Phillip Read, David A. Baker, Jeffrey Post, Robert Finlayson, Mark Bloch, Joseph Doyle, David Shaw, Margaret Hellard, Ecaterina Filep, Gregory Dore, Gail Matthews

- 700 Community Pop-Up Clinic: Cascade of Care and HCV Treatment of Vancouver's Inner-City PWID Population**
Brian Conway, Saina Beitari, Shawn Sharma, Rossitta Yung, Shana Yi
- 701 Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan**
Guan-Jhou Chen, Hsin-Yun Sun, Kuan-Yin Lin, Chien-Ching Hung
- 702 High Completion and Cure Rates With a Decentralized, Integrated HCV Treatment Approach in Vietnam**
Nhan T. Do, Nhung T. Vo, Huong T. Phan, Dung A. Tran, Thuy T. Pham, Chieu V. Vu, Linh An T. Tong, Hang T. Duong, Duy T. Nguyen, Mai T. Pham, Lisa A. Cosimi, **Todd Pollack**
- 703 High Rate of Hepatitis C Incidence in Vietnamese MSM Living With HIV**
Donn J. Colby, Minh T. Nguyen, Lan A. Do, Tam C. Le, Huu T. Tran, Binh Q. Luong, Phuong K. Doan, Khang Q. Do, Hung Van, An Bao
- 704 Cost Savings Modeling of Telehealth Services for Hepatitis C Virus Infection, Cherokee Nation**
Jorge Mera, Molly A. Feder, Jeri Sawyer, Gretchen Greene, Brigg Reilley, Ashley Wirth, David Stephens, Jessica Leston
- 705 Using County Notification Data to Characterize Recently Reported Hepatitis C Cases, Los Angeles**
Cassidy J. Hernandez-Tamayo, Lokesh Bhardwaj, Riya Shah, Chrysovalantis Stafylis, Prabhu Gounder, Mirna Ponce Jewell, Jeffrey D. Klausner, for Hepatitis C Linkage to Care Team
- 706 A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective Study in Southern Italy**
NIS Antonio Russo, Mariantonietta Pisaturo, Alessio Loredana, Stefania De Pascalis, Margherita Macera, Vincenzo Messina, Lorenzo Onorato, Carmine Minichini, Maria Stanzione, Gianfranca Stornaiuolo, Mario Starace, Caterina Monari, Caterina Sagnelli, Nicola Coppola
- 707 Hepatitis C Screening in the Emergency Department: The Multi-Center DETECT Hep C Clinical Trial**
LB Jason Haukoos, Sarah Rowan, Emily Hopkins, James Galbraith, Richard E. Rothman, Yu-Hsiang Hsieh, Stephanie Gravitz, Kevin Kamis, Carolynn Lyle, Michael S. Lyons, Douglas White, Alia Al-Tayyib, Edward Gardner, David L. Wyles, for the DETECT Hep C Screening Trial Investigators
- 708 Navigation is Superior to Clinician Referral for Linkage to HCV Care from the Emergency Department**
LB Sarah E. Rowan, Jason Haukoos, Kevin Kamis, Emily Hopkins, Matthew Minturn, David Higgins, Erika Becerra-Ashby, Carolynn Lyle, Stephanie Gravitz, Robert McGoey, Meghan Bellamy, Alia Al-Tayyib, Edward Gardner, David L. Wyles, for the DETECT Hep C Linkage-to-Care Trial Investigators
- 709 Peripartum Linkage to Care in Hepatitis C: Infant Testing and Maternal Treatment**
John Cafardi, Hong Lin, Lana Lange, Lacey Kelley, Kelly Lemon, Elisabeth Odegard, Heidi L. Meeds, Jason T. Blackard, Judith Feinberg

710 Intracellular Sofosbuvir Concentrations in Pregnant Women With Hepatitis C Virus

Catherine A. Chappell, Kristina M. Brooks, Jennifer J. Kiser, Ingrid S. Macio, Leslie A. Meyn, Kyung-min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Sharon L. Hillier

711 Transfer of Sofosbuvir/Velpatasvir Into Breast Milk

LB Catherine A. Chappell, Kristina M. Brooks, Jennifer J. Kiser, Brandon Klein, David Nerguzian, Lane Bushman, Hollis J. Laird, Ellen Stewart, Katelyn Kasula, Kyung-min Kwon, Cathleen Letterio, Bruce Kreter, Elizabeth E. Krans

712 Validation of a Point-of-Care Test Based on RT-LAMP for HCV Detection by Capillary Sampling

Sonia Arca-Lafuente, Cristina Yépez-Notario, Pablo Cea-Callejo, Violeta Lara Aguilar, Celia Crespo-Bermejo, Luz Martín-Carbonero, Ignacio De los Santos, Verónica Briz, Ricardo Madrid

713 Prevalence and Resistance Profiles of “Unusual” HCV Subtypes in Italy

Collins Ambe Chenwi, Velia Chiara Di Maio, Mohammad Al Khatib, Elisabetta Teti, Ada Bertoli, Stefania Paolucci, Nicola Coppola, Teresa Pollicino, Bianca Bruzzone, Omar El Khalili, Sohaib Khan, Massimo Puoti, Maurizio Zazzi, Francesca Ceccherini-Silberstein, for the HCV Virology Italian Resistance Network Vironet C

714 Simultaneous Start Strategy With BIC/FTC/TAF in Individuals With HIV/HCV Coinfection in China

Qing Lin, Feng Wang, Li Li, Hongmei Zhu, Yuan Yao, Jingchun He, Zheng Li, Zhenglin Wang, Qingmei Zhou, Zuwei Xia, Yiping Yang, Zehu Deng

Poster Session-I2 | Life After HCV Sustained Virologic Response

2:30 PM - 4:00 PM • Poster Hall C-D

715 Similar Mortality Among Individuals With HIV/HCV-Coinfection and HCV-Monoinfection After SVR

Anais Corma-Gomez, Jessica Martin-Carmona, Francisco Tellez, Miriam Serrano-Fuentes, Luis E. Morano, Diana Corona-Mata, Maria Jose Rios, Francisco J. Vera-Mendez, Isabel Barroso, Rosario Palacios, Ignacio de los Santos, Paloma Geijo, Juan Antonio Pineda, Juan Macias, for the GEHEP-011 Study Group

716 Direct-Acting Antivirals and Risk of Hepatocellular Carcinoma in People With HIV/HCV Coinfection

NIS Daniela K. van Santen, for the HepCAUSAL Collaboration

717 Predictors of Liver-Related Events Following DAA HCV Cure in PWH With Advanced Fibrosis/Cirrhosis

Juan Berenguer, Teresa Aldamiz-Echevarría, Víctor Hontañón, Chiara Fanciulli, Carmen Quereda, Carmen Busca, Lourdes Domínguez, Cristina Hernández, Jorge Vergas, Lucio J. García-Fraile, Marta De Miguel, Cristina Díez, José M. Bellón, Juan González-García, for the GeSIDA 10318-MARATHON Study Team

718 **NIS** **Immunophenotypic Profile Modifications After Spontaneous HCV Clearance or DAA Treatment in PWHIV**

Camille Jacqueline, Violeta Lara Aguilar, Manuel Llamas-Adán, Cristina González Díaz, **Sergio Grande-García**, Celia Crespo-Bermejo, Sonia Arca-Lafuente, Luz Martín-Carbonero, Pablo Ryan, Ignacio De los Santos, Verónica Briz, Amanda Fernández-Rodíguez

719 **NIS** **Influence of Markers Related to Biologic Aging on Liver Regeneration in HCV Patients Achieving SVR**

Alejandro González-Serna, Anais Corma-Gomez, Chiara Del Pietro, Mercedes Cano, Marta Santos, Carmen Martín-Sierra, Pilar Rincón, Juan Antonio Pineda, Luis M Real, Juan Macias

720 **HCV Reinfection After DAA Therapy in People With HIV in the Country of Georgia**

Akaki Abutidze, Nikoloz Chkhartishvili, Lali Sharvadze, Pati Gabunia, Marine Mirzashvili, Alexi Abramishvili, Shorena Dvali, Tengiz Tsartsadze

721 **Hepatitis C Reinfection Among Men Who Have Sex With Men in an Acute HIV Cohort in Thailand**

Pathariya Promsena, Ferron F. Ocampo, Carlo P. Sacdalan, Suteeraporn Pinyakorn, Nisakorn Ratnaratorn, Kultida Poltavee, Nitiya Chomchey, Somchai Sriplienchan, Nittaya Phanuphak, Sandhya Vasan, Lydie Trautmann, Donn J. Colby, for SEARCH010/RV254

722 **NIS** **Re-Infection Following a Minimal Monitoring Approach for Treatment of Hepatitis C Virus Infection**

Win Min Han, Sunil Suhas Solomon, Laura Smeaton, Sandra Wagner Cardoso, Jian Li, P.C. Parvangada, Mark Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evguenia Maiorova, David L. Wyles

723 **Impact of Healthcare Expenditure on HBV and HCV in Southern Western European Countries in 2000-2019**

Sonia Arca-Lafuente, Claudia Palladino, Rebeca Ramis, Ifeanyi J. Ezeonwumelu, Nuno Taveira, Verónica Briz

Poster Session-J1 | Cancer Pathogenesis and Natural History: Kaposi Sarcoma and General
2:30 PM - 4:00 PM • Poster Hall C-D

748 **WT1 Upregulation by Lytic Induction of Kaposi Sarcoma Herpesvirus**

Ayana E. Morales, Yun Yeong Jang, Ruby Gumenick, Ariene Ouedraogo, Shaun Hinds, Lesly Morocho, Ethel Cesarman

749 **NIS** **Saliva Kaposi Sarcoma Herpesvirus Levels as a Diagnostic Marker of Visceral Kaposi Sarcoma**

Matthew Witterholt, Tishiya Carey, Kathryn Lurain, Ralph Mangus, Anaida Widell, Irene Ekwede, Vickie Marshall, Nazzarena Labo, Kyle Moore, Wendell Miley, Romin Roshan, Elena M. Cornejo Castro, Denise Whitby, Robert Yarchoan, Ramya Ramaswami

750

Baseline KSHV T-Cell Responses Are Associated With Pre-Treatment Clinical Presentation in KS

NIS

Ralph Kamel, Minhee Kang, Carlee Moser, Richard Ambinder, Dirk Dittmer, Lara Hosey, Roy Matining, Mina Hosseinpour, Margaret Borok, Thomas Campbell, Susan E. Krown, Bernard Macatangay, Charles R. Rinaldo, for A5263/AMC066 and A5264/AMC067

751

Description of Clonal Hematopoiesis in a Hospital-Based Cohort of People Living With HIV

Manasa Bhatta, Myvizhi Esai Selvan, Daniel I. Nathan, Nikolaos Spyrou, Zeynep Gumus, Bridget Marcellino, **Keith Sigel**

752

Inflammatory Signatures Predict the Risk of Severe Non-AIDS Events, Especially Non-AIDS Cancers

Javier Martínez-Sanz, **Claudio Díaz-García**, Elena Moreno, Laura Martín-Pedraza, Laura Luna García, Juan Carlos López Bernaldo de Quirós, Jose I. Bernardino, Marta Montero, Enrique Bernal, Helena Albendín Iglesias, Santiago Moreno, Sergio Serrano-Villar, for the Cohort of the Spanish HIV/AIDS Research Network (CoRIS)

Poster Session-J4 | Other Cancers Complicating HIV Infection

2:30 PM - 4:00 PM • Poster Hall C-D

765

NIS

Contribution of HIV to the Burden of Merkel Cell Carcinoma in the US

Jacob T. Tribble, Karena Volesky-Avellaneda, Qianlai Luo, Michael Sargent, Isaac Brownell, Elizabeth Cahoon, Meredith Shiels, Ruth Pfeiffer, Adrienne Moreno, Brenda Hernandez, Eric Engels

766

NIS

Association Between HIV Infection and Survival for Head and Neck Cancers in the US From 2008-2020

Devesh S. Malgave, Ado S. Rivera, Christine Hartman, Jennifer R. Kramer, Peter Richardson, Efthalia Zafeiropoulou, Rulin Hechter, Matthew Boyer, Dong Yongquan, Lori Sakoda, Donna White, Wendy Leyden, Michael J. Silverberg, Elizabeth Y. Chiao

Poster Session-K1 | Cardiovascular Disease Biomarkers

2:30 PM - 4:00 PM • Poster Hall C-D

767

Changes in Gut Microbiota Associated With Progression of Atherosclerosis in People With HIV

Javier García-Abellán, Marta Fernández-González, Vanesa Agulló, José Alberto García, **Sergio Padilla**, Catalina Robledano, Ronald Galdamez, Leandro López, Paula Mascarell, Angela Botella, Nuria Ena, Lidia García, María José Gosalbez, Félix Gutiérrez, Mar Masiá

768

NIS

Plasma IL-1 β Predicts Incident Coronary Artery Disease and Pulmonary Embolism in PWH on ART

Sannidhi Sarvadhabhatla, Lei Shi, Junzhe Shao, Maria Sophia B. Donaire, Vivian Pae, Alton Barbehenn, Danny Li, Xiuping Chu, Colin T. Maguire, Priscilla Y. Hsue, Jingshen Wang, Rafick P. Sekaly, Brian K. Agan, Jeffrey A. Tomalka, Sulaggi A. Lee

769 Clonal Hematopoiesis in HIV and Atherosclerosis, Arterial Inflammation, and Hematopoietic Activity

Matthew S. Durstenfeld, Katherine J. Kentoffio, Alexandra J. Teng, Shady Abohashem, Danny Li, Rebecca Hoh, Steven G. Deeks, Alexander G. Bick, Ahmed A. Tawakol, Priscilla Y. Hsue

770 Activated and Exhausted CD8+ T-Cell Subsets Associate With Carotid Atherosclerotic Plaques in PLHIV

Marc Blaauw, Adriana Navas, Nadira Vadaq, Vasiliki Matzaraki, Elise M. Meeder, Wilhelm A. Vos, Albert L. Groenendijk, Louise E. van Eekeren, Gert Weijers, Marvin Berrevoets, Hans Koenen, Marien I. de Jonge, Andre J. van der Ven, Joost Rutten, Niels P. Riksen

771 Co-Occurrence of MASLD and CKD Increased Cardiovascular Incidence Among Thai HIV Population

Hay Mar Su Lwin, Tanakorn Apornpong, Win Min Han, Sivaporn Gatechompol, Siwat Thammapiwan, Porntep Amornritvanich, Stephen Kerr, Anchalee Avihingsanon

772 The Association of Mild Kidney Disease With Coronary Disease Is Stronger for People With HIV

Shradha J. Doshi, Barbra Richardson, Rashidah Nazzinda, Henry Mugerwa, Marcio Bittencourt, Geoffrey Erem, Aparna Narendrula, Carey Farquhar, Cissy Kityo, Chris T. Longenecker

773 Relating Pitavastatin Effects on Inflammatory Biomarkers to Plaque Changes in REPRIEVE

Steven Grinspoon, Michael T. Lu, Sara McCallum, Markella Zanni, Borek Foldyna, Kayla Paradis, Carl J. Fichtenbaum, Judith A. Aberg, Gerald S. Bloomfield, Carlos D. Malvestutto, Judith S. Currier, Thomas Mayrhofer, Julia Karady, Heather J. Ribaudo, Pamela S. Douglas

774 Endothelial Microvesicles: Circulating Biomarker and Mediator of Vascular Dysfunction With HIV-1

Emily I. Ostrander, Vinicius P. Garcia, Hannah K. Fndl, Auburn R. Berry, Hannah L. Cardenas, Jared J. Greiner, Brian L. Stauffer, Elizabeth Connick, Christopher DeSouza

775 Transcriptional Signatures Underlying Cardiovascular Disease in Persons Living With HIV

Laventa Obare, Heather Beasley, Xiuqi Zhang, Andrea G. Marshall, Rama D. Gangula, Yan Ru Su, Tarek Absi, Sara Gianella, Melanie R. McReynolds, Antentor O. Hinton, **Celestine Wanjalla**

776 Endothelial Dysfunction in HIV: Exploring Cytokine and Chemokine Dynamics

Celestine Wanjalla, Joey Stolze, Samuel Bailin, Mona Mashayekhi, Sheng Quanhu, Curtis L. Gabriel, Xiuqi Zhang, David G. Harrison, John Koethe

777 Elevated Triglycerides and Endothelial Vasodilator Dysfunction in Adults Living With HIV-1

Vinicius P. Garcia, Kelly A. Stockelman, Anthony R. Bain, Cynthia Firnhaber, Jared J. Greiner, Brian L. Stauffer, Elizabeth Connick, Christopher DeSouza

778 Spatial Profiling Reveals Immunometabolic Pathways Involved in Trained Immunity in PWH With CVD

Cheryl Cameron, Emily Bowman, Leah Zagore, Banumathi Tamilselvan, Brian Richardson, Thura Harfi, Susan L. Koletar, Jon Lomasney, Michael L. Freeman, Joseph Willis, Elizabeth Mayne, Michael M. Lederman, Matthew J. Feinstein, Nicholas Funderburg, **Mark Cameron**

779 IL-32 Isoforms Potentially Impact Bone and Cardiovascular Diseases in HIV Infection

Hardik Ramani, Madeleine Durand, Aurelie Cleret-Buhot, Remi Bunet, Carl Chartrand-Lefebvre, Benoit Trottier, Réjean Thomas, Jean-Pierre Routy, Claude Fortin, Valérie Martel-Laferrière, Alan Landay, Mohammad-Ali Jenabian, Mohamed El-Far, **Cécile Tremblay**

780 Myocardial Gene Profiling at Time of Sudden Death Demonstrates Increased Immune Responses in PWH

Tasha Tsao, David P. Maison, Brian H. LaFranchi, James Salazar, Arianne Caudal, Brielle Kinkead, Kosuke Nakasuka, Ellen Moffat, Andrew J. Connolly, Timothy J. Henrich, Zian H. Tseng

Poster Session-L1 | GLP-1 Receptor Agonists for Weight Loss in HIV

2:30 PM - 4:00 PM • Poster Hall C-D

797 Impact of Semaglutide on Weight Change Among People With HIV: A Stratified Analysis by Baseline BMI

Stephanie A. Ruderman, Lara Haidar, Heidi M. Crane, Robin M. Nance, Allison R. Webel, Geetanjali Chander, Bridget Whitney, Amanda Willig, Lyndsey S. Mixson, Alekhya Lavu, Laila Aboulatta, Mindy Dai, Andrew Hahn, Edward Cachay, Lydia N. Drumright, Sherif Eltonsy

798 Effects of Semaglutide on Inflammation and Immune Activation in HIV-Associated Lipohypertrophy

Allison Ross Eckard, Qian Wu, Abdus Sattar, Nicholas Funderburg, Kate Ailstock, Danielle Labbato, Grace A. McComsey

799 Effects of Semaglutide on Muscle Structure and Function in the SLIM Liver Study

Grace L. Ditzemberger, Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Raja Muthupillai, Pablo Belaunzarán-Zamudio, Todd T. Brown, Kathleen Corey, Alan Landay, Anchalee Avihingsanon, Fred R. Sattler, Kristine M. Erlandson

Poster Session-L3 | Weight Gain and Metabolism

2:30 PM - 4:00 PM • Poster Hall C-D

803 Dolutegravir Targets the Hypothalamus to Suppress Energy Expenditure via Estrogen Receptor

Ikrak Jung, Sunghee Jin, Woosub Yang, Yoonmi Cho, Becky Tu-Sekine, Frederick Anokye-Danso, In-Hyun Park, Todd T. Brown, **Sangwon F. Kim**

- 804 Weight Gain After Initiating ART Close to HIV Seroconversion: Is There a Return to Health Effect?**
Nikos Pantazis, Sophie Grabar, Marc Van der Valk, Caroline Sabin, Imma Jarrin, Laurence Meyer, Christina Carlander, John Gill, Shema Tariq, Alain Volny Anne, Fiona Burns, Elisa Ruiz-Burga, Giota Touloumi, Kholoud Porter, for the CASCADE Collaboration
- 805 Switching to Integrase Strand Transfer Inhibitors and the Risk of Diabetes in Persons With HIV**
Y. Joseph Hwang, Catherine Lesko, Todd T. Brown, Jeanne C. Keruly, LaQuita N. Snow, Jarratt D. Pytell, Oluwaseun Falade-Nwulia, Richard D. Moore, Anthony Fojo
- 806 Effect of TDF and TAF on Duodenal Enterocytes: A Hypothesis for Different Effect on Body Weight**
Kai J. Kauppinen, Nelli Sjöblom, Inka Aho, Perttu Arkkila, Jussi Sutinen
- 807 Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US**
Karam Mounzer, Laurence Brunet, Michael Sension, Ricky K. Hsu, Jennifer S. Fusco, Yohance O. Whiteside, Gregory P. Fusco
- 808 Predictors of Weight Gain in the ADVANCE, NAMSAL, and WRHI Trials: EFV, TDF, and Baseline CD4+ Count**
Andrew Hill, Bryony Simmons, Francois Venter, Alexandra Calmy, Eric Delaporte, Tamara Tovar-Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Godspower Akpomiemie, Bronwyn Bosch, Simiso Sokhela
- 809 The Relationship Between Plasma Oxylipins and InSTI-Associated Weight Gain in Women Living With HIV**
Chin-An Yang, Cyra C. Mehta, Qian Yang, Tsungirirai Maramba, Igbo Ofotokun, Kehmia Titanji, Anandi N. Sheth, Kristal M. Maner-Smith, Thomas R. Ziegler, Cecile D. Lahiri, Jessica A. Alvarez
- 810 Dolutegravir-Based Therapy, Diet, Activity, & Weight Gain: 48-Week Prospective Cohort in South Africa**
Nomathemba Chandiwana, Dessie Tien, Gugulethu Shazi, Geoffrey Chen, Smart Mabweazara, Mahomed-Yunus S. Moosa, Ravindra K. Gupta, Deenan Pillay, Vincent Marconi, Bethany Hett-Gauthier, Francois Venter, Mark J. Siedner, Suzanne McCluskey, Jennifer Manne-Goehler
- 811 Dolutegravir, Body Mass Index, and Metabolic Syndrome in the leDEA Sentinel Research Network**
Samir K. Gupta, Susan Ofner, Beverly Musick, Constantin Yiannoutsos, Gilles Wandeler, Belinda Chihota, Albert Minga, Ephram Mensah, Vidya Mave, Awachana Jiamsukul, Brenda E. Crabtree-Ramírez, Rodrigo d. Moreira, Suzanne Goodrich, Aggrey Semeere, for the Sentinel Research Network of leDEA
- 812 TDF and Efavirenz but Not InSTI or TAF Use Are Associated With Weight Gain During cART**
Henning J. Drechsler, Amneris Luque, Ikwo Oboho, John Hanna, Christopher Clark, Ngozi Enwerem, Roger Bedimo

813

Lipidome Composition and Weight Changes at 48-week 3TC-DTG and FTC/TAF/BIC: Data of the ICONA Cohort

Roberta Rovito, Valeria Bono, Camilla Tincati, Matteo Augello, Alessandro Tavelli, Alessandra Rodanò, Francesca Bai, Valentina Mazzotta, Andrea Antinori, Eugenia Quiros-Roldan, Andrea Giacomelli, Giovanni Guaraldi, Antonella D'Arminio Monforte, Giulia Marchetti, for the ICONA Foundation Study Group

814

Phase 4 DEFINE Switch Study to Manage InSTI-related Weight Gain: Metabolics and Biomarker Analysis

Johnnie Lee, **David Anderson**, Nina Ahmad, Richard B. Simonson, Ping Xu, Briana Journée, Tien-huei Hsu

815

Weight Gain in People With HIV (PWH) vs People Without HIV (PWoh) Over a 3-Year Period

Richard A. Elion, Joshua Gruber, Janna Radtchenko, Paul E. Sax, Megan Dunbar, Joseph J. Eron, Calvin Cohen, Gregory Huhn, Keri N. Althoff, Grace A. McComsey

816

Effect of Obesity on Response to Antiretroviral Therapy in SIV-Infected Rhesus Macaques

Kristin Sauter, Diana Takahashi, Melissa A. Kirigiti, Sarah R. Lindsley, Hannah Blomenkamp, Heather Hofmeister, Gabriela Webb, Oleg Varlamov, Jonah Sacha, Charles Roberts, Paul Kievit

Poster Session-L6 | Pulmonary and Sleep Complications

2:30 PM - 4:00 PM • Poster Hall C-D

825

Sleep Apnea in People With and Without HIV in Primary Care

Jennifer O. Lam, Craig E. Hou, Stacey Alexeef, Tory Levine, Varada Sarovar, Verena E. Metz, Michael A. Horberg, Derek D. Satre, Michael J. Silverberg

826

Outcome of a Multidimensional Intervention for Insomnia in a Cohort of People Living With HIV

Maria Mazzitelli, Mattia Trunfio, Lolita Sasset, Davide Leoni, Vincenzo Scaglione, Mauro Marini, Gianluca Gasparini, Angela Favaro, Annamaria Cattelan

827

Protease Activity in the Lung in HIV-Associated Obstructive Lung Disease (OLD)

Chris Wendt, Sarah Samorodnitsky, Monica Kruk, Eric Lock, Alison Morris, Janice Leung, Danielle Weise, Laurie Parker, Pratik Jagtap, Timothy Griffin, Ken Kunisaki

Poster Session-M1 | Post-Acute COVID-19 Syndrome: Predictors, Associations, and Clinical Manifestations

2:30 PM - 4:00 PM • Poster Hall C-D

844

Effects of HIV Status on Incidence of Post-COVID Conditions in Patients With SARS-CoV-2 (COVID-19)

Michael A. Horberg, Celeena R. Jefferson, Eric S. Watson, Lily F. Fathi, Seohyun S. Kim, Kelly A. Gebo, Brenna Hogan, Elizabeth Humes, Keri N. Althoff

845 Evaluating the Effect of Vaccination on Post-COVID Conditions Among Patients With and Without HIV

Michael A. Horberg, Eric S. Watson, Celeena R. Jefferson, Lily F. Fathi, Seohyun S. Kim, Kelly A. Gebo, Brenna Hogan, Elizabeth Humes, Keri N. Althoff

846 Post-Acute Sequelae of COVID-19 in an Early-Treated HIV Cohort in Thailand

Ferron F. Ocampo, Tyler Hamby, Carlo P. Sacdalan, Pasiri Sithinamsuwan, Suteeraporn Pinyakorn, Varaporn Unsombut, Somchai Sriplienchan, Nittaya Phanuphak, Robert Paul, Phillip Chan, Sandhya Vasan, Lydie Trautmann, Serena Spudich, for RV254/SEARCH010

847 Post-COVID Conditions Following COVID-19 Vaccination: A Matched Analysis of Patients With SARS-CoV-2

Deborah E. Malden, In-Lu Amy Liu, Lei Qian, Lina S. Sy, Bruno J. Lewin, Dawn T. Asamura, Denison S. Ryan, Cassandra Bezi, Sharon Saydah, Sara Y. Tartof, for the Vaccine Safety Datalink Team

848 Long COVID Between People With and Without HIV: A Statewide Cohort Analysis

Xueying Yang, Ziang Liu, Jiajia Zhang, Bankole Olatosi, Sharon Weissman, Xiaoming Li

849 COVID-19 Vaccine Protection Against Long COVID: A Population-Based Cohort Study

Xueying Yang, Ziang Liu, Jiajia Zhang, Bankole Olatosi, Sharon Weissman, Xiaoming Li

850 Sexual Minority Adults Experienced More Severe and Longer COVID-19 Symptoms Than Heterosexual Adults

NIS Xinyi Li, Jincong Q. Freeman, Yijin Xiang, Yong G. Lee, Victoria Umutoni

851 Persistence of Anxiety and Depression in US Adults by COVID-19 Vaccination Status, 2020-2023

Yanhan Shen, Kate Penrose, McKaylee Robertson, Rachael Piltch-Loeb, Sasha Fleary, Sarah Kulkarni, Chloe Teasdale, William You, Subha Balasubramanian, Surabhi Yadav, Bai Xi Jasmine Chan, Milton L. Wainberg, Scott Ratzan, Denis Nash, Angela Parcesepe

852 Predictors of Long COVID in Adults With Untreated Mild-To-Moderate COVID-19

Teresa H. Evering, Pooja T. Saha, Carlee Moser, Nikolaus Jilg, Rachel A. Bender Ignacio, Prasanna Jagannathan, Katya Corado, Kevin Wongsodirdjo, Justin Ritz, Jonathan Z. Li, Davey M. Smith, Michael D. Hughes, Judith S. Currier, Kara W. Chew, for the ACTIV-2/A5401 Study Team

853 Long COVID in Children Is Associated With Lower Anti-RBD IgG/IgA and Neutralizing Antibody Levels

NIS Jon Izquierdo-Pujol, Sara Morón-López, Núria Pedreño, Tetyana Pidkova, Victor Urrea, Judith Dalmau, Alba Gonzalez-Aumatell, Clara Carreras-Abad, Maria Mendez, Carlos Rodrigo, Julià Blanco, Jorge Carrillo, Benjamin Trinité, Javier Martínez-Picado

854**NIS**

Characterization of Circulating Biomarkers Levels in Participants With Long COVID

Ninon Marmont, Alejandro Garcia Leon, Grace Kenny, Colette Gaillard, Eoghan de Barra, Eoin Feeney, Stefano Savinelli, Mary Horgan, Obada Yousif, Aoife G. Cotter, Patrick Mallon

855

Relationship Between Serum Cortisol Level and Long COVID Symptoms in Post-Acute COVID-19

Thomas Dalhuisen, Joshua Hauser, Scott Lu, Lucas Kallás Silva, Rebecca Hoh, Steven G. Deeks, J. D. Kelly, Jeffrey Martin, Peter W. Hunt, Elizabeth Murphy, Timothy J. Henrich, Morrie Schambelan, Michael J. Peluso, for the LIINC Study Team

856

Association of Long COVID With Health-Related Quality-of-Life Outcomes

Malini M. Gandhi, Carlee Moser, Judith S. Currier, Justin Ritz, Joseph J. Eron, Eric Daar, David Wohl, William Fischer, Upinder Singh, Michael D. Hughes, Davey M. Smith, Teresa H. Evering, Kara W. Chew, for the ACTIV-2/A5401 Study Team

Poster Session-N1 | Pharmacologic and Other Programmatic Insights in Tuberculosis and Cryptococcal Meningitis

2:30 PM - 4:00 PM • Poster Hall C-D

869

Estimating Optimal Anti-TB Drug Concentrations in a Prospective, Observational Cohort in Brazil

Gustavo Amorim, David W. Haas, Marina C. Figueiredo, Cody Staats, Marcelo Cordeiro-Santos, Afrânio L. Kritski, Brian C. Hachey, Bruno B. Andrade, Timothy R. Sterling, Valeria C. Rolla, for the RePORT-Brazil Consortia

870

Pharmacogenetic Associations With HIV-1 Virologic Suppression Among Patients with TB/HIV in Brazil

Felipe Ridolfi, Gustavo Amorim, David W. Haas, Maria B. Arriaga, Cody Staats, Marcelo Cordeiro-Santos, Afrânio L. Kritski, Marina C. Figueiredo, Bruno B. Andrade, Timothy R. Sterling, Valeria C. Rolla

871

Pharmacokinetics of Isoniazid Metabolites During Pregnancy and Postpartum

Brandon Klein, Zixuan Wei, David Nerguzian, Amita Gupta, Adriana Weinberg, Grace Montepiedra, Mary Morrow, Samantha MaWhinney, Philippa Musoke, Linda Aupribul, Gaerolwe Masheto, Farah Abdelmawla, Lane Bushman, Peter L. Anderson, Kristina M. Brooks

872**LB**

Testicular Safety of a Pretomanid Regimen (BPaMZ) in Men With Pulmonary Drug-Resistant Tuberculosis

Pauline Howell, Francesca Conradie, William Brumskine, Lali Mikashvili, Joanna Moreira, Antonio Lombardi, Alda Holsta, Matthew Betteridge, Paul Bruinenberg, Maria Beumont, Eugene Sun

873

Cardiac Involvement in Tuberculosis Patients at the Start and End of Treatment in Southern Africa

Daryoush Samim, Guy Muula, Douglas Chibomba, Sihle Xulu, Nicolas Banholzer, Stefano De Marchi, Gunar Günther, Denise Evans, Carolyn Bolton, **Matthias Egger**, Thomas Pilgrim, Lukas Fenner, for leDEA Southern Africa (leDEA-SA)

874 Efficacy and Safety of endTB Regimens for Fluoroquinolone-Susceptible RR-TB in People With HIV

Gustavo E. Velásquez, M. Gouillou, E. Berikova, M. Bonnet, N. Lachenal, L. Lecca, L. Oyewusi, Michael L. Rich, Naseem Salahuddin, Kwonjune J. Seung, Sean Wasserman, Francis Varaine, Lorenzo Guglielmetti, Carole D. Mitnick, for the endTB Clinical Trial Group

875 Changes in Physical and Mental Health Among TB Patients During Treatment in Southern Africa

Nicolas Banholzer, Guy Muula, Denise Evans, Jacqueline Huwa, Idiovino Rafael, Cordelia Kunzekwenyika, Ballif Marie Ballif, Gunar Günther, Matthias Egger, Lukas Fenner, for leDEA Southern Africa (leDEA-SA)

876 NIS Cryptococcal Meningitis as an Indicator for Monitoring HIV Treatment Program Success in Botswana

James Milburn, Ookeditse Ntwayagae, Rachita Suresh, Kebatshabile Ngoni, Tony Chebani, Tshepo B. Leeme, David S. Lawrence, Daniel Grint, Mark W. Tenforde, Ava Avalos, Dinah Ramaabya, Justus Ogando, Margaret Mokomane, Madisa Mine, Joseph N. Jarvis

Poster Session-N2 | Issues in Tuberculosis Preventive Therapy

2:30 PM - 4:00 PM • Poster Hall C-D

877 Effect of Smoking on Longitudinal Interferon- γ Release Assay Results Among Tuberculosis Contacts

Maria B. Arriaga, Gustavo Amorim

878 Viral Suppression Among Adults Receiving Dolutegravir-Based ART and 3-Months Isoniazid-Rifapentine

Lelia H. Chaisson, Shafic Makumbi, David Dowdy, Carina Marquez, Derek T. Armstrong, Bishop Opira, Patrick P. Phillips, Fred C. Semitala, Christina Yoon

879 NIS Outcomes of Adults With HIV Receiving TB Preventive Therapy in Kampala, Uganda

Elise Dressel, Fred C. Semitala, Shafic Makumbi, Bishop Opira, Patrick P. Phillips, David Dowdy, Lelia H. Chaisson, Christina Yoon

880 Long-Acting Injectable Rifapentine With Activity in a Mouse Model of Tuberculosis Preventive Therapy

Henry Pertinez, Nicole C. Ammerman, Si Yang Li, Jonathan Massam, James J. Hobson, Alison C. Savage, Joanne Sharp, Joanne Herriott, Edtya Kijak, Eduardo Gallardo-Toledo, Megan Neary, Steve Rannard, Susan Swindells, Andrew Owen, Eric Nuermberger

881 LB One-Dose Efficacy of Long-Acting Injectable Diarylquinoline in Mouse Model of TB Preventive Therapy

James J. Hobson, Si Yang Li, Nicole C. Ammerman, Jonathan Massam, Joanne Sharp, Nader Fotouhi, Steve Rannard, Andrew Owen, **Eric Nuermberger**

Poster Session-N3 | Immunologic Risk and Immune Activation in Tuberculosis and Other Opportunistic Infections
2:30 PM - 4:00 PM • Poster Hall C-D

882 **NIS** **Single Cell Transcriptomics Reveals Depletion of TB-Specific Th1 and Th17 Cells After HIV Infection**

Rachel A. Pearson, Krista N. Krish, Wendy Whatney, Walter Jaoko, Kishor Mandaliya, Julie Overbaugh, Susan M. Graham, R. Scott McClelland, Sakeenah Hicks, Jeffrey Maurer, Christopher D. Scharer, Cheryl L. Day

883 **Monocyte Activation in Persons With HIV and Latent TB Co-Infection in the ACTG A5279/BRIEF TB Trial**

Moises A. Huaman, Manuel G. Feria Garzon, Ashley McKhann, Xinyu Du, Khuanchai Supparatpinyo, Claire A. Chougnat, Michelle A. Kendall, Frederick K. Sawe, Kristine M. Erlandson, Netanya S. Utay, Michael M. Lederman, Susan Swindells, Amita Gupta, Richard E. Chaisson, Carl J. Fichtenbaum

884 **Persistence of PD-1+ Mtb-Specific CD4+ T Cells Is Associated With CAD During and After TB Treatment**

Manuel G. Feria Garzon, Eduardo Ticona, Cecilia Chang, Wendy Guevara, Anissa Moussa, Alberto La Rosa, Javier R. Lama, Claire A. Chougnat, **Moises A. Huaman**

Poster Session-04 | Maternal Mental Health and HIV
2:30 PM - 4:00 PM • Poster Hall C-D

920 **A Multicomponent Intervention Improves Disclosure and ART Adherence for Pregnant/Postpartum Women**

Jane Kabami, Laura B. Balzer, Faith Kagoya, Jaffer Okiring, Joanita Nangendo, Emmanuel Ruhamyankaka, Peter Ssebutinde, Elizabeth Arinitwe, Michael Ayebare, Stella Kabageni, Anne R. Katahoire, Moses R. Kamya, Philippa Musoke, for the ENHANCED-SPS Study Team

921 **High Prevalence of Depression and Anxiety in Women Without HIV and Women With HIV on DTG-ART**

Kebaiphe Moabi, Gloria K. Mayondi, Allison LeMahieu, Paige L. Williams, Naledi Kamanga, Ame Diphoko, Kathleen M. Powis, Gaerolwe Masheto, Dinah Ramaabya, Francis Banda, Alexander C. Tsai, Betsy Kammerer, Adam R. Cassidy, Shahin Lockman

922 **NIS** **Dolutegravir Versus Efavirenz: Depression, Anxiety, and Sleep Disorders in Pregnancy and Postpartum**

Lena van der Wekken-Pas, Sylvia Nassiwa, Thokozile R. Malaba, Mohammed Lamorde, Landon Myer, Catriona Waitt, Helen Reynolds, Saye Khoo, Nengjie He, Elisabeth van Leeuwen, Duolao Wang, David Burger, Angela Colbers, for the DolPHIN-2 Study Group

923 **NIS** **Maternal Mental Health and Referral Outcomes Among Women Living With and Without HIV in Botswana**

Queen M. Balina, Sara R. Schenkel, Gosego Masasa, Samuel W. Kgole, Boitshepo Phale, Martha Ngwaca, Kathleen M. Powis

Poster Session-05 | Understanding Breastmilk, HIV, and Antiretrovirals

2:30 PM - 4:00 PM • Poster Hall C-D

924 Metabolomic Perturbations of Tryptophan & Arginine Metabolites in the Breast Milk of Women With HIV**Nicole H. Tobin**, Fan Li, Kathie G. Ferbas, John W. Slesman, Louise Kuhn, Grace M. Aldrovandi**925 Breast Milk Transfer and Infant Exposures to DTG, TAF, and TDF: Results From IMPAACT 2010/VESTED****Tk Nguyen**, Jung-Woo Chae, Lauren Ziemba, Anne Coletti, Kevin Knowles, Benjamin Johnston, Patrick Jean-Philippe, Tsungai Mhembere, Tariro Chawana, Deo Wabwire, Violet Korutaro, Shahin Lockman, Lameck Chinula, Jeremiah Momper, for the IMPAACT 2010/VESTED Protocol Team**926 1077BF: Breast Milk Reservoir, Tenofovir Levels, and HIV Transmission Among Breastfeeding Mothers****Maxensia Owor**, Patricia DeMarrais, Kristin Baltrusaitis, Lisa Frenkel, Brookie Best, Lynda Stranix-Chibanda, Dhayendre Moodley, Avy Violari, Brenda Kakayi, Mary G. Fowler, for the PROMISE 1077 Study Team**927 Could This Be Cell-Associated Perinatal HIV Transmission?****NIS Beatrice Cockbain**, Caroline Foster, Paula Seery, David Hawkins, Marta Boffito, Graham P. Taylor, Hermione Lyall**Poster Session-P3 | Exploring the Pediatric Reservoir**

2:30 PM - 4:00 PM • Poster Hall C-D

951 Expanded Cytotoxic T-Lymphocytes and NK Cell Subsets in Infants With Perinatal HIV**NIS Akshay Iyer**, Lesley de Armas, Vinh B. Dinh, Rajendra Pahwa, Suresh Pallikkuth, Paula Vaz, Maria Grazia Lain, Savita Pahwa**952 Distinct Populations of HIV-Infected Naive and Memory CD4+ T-Cell Clones in Children on ART****Victoria Neer**, Mary Grace Katusiime, Shuang Guo, Sean Patro, Wenjie Wang, Xiaolin Wu, Anna Horner, Ann Chahroudi, Jason W. Rausch, Maud Mavigner, Mary F. Kearney**953 Persistent Viremia With vpr/tat-Deleted HIV and No T-Cell Responses to HLA-Predicted HIV Peptides****Alyssa R. Oldroyd**, Mariam Aziz, Sheila Styrvak, Lennie Chen, Wenjie Deng, Melanie Gasper, Marley Bishop, Cooper James, Madelyn Shapiro, Ewelina Kosmider, Judith A. Guzman-Cottrill, Farah Cassis-Ghavami, James Mullins, Lisa Frenkel, Ana Gervassi

954

NIS

Proviral Landscape in Neonates With In Utero HIV-1 on Very Early ART in IMPAACT P1115

Soumia Bekka, Priya R. Khetan, Yufeng Liu, Adit Dhummakupt, Bryan S. Nelson, Camlin Tierney, Ellen G. Chadwick, Jennifer Jao, Yvonne Bryson, Anne Coletti, Nicol Nicodimus, Lynda Stranix-Chibanda, Guinevere Q. Lee, Stuart Ray, Deborah Persaud

955

CMV Coinfection Drives T-Cell Differentiation but Not Reservoir Size Among Children With HIV

Yves Fougère, Jason Brophy, Ari Bitnun, Michael T. Hawkes, Lindy Samson, Mi-Suk Kang Dufour, Christian Renaud, Stanley Read, Hinatea K. Dieumegard, Madeleine Aby Diallo, Jade Canape, Soren Gantt, Hugo Soudeyns, **Fatima Kakkar**

956

NIS

Reservoir Size and Dynamics by Age at Virologic Suppression and Sex in Youth With Perinatal HIV-1

Priya R. Khetan, Wendy Yu, Kunjal Patel, Joseph Szewczyk, Adit Dhummakupt, Sandra Burchett, Russell Van Dyke, Deborah Persaud, for the Pediatric HIV/AIDS Cohort Study (PHACS)

957

NIS

Latency Reversal Effects of TLR7 Agonist and HDACi in Long-Standing Perinatal HIV-1 Infection

Kristen E. Kelly, Adit Dhummakupt, Joseph Szewczyk, Weiqiang Zhou, Hongkai Ji, Ya Hui Chen, Thuy Anderson, Elise T. Ohene-Kyei, Allison Agwu, Deborah Persaud

958

Predictive Markers for Sustained Viral Suppression on Dual bNAbs During ART Interruption in Children

Jaspreet Banga, Bryan S. Nelson, Gbolahan Ajibola, Terence Mohammed, Nyaladzi Maphorisa, Oganne Batlang, Maureen Sakoi-Mosethi, Molly Pretorius Holme, Kathleen M. Powis, Shahin Lockman, Michael D. Hughes, Joseph M. Makhema, Daniel R. Kuritzkes, Mathias Lichtenfeld, Roger Shapiro

Poster Session-Q1 | Hazards Ahead: The Intersection of HIV and Substance Use

2:30 PM - 4:00 PM • Poster Hall C-D

995

Prescription Opioid Use and Disorder Among Older Adults With HIV in the US From 2008-2019

Stephanie Shiau, Fabrizio Drago, Kylie Getz, Greta Bushnell, Hillary Samples, Alexis Bender, Laura Bennett, Perry N. Halkitis, Tobias Gerhard, Jason A. Roy, Silvia S. Martins, Michael T. Yin, Stephen Crystal

996

The Impact of the COVID-19 Pandemic on Substance Use Disorder Risk Among People With HIV in the US

Jennifer P. Jain, Nadra E. Lisha, Carlos Moreira, David V. Glidden, Greer Burkholder, Heidi M. Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard D. Moore, Mallory Johnson, Katerina Christopoulos, Monica Gandhi, **Matthew A. Spinelli**

997

The Opioid Use Disorder Care Cascade for PWH Experiencing Homelessness in Low-Barrier HIV Care

Ayesha Appa, Gabriela Steiner, Matt Hickey, Elizabeth Imbert, Caycee Cullen, John Friend, Rodrigo Avila, Joi Jackson, Pierre-Cedric Crouch, Jon Oskarsson, Francis Mayorga-Munoz, Janet Grochowski, Monica Gandhi

- 998 Validation of a Cumulative Substance Use Biomarker Improves Methamphetamine Use Detection in PWH**
Ayesha Appa, Marjan Javanbakht, Rachel Bolanos, Hideaki Okochi, Karen Kuncze, Alexander Louie, Matthew A. Spinelli, Pamina Gorbach, Monica Gandhi
- 999 Trends and Correlates of Methamphetamine Use Among Men Who Have Sex With Men in the US, 2014-2021**
NIS
Michael P. Barry, Benjamin Meana, Sara N. Glick, David Katz, Travis H. Sanchez, Matthew Golden, Steven M. Goodreau
- 1000 Association Between Substance Use Disorder and Sustained Viral Suppression Among People With HIV**
Buwei He, Shujie Chen, Jiajia Zhang, Xueying Yang, Bankole Olatosi, Sharon Weissman, Xiaoming Li
- 1001 Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis**
Amanda P. Miller, Rhoda K. Wanyenze, Rose Naigino, Michael Ediau, Seth C. Kalichman, Nicolas A. Menzies, Mose H. Bateganya, Susan M. Kiene
- 1002 Biomarker Measure Strengthens Alcohol Use Association With HIV Viral Non-Suppression in PWH on ART**
Cristina Espinosa da Silva, Robin Fatch, Winnie Muyindike, Evgeny Krupitsky, Nneka Emenyonu, Sarah Puryear, Aaron Scheffler, Kaku So-Armah, Gabriel Chamie, Brian Beesiga, Kara Marson, Frank Palella, Phyllis Tien, Judith Hahn, for the MACS WIHS Combined Cohort Study / Intl URBAN Alcohol Research Collaboration on HIV/AIDS Center
- 1003 Associations of Alcohol Consumption With Long-Term Mortality of ART-Naive Persons Seeking HIV Care**
Daniel Fuster, Paola Zuluaga, Enric Abelli-Deulofeu, Laura Bermejo, Santiago Moreno, Lucio J. García-Fraile, Jose Antonio Iribarren, Cristina Moreno, Ines Suarez-Garcia, David Vinuesa, Vicente Estrada, Julian Olalla-Sierra, Juan Macias, Inma Jarrin, Robert Muga
- 1004 Pre-Pandemic Patterns of Cannabis Use Among Women With HIV in the United States**
Richard J. Wang, Brooke Bullington, Phyllis Tien, Bhatt Surya, M. Bradley Drummond, Gypsyamber D'Souza, Robert Foronjy, Antonina Foster, Deepa Lazarous, Anjali Sharma, Kathleen Weber, Deborah Jones Weiss, Danielle F. Haley, **Andrew Edmonds**
- 1005 Incarceration, Drug Use, and HIV: Optimizing Services for Women Who Use Drugs in Tanzania**
NIS
Kaitlyn Atkins, Haneefa T. Saleem
- 1006 Differences in Healthcare Access Among Persons Who Inject Drugs by Medicaid Expansion Policy, 2022**
Amy R. Baugher, **Rashunda Lewis**, Larshie Sutter, Maya Haynes, Cyprian Wejnert
- 1007 Unmet Need for Medication for Opioid Use Disorder Before and After the COVID-19 Pandemic**
Jacklynn De Leon, Anna Teplinskaya, Dafna Kanny, Senad Handanagic, Dita Broz, Teresa Finlayson, Cyprian Wejnert, for the NHBS Study Group

1008 HIV Prevention Service Use Among PWID in Washington, DC, Pre- and Post-COVID Pandemic Eras
NIS

Xinyi Li, Sydney Bornstein, Manya Magnus, Kate Drezner, Brittani Saafir-Callaway, Alan Greenberg, Hannah Latif, Irene Kuo

1009 Changes in HIV PrEP Awareness and Use Among PWID in 19 US Cities, 2018 and 2022

Johanna Chapin-Bardales, Dita Broz, Patrick Eustaquio, Jonathan Feelemyer, Teresa Finlayson, Savannah Harris, Cyprian Wejnert, for the NHBS Study Group

1010 Changes in PrEP Awareness Among Men Who Have Sex With Men and PWID: 19 US Cities, 2018 and 2022
NIS

Patrick Eustaquio, Janet Burnett, Ruthanne Marcus, Joseph Prejean, Johanna Chapin-Bardales, Susan Cha, for the National HIV Behavioral Surveillance Study Group

Poster Session-Q2 | HIV Transmission Among People Who Use Drugs

2:30 PM - 4:00 PM • Poster Hall C-D

1011 RDS Network Size Among People Who Inject Drugs in Kenya as a Predictor of HIV and HCV Positivity

Matthew Akiyama, Amirhossein Alvandi, Krista Gile, Yun Jiang, Lindsey Riback, Mercy Nyaokowa, Jebet Boit, Rose Wafula, Nazila Ganatra

1012 HIV Incidence & Changes in Network Structure Among PWID in New Delhi Following the COVID-19 Pandemic

Steven J. Clipman, Shruti Mehta, Aylur K Srikrishnan, Katie Zook, Shobha Mohapatra, Munirathnam S. Kumar, Gregory M. Lucas, Carl Latkin, Sunil Suhas Solomon

1013 Spatial Clustering of HIV Viremia Among People Who Inject Drugs (PWID) in India

Talia A. Loeb, Allison M. McFall, Michael R. Desjardins, Jiban J. Baishya, Ashwini Kedar, Archit Sinha, Aylur K Srikrishnan, Sunil Suhas Solomon, Gregory M. Lucas, Shruti H. Mehta

1014 HIV-1 Transmission Dynamics Among People Who Inject Drugs on the US/Mexico Border Amid COVID-19

Britt Skaathun, Steffanie Strathdee, Cho-Hee Shrader, Carrie Nacht, Annick Borquez, Irina Artamonova, Alicia Harvey-Vera, Carlos Vera, Gudelia Rangel, Caroline Ignacio, Brendon Woodworth, Antoine Chaillon, Tetyana Vasylyeva

1015 HIV-1 Outbreak Among PWID in Thessaloniki: Recent Expansion in the Midst of COVID-19 Pandemic
NIS

Evangelia G. Kostaki, F. Chatzopoulou, S. Roussos, E. Tsirogianni, M. Psichogiou, I. Goulis, L. Skoura, S. Metallidis, C. Tsiora, G. Magiorkinis, A. Beloukas, A. Hatzakis, V. Sypsa, D. Chatzidimitriou, D. Paraskevis

Poster Session-R2 | Partner Network Testing

2:30 PM - 4:00 PM • Poster Hall C-D

1093 HIV Outcomes Among Partners Reached by Phone vs In-Person for Assisted Partner Services in Kenya

Unmesha Roy Paladhi, Edward Kariithi, George Otieno, James P. Hughes, Harison Lagat, Monisha Sharma, Sarah Masyuko, Paul Macharia, Rose Bosire, Mary Mugambi, Carey Farquhar, David Katz

1094 Social Network Strategy for HIV Testing and Prevention in General Population, Nairobi County, Kenya

Javies N. Joel, Rebecca Wangusi, Jonathan Mwangi, Patrick Awuor, Emmah Momanyi, Robert Mulwa, Caroline Muthamia, Bernard Odhiambo, Joseph Mwangi, Antony Kiplagat, Sam Wafula, Immaculate Mutisya, Emily Koech

1095 Community Network Driven COVID-19 Testing of Vulnerable Populations in the Central US: A RADx-UP RCT

En-Ling Wu, Xiaoquan Zhao, Makenna Meyer, Ellen Almirol, Gjvar Payne, Kavita Bhavan, Nickolas Zaller, Jerome Montgomery, Anna Hotton, Russell Brewer, Michelle Johns, Matthew Aalsma, Amelia Knopf, Faye Taxman, John Schneider, for the C3 Investigators

1096 Targeting Key Populations With HIV Testing Services in Emergency Care in Nairobi, Kenya

Joshua Smith-Sreen, Beatrice Ngila, John W. Maina, Sankei Pirirei, John Kinuthia, David Bukusi, Harriet Waweru, Rose Bosire, Daniel Ojuka, David Katz, Carey Farquhar, Michael Mello, Adam Aluisio

Poster Session-S1 | Long-Acting Injectable PrEP: Implementation and Clinical Insights

2:30 PM - 4:00 PM • Poster Hall C-D

1107 First Case of HIV Seroconversion With Emergence of InSTI Resistance on CAB-LA PrEP in Routine Care

Catherine A. Koss, Monica Gandhi, Elias K. Halvas, Hideaki Okochi, Carolyn Chu, David V. Glidden, Lisa Georgetti Gomez, Amy L. Heaps, Amy A. Conroy, Michael Tran, Bhavna Chohan, James Ayieko, John W. Mellors, Urvi M. Parikh, for SeroPrEP Study Team

1108 Implementing Long-Acting Cabotegravir for HIV Preexposure Prophylaxis in a Large Urban HIV Clinic

Christian Turner, Gabriel Wagner, Allan Pfeil, Aaron Willcott, Tyler Lonergan, Lucas Hill, Jill Blumenthal

1109 Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort

Anthony Mills, Laurence Brunet, Karam Mounzer, Michael B. Wohlfeiler, Kevin R. Frost, Ricky K. Hsu, Gerald Pierone, Michael Sensen, Philip C. Lackey, Jennifer S. Fusco, Carolyn Brown, Vani Vannappagari, Michael Aboud, Piotr Budnik, Gregory P. Fusco

1110 Real-World Use of Cabotegravir Long-Acting for Preexposure Prophylaxis: Trio Health Cohort

Kenneth H. Mayer, Andrew J. Frick, Carolyn Brown, Gayathri Sridhar, Leigh Ragone, Jean Van Wyk, Anthony Mills, Steven Santiago, Richard A. Elion, Vani Vannappagari

Poster Session-S4 | Nonoccupational Postexposure Prophylaxis: Everything Old is New Again: How, Who, Do's, and Don'ts
2:30 PM - 4:00 PM • Poster Hall C-D

1130 A Matter of Time: Factors Associated With Delayed nPEP Initiation

NIS

Nicholas Brian Bana, Massimo Puoti, Chiara Baiguera, Alessandro Raimondi, Leonardo Rezzonico, Francesco Peracchi, Cristina Moioli, Leonardo Chianura, Giovanna Travi, Carloandrea Orcese, Fulvio Crippa, Carlotta Rogati, Marta Vecchi, Marco Merli, Roberto Rossotti

1131 HIV Post-Exposure Prophylaxis Prescription Trends: United States, 2013-2022

Mary R. Tanner, Wei Wei, Weiming Zhu, Ya-Lin A. Huang, Jesse G. O'Shea, Athena Kourtis, Karen W. Hoover

1132 Efficacy of Long-Acting Cabotegravir and Rilpivirine for PEP in a Macaque Model of RT SHIV Infection

Priya Srinivasan, Jining Zhang, Tiancheng Edwards, Chuong Dinh, Ayanna Green, Dawn Little, Maria Mendoza, Yi Pan, Frank Deyounks, Ryan Johnson, Athena Kourtis, Walid Heneine, Gerardo Garcia-Lerma, James Smith

1133 PrEP Following PEP: An Effective HIV Risk-Reduction Strategy

Gary Whitlock, Courtney Taylor, Lucy Turner, Holly Thompson

1134 BIC/FTC/TAF as HIV PEP Was Well-Tolerated With High Adherence and No Seroconversions

Darrell H. S. Tan, Reva Persaud, Attia Qamar, Isaac I. Bogoch, Arlene Chan, Allison Chris, Karla Fisher, Richard T. Lester, John Maxwell, James Murray, Hong Qian, Hubert Wong

1135 Uptake and Predictors of PEP Uptake in the SEARCH Dynamic Choice HIV Prevention Trials

James Ayieko, Laura B. Balzer, Elijah Kakande, Jane Kabami, Collette Aoko, Gabriel Chamie, Catherine A. Koss, Elizabeth Bukusi, Moses R. Kamya, Maya L. Petersen, Diane Havlir

Poster Session-T3 | Sexually Transmitted Infections in Women: Global Perspectives
2:30 PM - 4:00 PM • Poster Hall C-D

1163 Gaps in Sexual and Reproductive Health Care Among Cisgender Women With Diagnosed HIV

Sharoda Dasgupta, Stacy Crim, John Weiser, Angela Blackwell, Jen-Feng Lu, Margaret Lampe, Ada Dieke, Robyn N. Fanfair

1164 Genital and Exogenous Sexually Transmitted Infections Among Reproductive Age Women in Southern US

Nicholas F. Nogueira, Paola Beato Fernandez, Yue Pan, Ana Salazar, Maria G. Rodriguez, Gray Kelsey, Patricia Del Carmen Raccamarchi, Daniel Westreich, Seble Kassaye, Elizabeth F. Topper, Aadia Rana, Deborah Konkle-Parker, Deborah Jones Weiss, Anandi N. Sheth, Maria L. Alcaide

1165 **Prevalence and Risk Factors Associated With HPV Infections Among Women with HIV Women in Meru, Kenya**

NIS Celestine K. Nyamari, Anthony Kebira, Frank Onyambu

1166 **One-Dose HPV Vaccine Durability in a Moderate HIV Prevalence Setting: Mathematical Modeling Analyses**

Christine L. Hathaway, Grace Umutesi, Jesse A. Heitner, Rachel Jackson, Christine Wangeci, Wesley Mugambi, Lydia Khalayi, Valerian Mwenda, Lynda M. Oluoch, Mary Nyangasi, Rose E. Jalang'o, Nelly R. Mugo, Ruanne V. Barnabas

1167 **Integrated Antenatal HIV, Hepatitis B, & Curable STI Testing: A Pragmatic Study in Harare, Zimbabwe**

NIS Kevin Martin, Chido Dziva Chikwari, Ethel Dauya, Constance R. Mackworth-Young, Joseph D. Tucker, Victoria Simms, Tsitsi Bandason, Francis Ndowa, Leolin Katsidzira, Owen Mugurungi, Anna Machiha, Michael Marks, Katharina Kranzer, Rashida A. Ferrand

1168 **Genital Immune Correlates of Prevalent and Incident Herpes Simplex Virus 2 (HSV-2) Infection**

NIS Suji Udayakumar, James Pollock, Sanja Huibner, Mary Kung'u, Rhoda Kabuti, Erastus Irungu, Pauline Ngurukiri, Peter Muthoga, Wendy Adhiambo, Helen Weiss, Janet Seeley, Tara Beattie, Joshua Kimani, Rupert Kaul, for the Maisha Fiti Study Champions

Poster Session-T4 | Sexually Transmitted Infections in Key Populations

2:30 PM - 4:00 PM • Poster Hall C-D

1169 **HIV and STIs in US Bisexual Men and Gay Men: Clinical Implications and Service Needs**

NIS Thomas Carpino, Kaitlyn Atkins, Cristian S. Acero, Iaah Lucas, Hector Moran, Sarah Murray, Travis H. Sanchez, Stefan Baral

1170 **Relevance of Asymptomatic STIs in a High-Risk Population of MSM Undergoing Periodic Screening**

Rosario Palacios, Cristinia Gómez-Ayerbe, María López-Jódar, Isabel A. Pérez-Hernández, Isabel Viciana, Marina Villalobos, Victoria García, Jesús Santos

1171 **Lymphogranuloma Venereum Among Men Who Have Sex With Men: 7 Versus 21 Days Doxycycline Effectiveness**

NIS Angelo Roberto Raccagni, Alessia Siribelli, Sara Diotallevi, Michela Sampaolo, Nicola Clementi, Riccardo Lolatto, Roberto Burioni, Antonella Castagna, Silvia Nozza

1172 **Low Prevalence of Sexually Transmitted Infections Among Adolescents and Young Adults Living With HIV**

Lynda M. Oluoch, Paul Mwangi, Jane Gacheru, Irene Njeru, Kenneth Ngure, Linda Eckert, Denise A. Galloway, Anna Wald, Ruanne V. Barnabas, Nelly R. Mugo

Poster Session-U01 | HIV Care

2:30 PM - 4:00 PM • Poster Hall C-D

1177 Charting Achievable Milestones for HIV Care Enhancement and Prevention in the US Through 2035**Melissa Schnure**, Parastu Kasaie, David Dowdy, Maunank Shah, Emily Kendall, Anthony Fojo**1178 Evolving Trends in Early ART Initiation in South Africa: An Analysis of Integrated HIV Program Data****Dorina Onoya**, Khumbo Shumba, Cornelius Nattey, Dickman Gareta, Evelyn Lauren, William MacLeod, Koleka Mlisana, Jacob Bor, Matthew P. Fox**1179 Routine Collection of Patient-Reported Outcomes in HIV Clinics: Findings After >100,000 Assessments****Mindy Dai**, Lydia N. Drumright, Rob Fredericksen, Joseph A. Delaney, L. Sarah Mixson, Bridget Whitney, William B. Lober, Mari Kitahata, Kenneth H. Mayer, Jeffrey Jacobson, Edward Cachay, Laura Bamford, Katerina Christopoulos, Heidi M. Crane**1180 Ending the HIV Epidemic in Atlanta: A Mixed-Methods Study to Support the Local HIV/AIDS Response****Micah Piske**, Bohdan Nosyk, Justin C. Smith, Bianca Yeung, Benjamin Enns, Xiao Zang, Patrick S. Sullivan, Wendy S. Armstrong, Melanie Thompson, Gaea Daniel, Carlos del Rio**1181 Barriers of Early Enrollment and Rapid ART Initiation Among US HIV Care Facilities****Jesse G. O'Shea**, Xin A. Yuan, Jen-Feng Lu, Kate Buchacz, Kashif Iqbal, Marie E. Johnston, Linda Beer, John Weiser**1182 Strategic Advice and Expert Procurement Accelerates the Optimization to DTG in the Americas****Omar M. Sued**, Nora Giron, Kemel Hallar, Monica Alonso, Ruben Mayorga, Christopher Lim**1183 Evaluating Barriers to Care Among Adults With HIV Who Are Virally Unsuppressed in Philadelphia****Ngwi Tayong**, Tanner Nassau, Kathleen Brady**1184 Novel Post-Hospitalization Care Model Decreases Mortality in People With HIV in Zambia: Pilot Study****Cassidy W. Claassen**, Chiti Bwalya, Morley Mujansi, Linah Mwango, Kirsten Stoebenau, Caitlin Baumhart, Godfrey Muchanga, Brianna Lindsay, Mundia Mwitumwa, Nyuma Mbewe, Wilbroad Mutale, Michael Vinikoor**1185 The HIV Care Cascade in Medicaid, 2001-2015****Jacqueline E. Rudolph**, Keri Calkins, Corinne E. Joshu, Bryan Lau

1186 NIS Prevalence and Predictors of Advanced Disease Among People Living With HIV in Masaka Region, Uganda

Alex Daama, Fred Nalugoda, Asani Kasango, Betty Nantume, Grace N. Kigozi, Robert Ssekubugu, Absalom Ssetuba, Joseph Kagaayi, David Serwadda, Joseph Kabanda, Arthur G. Fitzmaurice, Nelson Sewankambo, Godfrey Kigozi, Gertrude Nakigozi

1187 Met and Unmet Health and Welfare Services Needs Amongst People With HIV in the UK

Anne Williamson, Fiona Lampe, Adamma Aghaizu, Annegret Pelchen-Matthews,, Alex Sparrowhawk, Janey Sewell, Clare Humphreys, Alison Rodger, Meaghan Kall, Colette Smith, for the PV2022 Study Group

Poster Session-U02 | PrEP, PEP, and Voluntary Medical Male Circumcision

2:30 PM - 4:00 PM • Poster Hall C-D

1188 Real-World Utilization of HIV PrEP Medication in a Population-Level PrEP Program in BC, Canada

Junine Toy, **Raquel M. Espinoza**, Jason Trigg, Tian Shen, Paul Sereda, Erin Ready, Viviane Dias Lima, Rolando Barrios, Julio Montaner

1189 NIS Community and Facility-Based PrEP Uptake and Adherence Among People Who Use Drugs in Uganda

Joseph Kibuuka, Patricia M. Smith, Timothy Muwonge, Peter Mudiope, Liz Komuhangi, Ritah Kansiime, Tara Wood, Florence Nambi, Mai Nakitende, Lyianne Nakabugo, Herbert Kadama, Peter Kyambadde, Sara N. Glick, Andrew Mujugira, Renee Heffron

1190 NIS Modeling the Potential Impact of Scaling Up Event-Driven PrEP Among Gay, Bisexual, and Other MSM

Christina Chandra, Kevin Maloney, Karen W. Hoover, Samuel M. Jenness

1191 PrEP Persistence and Ongoing HIV Risk Among Patients Initiating PrEP at an Urban Malawi STI Clinic

Sarah E. Rutstein, Jane Chen, Esther Mathiya, Griffin J. Bell, Beatrice Ndalambo, Tapiwa Munthali, Naomi Nyirenda, Naomi Bonongwe, Claire Pedersen, Edward Jere, Mina Hosseinipour, Zakaliah Mpande, Irving F. Hoffman, Mitch Matoga, for the ePrEP study team

1192 PrEP Knowledge and Use: Results From the Zambia Population-Based HIV Impact Assessment 2021

Nzali G. Kancheya, Brian Muyunda, Omega Chituwo, Megumi Itoh, Bupe Musonda, Mumbi Chola, Megan Bronson

1193 Sexual Health Outcomes Among Daily and On-Demand Oral PrEP Users in China

Chunyan Li, Zhuoheng Yin, **Weiming Tang**, Songjie Wu, Quanmin Li, Yifan Dai, Chengxin Fan, Ke Liang, Linghua Li, Wu Sun, Joseph D. Tucker, Haojie Huang, Jonathan Lio, Aniruddha Hazra, Renslow Sherer

1194 HIV Recency Surveillance Improves PrEP Uptake: Evaluation With Synthetic Controls**NIS**

Sara Wallach, Matthew R. Lamb, Claire Steiner, Eugenie Poirot, Samkelo Simelane, Dumile Sibandze, Vusie Lokotfwako, Aisha Pasha, Harriet Nuwagaba-Biribonwoha, Yen T. Duong, Melissa Arons, Munyaradzi Pasipamire, Suzue Saito, Lenhle Dube

1195 Expanding Event-Driven PrEP to People Assigned Male at Birth Across 3 African Countries

Lirica Nishimoto, Augustine Amedzi, Makhosazana Matsebulu, Bhekizitha Sithole, Rachel Lyimo, Huckins Reeves, Gertrude Nunoo, Ncamsile Dlamini, Gift Kamanga, Michael Odo, Nana Fosua Clement, Tiffany Lillie, Christa Fischer-Walker, **Chris Akolo**

1196 HIV Risk Factors and PrEP and Contraceptive Use Among Women Seeking Postabortal Care in Kenya**NIS**

Lavender A. June, Felix Mogaka, Torin T. Schaafsma, Katherine K. Thomas, Josephine Odoyo, Bernard Nyerere, Lydia Etyang, Margaret Mwangi, Nelly R. Mugo, Elizabeth Bukusi, Renee Heffron

1197 High Individual- and Community-Level Variability in Male Circumcision Coverage in Rakia, Uganda

Hadijja Nakawooya, Mary Kate Grabowski, Victor Ssempejja, Robert Ssekubugu, Anthony Ndyanabo, Joseph Kagaayi, Arthur G. Fitzmaurice, Ping T. Yeh, Larry W. Chang, Aaron A. R. Tobian, Ronald H. Gray, Maria J. Wawer, David Serwadda, Steven J. Reynolds, Godfrey Kigozi

POSTER SESSIONS BY DAY

TUESDAY, MARCH 5, 2024

Poster Session-A1 | Virus Variation and Evasion of Antivirals and Restriction Factors

2:30 PM - 4:00 PM • Poster Hall C-D

- 300** **LB** **Targeting Tat-Dependent Transcriptional Rewiring to Manipulate HIV Latency**
 William Cisneros, Shimaa Soliman, Miriam Walter, Eun-Young Kim, Ali Shilatifard, Steven M. Wolinsky, **Judd F. Hultquist**
- 301** **Impact of HIV-1 TAR Sequence Diversity on Its RNA Secondary Structure in HIV-1 DNA Genomes**
Mohith Reddy Arikatla, Pragya Khadka, Zheng Tang, Erika Benko, Colin Kovacs, Marina Caskey, Taddeo Kityamuweesi, Paul Bbuule, Stephen Tomusange, Aggrey Anok, Jeffrey Martin, Melissa Smith, Timothy J. Wilkin, R. Brad Jones, Guinevere Q. Lee
- 302** **NIS** **Crosstalk Between Resistance to the HIV-1 Capsid Inhibitor Lenacapavir and Viral Fitness**
Binh Nguyen, Alex Kleinpeter, Eric O. Freed
- 303** **LB** **Identification of a New Class of Capsid-Targeting Inhibitors That Specifically Block Nuclear Import**
 Aude Boulay, Emmanuel Quevarec, Isabelle Malet, Giuseppe Nicastro, Valerie Courgnaud, Yves L. Janin, Ian A. Taylor, Anne-Genevieve Marcellin, Laurent Chaloin, **Nathalie J. Arhel**
- 304** **Impact of Capsid Polymorphisms on Viral Fitness and the Susceptibility to Lenacapavir**
Derek Hansen, Silvia Chang, Stephen Yant, Ross Martin, Thomas Aeschbacher, Arthur Cai, Jason Perry
- 305** **NIS** **Massive Endocytosis Mechanisms are Involved in CD169-Mediated Uptake of HIV-1 by Dendritic Cells.**
Fernando Laguía-Nueda, Jakub Chojnacki, Itziar Erkizia, Elena Rebollo, Carlos Enrich, Maria Isabel Geli, Javier Martinez-Picado, Patricia Resa-Infante
- 306** **Antagonism of Viral Glycoproteins by Guanylate Binding Protein 5**
Hana Veler, Geraldine V. Vilmen, Abdul A. Waheed, Cheng Man Lun, Eric O. Freed
- 307** **NIS** **Retinoic Acid Blunts the Aryl Hydrocarbon Receptor/SAMHD1-Dependent HIV-1 Restriction in Macrophages**
Ramon Edwin Caballero, Jonathan Dias, Jean-Philippe Goulet, Jean-Pierre Routy, Andrew Mouland, Petronela Ancuta

Poster Session-B3 | HIV and the Gut Microbiome

2:30 PM - 4:00 PM • Poster Hall C-D

329 Cannabis Use Enhances Mucosal Immunity and the Microbiome in Individuals With HIV
NIS**Robert Langat**, Ryan K. Cheu, Christopher Basting, Courtney A. Broedlow, Michael Louella, Nina Isoherranen, Ann C. Collier, Peter W. Hunt, Jennifer A. Manuzak, Nichole R. Klatt**330 HIV, Not Integrase Inhibitor-Based ART, Modifies Gut Microbiota Composition in MSM****Marta Rosas Cancio-Suárez**, Luis Miguel Nieto-Salas, **Claudio Díaz-García**, Jorge Díaz-Álvarez, Alejandro G. García-Ruiz De Morales, Clara Crespillo Andujar, Laura Luna Garcia, Elena Moreno, Laura Martín-Pedraza, Maria Fons, Javier Martínez-Sanz, Raquel Ron, Santiago Moreno, Matilde Sánchez-Conde, Sergio Serrano-Villar**331 Microbe-Drug Interactions Between Antiretrovirals and the Gut Microbiome in HIV Infection**
NIS**Christopher Basting**, Ty Schroeder, Adrian Velez, Courtney A. Broedlow, Timothy Griffin, Candace Guerrero, Nichole R. Klatt**332 Gut-Microbiome Changes Over 4 Years in PLWH With Good Immune Status on ART****Aya Ishizaka**, Michiko Koga, Taketoshi Mizutani, Hiroshi Yotsuyanagi**333 Comparisons of Oral and Gut Bacteria Highlight Role of *Veillonella* in Systemic Inflammation in HIV****Grace Cho**, Julie Elliott, Katharine Newman, Fan Li, Nicole H. Tobin, Steven Shoptaw, Pamina Gorbach, Grace M. Aldrovandi, **Jennifer A. Fulcher****334 CX3CR1+ Vδ1 T-Cells Are Clonally Expanded and Driven by CMV, Microbiota, and HIV-1 in the Gut on ART**
NIS**Nived Collercandy**, Camille Vellas, Manon Nayrac, Mary Requena, Thomas Richarme, Justine Latour, Karl Barange, Laurent Alric, Nicolas Carrere, Guillaume Martin-Blondel, Matteo Serino, Jacques Izopet, Pierre Delobel**335 Bacteria-Induced Granzyme B Contributes to HIV-1-Mediated Gut CD4 T-Cell Depletion Ex Vivo**
NIS**Kaylee Mickens**, Stephanie M. Dillon, Kejun Guo, Ashley Thompson, Bradley S. Barrett, Mario L. Santiago, Cara C. Wilson**336 Distinct Intestinal Microbial Signatures Linked to Accelerated Biological Aging in People With HIV**
NIS**Shalini Singh**, Leila B. Giron, Maliha W. Shaikh, Shivanjali Shankaran, Phillip A. Engen, Zlata R. Bogin, Simona A. Bambi, Aaron Goldman, Toshitha Kannan, Ceylan E. Tanes, Kyle Bittinger, Alan Landay, Michael J. Corley, Ali Keshavarzian, Mohamed Abdel-Mohsen

Poster Session-B4 | SARS-CoV-2 Pathogenesis

2:30 PM - 4:00 PM • Poster Hall C-D

337
NIS
Deep Metabolic Profiling for Tissue-Specific Responses Against SARS-CoV-2 Variants in Hamster Models**Urvinder Kaur Sardarni**, Anoop Ambikan, Arpan Acharya, Samuel D. Johnson, Rajesh Rajaiah, Kabita Pandey, Ujjwal Neogi, Siddappa N. Byrareddy**338**
Markers of Microbial Translocation and Inflammatory Cytokines Are Predictive of Severe COVID-19**Ty Schroeder**, Christopher Basting, Kathie G. Ferbas, Adrian Velez, Courtney A. Broedlow, Erik Swanson, Melisa Bailey, Robert Langat, Luca Schifanella, Grace M. Aldrovandi, Nicole H. Tobin, Otto Yang, Jennifer Fulcher, Nichole R. Klatt**339**
LB
Pathogenic Monocyte, Th17, and NK Cell Immune Networks in the Lung From Critical COVID-19 PatientsIlya Tsukalov, Ildefonso Sanchez-Cerrillo, Olga Rajas, María Buzón, Meritxell Genescà, Noa Martín-Cófreces, Ignacio Santos, María Jose Calzada, Isidoro González-Álvaro, Jose Palacios, Arantzazu Alfranca, Julio Ancochea, Francisco Sánchez-Madrid, **Enrique Martín-Gayo****340**
Complement-Driven Type-I IFN Response Enhances mTOR Activation and T-Cell Immunity**Marta Bermejo Jambrina**, John L. van Hamme, Lieve van der Donk, Doris Wilflingseder, Teunis B. Geijtenbeek**341**
Prolonged SARS-CoV-2 Viral Burden and Impaired Immunity in SIV/SARS-CoV-2 Coinfected Macaques**Megan N. Fredericks**, Hannah Frizzell, Hillary Tunggal, Cecily C. Midkiff, Jeana Barrow, Anthony L. Cook, Robert V. Blair, Ankur Sharma, Deborah H. Fuller, Megan O'Connor**342**
NIS
Viral Shedding and Mucosal Lymphocyte Disruptions in SARS-CoV-2 Infection Exacerbated by Fatty Diet**Kelsie Brooks**, Arvind Sivanandham, Quentin Le Hingrat, Anna Jasinska, Delmy Ruiz, Lilly Carson, Lilas Tarnus, Makheni Jean Pierre, Mohammed Daira, Cristian Apetrei, Jason Brenchley, Ivona Pandrea**343**
NIS
Impact of COVID-19 Progression in Patients With Hypertension
Alba Sanchez, Silvia Chafino, Graciano García-Pardo, Frederic Gómez-Bertomeu, Miguel López-Dupla, Antoni Del Pino-Rius, Montserrat Olona, Francesc Vidal, Anna Rull, Joaquim Peraire**344**
NIS
SARS-CoV-2 Evolution, Reinfection, and Sustained Viremia in Cancer Patients**Juliana D. Siqueira**, Livia R. Goes, Brunna M. Alves, Marianne M. Garrido, João P. Viola, Marcelo A. Soares**345**
SARS-CoV-2 Mild Infection as Risk Factor for Herpes Human Viruses Reactivation**Serena Vita**, Elisa Petruccioli, Eleonora Cimini, Maria Beatrice Valli, Patrizia De Marco, Settimia Sbarra, Stefania Notari, Cecilia Lindestam Arlehamn, Alessandro Sette, Andrea Antinori, Carla Fontana, Fabrizio Maggi, Delia Goletti, Emanuele Nicastri, for the VIROMA-INMI Group

346 Neutrophil Activation and Their Derived Nets Contribute to Thrombotic Risk in Pulmonary PASCNatalie Subia, Dominic Chow, Cecilia Shikuma, **Juwon Park****347 Persistence of SARS-CoV-2 in Platelets and Megakaryocytes in Long COVID**Feifan He, Boxin Huang, Andrea Cottignies-Calamarte, Wiem Bouchneb, Agathe Gouvard, Faroudy Boufassa, Jacques Callebert, Dominique Salmon, **Morgane Bomsel****Poster Session-B5 | Persistent Immune Activation and Inflammation During Antiretroviral Therapy**

2:30 PM - 4:00 PM • Poster Hall C-D

348 Low-Level HIV Viremia Affects T-Cell Activation and Senescence in InSTI Era

NIS

Violeta Lara Aguilar, Manuel Llamas-Adán, Oscar Brochado-Kith, Celia Crespo-Bermejo, Sergio Grande-García, Sonia Arca-Lafuente, Ignacio De los Santos, María Carmen Prado, Mario Alía, Coral Sainz-Pinós, Amanda Fernández-Rodíguez, Luz Martín-Carbonero, Ricardo Madrid, Verónica Briz

349 Ultra-Low Level HIV p24 Production as a Driver of Immune Activation in Individuals Treated with ART

NIS

Enrico Richter, Theresa Bechtel, Antonia Büning, Marek Korencak, Trevor A. Crowell, Heiko Jessen, Juergen K. Rockstroh, Stefan Esser, Christoph Boesecke, Hendrik Streeck

350 CARD8 Activation in Myeloid Cells as a Driver of Inflammation in HIV Infection

NIS

Marilia R. Pinzone, Liang Shan

351 Increased Immune Activation Following Acute Sleep Deprivation in People With HIV on ARTPriya V. Borker, Benjamin Morris, Jennifer Roscher, Steven Swanger, Sanjay R. Patel, **Bernard J. C. Macatangay****352 Immunosuppressive Effects of LLDT-8 in ART-Treated SIV-Infected Rhesus Macaques**

Xiaosheng Liu, Tingxia Lv, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li

Poster Session-C4 | Immunity to SARS-CoV-2 Infection

2:30 PM - 4:00 PM • Poster Hall C-D

400 Peripheral Immune Progression to Long COVID (LC) Is Driven by Mitochondrial Gene Transcription

David P. Maison, Vedbar Khadka, Isam Mohd-Ibrahim, Michael J. Peluso, Timothy J. Henrich, Youping Deng, Mariana Gerschenzon

401 ERAPs Control In Vitro and Ex Vivo SARS-CoV-2 Infection by Triggering Antiviral Immune Response
NIS

Irma Saulle, Maria Luisa Murno, Fiona Limanaqi, Micaela Garziano, Sergio Strizzi, Claudia Vanetti, Sergio Lo Caputo, Mariacristina Poliseno, Teresa A. Santantonio, Mario Clerici, Mara Biasin

402 Innate Immune Response Through NOD1 Agonists Prevents SARS-CoV-2 Infection in Lung Epithelial Cells
NIS

Edurne Garcia-Vidal, Ignasi Calba, Eva Riveira-Muñoz, Elisabet García, Bonaventura Clotet, Pere Serra-Mitjà, Cecilia Cabrera, Ester Ballana, Roger Badia

403 SARS-CoV-2 Natural Infection Elicits Cross-Reactive Immunity to OC43
NIS

Micaela Garziano, Claudia Vanetti, Sergio Strizzi, Irma Saulle, Maria Luisa Murno, Fiona Limanaqi, Valentina Artusa, Mario Clerici, Daria Trabattoni, Mara Biasin

404 SARS-CoV-2-Specific T-Cells Correlate With Airway Virus Control During Early Acute Infection

Freya U. Hourani, Tabea M. Eser, Alison Tarke, Leo Swadling, Flora Deak, Kathrin Held, Mohammed I. Ahmed, Laura Olbrich, Andreas Wieser, Inge Kroidl, Alessandro Sette, Mala Maini, Michael Hoelscher, Christof Geldmacher

405 Sex-Specific Transcriptional Profiles Associate With Severe SARS-CoV-2 Infection

Guido Massaccesi, Ziqi Fu, Andrea Cox, Weiqiang Zhou, **Eileen P. Scully**

Poster Session-C5 | HIV Immunotherapy and Immunoprophylaxis

2:30 PM - 4:00 PM • Poster Hall C-D

406 Regulatory T-Cell Manipulation Is Limited by Anti-Antibody Responses in HIV-1 Env–Immunized RMs
NIS

Shuqin Gu, Kan Luo, Tarra Von Holle, Thaddeus C. Gurley, Hilary Bouton-Verville, Xiaoying Shen, Georgia D. Tomaras, Barton F. Haynes, M. A. Moody

407 Characterizing New and Boosted HIV-Specific T-Cell Responses Elicited by an HIV Therapeutic Vaccine
NIS

Lily Zemelko, Mansi Purwar, Kara W. Chew, Emma Reuschel, Megan Wise, Nicole M. Bedanova, Laurent Humeau, Nilu Goonetilleke, Rafick P. Sekaly, David B. Weiner, Steven G. Deeks, Rachel Rutishauser

408 Safety of Therapeutic HIV-1 Vaccine for Adolescents with Early Treated Perinatal HIV Infection

Shaun L. Barnabas, Mark F. Cotton, Nicola Cotugno, Britta Wahren, Pontus Blomberg, Ellen Turk, Mark S. de Souza, Els Dobbels, Yasmeen Akhalwaya, Samantha Fry, Hans Spiegel, Patrick Jean-Philippe, Paolo Palma, Merlin L. Robb, for the Hurricane Study Team

409 WITHDRAWN

410 **Linking TCR $\alpha\beta$ Chains to Costimulatory Signaling Domains Enhances HIV-Specific CD8 T-Cell Function**NIS **Marta Santos Bravo, Harris Goldstein****411 ABBV-382, an Anti- $\alpha 4\beta 7$ Ab That Enhances HIV-1 Antigen Presentation for Immune-Mediated Viral Control****Teresa Ng, Gautam K. Sahu, Domenick E. Kennedy, Tatyana Dekhtyar, Renee Miller, Liangjun Lu, Dolonchampa Maji, Silvino Sousa, Keenan Taylor, Sahana Bose, Joel F. Cohen-Solal, Axel Hernandez Jr., Victoria A. Pitney, Melanie J. Patterson, Jochen Salfeld****412 10e8.4/iMAb Bispecific Antibody for Immunoprophylaxis Against High-Dose Intravenous SHIV Exposure****Matthew S. Parsons, Hannah A. King, Decha Silsorn, Jumpol Sopanaporn, Panupat Nadee, Dutsadee Inthawong, Rawiwan Imerbsin, Caroline Subra, Lindsay Wieczorek, Victoria Polonis, Yaoxing Huang, David D. Ho, Sandhya Vasan, Julie Ake, Diane L. Bolton****413 Long Half-Life Broadly Neutralizing Killer Bispecifics Against HIV-1: Harnessing the Immune System**NIS **Sukanya Ghosh, Maya Singh, Mansi Purwar, Daniel Kulp, Luis J. Montaner, David B. Weiner****414 Targeting HIV-Infected Cells for Immunotherapy Through HLA-E**NIS **Niklas Bachmann, Srona Sengupta, Robert F. Siliciano****415 Instability of the HLA-E Peptidome of HIV Presents a Major Barrier to Therapeutic Targeting****Zoe Wallace, Tiaan Heunis, Richard J. Suckling, Dawn Gibbs-Howe, Luis F. Godinho, Praveen K. Singh, Lucy Dorrell****Poster Session-C6 | Mpox Immunity, Therapy, and Transmission****2:30 PM - 4:00 PM • Poster Hall C-D****416 Immune Responses Associated With Mpox Viral Clearance in People With and Without HIV Coinfection**NIS **Igor Moraes-Cardoso, Susana Benet, Julieta Carabelli, Daniel Perez-Zsolt, Adrià Mendoza, Vicente Descalzo, Yovaninna Alarcón-Soto, Alba Grifoni, Michael Marks, Nuria Izquierdo-Useros, Jorge Carrillo, Clara Suñer, Alex Olvera, Beatriz Mothe, for the MoViE-Immune Study Group****417 Orthopoxvirus-Specific IgG Upon Mpox Vaccination Among People With and Those Without HIV****Wang-Da Liu, Tai-Ling Chao, Hsin-Yun Sun, Kuan-Yin Lin, Yu-Chung Chuang, Yu-Shan Huang, Guei-Chi Li, Wen-Chun Liu, Cheng-Hsin Wu, Yi-Ching Su, Lan-Hsin Chang, Chia-Yi Lin, Yi Yao, Sui-Yuan Chang, Chien-Ching Hung****418 MPXV Replication Induces an IFN Response and Is Suppressed by IFN- γ** NIS **Alessandra D'Auria, Federica Frasca, Licia Bordi, Eleonora Lalle, Matteo Fracella, Leonardo Sorrentino, Gabriella D'Ettorre, Claudio Maria Mastroianni, Mauro Pistello, Guido Antonelli, Carolina Scagnolari**

- 419 Early Tecovirimat Treatment for Mpox Disease Among People With HIV: A Matched Cohort Analysis**
Bruce Aldred, Robert H. Lyles, Jane Y. Scott, Daniel J. Gromer, Amalia Aldredge, Kimberly Workowski, Boghuma K. Titanji, Minh Nguyen, Vincent Marconi, Colleen Kelley, Jesse T. Jacob, Jonathan Colasanti, Emily J. Cartwright, Valeria D. Cantos, for the Emory Mpox Analysis Patient Series (MAPS) Study Group
- 420 Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced HIV Infection**
Michael T. Duong, Pablo Tebas, Bhavya Ancha, Jillian Baron, Stuart N. Isaacs, **Zsofia Szep**
- 421 Mpox Virus Model of Sexual Transmission in Cynomolgus Macaque**
Cecile Herate, Audrey Ferrier Rembert, Francis Relouzat, Hélène Letscher, Quentin Pascal, Benoît Delache, Olivier Ferraris, Roger Le Grand, Jean-Nicolas Tournier
- 422 Tecovirimat Plasma Concentrations, Mpox Resistance Mutations Selection, and Clinical Outcomes**
Stephane Marot, Minh P. Le, Nicolas Visinoni, Claire Perillaud-Dubois, Ruxandra-Oana Calin, Vincent Berot, Valentin Leducq, Cécile Pouderoux, Olivier Ferraris, Laurence Morand-Joubert, Vincent Calvez, Gilles Pialoux, Gilles Peytavin, **Anne-Genevieve Marcellin**, Valerie Pourcher
- 423 Predictors of Treatment With Tecovirimat and Hospitalization Among People With Mpox and HIV**
Michalina Montano, Adrienne E. Shapiro, Rob Frederickson, Heidi M. Crane, H. Nina Kim, Richard D. Moore, George A. Yendewa, Laura Bamford, Greer Burkholder, Katerina Christopoulos, Kenneth H. Mayer, Sonia Napravnik, April Pettit, Mari Kitahata, Rachel A. Bender Ignacio
- 424 Predictors of Mpox Duration and Severity in the Italian Multicenter Mpox Icona Cohort**
Valentina Mazzotta, Silvia Nozza, Simone Lanini, Davide Moschese, Alessandro Tavelli, Roberto Rossotti, Fusco Francesco Maria, Lorenzo Biasioli, Giulia Matusali, Angelo Roberto Raccagni, Davide Mileto, Antonella D'Arminio Monforte, Antonella Castagna, Andrea Antinori, for the Mpox-Icona Study Group
- 425 Molecular Epidemiology of Human Mpox in Chicago**
Lacy M. Simons, En-Ling Wu, Maureen Bolon, Timothy Blanke, Maria Francesca Agnes, Anjelo M. Evans, Arghavan Alisoltanidehkordi, Chad Achenbach, Valentina Stoser, Kendall Kling, Egon Ozer, Judd F. Hultquist, Ramon Lorenzo-Redondo
- 426 Plausibility of Sexual Behavior Changes and Role of Vaccination in Mpox Outbreak Control Among MSM**
Davide Moschese, Alberto Rizzo, Angelo Roberto Raccagni, Andrea Giacomelli, Riccardo Lolatto, Loriana Morelli, Maria Vittoria Cossu, Maria Francesca Lucente, Valeria Micheli, Davide Mileto, Antonella Castagna, Maria Rita Gismondo, Andrea Gori, Giuliano Rizzardini, Silvia Nozza
- 427 Mpox Vaccination Uptake Among MSM During the 2022 Epidemic: A Single-Center Retrospective Study**
NIS Yanis Merad, Matthieu Godinot, Dulce Alfaiate, Agathe Becker, Florence Ader, Anne Conrad, Laurent Cotte

428

LB

Pharmacokinetics of Tecovirimat in Persons With Mpox: Results From ACTG 5418

Zixuan Wei, Grace Aldrovandi, Judith S. Currier, Joseph J. Eron, William Fischer, Rajesh T. Gandhi, Matthew M. Hamill, Lara Hosey, Arzhang C. Javan, Sharon Nachman, Davey M. Smith, Timothy J. Wilkin, Jason E. Zucker, Edmund Capparelli, Kristina M. Brooks

429

LB

Evaluation of a Protocol for Managing Cyclosporine and Nirmatrelvir/Ritonavir Drug-Drug Interaction

Pierre Giguere, Kyla Agtarap, Marie-Josée Deschênes, Lacey DeVreese, Jessica McDougall, Stephanie Hoar, Swapnil Hiremath

430

LB

Disparities in Mpox Vaccination Among Cis Men and Trans Persons With HIV in Los Angeles County

Colleen Leonard, Erin Nguyen, **Kathleen Poortinga**, Sherry Yin, Andrea A. Kim, Olivia Moir, Natalie Frey, Abraar Karan, Sonali Kulkarni, Rebecca Cohen, Kwa Sey, Shobita Rajagopalan, Mario J. Pérez

Poster Session-D1 | Integration Sites and Proviral Landscape in the Reservoir

2:30 PM - 4:00 PM • Poster Hall C-D

457

NIS

Intact Proviruses Persist in Expressed Genes in People With Non-Suppressible HIV on Long-Term ART

Joshua A. Gluck, Sean Patro, Elias K. Halvas, Kevin Joseph, Nathan McKenna, Shuang Guo, Shadab Parvez, Jason W. Rausch, Xiaolin Wu, John M. Coffin, John W. Mellors, Stephen Hughes, Mary F. Kearney

458

NIS

Host Gene Activation at the Integration Site Reduces HIV Expression by Transcriptional Interference

Sam Weissman, Miriam Viazmenski, Jack Collora, Yang-Hui Jimmy Yeh, Ya-Chi Ho

459

NIS

Role of HIV Integration Site on Clonal Expansion of Infected Cells and Maintenance of Latency

Virender K. Pal, Frauke Muecksch, Ali Danesh, Marie Canis, Tan T. Huynh, Theodora Hatzioannou, R. Brad Jones, Guinevere Q. Lee, Paul D. Bieniasz

460

NIS

HIV Integration Site Features Associated With Persistence of Infected Cells Under CD8 Pressure

Noemi L. Linden, Alexander McFarland, Ali Danesh, John Everett, Scott Sherrill-Mix, Carole Lee, Chanson J. Brumme, Dennis Copertino, Zabrina Brumme, Itzayana Miller, Tan T. Huynh, Aoife Roche, Jared Weiler, Frederic D. Bushman, R. Brad Jones

461

NIS

HIV Proviruses Among CMV-Reactive Cells Are Abundant, Defective, and Polyclonal After 4 Years of ART

Filippo Dragoni, Maura Manion, Hao Zhang, Angelica Camilo-Contreras, Frank Maldarelli, Irini Sereti, Francesco R. Simonetti

462

Differential Gene-Specific Selection Pressures on HIV-1 Defective Proviruses During ART

Thuy Nguyen, Mary-Elizabeth Zipparo, Lindsey Adams, Annemarie Glassey, Ulisses Santamaria, Catherine A Rehm, Jessica Earhart, Wei Shao, Chuen-Yen Lau, Frank Maldarelli

463**LB****In-Depth Proviral Sequence Analysis Reveals Conserved Reservoir Landscape Composition Across Group M**

Hannah J. MacLeod, Elizabeth A. Ferrer, Hanna R. Marks, Mian Cai, Qiuyan Ma, Evgenia Aga, Grace M. Aldrovandi, Ronald J. Bosch, Albine Martin, Gregory M. Laird

464**Solo LTR Formation Promotes Elimination of Proviruses in Persons Living With HIV**

Feng Li, Guanhui Li, Francesco R. Simonetti, Shawn Hill, Robert Gorelick, Chuen-Yen Lau, Frank Maldarelli

465**Longitudinal Evaluation of Viral Tropism in Archived Intact DNA Genomes in Acute HIV-1 Infections**

Kavidha Reddy, Elena Giorgi, Kamini Gounder, Nelson Sonela, Krista L. Dong, Bruce D. Walker, Thumbi Ndung'u, **Guinevere Q. Lee**

Poster Session-D2 | Transcription in the HIV Reservoir

2:30 PM - 4:00 PM • Poster Hall C-D

466**NIS****Multomics Profiling of HIV-Transcribing Cells in People With HIV on Suppressive ART**

Julie Frouard, Xiaoyu Luo, Sushama Telwatte, Douglas Arneson, Jason Neidleman, Kailin Yin, Antoine Chaillon, Rebecca Hoh, Steven G. Deeks, Sara Gianella Weibel, Davey M. Smith, Sulggi A. Lee, Phyllis Tien, Steven A. Yukl, Nadia R. Roan

467**HIV-1 Transcriptional Activity Is Largely Driven by Defective Proviruses**

Mareva Delporte, Evy E. Blomme, Evelien De Smet, Maxime Verschoore, Marie-Angélique De Scheerder, Sofie Rutsaert, Sarah Gerlo, Wim Trypsteen, Linos Vandekerckhove

468**Dynamics of Different Proviruses and HIV Transcripts After Acute ART Treatment**

Julie Janssens, Sun Jin Kim, Adam Wedrychowski, Gayatri N. Kadiyala, Satish K. Pillai, Timothy J. Henrich, Nadia R. Roan, Steven G. Deeks, Sulggi A. Lee, Steven A. Yukl

469**Multomics of Detectable vs Undetectable Monocyte Cell-Associated HIV RNA During Acute HIV**

Michael J. Corley, Ivo Sahbandar, Phillip Chan, Alina Pang, Nittaya Phanuphak, Carlo P. Sacdalan, Sandhya Vasan, Lydie Trautmann, Serena Spudich, Lishomwa Ndhlovu, for the SEARCH010/RV254 Study Group

470**Antiretroviral Therapy Within 2 Years of HIV Acquisition Is Associated With Fewer Viral Blips**

Trevor A. Crowell, Hsing-Chuan Hsieh, Xun Wang, Xiuping Chu, Britt Gayle, Catherine M. Berjohn, Jason M. Blaylock, Joseph M. Yabes, Derek T. Larson, Robert J. O'Connell, Anuradha Ganesan, Brian K. Agan, for the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group

471**NIS****Reduced HIV RNA Transcription During Long-Term ART Is Associated With Increased Ki67+ CD8+ T-Cells**

Alan Wells, Christophe Vanpouille, Noah Gaitan, Antoine Chaillon, Stephen Rawlings, Victor DeGruttola, Xinlia Zhang, Miranda Lynch, Xin Tu, Alan Landay, Eileen P. Scully, Jonathan Karn, Sara Gianella Weibel

472 HIV-2 Transcription in Blood CD4+ T-Cells Is Inhibited by Blocks to Elongation and Completion

Adam Wedrychowski, Julie Janssens, Sun Jin Kim, Gayatri N. Kadiyala, Sushama Telwatte, Stacey M. Gaudreau, Susan Cu-Uvin, Athé Tsibris, Steven A. Yukl

473 Variable Persistence of Non-Suppressible Viremia on Antiretroviral Therapy

Elias K. Halvas, Evgenia Aga, Ronald J. Bosch, Christine Scello, Sheldon Tetewsky, Joshua C. Cyktor, Joseph J. Eron, Rajesh T. Gandhi, Deborah K. McMahon, John W. Mellors

Poster Session-D3 | HIV Latency and Latency Reversal

2:30 PM - 4:00 PM • Poster Hall C-D

474 Different Impact of Latency Reversal in Cells From People With HIV Viremia and With ART Suppression

Remi Fromentin, Amélie Pagliuzza, Hiroshi Takata, William Brantley, Benjamin Varco-Merth, Afam A. Okoye, Lydie Trautmann, Nicolas Chomont

475 Strong Latency Reversal by *C. megalobotrys* Extract in ART-Suppressed PBMC and Humanized Mice

Khumoekae Richard, Zhe Yuan, Riza Kuthu, Emery T. Register, Paridhima Sharma, Brian N. Ross, Pau Zuck, Carol Cheney, Jessicamarie Morris, Guoxin Wu, Karam Mounzer, Kerstin Andrae-Marobela, Ian Tietjen, Luis J. Montaner

476 Transcriptomic HIV Reservoir Profiling Reveals a Role for Mitochondrial Functionality in HIV Latency

Shirley Man, Stefanie Kroese, Jade Jansen, Teunis B. Geijtenbeek, Neeltje Kootstra

477 Investigating the Effects of Chromatin Spatial Folding on HIV-1 Latency

Nawal K. S. Al Burtamani, Jose De Las Heras, Khushi Goel, Alex Ward, Helen Rowe, Ariberto Fassati

478 Modulation of IRF7-Driven Transcription as a Strategy to Control HIV-1 Latency

Ifeanyi J. Ezeonwumelu, Edurne Garcia-Vidal, Eudald Felip, Bonaventura Clotet, Roger Badia, Ester Ballana, Eva Riveira-Muñoz

479 Reversing HIV-1 Latency by Targeting RasGRP1-Dependent Biogenesis of P-TEFb

Uri Mbonye, Ana Bellomo, Eleonora Elhalem, Lucia G. Donadio, Maria J. Comin, Jonathan Karn

480 Monovalent and Bivalent SMAC Mimetics Reverse HIV Latency and Decreases the HIV Reservoir

Youry Kim, Kiho Tanaka, Jesslyn Ong, Carolin Tumpach, James H. McMahon, Ajantha Rhodes, Rebecca Hoh, Steven G. Deeks, Sushama Telwatte, Michael Roche, Sharon R. Lewin

481 Optimal Administration Timing of Latency Reversal Agents to Reduce Effectively the HIV Reservoir

Erick De La Torre Tarazona, Sergio Serrano-Villar, Raúl Vaquer, Marta Rava, Laura Luna García, Sonsoles Sánchez-Palomino, Teresa Aldámiz-Echevarría, Rafael Mican, Adrià Curran, Melchor Riera, José Alcamí, Inma Jarrín, Santiago Moreno

Poster Session-E4 | Vascular Pathogenesis of NeuroHIV and NeuroCOVID-19

2:30 PM - 4:00 PM • Poster Hall C-D

564 Brain White Matter Hyperintensity Accumulation in an Acute HIV Cohort Over 2 Years

Kathryn Holroyd, **Jacob Bolzenius**, Carlo P. Sacdalan, Netsiri Dumrongpisutikul, Somchai Sriplienchan, Pathariya Promsena, Sandhya Vasan, Lydie Trautmann, Serena Spudich, Phillip Chan, Robert Paul, for the RV/SEARCH Study Team

565 Atherosclerotic Cardiovascular Disease Risk Score and Cognition by HIV Serostatus and Sex

Hannah Begna, Ali Mirzazadeh, Maria L. Alcaide, Monica M. Diaz, Cecile D. Lahiri, Gypsyamber D'Souza, Deborah Gustafson, Seble Kassaye, Jeremy Martinson, Matthew J. Mimiaga, Kathleen Weber, Pariya Wheeler, Leah H. Rubin, **Felicia C. Chow**

566 Cumulative Exposure to CVD Risk Factors More Adversely Affects Cognition in Women With & Without HIV

Abel C. Obosi, Yifei Ma, Maria L. Alcaide, Cecile D. Lahiri, Monica M. Diaz, Gypsyamber D'Souza, Deborah Gustafson, Seble Kassaye, Matthew J. Mimiaga, Kathleen Weber, Robert Paul, Leah H. Rubin, Adesola Ogunniyi, Babafemi Taiwo, Felicia C. Chow

567 Circulating Endothelial Microvesicles With HIV-1 Promote Cerebral Endothelial Cell Stroke Profile

Auburn R. Berry, Samuel Ruzzene, Kendra Wegerson, Emily I. Ostrander, Hannah L. Cardenas, Hannah K. Fandl, Jared J. Greiner, Vinicius P. Garcia, Elizabeth Connick, Christopher DeSouza

568 NIS Vascular Inflammation in Neuropsychiatric Post-Acute Sequelae of COVID-19

Lindsay S. McAlpine, Hailey Reisert, Bibhuprasad Das, Allison Nelson, Jennifer Chiarella, Shelli Farhadian, Serena Spudich

Poster Session-E5 | NeuroHIV in Global Settings

2:30 PM - 4:00 PM • Poster Hall C-D

569 Verbal Learning and Memory in Well-Controlled HIV Is Similar to People Without HIV in Uganda

Noeline Nakasujja, Leah H. Rubin, Deanna Saylor, Aggrey Anok, Stephen Tomusange, Maria J. Wawer, Jacob Bolzenius, Robert Paul, Gertrude Nakigozi

570 Prevalence of Stigma, Depression, and Anxiety in a Cohort of PLWH in Lebanon: A Cross-Sectional Study

Remie L. El Helou, Alison Haidar, **Nesrine Rizk**

571 Plasma Inflammatory Biomarkers Link to Worse Cognition Among Africans Living With HIV

Samuel Wilson, Andjelika Milicic, Rither Langat, Winnie Rehema, Gloria David, Nkechinyere Harrison, Hannah Kibuuka, Hendrik Streeck, Allahna Esber, Shireen Javandel, Isabel Allen, Lishomwa Ndhlovu, Julie Ake, Victor Valcour, for AFRICOS

572 **Improving Diagnosis of Central Nervous System Infections in High-HIV Prevalence African Settings**

James Milburn, Taddy Mwarumba, Rachita Suresh, Kebatshabile Ngoni, Tavengwa Manenji, F. Kathryn Boyd, Lenon Gwuanza, Tiny Mazhani, Ronan Doyle, Katharina Kranzer, Madisa Mine, Margaret Mokomane, Gift Ngwende, Chiratidzo Ndhlovu, Joseph N. Jarvis

573 **Mental Health Phenotypes of Well-Controlled HIV in Uganda**

Leah H. Rubin, Kyu Cho, Jacob Bolzenius, Julie Mannarino, Aggrey Anok, Stephen Tomusange, Raha M. Dastgheyb, Eran F. Shorer, Deanna Saylor, Maria J. Wawer, Noeline Nakasujja, Gertrude Nakigozi, Robert Paul

Poster Session-E6 | Cerebrospinal Fluid, Blood Biomarkers, and Neurodegeneration in NeuroHIV

2:30 PM - 4:00 PM • Poster Hall C-D

574 **Asymptomatic CSF HIV-1 Escape: Incidence and Effects on CNS Biomarkers**

Gustaf Ulfhammar, Arvid Edén, Aylin Yilmaz, Lars Hagberg, Erik Sörstedt, Erika Tyrberg, Åsa Mellgren, Staffan Nilsson, Kristina Nyström, Henrik Zetterberg, Dietmar Fuchs, Johanna Gostner, Magnus Gisslén

575 **HIV-1 Infection and Alzheimer's Disease Pathobiology in a Novel Humanized APP-Knock in Mouse Model**

Shaurav Bhattachari, Pravin Yeapuri, Jatin Machhi, Yaman Lu, Rana Kadry, Emma G. Foster, Krista L. Namminga, Emiko M. Waight, Chen Zhang, Prasanta Dash, Santhi Gorantla, Larisa Poluektova, Rodney L. Mosley, Howard E. Gendelman

576 **Increased mtDNA Level in Neuron-Derived Extracellular Vesicles in African Americans With HIV**

Vladimir Berthaud, Waldemar Popik, Tarik Smith, Derek Wilus, Venkateswara R. Amara, Franklin Nouvet

577 **Cerebrospinal Fluid NfL Decreases After Initiation of ART, but Slower Than Inflammatory Biomarkers**

Linn Renborg, Aylin Yilmaz, Staffan Nilsson, Henrik Zetterberg, Kaj Blennow, Magnus Gisslén

578 **Protein Modifications by Lactate Associate With Lower Risks of Neurocognitive Impairment and Death**

Danying Cao, Liangliang Zhang, James Galligan, Corrilynn O. Hileman, Asha Kallianpur, Alan Landay, Ronald J. Ellis, Frank Palella, Susan L. Koletar, Katherine Tassiopoulos, **Robert C. Kalayjian**

579 **Tryptophan and Kynurenone Pathway Activation and Cognition in Virally Suppressed Women With HIV**

Eran F. Shorer, Raha M. Dastgheyb, Audrey L. French, Elizabeth Daubert, Ralph Morack, Clary B. Clish, Kevin Bullock, Deborah Gustafson, Anjali Sharma, Andrea Rogando, Qibin Qi, Helen Burgess, Leah H. Rubin, Kathleen Weber

580 **Impact of Recombination on HIV-1 Evolutionary Dynamics in CSF and Plasma**

Li Li, Leslie St. Bernard, Daniel Dunn, Douglas F. Nixon, Weigang Qiu, **Teresa H. Evering**

- 581** **Effects of Recent Air Pollution Exposure on Cognition, Inflammation, and Neurodegeneration in HIV**
Sarah Cooley, Julie Wisch, Tricia Burdo, Dianne Langford, Rajan Chakrabarty, Payton Beeler, Beau Ances

- 582** **Higher Mitochondrial DNA (mtDNA) Heteroplasmy Burden Associates With Depression in People With HIV**
LB Emmanuel Saake, Chunyu Liu, Kavita Sharma, Donald Franklin, Todd Hulgan, David C. Samuels, Robert K. Heaton, Scott L. Letendre, Ronald J. Ellis, **Asha R. Kallianpur**

Poster Session-F2 | Important Antiretroviral Adherence and Pharmacokinetic Measures

2:30 PM - 4:00 PM • Poster Hall C-D

- 609** **Tenofovir Diphosphate Benchmarks in Dried Blood Spots in PWH Receiving TAF-Based ART (QUANTI-TAF)**
NIS **Ryan P. Coyle**, Mary Morrow, Vincent Mainella, Sarah C. Mann, Nicholas Barker, Lucas Ellison, Samuel L. Ellis, Pamela E. Alpert, Tony C. Carnes, D. Eric Buffkin, Lane Bushman, Samantha MaWhinney, Kristina M. Brooks, Jose R. Castillo-Mancilla, Peter L. Anderson
- 610** **Factors Affecting TVF-DP Concentrations in PBMC and Relationships With DBS in PWH on TAF-Based ART**
NIS **Stefanie Schwab**, Mary Morrow, Corwin Coppinger, Ryan P. Coyle, Vincent Mainella, Sarah C. Mann, Nicholas Barker, Lucas Ellison, Samuel L. Ellis, Pamela E. Alpert, Lane Bushman, Samantha MaWhinney, Kristina M. Brooks, Jose R. Castillo-Mancilla, Peter L. Anderson
- 611** **Adherence Markers for Doxy-PEP in Plasma and Urine**
Richard Haaland, Jeffrey Fountain, Chuong Dinh, Tiancheng Edwards, Deborah Omoyege, Christopher Conway-Washington, Colleen Kelley, Walid Heneine
- 612** **Safety and PK/PD of a Tenofovir Rectal Douche Administered in Different Sequences, DREAM-03**
NIS **Ruohui Zheng**, Ken Ho, Edward J. Fuchs, Alex Carballo-Díéguez, Lisa C. Rohan, Rebecca Giguere, Rhonda M. Brand, Stacey Edick, Rahul P. Bakshi, Teresa L. Parsons, Cindy E. Jacobson, Christina Bagia, Lin Wang, Mark Marzinke, Craig W. Hendrix
- 613** **Early Identification of ART Missed Doses: Baseline Data From the RETAIN Study**
Lauren Jennings, Chantel Schreuder, Richard Madimabe, Campbell McDuling, Tebogo Mosina, Lora Sabin, **Catherine Orrell**
- 614** **Baseline Urine Methamphetamine (UTOXM) Predicts ART Adherence and Poor Retention in Care Attributes**
Sara Browne, Anya Umlauf, Sarah Rojas, Theodoros Katsivas, Florin Vaida, Constance A. Benson

Poster Session-G3 | Should I Stay or Should I Go: Switching Oral Antiretroviral Therapy

2:30 PM - 4:00 PM • Poster Hall C-D

641 Switching From a Second-Line Boosted PI Regimen to B/F/TAF: Results of a Randomized Clinical Trial

LB

Samuel Pierre, Jean Bernard Marc, Fabienne Homeus, Guirlaine Rivette Bernadin, Letizia Trevisi, Evens Jean, Emelyne Dumont, Sanjana Sundaresan, Vanessa Rivera, Dennis Israelski, Sean E. Collins, Jean W. Pape, Patrice Severe, Paul E. Sax, Serena Koenig

642 Phase II Study of Switch to Daily BIC + LEN in Individuals on a Multitablet HIV Treatment Regimen

Karam Mounzer, Jihad Slim, Moti Ramgopal, Malcolm Hedgcock, Mark Bloch, Jorge Santana, Ines Mendes, Ying Guo, Priyanka Arora, Jairo M. Montezuma-Rusca, Hal Martin, Peter Sklar, Jared Baeten, Sorana Segal-Maurer

643 A Randomized Trial Switching Adults \geq 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results

Loice A. Ombajo, Jeremy Penner, Joseph Nkuranga, Edwin Otieno, Victor Mbewa, Jared O. Mecha, Simon Wahome, Florentius Ndinya, Sanjay Bhagani, Anton Pozniak, for the B/F/TAF Study Group

644 Impact of Switching From Dual to Triple Therapy on Inflammation: INSTINCT Study

NIS

Sergio Serrano-Villar, **Laura Martín-Pedraza**, Carmen Busca, Juan Manuel Tiraboschi, Jesús Santos, Luis Fernando López-Cortés, Carmen Hidalgo Tenorio, Vicente Estrada, María José Crusells Canales, Alfonso Cabello Úbeda, Alberto Díaz de Santiago, María Novella, Miguel Torralba, Marta De Miguel, Santiago Moreno

645 Switching to DTG+3TC vs 3-Drug Regimens in Routine Clinical Care: Long-Term Swedish Data

Erik Sörstedt, George Nduva, Saara Hiltunen, Johanna Repits, Fredrik Måansson, Åsa Mellgren, Eva Fernvik, Adam Stubbs, Melanie Schroeder, Johanna Brännström, Christina Carlander

646 Impact of Switch to 3TC/DTG on the HIV-1 Transcriptional Reservoir in a Randomized Controlled Trial

NIS

Evy E. Blomme, Evelien De Smet, Mareva Delporte, Wim Trypsteen, Sophie Degroote, Sophie Vanherwege, Els Caluwe, Marie-Angélique De Scheerder, Linos Vandekerckhove

647 Impact of DTG+3TC as First-Line ART on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood

Jose Molto, Maria C. Garcia-Guerrero, Lucía Bailón, Igor Moraes-Cardoso, Ester Aparicio, Pep Coll, Angel Rivero, Elias P. Rosen, Jacob D. Estes, Julià Blanco, Alex Olvera, Maria C. Puertas, Beatriz Mothe, Javier Martinez-Picado, for the DUALITY Study Group

Poster Session-G6 | Treatment and Prevention of SARS-CoV-2 Infection

2:30 PM - 4:00 PM • Poster Hall C-D

657

Effect of Remdesivir on Post-COVID Conditions Among Individuals Hospitalized With COVID-19 by Age

LB
Mark Berry, Amanda M. Kong, Roger Paredes, Rohan Shah, Gina Brown, Rikisha Gupta, Sohul A. Shuvo, Robert L. Gottlieb, Lourdes Mateu, Mazin Abdelghany, Jason D. Goldman, Anand P. Chokkalingam

658

Extended Nirmatrelvir/Ritonavir Treatment Durations for Immunocompromised Patients With COVID-19

LB
Edward Weinstein, Annie Gardner, Mary Almas, Mary Lynn Baniecki, Shunjie Guan, Elena Tudone, Simone Antonucci, Kevin Gregg, Roger Paredes, Carolina Garcia-Vidal, Adrian Camacho, Wayne Wisemandle, Steven Terra, Jennifer Hammond, James Rusnak

659

Nirmatrelvir/Ritonavir Reduces COVID-19 Symptom Duration Across Subgroups of Patients at High Risk

Heidi Leister-Tebbe, Weihang Bao, Wayne Wisemandle, Romina Quercia, Jennifer Hammond, James Rusnak

660

Large Fraction of COVID-19 Hospitalizations Preventable With Oral SARS-CoV-2 Antiviral Treatment

Matthew E. Levy, Evanette Burrows, Vanessa Chilunda, Dana Wyman, Andrew Dei Rossi, Hang Dai, Magnus Isaksson, Lisa McEwen, Nicole L. Washington, Tracy Basler, Kevin Tsan, Jason Nguyen, Jimmy Ramirez, Efren Sandoval, Shishi Luo

661

Pooled Analysis of Randomized Trials Comparing Drug Efficacy for Early COVID-19 During Omicron Waves

Valentina Mazzotta, Fulvia Mazzaferrri, Simone Lanini, Massimo Mirandola, Alessandro Cozzi-Lepri, Alessandra Vergori, Alessia Savoldi, Francesca Bai, Gaia Maccarrone, L. Sarmati, Carlo Tascini, Enrico Girardi, Annamaria Cattelan, Andrea Antinori, Evelina Tacconelli

662

Predictors of Failure to COVID-19 Early Therapies and Drugs Efficacy Comparison by Emulation Trial

Valentina Mazzotta, Alessandro Cozzi-Lepri, Cosmo Del Borgo, Silvia Rosati, Martina Rueca, Enrico Girardi, L. Sarmati, Claudio Maria Mastroianni, Massimo Fantoni, Fabrizio Maggi, Emanuele Nicastri, Miriam Lichtner, Andrea Antinori, for the Early Treatment for COVID-19 Lazio Study Group

663

Disparities in Treatment Initiation by Race and Ethnicity Among Patients Hospitalized for COVID-19

Essy Mozaffari, Aastha Chandak, Alpesh N. Amin, Robert L. Gottlieb, Andre C. Kalil, Mark Berry, Gina Brown, Jason F. Okulicz, Chidinma Chima-Melton

664

Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalised for COVID-19 During Omicron

LB
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Chidinma Chima-Melton, Mark Berry, Alpesh N. Amin, Tobias Welte, Paul E. Sax, Andre C. Kalil

665

LB

Remdesivir+Dexamethasone vs Dexamethasone for the Treatment of COVID-19: Real-World Study in the US

Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Chidinma Chima-Melton, Mark Berry, Thomas Oppelt, Jason F. Okulicz, Alpesh N. Amin, Andre C. Kalil, Tobias Welte, Paul E. Sax

666**Real-Life Experience on the Use of Remdesivir: A Propensity Score Matched Analysis**

Francesco Di Gennaro, Luisa Frallonardo, Giacomo Guido, Francesco Vladimiro Segala, Nicola Veronese, Annalisa Saracino

667**Molnupiravir vs Favipiravir: An RCT in Outpatients At-Risk for COVID-19 in Thailand**

Nicolas Salvadori, Gonzague Jourdain, Rungroj Krittayaphong, Taweegrit Siripongboonsitti, Subsai Kongsaengdao, Parichart Sakulkonkij, Nasikarn Angkasekwina, Sarunyou Chusri, Tanavit Mekavuthikul, Anucha Apisarnthanarak, Sirawat Srichatrapimuk, Suraphan Sangsawang, Piya Hanvoravongchai, Pra-ornsuda Sukrakanchana, Prasert Auewarakul

668

LB

AGILE CST-8 Phase I Trial of Combined Nirmatrelvir/r and Molnupiravir for Mild-Moderate COVID-19

Saye Khoo, Richard J. Fitzgerald, Shazaad Ahmad, Chris Edwards, Geoff Saunders, Emma Knox, Calley Middleton, William Greenhalf, Laura Else, Victoria Shaw, Thomas Fletcher, Helen Reynolds, Gareth Griffiths, for the AGILE CST-8 Study Team

669**Viral and Symptom Rebound After COVID-19 Monoclonal Antibody Therapy in the ACTIV-2 Trial**

Kara W. Chew, Brooke McGinley, Carlee Moser, Jonathan Z. Li, Teresa H. Evering, Justin Ritz, David Margolis, David Wohl, Michael D. Hughes, Eric Daar, Judith S. Currier, Joseph J. Eron, Davey M. Smith, for the ACTIV-2/A5401 Study Team

670**Risk of SARS-CoV-2 Infection in Patients With Hematologic Diseases Receiving Tixagevimab/Cilgavimab**

Alessandra Vergori, Alessandro Cozzi-Lepri, Marta Chiuchiarelli, Valentina Mazzotta, Elisabetta Metafuni, Giulia Matusali, Valentina Siciliano, Jessica Paulicelli, Eleonora Alma, Agostina Siniscalchi, Elisabetta Abruzzese, Simona Sica, Massimo Fantoni, Andrea Antinori, **Antonella Cingolani**

671**Immunogenicity of Tixagevimab/Cilgavimab for COVID-19 in Immunocompromised Children and Adolescents**

Jassada Buaboonnam, **Supattra Rungmaitree**, Nuntawan Piyaphanee, Sirirat Charuvanij, Onsiri Pititsutthithum, Katherine Copeland, Chatkamol Pheerapanyawaranun, Suvimol Niyomnaitham, Kulkanya Chokephaibulkit

672**Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1**

Lee Tatham, Joanne Sharp, Megan Neary, Joanne Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Helen Cox, Chloe Bramwell, Anthony Valentijn, Usman Arshad, Henry Pertinez, Paul Curley, Rajith Rajoli, James P. Stewart, Andrew Owen

673**First-in-Human Phase I Trial of an Adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine**

Natalie Collins, Brittany Ober Shepherd, Paul T. Scott, Melanie McCauley, Jack Hutter, Christine Lee, Iyelese Guzman, Adrian McDermott, Shelia Peel, M. Gordon Joyce, Merlin L. Robb, Nelson L. Michael, Sandhya Vasan, Kayvon Modjarrad, for the SpFN/ALFQ Study Group

674**PREVENT: Phase I Clinical Trial of a Q-Griffithsin (Q-GRFT) Nasal Spray for Prevention of SARS-CoV-2**

Katherine E. Bunge, Lin Wang, Lisa C. Rohan, Sravan Patel, Leslie A. Meyn, Ingrid S. Macio, Catherine A. Chappell, Amanda Lasnik, Kathleen Kitterman, Nobuyuki Matoba, Kenneth Palmer, Sharon L. Hillier

Poster Session-H3 | Broadly Neutralizing Antibodies and Resistance

2:30 PM - 4:00 PM • Poster Hall C-D

687**Env Conformational Flexibility Modulates HIV-1 Sensitivity to VRC01-Mediated Prevention**

Durgadevi Parthasarathy, Karunakar R. Pothula, Ruth Parsons, Xiao Huang, Salam Sammour, Katarzyna Janowska, Miranda Harris, Joseph Sodroski, Priyamvada Acharya, Alon Herschhorn

688**HIResist: A Database of HIV-1 Resistance to Broadly Neutralizing Antibodies**

Milind Misra, **Jeffy Jeffy**, Charis Liao, Stephannie Pickthorn, Kshitij Wagh, Alon Herschhorn

689**New HIV-1 Cell-Cell Transmission Assay Identifies Cell Type Dependency of PG9 And P16 Neutralization**

Dmitriy Mazurov, Alon Herschhorn

690**Development of Individualized Antibody Treatment Regimens for Patients With Multidrug-Resistant HIV**

M. A. Rai, Jana Blazkova, Jesse S. Justement, Victoria Shi, Brooke D. Kennedy, Maegan R. Manning, Mary McLaughlin, Michael C. Sneller, Alice K. Pau, Susan Moir, Tae-Wook Chun

691**Teropavimab and Zinlirvimab Sensitivity in People Living With MDR HIV-1: PRESTIGIO Registry Data**

Vincenzo Spagnuolo, Laura Galli, Aiyappa Parvangada, Keith J. Dunn, Filippo Lagi, Roberta Gagliardini, L. Sarmati, Annamaria Cattelan, Andrea Giacomelli, Maria Mercedes Santoro, Maurizio Zazzi, Christian Callebaut, Antonella Castagna, Laurie VanderVeen

692**Studying Dual Role of Glycosylation in Resistance to Broadly Neutralizing Antibodies In Vitro**

Teresa Murphy, Rebecca Lynch, Gabe Galeotos

Poster Session-I3 | HBV and HDV: Epidemiology, Natural History, and Pathogenesis

2:30 PM - 4:00 PM • Poster Hall C-D

724**Epidemiologic Burden of Hepatitis D Virus in the United States**

Elizabeth M. Marlowe, Brooke E. Swanson, Susan E. Realegeno, Ron M. Kagan, William A. Meyer

725**Incidence and Outcome of HDV Infection in People With HIV in the Era of Tenofovir-Containing Therapy**

Yu-Shan Huang, Shu-Yuan Ho, Li-Hsin Su, Yi-Ching Su, Wen-Chun Liu, Hsin-Yun Sun, Wang-Hui Sheng, Szu-Min Hsieh, Yu-Chung Chuang, Sui-Yuan Chang, Chien-Ching Hung

726 Risk of Liver-Related Events in Individuals With HBV/HIV Coinfection With and Without HDV

Laura E. Telep, **Grace M. Chee**, Amanda W. Singer, Anand P. Chokkalingam, David L. Wyles

727 Changes in Liver Fibrosis Stage Among People Living With Untreated Hepatitis B in Senegal

Adrià Ramírez Mena, Bruce Wembulua Shinga, Aboubakar S. Badiane, Kiné Ndiaye, Judicaël Tine, Alassane Ndiaye, Maguett Fall, Hubert Akotia, Melissa S. Pandi, Daye Ka, Louise Fortes, Ousseynou Ndiaye, Ndeye Fatou Ngom, Moussa Seydi, Gilles Wandeler, for SEN-B

728 Prevalence and Incidence of Hepatitis B Among People Living With HIV in 4 Sub-Saharan Countries

Josphat Kosgei, Nicole Dear, Hannah Kibuka, John Owuoth, Jonah Maswai, Valentine Sing'oei, Emmanuel Bahemana, Victor Anyebe, Debika Bhattacharya, Georg Lauer, Arthur Kim, Trevor A. Crowell, Neha Shah, Julie Ake, for the AFRICOS Study Group

729 Loss of Serologic Response in Young People With HIV (PWH) Who Had Undergone HBV Revaccination

Yi-Chia Huang, Hsin-Yun Sun, Sung-Hsi Huang, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Aristine Cheng, Wang-Da Liu, Chiao-Wen Huang, Wen-Chun Liu, **Chien-Ching Hung**

730 Chronic Hepatitis B Increases Mortality Risk in COVID-19 While Vaccination Is Protective

George A. Yendewa, Temitope Olasehinde, Frank Mulindwa, Amir M. Mohareb, Jeffrey Jacobson

731 IL-21 Ameliorates Liver Inflammation by Enhancing MDSC Activity in Chronic HBV Infection

Xiaoyi Li, Zhipeng Liu, Guofu Ye, Shihong Zhong, **Shuqin Gu**, Libo Tang, Yongyi Li

Poster Session-I4 | HBV and HDV Treatment and Cure

2:30 PM - 4:00 PM • Poster Hall C-D

732 Factors Associated With HBV Response to B/F/TAF vs DTG + F/TDF at W96 in People With HIV-1 and HBV

Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien-Ching Hung, Sasisopin Kiertburanakul, Man-Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Jason Hindman, Hongyuan Wang, Hui Liu, Taisheng Li

733 Novel Biomarkers as Determinants of HBsAg Loss in Persons With HIV/HBV on Tenofovir

NIS **Lorin Begré**, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Charles Béguelin, Franziska Suter-Riniker, Caroline Scholtes, Juergen K. Rockstroh, Karine Lacombe, Lars Peters, Massimo Levrero, Andri Rauch, Fabien Zoulim, Gilles Wandeler

734 Circulating HBV RNA Helps Characterize HBV Disease in Senegal

NIS **LB** **Lorin Begré**, Hubert Akotia, Bruce Wembulua Shinga, Melissa S. Pandi, Ousseynou Ndiaye, Judicaël Tine, Pascal Bittel, Christoph Niederhauser, Martin Stoltz, Andri Rauch, Ndeye Fatou Ngom, Adrià Ramírez Mena, Moussa Seydi, Gilles Wandeler, for SEN-B

735 Efficacy and Safety of BLV 2 or 10 mg for 96 Weeks in CHD**Including in 2 Patients With HIV/HBV/HDV**

Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, **David L. Wyles**, Viacheslav Morozov, Vladimir Chulanov, Ben Da, Renee-Claude Mercier, Grace M. Chee, Mingyang Li, Pietro Lampertico

736 Transaminase Elevations Among Patients With Occult HBV Infection on 2-Drug Antiretroviral Regimens

NIS Luca Mezzadri, Bianca Monti, Alice Ranzani, Anna Cappelletti, Silvia Limonta, Alessandro Soria, Elisa Colella, Ilaria C. Caramma, Nicola Squillace, Paolo Bonfanti, Giuseppe Lapadula

737 Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen

Giulia Morsica, Riccardo Lolatto, Sara Diotallevi, Valentina Svicher, Costanza Bertoni, Alessia Siribelli, Hamid Hasson, Sabrina Bagaglio, **Tommaso Clemente**, Arianna Forniti, Romina Salpini, Caterina Uberti-Foppa, Antonella Castagna, Nicola Gianotti

738 Circulating HBsAg-Specific B-Cells Are Partially Rescued After Achieving Functional Cure

NIS Shuqin Gu, Libo Tang, Guofu Ye, Ling Guo, Shihong Zhong, Xiaoyi Li, Nikolai Novikov, Simon P. Fletcher, Sarah Valencia, M. Anthony Moody, Yongxin Li

739 Monthslong HBV Suppression by TFV Double Ester Prodrugs

NIS Srijanee Das, Weimin Wang, Samiksha Raut, Murali Ganesan, Grace A. Bybee, Nam Thai Hoang Le, Howard E. Gendelman, Natalia A. Osna, Larisa Poluektova, Benson Edagwa

740 Evaluation of the Hepatitis B Virus Reservoir With Fine Needle Aspiration and Serum Biomarkers

Barbara Testoni, Armando Andres Roca Suarez, Marie-Laure Plissonnier, Caroline Scholtes, Floriana Facchetti, Marinta Heil, François Villeret, Yasmina Chouik, Massimo Leviero, Upkar Gill, Patrick Kennedy, Pietro Lampertico, **Fabien Zoulim**

741 Intrahepatic cccDNA and Circulating HBV Markers in HBeAg-Negative Chronic Infection in Senegal

LB Adrià Ramírez Mena, Aleksei Suslov, Hubert Akotia, Pascal Bittel, Andreas Limacher, Judicaël Tine, Christoph Niederhauser, Bruce Wembulua Shinga, Melissa S. Pandi, Ndeye Fatou Ngom, Stefan Wieland, Markus Heim, Moussa Seydi, Gilles Wandeler

Poster Session-J3 | Anal and Cervical Cancer: Pathogenesis, Screening, and Treatment

2:30 PM - 4:00 PM • Poster Hall C-D

759 Clinical Predictors and Outcomes of Anal Cancer for People With HIV in an Inception Cohort

Edward Cachay, Tari Gilbert, Huifang Qin, Christopher Mathews

760 Evaluation of the Performance of Different High-Resolution Anoscopy Triage Strategies in MSM LWH

Eugenio Nelson Cavallari, Federica Alessi, Chiara Eberspacher, Marco Ridolfi, Ilyass El Abboubi, Alessandra Latini, Angelina Pernazza, Daniela Bosco, Domenico Mascagni, Claudio Maria Mastrianni, Gabriella D'Ettorre

761 **Anal Self-Sampling Is Suitable for Anal Cancer Screening Among Men Who Have Sex With Men in Togo**

Valentine M. Ferré, Arnold Sadio, Romane Guilbaud, Meryem Zaidi, Mawussé K. Attiso, Mounerou Salou, Laurent Abramowitz, Mélanie Bertine, Amivi P. Amenyah-Ehlan, Ephram Mensah, Claver Anoumou Dagnra, Jade Ghosn, Diane Descamps, Didier Koumavi Ekouevi, Charlotte Charpentier

762 **Long-Term ART Is Not Associated With Reduced Anogenital Cancer Risk: A Case-Cohort Study**
NIS

Maanasa Mendu, Taolo Ntloedibe, Memory Bvochora-Nsingi, Sebathu Chiyapo, Kutlo Manyake, Isaac Nkele, Rebecca Luckett, Tendani Gaolathe, Joseph M. Makhema, Peter Vuylsteke, Shahin Lockman, Scott Dryden-Peterson

763 **Trial Comparing Cryotherapy to LEEP in Women With HIV: CIN2+ Recurrence After 9 Years**

Douglas K. Gaitho, Marleen Temmerman, Evans Nyongesa-Malava, Shahin Sayed, Stephen Hawes, Andrew Nagy, Samah Sakr, Judith Lukorito, Aisha Bwanaali, Dennis Omondi, Nelly R. Mugo, James Kiarie, **Michael Chung**, Carey Farquhar, Christine McGrath

764 **Prioritizing Anal Cancer Screening in PWH: Not All Are at the Same Risk**
LB

Raquel Martin-Iguacel, Boris Revollo, Jordi Aceiton, Pere Domingo, Joaquín Burgos, Patricia Sorni, María Saumoy, Hernando Knobel, Marta Navarro, Elena Leon, Amat Ortí, José M Miró, Jordi Casabona, Josep M. Llibre, for the PISCIS Cohort Study Group

Poster Session-K2 | Cardiovascular Disease Trends and Risk Factor Modification

2:30 PM - 4:00 PM • Poster Hall C-D

781 **Factors Affecting Risk of Major Adverse Cardiovascular Events Among People With HIV in REPRIEVE**
LB

Markella Zanni, Maya Watanabe, Heather J. Ribaud, Gerald S. Bloomfield, Kathleen V. Fitch, Carl J. Fichtenbaum, Triin Umbleja, Judith S. Currier, Judith A. Aberg, Carlos D. Malvestutto, Marissa Diggs, Michael T. Lu, Pamela S. Douglas, **Steven Grinspoon**, for REPRIEVE Investigators

782 **Performance of the ACC/AHA Pooled Cohort Equations for Risk Prediction in the Global REPRIEVE Trial**
LB

Steven Grinspoon, Heather J. Ribaud, Virginia Triant, Kathleen V. Fitch, Amy Kantor, Judith S. Currier, Gerald S. Bloomfield, Marissa Diggs, Judith A. Aberg, Carlos D. Malvestutto, Carl J. Fichtenbaum, Michael T. Lu, Markella Zanni, Pamela S. Douglas, for the REPRIEVE Investigators

783 **Residual HIV Viremia Doubles Cardiovascular Disease Incidence Independent of Classic Risk Factors**
LB

Twan Otten, Marc Blaauw, Wilhelm A. Vos, Albert L. Groenendijk, Louise E. van Ekeren, Olivier Richel, Mihai Netea, Jan van Lunzen, Niels P. Rijsen, Linos Vandekerckhove, Andre J. van der Ven, for 2000HIV Human Functional Genomics Partnership Program

784 Temporal Trends of Cardiovascular Disease Incidence in People With HIV From 2001-2021

NIS

Nadine Jaschinski, for the RESPOND and D:A:D Study Groups

785 The Effect of Dolutegravir on Whole-Body Glucose Disposal and Lipid Metabolism in Healthy VolunteersShahid A. Bukhari, Roya Movahedi, James Nesbitt, Sujin Kang, Betsabe Rodriguez Mateos, Krestine Elecito, Arnold Xhikola, Graeme Moyle, Ana Milinkovic, **Marta Boffito**, Ruth Byrne**786 Factors Associated With Smoking Cessation Among Patients in the HIV Outpatient Study, 2007-2022**Jun Li, Carl Armon, Alexander C. Ewing, Jonathan Mahnken, Ellen M. Tedaldi, Frank Palella, Richard Novak, Cynthia Firnhaber, Stockton Mayer, Andrea Wendrow, Gina Simoncini, Linda Battalora, Kimberly Carlson, **Kate Buchacz**, for the HIV Outpatient Study (HOPS) Investigators**787 Associations Between Antiretroviral Therapy and Cardiovascular Events in People With Treated HIV**

NIS

Luis Parra-Rodriguez, John Sahrmann, Anne M. Butler, Margaret A. Olsen, William G. Powderly, Jane A. O'Halloran

788 Modifiable Factors Associated With Cardiovascular Disease Risk Among Women With and Without HIV

Jenni Wise, Elizabeth Jackson, Liang Shan, Andrew Edmonds, Deborah Konkle-Parker, Maria L. Alcaide, Gina Wingood, Tracey Wilson, Kathleen Weber, Aruna Chandran, Seble Kassaye, David B. Hanna, Anna Leddy, John Cleveland, Mirjam Colette-Kempf, for the Multicenter AIDS Cohort Study (MACS) & Women's Interagency HIV Study (WIHS) Combined Cohort Study

Poster Session-K3 | Hypertension: Risk Factors and Interventions

2:30 PM - 4:00 PM • Poster Hall C-D

789 No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for HIV PrEP in HPTN 083

LB

Raphael J. Landovitz, Heather J. Ribaudo, Younjung Choi, Kari Chansky, Zoe Wang, Mina Hosseiniipour, Sinead Delany-Moretlwe, Lydia Soto-Torres, Sheryl Zwierski, Marybeth McCauley, James F. Rooney, Alex R. Rinehart, Beatriz Grinsztejn

790 Higher Risks of Hypertension With Use of DTG Versus PI/r in the VISEND TrialLloyd B. Mulenga, Kaitlyn M. McCann, Lameck Chirwa, Manya Mirchandani, **Andrew Hill**, for the VISEND Study Team**791 Hypertension Treatment Gap Among People With/Without HIV in Kenya, Nigeria, Tanzania, and Uganda**

Matthew Romo, Nicole Dear, Trevor A. Crowell, Seth Frndak, Hannah Kibuuka, John Owuoth, Valentine Sing'oei, Jonah Maswai, Emmanuel Bahemana, Victor Anyebe, Zahra Parker, Julie Ake, J. Sean Cavanaugh, Neha Shah, for the African Cohort Study (AFRICOS) group

Poster Session-L4 | Antiretroviral Therapy: Immunologic Effects

2:30 PM - 4:00 PM • Poster Hall C-D

817**NIS****Transcriptomics and Proteomics Reveal Differential Pathways in DTG/3TC vs 3DR Regimens in PLHIV**

Victoria Rios-Vazquez, Wilhelm A. Vos, Marc Blaauw, Louise E. van Ekeren, Albert L. Groenendijk, Quirijn de Mast, Leo Joosten, Mihai Netea, Willem L. Blok, Janneke E. Stalenhoef, Jan van Lunzen, Andre J. van der Ven

818**Inflammatory Profile of B/F/TAF, DTG/ABC/3TC, and DTG+F/TAF Over 5 Years and Effects of Viral Blips**

Nicholas Funderburg, Susie S. Huang, Calvin Cohen, Kate Ailstock, Jean Lee, Brenda Ng, Kirsten White, Jeff J. Wallin, Bryan Downie, Grace A. McComsey

819**NIS****Impact of Raltegravir Intensification on the Gut Microbiota of People With Chronic HIV-1 Infection**

Maria Casadellà, Aleix Elizalde-Torrent, Francesc Català-Moll, Alessandra Borgognone, Mariona Parera, Marc Noguera-Julian, Roger Paredes

820**Blood Telomere Length in ART-Naive PLWH Starting DTG+3TC vs Triple Regimen With 2 Nucleosides**

Francesca Lombardi, Alessia Sanfilippo, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Valentina Iannone, Damiano Farinacci, Pierluigi Francesco Salvo, Enrica Tamburini, Simona Di Giambenedetto

Poster Session-L5 | Sex Differences in Comorbidities and Inflammation

2:30 PM - 4:00 PM • Poster Hall C-D

821**NIS****Age Modifies the Association Between Sex and the Plasma Inflammatory Proteome in Treated HIV**

Rebecca Abelman, Samuel R. Schnittman, Gabriele B. Beck-Engeser, Noah Aquino, Gabrielle C. Ambayec, Carl Grunfeld, Edward Cachay, Joseph J. Eron, Michael S. Saag, Robin M. Nance, Joseph A. Delaney, Heidi M. Crane, Adam Olshen, Peter W. Hunt, for the CFAR Network of Integrated Clinical Systems (CNICS) Group

822**NIS****Consequences of Low-Level Viremia by Sex Among People With HIV in the United States**

Amalia Aldredge, Cyra C. Mehta, Cecile D. Lahiri, Maria L. Alcaide, Kathryn Anastos, Todd T. Brown, Audrey L. French, Frank Palella, Michael Schneider, Phyllis Tien, Anandi N. Sheth, Lauren F. Collins

823**Short- and Long-Term Body Weight Gain Following Switch to Integrase Inhibitors Differs by Sex**

Cecile D. Lahiri, Cyra C. Mehta, Qian Yang, Joffi Musonge-Effoe, Julie B. Dumond, Maria L. Alcaide, Jordan E. Lake, Leah H. Rubin, Audrey L. French, Jennifer Cocohoba, Seble Kassaye, Anjali Sharma, Anandi N. Sheth, Igbo Ofotokun, Jessica A. Alvarez

824**Body Composition Changes Among DMPA and Non-Hormonal Users on TDF Based ART Switched to B/F/TA**

Flavia Kiweewa Matovu, Martin Nabwana, Esther Isingel, Philippa Musoke, Mary G. Fowler, John Pettifor, Todd T. Brown, Mags Bekinska, for the BONE: STAR Study Team

Poster Session-L7 | Renal Outcomes

2:30 PM - 4:00 PM • Poster Hall C-D

828 Safety of Tenofovir Alafenamide in Individuals With a History of Proximal Renal Tubulopathy on TDF

Lucy Campbell, Birgit Barbini, Ben Cromarty, Lisa Hamzah, Margaret Johnson, Deborah Williams, Alan Winston, **Frank A. Post**, for the FANTA Trial Team

829 Urinary Exosome-Derived MicroRNAs as Biomarkers of TDF Renal Toxicity in People Living With HIV

Jose L. Casado, Isabel Izuzquiza, Pilar Vizcarra, Carmen Santiuste, Jose M. Del Rey, Alejandro Vallejo

830 Biomarkers Influence Kidney Function Estimates More So Than Race Among Persons With HIV

Peggy-Ita A. Obeng-Nyarkoh, Amanda B. Spence, Richard Teran, Christopher A. Loffredo, Bruce Luxon, Joseph Timpone, Princy Kumar, Jason Umans, Seble Kassaye

831 Markers of Macrophage Activation and Kidney Function in People With and Without HIV

Molly Fisher, David B. Hanna, Anjali Sharma, Todd T. Brown, Michelle Floris-Moore, Frank Palella, Jordan E. Lake, Seble Kassaye, Susan L. Koletar, Eric Seaberg, Igbo Ofoekun, Aubri Hickman, Alan Landay, Robert Kaplan, Michael Ross

832 Anti- α 4 β 7 Antibody Facilitates Improved Renal Function During SIV Infection in Macaques

Samuel D. Johnson, Thomas A. Premeaux, Nageswara Pilli, Jianshi Yu, Lishomwa Ndhlovu, Maureen A. Kane, Siddappa N. Byrareddy

Poster Session-M2 | Factors Affecting Outcome of Acute COVID-19

2:30 PM - 4:00 PM • Poster Hall C-D

857 Predictors of Breakthrough COVID-19 Infection From the STOPCoV Cohort

Sharon Walmsley, Majid Nabipoor, Leif Erik Lovblom, Rizani Ravindran, Roaya M. Dayam, Dorin Manase, Karen Colwill, Anne-Claude Gingras, for the StopCov Research Team

858 Immunosuppressive Conditions Are Associated With Poor Outcomes in Patients Hospitalized for COVID-19

Vijeeth Guggilla, Jennifer Pacheco, Alexandre Carvalho, Anna Pawlowski, Grant Whitmer, Chad Achenbach, Theresa Walunas

859 Characteristics and Outcomes of Patients with Kidney Transplant Hospitalized for COVID-19 in the US

Essy Mozaffari, Aastha Chandak, Andre C. Kalil, Chidinma Chima-Melton, Alpesh N. Amin, Mark Berry, Jason F. Okulicz, Robert L. Gottlieb

860 COVID-19 Omicron Infection and Severe Outcomes in HIV and Matched Non-HIV Cohorts in Ontario, Canada

Ann N. Burchell, Catharine Chambers, Lena Nguyen, Curtis L. Cooper, Abigail E. Kroch, Hasina Samji, Cecilia T. Costiniuk, Aslam H. Anis, Jeffrey C. Kwong, Rahim Moineddin, Sarah A. Buchan, Lawrence Mbuagbaw, Claire E. Kendall, Devan Nambiar, for the COVAXHIV Team

861 SARS-CoV-2 Infection and Hospitalization in Immunocompromised Children: A Population-Based Study

Costanza Di Chiara, Arianna Giugni, Marthe Le Prevost, Elisa Barbieri, Angela Lupatelli, Carlo Giaquinto, Daniele Donà, Anna Cantarutti

862 Epidemiology, Clinical Features, and Severity of COVID-19 in Immunocompromised Children in Canada

Costanza Di Chiara, Tilmann Schober, Daniel S. Farrar, Julie A. Bettinger, Joanne E. Embree, Scott A. Halperin, Tajdin Jadavji, Kescha Kazmi, Rupeena Purewal, Manish Sadarangani, Laura Sauvé, Karina A. Top, Fatima Kakkar, Jesse Papenburg, Shaun K. Morris

863 In-Hospital Mortality During Different SARS-CoV-2 Variant Waves in the EuCARE Multinational Cohort

Pontus Hedberg, Milosz Parczewski, Giulia Marchetti, Björn Jensen, Francis Drobniowski, Daniel Naumovas, Francesca Ceccherini-Silberstein, Gibran Horemheb Rubio Quintanares, Matilu Mwau, Cristina Toscano, Maurizio Zazzi, Alessandro Cozzi-Lepri, Anders Sönnnerborg, Pontus Nauclér, for the EuCARE WP3

864 Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among People With HIV

Markella Zanni, Triin Umbleja, Carl J. Fichtenbaum, Kathleen V. Fitch, Sara McCallum, Judith A. Aberg, Edgar T. Overton, Carlos D. Malvestutto, Gerald S. Bloomfield, Judith S. Currier, Samuel R. Schnittman, Michael T. Lu, Pamela S. Douglas, Heather J. Ribaudo, **Steven Grinspoon**

865 The Effect of COVID-19 Infection on Fat, Lean Mass, and Bone Mineral Density

Ornina Atieh, Jared Durieux, Jhony Baissary, Christian F. Mouchati, Danielle Labbato, Grace A. McComsey

866 ICU-Acquired Infections More Common in Patients With COVID-19 Than in Patients With Influenza

NIS
Josefine Beck-Friis, Magnus Gisslén, Aylin Yilmaz, Anna Lindblom, Jonatan Oras

867 Plasma Thrombomodulin Predicts Thrombotic Events & Mortality in Patients Hospitalized With COVID-19

Sergio Padilla, Pascual Marco, Ana Marco-Rico, Christian Ledesma, Carolina Ding, Marta Fernández-González, Alba de la Rica, Javier García-Abellán, Paula Mascarell, Angela Botella, Nuria Ena, Lidia García, Jose Carlos Asenjo, Mar Masiá, Félix Gutiérrez

868 Decline in Time to Recovery From Mild-Moderate COVID-19 in a Large Platform Placebo-Controlled Trial

Ahmad Mourad, Yue Gao, Thomas Stewart, Adrian F. Hernandez, Susanna Naglie, Christopher J. Lindsell, for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators

Poster Session-N4 | Mortality Risk in Cryptococcal Meningitis and Other Invasive Mycoses

2:30 PM - 4:00 PM • Poster Hall C-D

885 NIS Suppression of Immunoglobulin Production and Mortality in HIV-Associated Cryptococcal Meningitis

Ronan Doyle, F. Kathryn Boyd, David S. Lawrence, Kwana Lechiile, Tshepo B. Leeme, Nabila Youssouf, Thomas S. Harrison, Cecilia Kanyama, Mosepele Mosepele, Henry C. Mwandumba, Chiratidzo Ndhlovu, James Scriven, Joseph N. Jarvis, for the AMBITION Study Group

886 Recent ART Initiation and Mortality Risk in HIV-Associated Cryptococcal Meningitis

Melanie Moyo, Newton Kalata, James Jafali, David S. Lawrence, Síle Molloy, Henry C. Mwandumba, Johnstone J. Kumwenda, Thomas S. Harrison, Joseph N. Jarvis, for AMBITION-cm and ACTA

887 NIS CSF HIV Viral Escape Is Associated With Improved Survival in Adults With HIV-Associated Meningitis

Jayne P. Ellis, Biyue Dai, Laura Nsangi, Gila Hale, Emmanuel Mande, Jane Gakuru, Enock Kagimu, Timothy Mugabi, Suzan Namombwe, Derrick Kasozi, Sara Kimuda, Asmus Tukundane, David B. Meya, David R. Boulware, Fiona Cresswell

888 Quantitative Antifungal Activity of Daily Liposomal Amphotericin With 5FC in Cryptococcal Meningitis

David R. Boulware, Biyue Dai, Laura Nsangi, Jane Gakuru, Enock Kagimu, Enos Kigozi, Timothy Mugabi, Derrick Kasozi, Suzan Namombwe, Sara Kimuda, Jayne P. Ellis, Caleb P. Skipper, Ann Fieberg, Conrad Muzoora, David B. Meya

889 IgG Responses Are Associated With Severe Disease and Mortality in AIDS-Associated Talaromycosis

Shanti Narayanasamy, Matthew T. Burke, Ngo Thi Hoa, Thuy Le, Thu T. Nguyen, Vo Trieu Ly

Poster Session-03 | Chronic Diseases, Pregnancy, and HIV

2:30 PM - 4:00 PM • Poster Hall C-D

910 Hypertension in Pregnant Persons by HIV Status and by DTG vs EFV Use in Botswana

Denise L. Jacobson, Modiegi Diseko, Judith Mabuta, Ellen Caniglia, Kathleen M. Powis, Lynn Yee, Joseph M. Makhema, Shahin Lockman, Roger Shapiro, Rebecca Zash

911 Gestational Diabetes in South African Women With HIV on Dolutegravir: Results From the ORCHID Study

Jennifer Jao, Elton Mukonda, Landon Myer, Elaine J. Abrams, Hlengiwe Madlala, Jack Hu, Jody Rusch, Jami Josefson, Julia Goedecke, Patrick Catalano

912 Pregnancy History Affects Age-Related Comorbidity Burden in US Women With and Without HIV

Lauren F. Collins, Cyra C. Mehta, Ava Cox, Qian Yang, Tina Tisdale, Martina Badell, Igbo Ofoekun, Daniel Westreich, Adaora Adimora, Seble Kassaye, Elizabeth F. Topper, Deborah Konkle-Parker, Aadia Rana, Maria L. Alcaide, Anandi N. Sheth

913 **Maternal HIV Is Associated With Lower Risk of Preeclampsia Among Zambian Women**

NIS

Katelyn J. Rittenhouse, Margaret Kasaro, M. Bridget Spelke, Yuri Sebastian, Humphrey Mwape, Kenneth Chanda, Nelly Mandona, Bellington Vwalika, Jeffrey S. Stringer

914 **Pregnancy Inflammatory Markers Predict Postpartum Weight in South African People Living With HIV**

Hlengiwe P. Madlala, Landon Myer, Hayli Geffen, Jody Rusch, Muki Shey, Demi Meyer, Julia Goedecke, Thokozile R. Malaba, Clive Gray, Marie-Louise Newell, **Jennifer Jao**

915 **Changes in Body Composition During Pregnancy in South African Women Living With HIV on ART**

Hlengiwe P. Madlala, Lara Dugas, Jennifer Jao, Elaine J. Abrams, Elton Mukonda, Hayli Geffen, Julia Goedecke, Patrick Catalano, Grace A. McComsey, Allison Zerbe, Justine Legbedze, Landon Myer

916 **Association of HIV and Dolutegravir With Changes in Blood Pressure During Pregnancy and Postpartum**

Landon Myer, Elaine J. Abrams, Mustafa Shuaib, Hlengiwe P. Madlala, Sandisiwe Matyseni, Phindi Zwane, Allison Zerbe, Justine Legbedze, Elton Mukonda, **Jennifer Jao**

917 **High Proportions of Adverse Births in Women With HIV and Non-Communicable Disease Comorbidities**

NIS

Amohelang Lehloa, Emma Kalk, Mary-Ann Davies, Dorothy Nyemba, Ushma Mehta, Thokozile R. Malaba, Gregory Petro, Andrew Boulle, Landon Myer, Hlengiwe P. Madlala

918 **DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure**

NIS

Thokozile R. Malaba, Sylvia Nassiwa, Nengjie He, Helen Reynolds, Jim Read, Lucy Read, Catherine Orrell, Angela Colbers, Catriona Waitt, Mohammed Lamorde, Saye Khoo, Duolao Wang, Landon Myer, for the DOLPHIN-2 Study Group

919 **The Impact of HIV and the Postpartum Period on the Gut Microbiota in South African Women**

LB

Lara R. Dugas, Hlengiwe P. Madlala, Gertrude Ecklu-Mensah, Candice Choo-Kang, Julia Goedecke, Amy Mendham, Jess Davies, Chad Africa, Demi Meyer, Jack Gilbert, Brian Layden, Jennifer Jao, Elaine J. Abrams, Angela Bengtson, Landon Myer

Poster Session-06 | HIV and Birth Outcomes**2:30 PM - 4:00 PM • Poster Hall C-D****928** **Arteriolar Dysfunction in Placentas of HIV-Exposed, Small-for-Gestational-Age Neonates**

Rachel K. Scott, Jason Umans, Sean Dalby, Katherine Michel, Christopher Wilcox, Dan Wang

929 **A Target Trial of Preconception Switch From Nevirapine- to Dolutegravir-Based ART on Birth Outcomes**

Ellen Caniglia, Rebecca Zash, **Modiegi Diseko**, Judith Mabuta, Mompati Mmalane, Shahin Lockman, Gloria K. Mayondi, Gaerolwe Masheto, Joseph M. Makhema, Roger Shapiro

930 HIV and Syphilis Coinfection in Pregnancy and Adverse Birth Outcomes in Uganda

Timothy Kintu, Mehal Churiwal, Onesmus Byamukama, Ingrid V. Bassett, Mark J. Siedner, Anacret Byamukama, Edna Tindimwebwa, Julian Adong, Elias Kumbakumba, Stephen Asiimwe, Joseph Ngonzi, Lisa M. Bebell

931 Maternal and Pregnancy Outcomes in Women Initiating and Declining PrEP in Pregnancy: IMPAACT 2009

LB

Benjamin H. Chi, Deborah Kacanek, Emily Brown, K. Rivet Amico, Sharon Huang, Teacler Nematadzira, Elizea Horne, Clemensia Nakabiito, Sharon K. Mambiya, Violet Korutaro, Benjamin Johnston, James F. Rooney, Lynda Stranix-Chibanda, for the IMPAACT 2009 Study Team

932 Outcomes Following Prenatal Exposure to Raltegravir: A Multi-Cohort European Study

Rebecca Sconza, Georgina Fernandes, Karoline Aebi-Popp, Luminita Ene, Antoinette Frick, Anna Gamell, Marta Illán Ramos, Christian Kahlert, Helen Peters, Luis M. Prieto Tato, Anna Samarina, Carlo Giaquinto, Claire Thorne, for the EPPICC Pregnancy Study Group

933 Birth Outcomes Following Bictegravir Use During Pregnancy

LB

Rosemary M. Olivero, Paige L. Williams, George Sawyer, Lynn Yee, Kunjal Patel, Sonia Hernandez-Diaz, Kathleen M. Powis, Mary Paul, Ellen G. Chadwick, for the Pediatric HIV/AIDS Cohort Study (PHACS)

Poster Session-P1 | Health and Outcomes of Children Exposed to Antiretrovirals in Utero

2:30 PM - 4:00 PM • Poster Hall C-D

934 First Trimester Exposure to Newer Antiretroviral Agents and Congenital Anomalies in a US Cohort

Kelly Fung, Sonia Hernandez-Diaz, Rebecca Zash, Ellen G. Chadwick, Russell Van Dyke, Carly Broadwell, Jennifer Jao, Kathleen M. Powis, Lynn Yee, **Paige L. Williams**, for the Pediatric HIV/AIDS Cohort Study (PHACS)

935 Cancer Incidence in Children Who Are HIV-Exposed and Uninfected in England: Data Linkage Study

Laurette L. Lukasa, **Claire Thorne**, Mario Cortina-Borja, Helen Peters, Pia Hardelid

936 Maternal Imprinted Immune Perturbations in HIV-Exposed Uninfected (HEU) Infants Persist for 6 Months

Li Yin, Bernard M. Fischer, Guglielmo M. Venturi, Upasana Nepal, Shivangi Choudhary, Jerry Shen, Kai-Fen Chang, Isaac D. Raplee, Samiksha A. Borkar, Julie J. Kim-Chang, Kristina De Paris, Maureen M. Goodenow, John W. Sleasman

937 Brain Structure of South African HEU Children Exposed to Dolutegravir versus Efavirenz

NIS

Layla E. Bradford, Jessica E. Ringshaw, Catherine J. Wedderburn, Niall J. Bourke, Helene Theunissen, Thokozile R. Malaba, Lauren Davel, Nengjie He, Helen Reynolds, Angela Colbers, Duolao Wang, Saye Khoo, Landon Myer, Kirsten A. Donald

938

Neurodevelopment in Children Exposed In Utero to Dolutegravir- or Efavirenz-Based ART in Botswana

Adam R. Cassidy, Gloria K. Mayondi, Kebaiphe Moabi, Allison LeMahieu, Paige L. Williams, Naledi Kamanga, Kathleen M. Powis, Dinah Ramaabya, Francis Banda, Joseph M. Makhema, Betsy Kammerer, Shahin Lockman

939

Prenatal PrEP Exposure and Neurodevelopment Among Children at 48 months

NIS

Lauren A. Gomez, John Kinuthia, Felix Abuna, Sarah Benki-Nugent, Julia Dettinger, Anna Larsen, Mary Marwa, Ben Ochieng, Nancy Ngumbau, Saphine Watoyi, Joshua Stern, Barbra Richardson, Grace John-Stewart, Jillian Pintye

Poster Session-P2 | Pharmacokinetics, Dosing, and Safety of Antiretrovirals for Infants, Children, and Adolescents

2:30 PM - 4:00 PM • Poster Hall C-D

940

Simplifying Dosing by Harmonizing Weight-Band-Based Dosing Across Therapeutic Areas in Children

NIS

Hylke Waalewijn, Mounier Almett, Roeland E. Wasemann, Tim R. Cressey, Phillipa Easterbrook, Peter Ehizibue Olumese, Anneke C. Hesseling, Joel Tarning, Anna Turkova, Elin Svensson, Angela Colbers, Wilson M. Were, Paolo Denti, Martina Penazzato

941

Single-Dose PK/Safety of DTG-Dispersible Tablets in Neonates Supports Multi-Dosing: Petite-DTG Study

Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-in-at, Maria Groenewald, Edmund Capparelli, Andrew Owen, Ratchada Cressey, Marc Lallement, Mark F. Cotton, **Tim R. Cressey**, for the PETITE-DTG Study Team

942

Lamivudine (3TC) Dosing for Preterm Neonates Exposed to HIV

Adrie Bekker, Edmund Capparelli, Mark Mirochnick, Diana F. Clarke, Mark F. Cotton, Roger Shapiro, Katie McCarthy, Jack Moye, Avy Violari, Kulkanya Chokephaibulkit, Elaine J. Abrams, Martina Penazzato, Theodore Ruel, Tim R. Cressey

943

High Drug Exposures in Neonates Using ABC/3TC Dispersible Tablets During the First Week of Life

Navarat Panjasawatwong, Adrie Bekker, Helena Rabie, Nicolas Salvadori, Samantha du Toit, Kanchana Than-in-at, Maria Groenewald, Edmund Capparelli, Ratchada Cressey, Marc Lallement, Mark F. Cotton, Tim R. Cressey, for the PETITE study team

944

A Single Once Daily ABC/DTG/3TC Tablet Predicts Safe and Effective Exposures in Children 3 to <6kg

Hardik Chandasana, **Kristina M. Brooks**, Ann M. Buchanan, Lionel Tan, Hilda A. Mujuru, Angela Colbers, Judy Hopking, Marika Ciuffa, Michael McKenna, Andrew Wiznia, Sean Brummel, Adrie Bekker, Tim R. Cressey, Helena Rabie

945

Population Pharmacokinetics of ABC/DTG/3TC FDC to Support Dosing in Peds With HIV-1: IMPAACT 2019

Hardik Chandasana, Sven C. van Dijkman, **Rashmi Mehta**, Mark Bush, Helena Rabie, Patricia M. Flynn, Tim R. Cressey, Edward Acosta, Kristina M. Brooks, for the IMPAACT 2019 Protocol Team

946

NIS

Pharmacokinetics of Once-Daily DTG/3TC FDC in Children Living With HIV: D3/PENTA21 Sub-Study

Lisanne Bevers, Man Chan, Dickson Bbuye, Adeodata R. Kekitiinwa, Cissy Kityo, Elizabeth Kaudha, Grace M. Ahimbisibwe, Tiyara Arumugan, Tumelo Moloantoa, Justine Boles, Isabelle Deprez, Carlo Giaquinto, Anna Turkova, Angela Colbers, for the D3/PENTA21 Trial Team

947

Pediatric PBPK Scaling Model for a New Long-Acting, 3 HIV Drug Combination in a Single Injection

Simone Perazzolo, Zachary R. Stephen, Rachele Delle Fratte, Rachel A. Bender Ignacio, Christine Jonsson, Matthew Hartman, Pablo Belaunzarán-Zamudio, Keith W. Crawford, Brett Hanscom, Ann C. Collier, Ann J. Melvin, Rodney J. Ho

948

Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy

N. Rakhmanina, Aditya Gaur, Jaime G. Deville, Pope Kosalaraksa, Renate Strehlau, Eva Natukunda, Elizabeth Castaño, Vinicius A. Vieira, Kathryn Kersey, Rory Leisegang, Susanne Crowe, Catherine Gordon

949

IMPAACT 2017 Adolescent/Parent Experiences With LA Cabotegravir Plus Rilpivirine for HIV Treatment

Elizabeth D. Lowenthal, Jennifer C. Chapman, Martina Zapata Vaca, Shawn Ward, Ryan Milligan, Andres Camacho-Gonzalez, Gaerolwe Masheto, Cindy McCoig, Andi Ace, Rodica Van Solingen, Dwight Yin, Sarah Buisson, Carolyn Bolton, Aditya Gaur, for the IMPAACT 2017 Team

950

Cabotegravir PopPK Analysis of Adults & Adolescents Living With/At Risk for HIV Receiving PrEP

Yu-Wei Lin, S. Y. Amy Cheung, Isabelle Deprez, **Susan Ford**, Jon Collins, Cindy McCoig, Conn M. Harrington, Aditya Gaur, Carolyn Bolton, Lynda Stranix-Chibanda, Sybil Hosek, Mark Marzinke, Brookie Best, Edmund Capparelli, for the IMPAACT 2017 Team

Poster Session-P4 | Infants With HIV Infection: Diagnosis, Mortality, Morbidity, and Treatment Response

2:30 PM - 4:00 PM • Poster Hall C-D

959

High Proportion of False-Positive HIV Results With Point-of-Care Birth Testing in Botswana

Gbolahan Ajibola, Nyaladzi Maphorisa, Aischia Niesar, Terence Mohammed, Maureen Sakoi-Mosethi, Oganne Batlang, Sikhulile Moyo, Molly Pretorius Holme, Kathleen M. Powis, Shahin Lockman, Joseph M. Makhema, Mathias Lichtenfeld, Roger Shapiro

960

Rapid Antiretroviral Therapy Initiation Following Point-of-Care Early Infant Diagnosis in Uganda

Stella M. Migamba, **Tamara N. Nyombi**, Edirisa Nsubuga, Andrew Kwiringira, Benon Kwasiga, Steven N. Kabwama, Mary Nakafeero, Daniel Kadobera, Phoebe Mayambala, Lilian Bulage, Alex Ario, Julie Harris

961

Resistance in Young Children Newly–Diagnosed With HIV in Western Cape, South Africa

Kim Anderson, Gert U. van Zyl, Nei-yuan Hsiao, Vanessa Mudaly, Jacqueline Voget, Alexa Heekes, Emma Kalk, Florence Phelanyane, Andrew Boulle, Gayathri Sridhar, Leigh Ragone, Vani Vannappagari, Mary-Ann Davies

962**NIS**

CMV Viraemia Is Associated With Mortality Among Children With HIV Starting ART in Sub-Saharan Africa

Temitope Fisayo, Ceri Evans, Kuda Mutasa, Moira Spyer, Sandra Rukobo, Dagmar Alber, Mutsawashe Bwakura-Dangarembizi, Victor Musiime, Kusum Nathoo, Adeodata R. Kekitiinwa, Cissy Kityo, Diana Gibb, Nigel Klein, Sarah Walker, Andrew Prendergast

963

Sex Differences in Growth Trajectories Between Early-Treated Infants With HIV and Controls

Ana Barrios-Tascon, Renate Strehlau, Faeezah Patel, Megan Burke, Stephanie Shiao, Yanhan Shen, Stephen M. Arpadi, Elaine J. Abrams, Caroline T. Tiemessen, Louise Kuhn, for the LEOPARD Study Team

964

1 in 5 Sub-Saharan Infants Switches From Undetectable to Detectable HIV Viral Load During Follow-Up

Sheila Fernández-Luis, Sara Dominguez-Rodriguez, Louise Kuhn, Mark F. Cotton, Carlo Giaquinto, Paolo Rossi, Anita Janse van Rensburg, Avy Violari, Maria Grazia Lain, Elisa López-Varela, Mariam Sylla, Pauline Amugue, Pablo Rojo, **Alfredo Tagarro**, for EPIICAL

965

Causes of Death After Early ART in Infants Living With HIV From 3 Sub-Saharan African Countries

Alfredo Tagarro, Sheila Fernández-Luis, Sara Dominguez-Rodriguez, Alvaro Ballesteros, Louise Kuhn, Mark F. Cotton, Carlo Giaquinto, Paolo Rossi, Moira Spyer, Kennedy Otwombe, Osee Behuhuma, Paula Vaz, Caroline Foster, Pablo Rojo, for EPIICAL

966

Usefulness of Clinical Signs for Tuberculosis Diagnosis in Infants Living With HIV With Pneumonia

Tisungane Mvalo, Cinta Moraleda, William C. Buck, Victor Musiime, Sara Dominguez-Rodriguez, Chishala Chabala, Hilda A. Mujuru, Alfredo Tagarro, Pui-Ying Iroh Tam, Jahit Sacarlal, Abner Tagoola, John Tembo, Sheila Fernández-Luis, Pablo Rojo, for the EMPIRICAL Clinical Trial Group

Poster Session-P6 | Pediatric Antiretroviral Therapy Optimization: Dolutegravir in Action

2:30 PM - 4:00 PM • Poster Hall C-D

981**NIS**

No Early Signal That DTG Improves 24-Week Viral Suppression in Infants in Botswana

Maureen Sakoi-Mosetlhi, Gbolahan Ajibola, Oganne Batlang, Kenneth Maswabi, Molly Pretorius Holme, Kathleen M. Powis, Shahin Lockman, Michael D. Hughes, Joseph M. Makhema, Daniel R. Kuritzkes, Mathias Licherfeld, Roger Shapiro

982

HIV Viral Suppression Among Children and Adolescents 2 Years After Transition to Dolutegravir

Akash Devendra, Maurus Kohler, Motlatso Letsika, Hape Khooa, Lipontšo Motaboli, Malebanye Lerotholi, Nadine Tschumi, **Niklaus D. Labhardt**, Jennifer A. Brown

983

Longitudinal Viral Outcomes in Kenyan Youth With HIV Switching to Dolutegravir-Based Therapy

Vlad Novitsky, Winstone Nyandiko, Allison DeLong, Edwin Sang, Joel Hague, Ashley Chory, Josephine Aluoch, Eslyne Jepkemboi, Millicent Orido, Joseph Hogan, Rachel Freeman, Rami Kantor

984 Global Transition to Dolutegravir-Based ART in Children and Adolescents 0-19 Years Living With HIV

Sophie Desmonde, Kim Anderson, Joyeux Bwami, Du tuan Quy, Winstone Nyandiko, Christella Twizere, Marco T. Luque, Renee De Waal, Vohith Khol, Patricia Lelo, Vanessa Rouzier, Frankie Odhiambo, Valeriane Leroy, for leDEA

985 Treatment Interruption Patterns Among Young People in USAID-Supported PEPFAR Programs

Tishina Okegbe, Lana Lee, Nashiva McDavid, Madeline Schneider

986 Dolutegravir and Growth in Pediatric Populations With HIV-1: IMPAACT P1093 and IMPAACT 2019

Michael McKenna, Zrinka Lulic, Ann M. Buchanan, Cynthia Brothers, Lionel Tan, Marcia Wang, Sean Brummel, Lauren Ziembra, Theodore Ruel, Patricia M. Flynn, Helena Rabie, Andrew Wiznia

987 Pharmaco-Virological Outcome and Resistance Profiles Among Togolese Adolescents Transitioning to DTG

Yao R. Konu, Elom Takassi, Gilles Peytavin, Nina Dapam, Florence Damond, Adama Oumarou, Meryem Zaidi, Anna-Maria Franco-Yusti, Quentin Le Hingrat, Romain Coppée, Claver Anoumou Dagnra, Diane Descamps, Didier Koumavi Ekouevi, **Charlotte Charpentier**

988 Emerging Integrase Resistance in the Perinatal Virtual Clinic: The Need for Protease Inhibitors

Caroline Foster, Ayolola Eni-Oluta, Angela Bailey, Alasdair Bamford, Hermione Lyall, Julia Kenny, Leon Levin, Katherine R. Simon, Tiago Milheiro Silva, Neil Tickner, Anna Turkova, Steven Welch, **Nicola Mackie**, for the Perinatal Virtual Clinic

Poster Session-Q3 | HIV Disparities and Social Determinants of Health

2:30 PM - 4:00 PM • Poster Hall C-D

1016 Disparities in HIV Care Among Hispanic/Latino Persons by Birthplace and SVI: United States, 2021

Juliet A. Morales, Zanetta Gant Sumner, Xiaohong Hu, Shacara Johnson Lyons, Anna Satcher Johnson

1017 Prevalence of HIV Testing and HIV Positivity in the Hispanic Community Health Study/Study of Latinos

Mario J. Trejo, Jonathan Ross, Robert Kaplan, Tonia C. Poteat, Linda C. Gallo, Krista M. Perreira, Bonnie E. Shook-Sa, Gregory A. Talavera, David B. Hanna

1018 Association Between Social Vulnerability, HIV Testing, and Positivity: United States, 2020-2022

Wei Song, Mesfin S. Mulatu, Nicole Crepaz, Guoshen Wang, Aba Essuon, Mingjing Xia

1019 Using the ICE Method to Examine Income/Racial Segregation and HIV Outcomes: US, 2021

Zanetta Gant Sumner, **André Dailey**, Xiaohong Hu, Shacara Johnson Lyons, Anna Satcher Johnson

1020 The TIME Study: Trans People Living With HIV Throughout Europe: Clinical Outcomes and Stigma

Jo Smith, Jose Eduardo de Carvalho Peres, Sujin Kang, Tara Suchak, Lorena de la Mora Cañizo, Amanda Clarke, Tanya Adams, Sally Jewsbury, Yu Tang, Andrea Calcagno, Emanuele Drappero, Anna Serra, Maria Mazzitelli, Annamaria Cattelan, Marta Boffito, for the TIME Study Group

1021 Hazardous Impact of Social Determinants of Health on HIV Incidence in Brazilian Transgender Women

Carolina Coutinho, Emilia M. Jalil, Eduardo M. Peixoto, Laylla Monteiro, Biancka Fernandes, Mayara Secco Torres da Silva, Monica D. Pedrosa, Cristiane R. Castro, Marcos D. Sousa, Ruth K. Friedman, Ronaldo Moreira, Sandra W. Cardoso, Valdilea Veloso, Beatriz Grinsztejn

Poster Session-Q4 | HIV Incidence, Prevalence, and Risk Factors

2:30 PM - 4:00 PM • Poster Hall C-D

1022 HIV Situation in Areas Surrounding Larkana: Findings From Community Test and Treat Implementation

LB

Muhammad S. Jamil, Muhammad S. Pasha, Tanweer Hussain, Shahida Memon, Atif Ali, Altaf A. Soomro, Saima Mushtaq, Sikandar Memon, Joumana Hermez

1023 Narrowing Disparities in HIV Incidence Between Males and Females in Rural KwaZulu-Natal South Africa

Elphas Okango, Paul Mee, Khai Hoan Tram, Hae-Young Kim, Alex Edwards, Dickman Gareta, Maxime Inghels, Kobus Herbst, Henry Mwambi, Adrian Dobra, Frank Tanser

1024 Rapidly Changing Socio-Economic Patterns of HIV Incidence in Rural KwaZulu-Natal, South Africa

Paul Mee, Elphas Okango, Hae-Young Kim, Adrian Dobra, **Khai Hoan Tram**, Dickman Gareta, Kobus Herbst, Frank Tanser

1025 Ultra-High Resolution GPS to Measure Human Mobility in High HIV Prevalence Areas in Rural S. Africa

NIS

Khai Hoan Tram, Elphas Okango, Thulile Mathenjwa, Paul Mee, Hae-Young Kim, Till Bärnighausen, Adrian Dobra, Frank Tanser

1026 HIV Seroprevalence, Incidence, and Viral Suppression Among Ugandan Female Barworkers

NIS

Xinyi Feng, Slisha Shrestha, Fred Nalugoda, Godfrey Kigozi, Robert Ssekubugu, Larry W. Chang, Andrea Wirtz, Caitlin E. Kennedy, Arthur G. Fitzmaurice, Gertrude Nakigozi, Aaron A. R. Tobian, Steven J. Reynolds, Joseph Kagaayi, Mary Kate Grabowski

1027 Large Decline in HIV Prevalence Among Female Sex Workers in Zimbabwe, 2011-2023

LB

James Hargreaves, **Sungai Chabata**, Sanni Ali, Tsitsi Hove, Harriet Jones, Loveleen Bansi-Matharu, Owen Mugurungi, Raymond Yekeye, Sithembile Musumburi, Jeffrey Dirawo, Primrose Matambanadzo, Fortunate Machingura, Andrew Phillips, Frances M. Cowan

1028 HIV Incidence by Self-Reported Frequency of Condom Use: A Population-Based Cohort Study in Uganda

Victor Popoola, Fred Nalugoda, Caitlin E. Kennedy, Godfrey Kigozi, Gertrude Nakigozi, Steven J. Reynolds, Aaron A. R. Tobian, Victor Ssempijja, Justin Lessler, Arthur G. Fitzmaurice, Maria J. Wawer, Larry W. Chang, Ronald M. Galiwango, Joseph Kagaayi, **Mary Kate Grabowski**

1029 An HIV-1 Risk Assessment Tool for Women in 15 African Countries: A Machine Learning Approach

Nora E. Rosenberg, Bonnie E. Shook-Sa, Amber M. Young, Yating Zou, Lynda Stranix-Chibanda, Marcel Yotebieng, Nadia Sam-Agudu, Sam Phiri, Linda-Gail Bekker, Sizulu Moyo, Manhattan Charurat, Jessica E. Justman, Michael Hudgens, Benjamin H. Chi

1030 Recent HIV Infections and HIV Incidence in PrEP Among Adolescents From Key Populations in Brazil

Diana Reyna Zeballos Rivas, Fabiane Soares, Laio Magno, Celia Landmann, Orlando Ferreira, Matheus Westin, Dirceu Greco, Alexandre Grangeiro, Ines Dourado, for the PrEP1519 Study Group

1031 HIV Incidence and Factors Associated With Never Testing for HIV Among Young MSM: Conectad@s Study

Sylvia L.M. Teixeira, Emilia Jalil, Cristina M. Jalil, Rodrigo Scarparo, Valdilea Veloso, Erin Wilson, Willi McFarland, Beatriz Grinsztejn, Thiago S. Torres, for the Conectad@s Study Team

1032 Declines in HIV Incidence Among Gay, Bisexual and Other MSM in Vancouver, Canada, 2012-19 to 2017-23

David Moore, Lu Wang, Allan Lal, Justin Barath, Julio S. Montaner, Mark Hull, Junine Toy, Viviane Dias Lima, Paul Sereda, Robert Hogg, Nathan Lachowsky

1033 62% of New HIV Infections and 63% of Deaths Now Reported in Countries Outside Southern/East Africa

Toby Pepperrell, **Andrew Hill**

Poster Session-Q5 | HIV Viremia and Viral Rebound

2:30 PM - 4:00 PM • Poster Hall C-D

1034 Factors Associated With Low-Level Viremia in People Living With HIV: 9-Year Retrospective Study

Eunmi Yang, Doh Hee Kim, Subin Kim, Mi Young Ahn, Dong Hyun Oh, Jae-Phil Choi

1035 Incidence of Viral Rebound and Associated Risk Factors Among Adults Living With HIV in Tanzania

Patrick E. Mwanahapa, Andrew E. Mganga, Shafii S. Mgenzi, Goodlucky Ngoda, Emanuel Sarakikya, Stephen W. Kazimir, Paschal Muhonde, Melissa Kyamani, Mbaraka Amuri, Jonathan Grund, Swaminathan Mahesh, Andrea Mbunda, Josephine J. Mwakisambwe, Theodora Mbunda

1036 Detectable Viral Load Predicts Virological Failure at Follow-Up

Pido Bongomin, Victor Williams, Normusa Musarapasi, Magnus Beneus, Makhosazana Dlamini, Thokozani Maseko, Phetsile Mdluli, Elisha Nyandoro, Rhinos Chekenyere, Rufaro Mapona, Clara Nyapokoto, Arnold Mafukidze, Deus Bazira, Samson Haumba, Sylvia Ojoo

1037 HIV Data Informed Care: Using Routine Data to Identify Persons At Risk of Developing Viremia

Thomas Martin, Ravi Goyal, Gordon Honerkamp Smith, Alan Wells, Samantha Tweeten, Diana Corona-Mata, Susan J. Little

1038 Longitudinal Viral Load Clustering for People With HIV Using Functional Principal Component Analysis

Jiayang Xiao, Yunqing Ma, Xueying Yang, Bankole Olatosi, Xiaoming Li, Jiajia Zhang

Poster Session-R3 | Self-Testing, Adherence, and Drug Resistance Monitoring

2:30 PM - 4:00 PM • Poster Hall C-D

1097 Method for Analyzing Cabotegravir and Rilpivirine in Hair May Help Identify Risk Factors for Failure

Monica Gandhi, Alexander Louie, Matthew Spinelli, Jennifer Velloza, Catherine A. Koss, Andrew Riselli, Pieter Van Brantegem, Erica Beckerdite, Hana Rivera Garza, Karen Kuncze, Hideaki Okochi

1098 Toward Near-Patient HIV Drug Level Feedback: Implementing an Enzymatic Assay on a Portable Reader

LB Megan Chang, John Tatka, Cosette Craig, Shane Gilligan-Steinberg, Nuttada Panpradist, Barry Lutz, **Ayokunle Olanrewaju**

1099 Full Pol-Gene PCR and Rapid ONT Library Preparation for Accurate Drug Resistance Sequencing

Nicola Coetzee, Conan K. Woods, Kayla E. Delaney, Mathilda Claassen, Carli Gordijn, Emma Sauermann, Kim Steegen, Urvi M. Parikh, P. Richard Harrigan, Gert U. van Zyl

1100 A Rapid Emtricitabine Urine Lateral Flow Assay for Monitoring Daily Adherence to ART and PrEP

Thomas H. Vanderford, Xierong Wei, Ae S. Youngpairoj, Ayanna Green, Richard Haaland, Jeffrey A. Johnson, Walid Heneine

1101 User-Friendly and Efficient Multiplex HIV, Syphilis, and Hepatitis B & C Self-Screening in Thailand

Nicolas Salvadori, Jullapong Achalapong, Thitipan Akarasereenont, Sawitree Nangola, Chiraphat Kloypan, Eakkapote Prompunt, Naruepon Wongpluesin, Surachet Arunothong, Woottichai Khamduang, Nicole Ngo-Giang-Huong, Sakorn Pornprasert, Sumet Ongwandee, Gonzague Jourdain, for the Napneung Project Team

1102 Effectiveness of Using HIV Self-Tests as an Incentive for Testing Within Assisted Partner Services

NIS **Unmesha Roy Paladhi**, David Katz, George Otieno, James P. Hughes, Harsha Thirumurthy, Harison Lagat, Sarah Masyuko, Monisha Sharma, Paul Macharia, Rose Bosire, Mary Mugambi, Edward Kariithi, Carey Farquhar

Poster Session-R4 | Optimizing PrEP and Treatment

2:30 PM - 4:00 PM • Poster Hall C-D

- 1103 Increased HIV RNA Testing of PrEP Users Following 2021 CDC Guidance: United States, 2019-2023**

Weiming Zhu, Ya-Lin A. Huang, Kevin Delaney, Athena Kourtis, Karen W. Hoover

- 1104 Evidence of HIV Infection Prior to Rapid Antibody Test Positivity in PrEP Breakthrough Infections**

Vivian I. Avelino-Silva, Mars Stone, Sonia Bakkour, Clara Di Germanio, Michael Schmidt, Ashtyn Conway, David Wright, Brian Custer, Steven Kleinman, Jairam Lingappa, Patricia Defechereux, Megha Mehrotra, Robert Grant, Michael P. Busch, Philip P. Norris

- 1105 Costs and Clinic Flow of Point-of-Care Urine Tenofovir and HIV Viral Load Testing in South Africa**

Melody Wang, Pravi Moodley, Mlungisi Khanyile, Elliot Bulo, Makhosazane Zondi, Keshani Naidoo, Yukteshwar Sookrajh, Jienchi Dorward, Nigel Garrett, Paul K. Drain, Monisha Sharma

- 1106 A Capillary Blood-Based Self-Collection Method for Monitoring HIV Viral Load During ART Interruption**

Livio Azzoni, Daniel S. Rosenbloom, Jessicamarie Morris, Jennifer Nguyen, Brian N. Ross, Matthew Fair, Emmanouil Papasavvas, Kenneth Lynn, Emily Hiserodt, Brian Squadroni, Brad R. Evans, Pablo Tebas, Karam Mounzer, Bonnie Howell, Luis J. Montaner

Poster Session-S2 | Biomarkers and Other Assessments of PrEP Adherence

2:30 PM - 4:00 PM • Poster Hall C-D

- 1111 Drug Level Monitoring for PrEP Users: Feasible and Acceptable, but Is It Necessary?**

Erica R.M. Pool, Abigail Severn, Jose L. Paredes Sosa, Oliver Stirrup, Claire-Marie Mullender, Marzia Fiorino, Manik Kohli, Irfaan Maan, Rhiannon Owen, Deirdre Sally, Emmi Suonpera, David Dunn, Richard Gilson, John Saunders

- 1112 A Point-of-Care Urine Test Improves Accuracy of Self-Reported PrEP Adherence Among Women in Uganda**

Kidist Zewdie, Timothy Muwonge, Timothy Ssebuliba, Felix Bambia, Josephine Badaru, Olivia Nampewo, Gabrielle Stein, Kenneth K. Mugwanya, Katherine K. Thomas, Christina Wyatt, Michael T. Yin, Monica Gandhi, Andrew Mujugira, Renee Heffron

- 1113 PrEP Counseling Based on a Tenofovir Urine Assay Decreases Overall Non-Adherence Among Kenyan Women**

Monica Gandhi, David V. Glidden, Matthew A. Spinelli, Charlene Biwott, Gakuo Maina, Irene Njeru, Catherine Kiptinness, Phelix Okello, Purba Chatterjee, Guohong Wang, Vallery Ogello, Hideaki Okochi, Deepalika Chakravarty, Nelly R. Mugo, Kenneth Ngure

1114 Point-of-Care Urine Tenofovir Test Predicts Future PrEP Discontinuation Among Young PrEP Users

Matthew A. Spinelli, Rikki Montoya, Carlos Morerira, Karen Kuncze, Kevin Sassaman, David V. Glidden, K Rivet Amico, Emily Arnold, Susan P. Buchbinder, Leah Davis Ewart, Adam Carrico, Guohong Wang, Hideaki Okochi, Hyman Scott, Monica Gandhi

1115 Accuracy of PrEP Adherence Measures Among Transwomen and Young MSM in Latin America: ImPrEP Study

Thiago S. Torres, Mayara Secco Torres da Silva, Carolina Coutinho, Pedro Leite, Ronaldo Moreira, Brenda Hoagland, Juan V. Guanira, Marcos Benedetti, Hamid Vega, Sergio Bautista, Carlos Caceres, Peter L. Anderson, Beatriz Grinsztejn, Valdilea Veloso, for the ImPrEP Study Group

Poster Session-S3 | PrEP Implementation Around the World: Successes, Challenges, and Disparities

2:30 PM - 4:00 PM • Poster Hall C-D

1116 Inequities in PrEP Annualized Pill-Day Coverage: United States, 2018-2022

Patrick S. Sullivan, Eric Hall, Heather Bradley, Travis H. Sanchez, Elizabeth S. Russell

1117 Out-of-Pocket Payments for PrEP Ancillary Services Among US Commercially-Insured Persons, 2017-2021

Ya-Lin A. Huang, Weiming Zhu, Sloane A. Bowman, Karen W. Hoover

1118 PrEP Indicators by Race/Ethnicity Among Heterosexual Women Receiving CDC-Funded HIV Testing Services

Deesha Patel, Weston O. Williams, Carolyn Wright, Shaliondel Benton, Mesfin S. Mulatu

1119 Optimizing PrEP Outcomes for MSM Who Sell Sex: The Role of NIS Stigma, Violence, and Mental Health

Kaitlyn Atkins, John Mark Wiginton, Thomas Carpino, Travis H. Sanchez, Stefan Baral

1120 Behavioral and Structural Interventions for PrEP Adherence Among Young Female Sex Workers in Kenya

Kawango Agot, Domonique M. Reed, Matthew R. Lamb, Dan Omollo, Julie Franks, Jane Moraa, Joanne E. Mantell, Allison Zerbe, Timothy Okello, Maria Lahuerta, Doris Naitore, Wafaa El-Sadr

1121 Factors Associated With Inadequate PrEP Adherence Among TGW and Young MSM: ImPrEP Study

Mayara Secco Torres da Silva, Thiago S. Torres, Carolina Coutinho, Iuri Leite, Ronaldo Moreira, Brenda Hoagland, Cristina Pimenta, Kelika A. Konda, Hamid Vega, Sergio Bautista, Carlos Caceres, Peter L. Anderson, Valdilea Veloso, Beatriz Grinsztejn, for the ImPrEP Study Group

1122 Alcohol Use and the Preexposure Prophylaxis Continuum of Care Among Men in Rural South Africa

Alison C. Castle, Jacob Busang, Jaco Dreyer, Carina Herbst, Nonhlanhla Okesola, Natsayi Chimbindi, Thembelihle Zuma, Jana Jarolimova, Christina Psaros, Judith Hahn, Sheela Shenoi, Maryam Shahmanesh, Mark J. Siedner

- 1123 Characterizing HIV Preexposure Prophylaxis (PrEP) Discontinuation Among Men Who Have Sex With Men**
Wenting Huang, Travis H. Sanchez, Marissa J. Hannah, Kelsey C. Coy, Cristian S. Acero, Aaron J. Siegler
- 1124 PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP**
Li Tao, Juan Yang, J.C. Hojilla, Anand P. Chokkalingam, Christoph Carter, Moupani Das
- 1125 Outcomes of a Community-Clinic Hybrid PrEP Trial in China During COVID Lockdowns, 2021-2023**
Zhuoheng Yin, Yifan Dai, Chengxin Fan, Gifty Marley, Chunyan Li, Songjie Wu, Quanmin Li, Joseph D. Tucker, Jonathan Lio, Haojie Huang, Ke Liang, Linghua Li, Aniruddha Hazra, Renslow Sherer, Weiming Tang
- 1126 Homelessness, HIV Vulnerability, and PrEP Willingness Among Young Transgender Women in Lima, Peru**
NIS Dorothy Apedaile, Alfonso Silva-Santisteban, Leyla Huerta, Segundo R. Leon, Sari Reisner, Amaya Perez-Brumer
- 1127 PrEP Uptake and Persistence Among Incarcerated People in Zambia: Early Results From a Cohort Study**
Cassidy W. Claassen, Brianna Lindsay, Muyunda Siyambango, Linah Mwango, Caitlin Baumhart, Nasho Nyirongo, Gideon Daka, Clement Moonga, Chiti Bwalya, Maurice Musheke, Michael Herce
- 1128 Social Determinants of Health and PrEP Uptake in the US: Repeated Measures Correlational Study**
Hollie David, Alan Wells, Susan J. Little, Sanjay R. Mehta, Thomas Martin
- 1129 Association of US Medicaid Expansion and Number of Persons Prescribed PrEP, 2017-2021**
LB Karen W. Hoover, Weiming Zhu, Sheila Salvant Valentine, Ya-Lin A. Huang

Poster Session-S5 | PrEP: Novel Products, Strategies, and Delivery Systems

2:30 PM - 4:00 PM • Poster Hall C-D

- 1136 CAPRISA 018 Trial: Acceptability of Tenofovir Alafenamide Implants for HIV PrEP in African Women**
NIS Tanuja N. Gengiah, Craig J. Heck, Lara Lewis, Leila E. Mansoor, Ishana Harkoo, Diana Chetty, Nqobile Myeni, Marc M. Baum, John A. Moss, James F. Rooney, Catherine Hankins, Bruno Pozzetto, Quarsha Abdool Karim, Salim S. Abdool Karim
- 1137 Safety and Pharmacokinetics of Ultra-Long-Acting Dolutegravir In-Situ Forming Implant**
Thy Le, Isabella C. Young, Craig Sykes, Amanda P. Schauer, Mackenzie Cottrell, Angela D. Kashuba, S. Rahima Benhabbour
- 1138 RCT of *Lactobacillus crispatus* CTV-05 to Lower HIV Risk in Young South African Women**
Anke Hemmerling, Caroline Mitchell, Suuba Demby, Musie Gebremichael, Joseph Elsherbini, Jiawu Xu, Nondumiso Xulu, Johnathan Shih, Krista L. Dong, Vaneshree Govender, Vanessa S. Pillay, Thomas P. Parks, Thumbi Ndung'u, Doug S. Kwon, Craig R. Cohen

1139 A Dual Prevention Pill for HIV and Pregnancy Prevention:**A Pilot Study Among Young Women in Zimbabwe**

Barbara A. Friedland, Brady Zieman, Sanyukta Mathur, Irene V. Bruce, Adlight Dandadzi, Petina Musara, Caroline Murombedzi, Lisa B. Haddad, Nyaradzo Mgodi

Poster Session-T5 | New Directions in Sexual and Reproductive Health and HIV Prevention

2:30 PM - 4:00 PM • Poster Hall C-D

1173 Reaching ECP Users With HIV and PEP Services in Kenyan Pharmacies**NIS**

Nicholas Kipkurui, Dorothy Oketch, Scholastica Wanjiru, Gerald O. Owuor, Alloys Koloo, Elizabeth Bukusi, Alison Roxby, Kawango Agot

1174 Stability of Penile Bacteria Associated With HIV Seroconversion, Inflammation, and Cells (BASICs)

Sydney G. Nelson, Ronald M. Galiwango, Daniel E. Park, Sanja Huibner, Juan E. Salazar, Maliha Aziz, Edward Sung, Aggrey Anok, James Nnamutete, John Bosco Wasswa, Godfrey Kigozi, Aaron A. R. Tobian, Jessica L. Prodger, Rupert Kaul, Cindy Liu

1175 Vaginal Immune Dysregulation in Transgender/Non-Binary Individuals on Masculinizing Hormone Therapy**NIS**

Matilde P. Jacobson, Janja Kovacic, Eleanor Capozzi, Megan Gooding, Hubert Garcia, Fernando Cabezas Mejia, Janelle Schrag, Lynsay MacLaren, Christopher Cannon, Mimi Ghosh

1176 Forced Vaginal Sex Is Associated With Genital Immune Changes That May Increase HIV Susceptibility**NIS**

James Pollock, Mary Kung'u, Sanja Huibner, Rhoda Kabuti, Hellen Babu, Erastus Irungu, Pauline Ngurukiri, Helen Weiss, Janet Seeley, Tanya Abramsky, Joshua Kimani, Tara Beattie, Rupert Kaul, for the Maisha Fiti Study Champions

Poster Session-U03 | Viral Load Suppression

2:30 PM - 4:00 PM • Poster Hall C-D

1198 Increased Viral Suppression With Adherence Counseling Incorporating a Point-of-Care Urine TFV Test

Leonard T. Bikinesi, Matthew A. Spinelli, Ntombizodwa M. Nyoni, Jesaya Hifindwako, Assegid Mengistu, Jacques Kamangu, Gram Mutandi, Daniella Mouton, Fekir Negussie, Rachel S. Beard, Monica Gandhi, Steven Y. Hong

1199 Persistent Challenges With Viral Suppression a Year After Return to Care: Evidence From South Africa

Claire M. Keene, Jonathan Euvrard, Tali Cassidy, Mike English, Jacob McKnight, Catherine Orrell, Ingrid Katz

1200 Durability of Viral Suppression Among People on HIV Treatment in S Africa: A National Cohort Study

Jacob Bor, Evelyn Lauren, Dickman Gareta, Khumbo Shumba, Mazvita Muchengeti, Wendy Stevens, Dorina Onoya, Koleka Mlisana

- 1201 Motivational Interviewing Training Effect on HIV Viral Suppression: A Cluster Randomised Pilot Trial**
Dorina Onoya, Tembeka Sineke, Idah Mokhele, Robert A. Ruiter, Marnie Vujovic, Khumbo Shumba, Jacqui Miot
- 1202 Undisclosed ART Use Found by Urine LFA Is Common in South Africa, Not Associated With Lower TB Risk**
Nsika N. Sithole, Indira Govender, Matthew A. Spinelli, Theresa Smit, Meighan Krows, Connie Celum, Alison Grant, Monica Gandhi, Adrienne E. Shapiro
- 1203 Impact of Proactive Adherence Interventions on HIV RNA Using Prescription Claims**
Neha S. Pandit, Abree Johnson, Tsung-Ying Lee, Eberechukwu Onukwugha, Hope Cassidy-Stewart
- 1204 Antiretroviral Therapy Outcomes at 6 Months by HIV Recent Infection Classification, Rwanda 2021-2022**
Monita R. Patel, Eugenie Poirot, Straso Jovanovski, Beata Sangwayire, Jean Claude Irabona, Veronicah Mugisha, Collins Kamanzu, Eric Remera, Elysee Tuyishime, Giles A. Reid, Tom Oluoch, Suzue Saito, Gallican Rwibasira, for the Rwanda HIV Recency Evaluation Study Team
- 1205 Impact of Natural Disasters on HIV Risks and Viral Suppression in Ugandan Fishing Village**
Hadijja Nakawooya, Victor Ssempijja, Anthony Ndyanabo, Fred Nalugoda, Maria J. Wawer, David Serwadda, Ronald H. Gray, Joseph Kagaayi, Steven J. Reynolds, Tom Lutalo, Godfrey Kigozi, Ping T. Yeh, Larry W. Chang, Mary Kate Grabowski, Robert Ssekubugu
- 1206 Prevalence of HIV and Viral Load Suppression Among Refugees in Uganda, October to December 2021**
Samuel Biraro, Shannon M. Farley, Joshua Musinguzi, Wilford Kirungi, David Okimait, Veronicah Mugisha, Ronald Nyakoojo, Sam Sendagala, Herbert Kiyingi, Jennifer Nel, Lisa Nelson, Brittany Gianetti, Christine West, David Hoos, Wafaa El-Sadr

Poster Session-U04 | COVID-19 Prevention

2:30 PM - 4:00 PM • Poster Hall C-D

- 1207 COVID-19–Associated ART Disruptions and HIV Suppression: A Population-Based Study in Uganda**
Charles Ssuuna, Hadijja Nakawooya, Caitlin E. Kennedy, Joseph G. Rosen, Ronald M. Galiwango, Aggrey Anok, Fred Nalugoda, Arthur G. Fitzmaurice, Victor Ssempijja, Joseph Kagaayi, Godfrey Kigozi, Larry W. Chang, Thomas C. Quinn, Mary Kate Grabowski, Steven J. Reynolds
- 1208 Uptake of COVID-19 Vaccine Among Persons Living With HIV on Antiretroviral Therapy, Siaya, Kenya**
Philip Opere, Benard Onguche
- 1209 Scaling Up COVID-19 Vaccine Uptake Among PLHIV: Insights & Lessons From Kigoma, Shinyanga, and Pwani**
John Roman, Julius Zelothe, Amos Scott, Damian Laki, Alexander Christopher J. Christopher, Frederick Ndossi, Yudas Ndugile, Kokuhabwa Mukurasi, Eva Matiko, Redempta Mbatia

1210 COVID-19 Vaccine Effectiveness Against Different Variants Among a Population-Based HIV Cohort

Ziang Liu, Xueying Yang, Bankole Olatosi, Sharon Weissman, Xiaoming Li, Jiajia Zhang

1211 A Network-Based Modeling Analysis of Interventions for SARS-CoV-2 Prevention Among Jailed Adults

Isaac Schneider, Karina Wallrafen-Sam, Shanika Kennedy, Matthew Akiyama, Anne C. Spaulding, Samuel M. Jenness

1212 Safety Outcomes in Trial of COVID-19 mRNA Vaccine Among People With HIV in Sub-Saharan Africa

Simone Lara Hendricks, Bongile Mabilane, Asa Tapley, Jia Jin Kee, Veronique Bailey, Ethel Kamuti, Harriet Nuwagaba-Biribonwoha, Zvavahera Chirenje, Joseph M. Makhemba, Taraz Samandari, Laura Polakowski, Manuel Villaran, Nyaradzo Mgodi, Azwidihwi Takalani, for the CoVPN 3008 Ubuntu Study Team

Poster Session-U05 | Key and Vulnerable Populations

2:30 PM - 4:00 PM • Poster Hall C-D

1213 Data Science Linkage of Public Jail Registries and Surveillance Data for Public Health Action

Steven Erly, Leighton Hill, Rachel Amiya

1214 Undetectable = Untransmissible: Key Populations With HIV Lag in Sustaining Undetectable Viral Load

Abimbola S. Phillips, Dorcas Magbadelo, Francis Ogirima, Pius Christopher-Izere, Collins Imarhiagbe, Sabra Custer, Sharon Weissman, Bankole Olatosi, Xiaoming Li, Oluwafemi Adeagbo, Akanmu Sulaimon, Akinbami Akinsegun, Bola Oyeledun, Jude Orjih, Dennis Onotu, for the CDC Research Group

1215 PrEP Persistence Among Adolescents Men Who Have Sex With Men and Transgender Women in Brazil

Fabiane Soares, Laio Magno, Jony Arrais Pinto Junior, Diana Reyna Zeballos Rivas, Dirceu Greco, Alexandre Grangeiro, Ines Dourado

1216 NICE: A Structural Intervention to Increase Status Neutral Care Among Sexual and Gender Minorities

Rebecca Eavou, Ellen Almirol, **Victoria Umutoni**, John Schneider, Mickyala Jones

1217 DREAMS RE-AIM Assessment in Zambia Demonstrates High Uptake and Reach of AGYW With HIV Prevention

Brianna Lindsay, Kirsten Stoebenau, Caitlin Baumhart, Linah Mwango, Godfrey Muchanga, Choolwe Maambo, Mwangala Mwale, Monde Mwamba, Chiti Bwalya, Samara Toussaint, **Cassidy W. Claassen**, Angshuman Kashyap

1218 Intention to Initiate PrEP Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in Peru

Carlos Benites, Mary Reyes, Patricia Alarcón, Ricardo Alfaro, Jorge A. Gallardo-Cartagena, **Juan J. Montenegro-Idrogo**, Kelika A. Konda, Jorge L. Sánchez, César Munayco

- 1219 Assessing Antiretroviral-Focused HIV Prevention and Treatment Among Key Population in Kenya**
Patrick E. Amakulie, Kinley M. Samwel, Edward Mboya, Violet Booko, Peter Kyalo
- 1220 The Motivational PrEP Cascade Among Peruvian Men Who Have Sex With Men (MSM)**
Jorge A. Gallardo-Cartagena, Patricia Alarcón, Juan J. Montenegro-Idrogo, Javier R. Lama, Javier A. Valencia, Robinson Cabello, Martín Casapía, David Velasquez, Hugo Sánchez, Yamir Salazar, Felipe Vilcachagua Tadeo, José L. Castro, Kelika A. Konda, Susan P. Buchbinder, Jorge L. Sánchez
- 1221 The Need to Address Violence for PrEP Uptake Among Adolescent Girls and Young Women in South Africa**
Courtney P. Bonner, Felicia A. Browne, Jacequeline W. Ndirangu, Alexandra M. Minnis, Ilene Speizer, Laura Nyblade, Khatija Ahmed, Tracy Kline, Wendee M. Wechsberg

Poster Session-U06 | Behavioral Predictors and Interventions

2:30 PM - 4:00 PM • Poster Hall C-D

- 1222 Stigma in Young Kenyan Women Offered PrEP in a Peer-Supported, Community-Based PrEP Delivery System**
NIS
Bernard Nyerere, Nicholas Musinguzi, Kevin Oware, Lawrence Juma, Josephine Odoyo, Vincent Momanyi, Aaron J. Siegler, Lindsey E. Garrison, Jared Baeten, Elizabeth Bukusi, Jessica Haberer
- 1223 A Social Network-Based Intervention to Promote HIV Prevention and Treatment Among Fishermen in Kenya**
Zachary A. Kwena, Lila Sheira, Benard Ayieko, Edwin Charlebois, Kawango Agot, Sarah Gutin, Phoebe Olugo, Monica Gandhi, Elizabeth Bukusi, **Carol S. Camlin**, Harsha Thirumurthy
- 1224 Hopefulness as a Predictor of Viral Suppression in Patients Newly Diagnosed With HIV**
Marie Flore Pierre, Fabienne Homeus, Jean Bernard Marc, Vanessa Rivera, Manasi Mohan, Nakul Vij, **Samuel Pierre**, Nancy Dorvil, Dominique Lespinasse, Maria Linda Aristhomène, Guirlaine Bernadin, Alianne Julien, Jean W. Pape, Serena Koenig
- 1225 Homelessness and Antiretroviral Use Among MSM in the Context of Varying Levels of Federal Funding**
NIS
Amrita Rao, Yuanqi Mi, Katherine Rucinski, John Mark Wiginton, Carrie Lyons, Kalai Willis, Tiara Willie, Travis H. Sanchez, Stefan Baral
- 1226 Violence and HIV Sexual Risk Behaviours Among Adolescent Girls and Young Women: Eswatini Experience**
NIS
Siphiwe M. Shongwe-Gama, Cebisile Ngcamphalala, Mabutho C. Mamba, Harrison Kamiru, Poppy M. Sithole, Bonisile Nhlabatsi, Choice Ginindza, Michelle Li, Kaye Seya Marie, Francis B. Annor, Luara Chiang, Ruben Sahabo

1227 Older Adults Living With HIV Have Low Expectations Regarding Aging, Despite Improved Survival

Alice Zhabokritsky, Darrell H. Tan, Marianne Harris, graham Smith, Julian Falutz, Nisha Andany, Silvia Guillemi, Gordon Arbess, Mona Loufty, Ron Rosenes, **Sharon Walmsley**, for the CHANGE HIV Study Team

1228 Strategies for Eliminating Racial/Ethnic Disparities in HIV Incidence in the United States

Evin Jacobson, Alex Viguerie, Katherine Hicks, Laurel Bates, Amanda Honeycutt, Justin Carrico, Paul Farnham

Poster Session-U07 | Cost and Cost-Effectiveness

2:30 PM - 4:00 PM • Poster Hall C-D

1229 Cost-Effectiveness of Differentiated HIV Treatment Delivery in Sub-Saharan Africa: A Modeling Study

Shiying You, Hae-Young Kim, Daniel T. Citron, David Kaftan, Andrew Phillips, Loveleen Bansi-Matharu, Valentina Cambiano, Brooke Nichols, Youngji Jo, Anna Bershteyn

1230 Model Comparison of the Cost-Effectiveness of Long-Acting Cabotegravir for HIV PrEP in South Africa

Jesse A. Heitner, Sarah Stansfield, Lise Jamieson, Gesine Meyer-Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer Smith, Valentina Cambiano, Loveleen Bansi-Matharu, Andrew Phillips, Mia Moore, Ruanne V. Barnabas, Marie-Claude Boily, Dobromir Dimitrov

1231 Cost-Effectiveness of a Urine Tenovir Point-of-Care Assay for ART Adherence Feedback in Namibia

Ntombizodwa M. Nyoni, Sigal Maya, Jacques Kamangu, Daniella Mouton, Assegid Mengistu, Matthew A. Spinelli, Pearl Kalimugogo, Gram Mutandi, Steven Y. Hong, Jim Kahn, Peter Minchella, Monica Gandhi, Leonard T. Bikinesi

1232 Increased Medicare Spending Among Beneficiaries With HIV in the 12 Months Prior to Death

Jose F. Figueroa, Ciara E. Duggan, Jessica Phelan, Florence Ebem, Parastu Kasaie, Luke Ang, Keri N. Althoff, E J. Orav, **Emily P. Hyle**

1233 Estimated Costs of Eliminating Medicaid Prior Authorizations for Antiretrovirals in Washington State

Matthew Golden, Ryan Taketomo, Ryan Pistoresi

1234 Cost-Effectiveness of Integrated Multi-Month Dispensing for HIV and Hypertension in South Africa

Youngji Jo, Sydney Rosen, Brooke Nichols, Robert Horsburgh

POSTER SESSIONS BY DAY

WEDNESDAY, MARCH 6, 2024

Poster Session-A2 | Virus Replication in Host and Nonhuman Models

2:30 PM - 4:00 PM • Poster Hall C-D

308

NIS

Monitoring the infection of a new strain of simian betaretrovirus in Southern Muriquis from Brazil

Thamiris S. Miranda, Pedro H. Carneiro, Marcus Vinicius de Mattos Silva, Ronaldo da Silva Mohana Borges, Silvia B. Moreira, Alcides Pissinatti, Orlando da Costa Ferreira Júnior, Marcelo A. Soares, André Felipe Andrade dos Santos

309

WITHDRAWN

310

Species-Specific APOBEC3 Splicing and Variations in Viral Mutagenesis

Azad Khosh, Rachael Springman-Rodriguez, Armando Mendez, Kathryn Jackson-Jones, Margarita Rzhetskaya, Judd F. Hultquist, **Diako Ebrahimi**

311

High Replication Fitness and Potent Innate Immune Evasion Function of a HIV-1 VB Strain

Dorota J. Kmiec, Kerstin Regensburger, Frank Kirchhoff

312

The HIV-1 Protein ASP Promotes Viral Replication and Is Associated with Faster Disease Progression

Mohd. Shameel Iqbal, Myriam Houmey, Ziyan Xu, Yuchu Wang, Kabir Khan, Isabella Caico, Rui Li, Jean-Michel Mesnard, Nathalie Chazal, Angelo Pavesi, **Fabio Romerio**

313

In Vivo Detection of HIV-1 Antisense Transcripts in Donors Before and During ART

Adam A. Capoferro, Toluleke O. Famuyiwa, Rachel Sklutuis, Sachi Pathak, Jennifer L. Groebner, Rui Li, Jason W. Rausch, Steven G. Deeks, John W. Mellors, John M. Coffin, Fabio Romerio, Mary F. Kearney

314

NIS

Exacerbation of the RSV Infectivity by SARS-CoV-2 in an In-vitro Co-Infection Cellular Model

Claudia Vanetti, Silvia Zecchini, Gioia Cappelletti, Micaela Garziano, Irma Saulle, Sergio Strizzi, Fiona Limanaqi, Claudio Fenizia, Claudia Moscheni, Antonella Tosoni, Manuela Nebuloni, Mario Clerici, Daria Trabattoni, Mara Biasin

Poster Session-B6 | Correlates of HIV Infection Outcome

2:30 PM - 4:00 PM • Poster Hall C-D

353

NIS

Circulating Immunoregulatory Proteins Indicative of Poor CD4 Recovery in People With HIV on ART

Preeti Moar, Thomas A. Premeaux, Scott Bowler, Courtney Friday, Sara Gianella, Alan Landay, Lishomwa Ndhlovu

354

LB

Suppressing Asymptomatic CMV With Letermovir Reshapes Cardiometabolic Proteome in Treated HIV

Sara Gianella Weibel, Douglas W. Kitch, Gabriele B. Beck-Engeser, Milenka Meneses, Scott L. Letendre, Michael Dube, Lawrence Fox, John Koethe, Priscilla Y. Hsue, Ahmed A. Tawakol, Adam Olshen, Michael L. Freeman, Davey M. Smith, Peter W. Hunt

355**DNA Methylation-Based Telomere Length Is Associated With HIV Infection and Cancer in Relation to HIV**

Xiaoyu Liang, Brad Aouizerat, Lesley S. Park, Kaku So-Armah, **Vincent Marconi**, Ke Xu, Amy C. Justice

356

NIS

Methamphetamine Use in PWH on ART Is Associated With Inflammation and Residual HIV Transcription

Maria Sophia B. Donaire, Fernanda C. Coirada, Sun Jin Kim, Sannidhi Sarvadhabavabhatla, Vivian Pae, Alton Barbehenn, Cassandra Yun, John C. Halifax, Nitasha A. Kumar, Paula J. Lum, Kara Lynch, Steven A. Yukl, Rafick P. Sekaly, Susan P. Ribeiro, Sulggi A. Lee

357

NIS

Singular CD4+ and CD8+ T-Cell Proteomic Profiles in PLHIV Immunological Non-Responders Before ART

Marina Flores-Piñas, Silvia Chafino, Consuelo Viladés, Pere Domingo, Miguel López-Dupla, Alexy Inciarte, Jordi Navarro, Julià Blanco, Francesc Vidal, Joaquim Peraire, Anna Rull

358

NIS

Evaluating Biomarkers and Mortality by Sex in People With Late HIV Starting Antiretroviral Therapy

Brian P. Epling, Jing Wang, Adam Rupert, Virginia Sheikh, Gregg Roby, Douglas Shaffer, Nittaya Phanuphak, Jintanat Ananworanich, Frederick K. Sawe, Irini Sereti

359**Glycomic Markers of Biological Aging in Trans Women With HIV Versus Cis Men and Cis Women With HIV**

Leila B. Giron, Ana N. Hyatt, Mohamed Elkaeid, Paula Debroy, David B. Hanna, Igbo Ofoutokun, Margaret A. Fischl, Daniel Merenstein, Sabina Haberlen, Alan Landay, Frank Palella, Phyllis Tien, Todd T. Brown, Jordan E. Lake, Mohamed Abdel-Mohsen

360**Signature of CD4 T-Cells During Acute HIV-1 Infection Is Predictive of Disease Progression**

Dominic Paquin-Proulx, Bonnie M. Slike, Ningbo Jian, Boonrat Tassaneetrithip, Leigh-Anne Eller, Gina Donofrio, Matthew Creegan, Sandhya Vasan, Julie Ake, Mary A. Marovich, Nelson L. Michael, Merlin L. Robb, Michael A. Eller, Shelly J. Krebs, for the RV217 Study Team

361

LB

Distinct Plasma Protein Changes Precede Loss of Spontaneous HIV Control

Nadira Vadaq, Albert L. Groenendijk, Jessica D. Santos, Wilhelm A. Vos, Marc Blaauw, Louise E. van Ekeren, Leo Joosten, Vasiliki Matzaraki, Jan van Lunzen, Susan M. Schader, Casper Rokx, Annelies Verbon, Mihai Netea, Ferdinand Wit, Andre J. van der Ven

Poster Session-B7 | Animal Models of Viral Pathogenesis**2:30 PM - 4:00 PM • Poster Hall C-D****362****HIV-Induced Lung Inflammation in Humanized Mice**

Leyao Wang, Sara Nicholson, Hongbo Gao, Liang Shan

363 Exogenous Estrogen Increases HIV Target Cell Frequency in the Rectal Mucosa of Male Primates

Patricia A. Hahn, Eric S. Alexander, Kimberly Weisgrau, Tianling Ou, Wenhui He, Eva Rakasz, Michael Farzan, Joseph R. Kurian, Mauricio A. Martins

364 Enema Use Minimally Impacts Immunity and Does Not Affect Susceptibility to Low-Dose Intrarectal SIV

Alexandra Ortiz, Fabiola Castello Casta, Brandon Keele, Jason Brenchley

365 SIV Infection in Sooty Mangabeys Does Not Impact Survival but Changes Cause of Death

Cristina Ceriani, Brianne Beisner, Maria Crane, Joyce Cohen, Ian N. Moore, Deanna A. Kulpa, Guido Silvestri

366 Positive Reinforcement Training Reduces Stress in SIV-Infected Macaque Models of HIV Infection

Selena M. Guerrero-Martin, Bess W. Carlson, Samuel A. Brill, Erin N. Shirk, Suzanne Queen, Leah H. Rubin, Melanie J. Graham, Lydia M. Hopper, Lucio Gama, Christine Zink, Joseph Mankowski, Janice E. Clements, **Kelly A. Metcalf Pate**

Poster Session-C7 | Mucosal Immunity to HIV

2:30 PM - 4:00 PM • Poster Hall C-D

431 A Novel Non-Invasive Approach to Sample Female Genital Tract Immune Cell Populations

M. Quinn Peters, Eva Domenjo-Vila, Melanie Gasper, Smritee Dabee, Blair Armistead, Christopher Whidbey, Heather Jaspan, Martin Prlic, Whitney E. Harrington

432 Identification of Innate Lymphoid Cell Subsets in the Human Female Genital Tract That Respond to HIV

Alexandra E. Werner, Laura Moreno de Lara, Francisco J. Carrillo-Salinas, Anna Borchers, Siddharth Parthasarathy, Marta Rodriguez-Garcia

433 The Cervicovaginal Neutrophil Protein CRISP3 Is a Correlate of HIV Protection

Christina Farr, Laura Noël-Romas, Michelle Perner, Marina Costa-Fujushima, Sausan Azzam, Marlon De Leon, Stefanie Avril, Vanessa Poliquin, Alicia R. Berard, Lyle McKinnon, Thomas Murooka, Sharon L. Hillier, Zvavahera Chirenje, Jeanne Marrazzo, **Adam Burgener**

434 CD101 Variants Are Associated With Lower Levels of Genital HIV-Inhibiting and Tissue Repair Factors

Sarah C. Vick, Corinne M. Mar, Bhavna Chohan, Katherine K. Thomas, James W. MacDonald, Theo K. Bammler, Kenneth Ngure, Nelly R. Mugo, Jennifer M. Lund, Jairam Lingappa

435 Synergistic Effects of HIV, HPV, and Polyomaviruses on Interferon Response in Male Anal Mucosa

Matteo Fracella, Sara Passerini, Letizia Santinelli, Leonardo Sorrentino, Luca Maddaloni, Ginevra Bugani, Eugenio Nelson Cavallari, Alessandra Pierangeli, Guido Antonelli, Claudio Maria Mastroianni, Gabriella D'Ettorre, Valeria Pietropaolo, Carolina Scagnolari

Poster Session-C8 | NK and T-Cell Responses to HIV

2:30 PM - 4:00 PM • Poster Hall C-D

436**NIS****Circulating Acyl-CoA-Binding Protein Abates T-Cell Function in People Living With HIV**

Stephane Isnard, Léna Royston, Tsoarello Mabanga, Simeng Bu, Carolina A. Berini, Nicole F. Bernard, Julien van Grevenynghe, Guido Kroemer, Jean-Pierre Routy

437**NIS****Immunological Non-Responders Have CD4+ Immunosenescence and Impaired Lymphocyte Cytokine Production**

Wilhelm A. J. W. Vos, Adriana Navas, Elise M. Meeder, Albert L. Groenendijk, Marc Blaauw, Louise E. van Eekeren, Twan Otten, Maartje C. Cleophas, Nadira Vadaq, Vasiliki Matzaraki, Kees Brinkman, Jan van Lunzen, Andre J. van der Ven, Willem L. Blok, Janneke E. Stalenhoef

438**Phenotype of Gamma-Delta T-Cells in Acute HIV-1 Infection Predict Neutralization Breadth**

Gina L. Griffith, Matthew Creegan, Kawthar Machmach Leggat, Margaret Constanzo, Isabella Swafford, Ningbo Jian, Leigh-Anne Eller, Merlin L. Robb, Samantha M. Townsley, Shelly J. Krebs, Julie Ake, Dominic Paquin-Proulx, for the RV217 Study Group

439**NIS****NK Cells During Acute HIV Infection Are Associated With Slow Disease Progression in Subtype A**

Aljawharah Alrubayyi, Amin S. Hassan, Jonathan Hare, Anthony Hsieh, Jill Gilmour, Matt A. Price, William Kilembe, Etienne Karita, Eugene Ruzagira, Joakim Esbjörnsson, Eduard J. Sanders, Dimitra Peppa, Sarah Rowland-Jones

440**PWH on ART and Tyrosine Kinase Inhibitors Show High Cytotoxic Activity Against HIV-1–Infected Cells**

Clara Sánchez Menéndez, Guiomar Casado Fernández, Lorena Vigón, Mario Manzanares, Elena Mateos, Juan Ambrosioni, Vicente Estrada, Miguel Cervero Jiménez, Valle Gómez, Christoph Wyen, Christian Hoffmann, Montserrat Torres, Verónica Briz, Vicente Planelles, **Mayte Coiras**

441**A Skewed NK Cell Repertoire Persists in People With HIV-1 Despite Long-Term ART**

Renee R. Anderko, Allison E. DePuyt, Rhi Bronson, Arlene C. Bullotta, Evgenia Aga, Ronald J. Bosch, R. Brad Jones, Joseph J. Eron, John W. Mellors, Rajesh T. Gandhi, Deborah K. McMahon, Bernard Macatangay, Charles R. Rinaldo, Robbie B. Mailliard

442**NIS****Trained Immunity in Monocytes Is Associated With Persistent Elite Controller Status**

Jessica D. Santos, Suzanne Ruijten, Albert L. Groenendijk, Nadira Vadaq, Rainer Knoll, Rob t. Horst, Marc Blaauw, Louise E. van Eekeren, Wilhelm A. Vos, Victoria Rios-Vazquez, Vasiliki Matzaraki, Jan van Lunzen, Leo Joosten, Mihai Netea, Andre J. van der Ven

443**NIS****Effective Elimination of HIV-1 Infected CD4+ T-Cells by NKG2C+ “Memory-Like” NK Mediated by Trail**

Ildefonso Sánchez, Marta Calvet Mirabent, Olga Popova, Ignacio de los Santos, Lucio J. García-Fraile, Ilya Tsukalov, Arantza Alfranca, María Buzón, María A. Muñoz-Fernández, Francisco Sánchez-Madrid, Enrique Martín-Gayo

444 **Single-Cell, Multi-Omics Analysis of SIV-Specific CD8 T-Cells Across Multiple Anatomical Sites**
Jennifer Simpson, Paul Schaughency, Justin Lack, Jason Brenchley

445 **NIS Revealing the Role of Tissue-Resident NK Cells in HIV Infection Using Tissue Explant Models**
David Perea, Nerea Sanchez Gaona, Ana Gallego Cortes, Stefania Landolfi, Felix Pumarola, Nuria Ortiz, Ines Llano, Juan Lorente, Vicenç Falcó, Meritxell Genescà, María Buzón

446 **LB Post-Intervention HIV Control Linked to Early In Vivo CD8+ T-Cell Proliferative Response to Rebound**
Demi A. Sandel, Michael J. Peluso, Michiko Shimoda, Lily Zemelko, Alaa A. Latif, Amelia N. Deitchman, Gina Borgo, Nitasha A. Kumar, Meghann C. Williams, Barbara K. Felber, Gabriela Fragiadakis, Matthew H. Spitzer, Lillian Cohn, Steven G. Deeks, Rachel L. Rutishauser

447 **LB HIV Post-Treatment Controllers Show Enhanced CD8+ T-Cell Proliferative Capacity After ART Cessation**
Charles R. Crain, Anusha Nathan, Behzad Etemad, Prerana Shrestha, Rachel L. Rutishauser, Steven G. Deeks, Jonathan Z. Li, Gaurav D. Gaiha

Poster Session-C9 | Inflammation and Innate Immunity to HIV/SIV

2:30 PM - 4:00 PM • Poster Hall C-D

448 **Cannabis-Induced DNA Methylation Changes Mediate Immune Response in PLHIV**
Xun Jiang, Elise M. Meeder, Manoj K. Gupta, Zhenhua Zhang, Yang Li, Mihai Netea, Andre J. van der Ven, Cheng-Jian Xu

449 **NIS Immunomodulatory Effects of Cannabis Use in PLHIV**
Elise M.G. Meeder, Jiang Xun, Adriana Navas, Louise E. van Eekeren, Wilhelm A. Vos, Marc Blaauw, Albert L. Groenendijk, Twan Otten, Nadira Vadaq, Mihai Netea, Vasiliki Matzaraki, Cheng-Jian Xu, Andre J. van der Ven, Arnt F. Schellekens

450 **Impact of Hormone Therapy and HIV on the Immunometabolic Landscape in a Cohort of Transgender Women**
Erin Mihealsick, Emilia Jalil, Beatriz Grinsztejn, Eileen Scully

451 **NIS IRF5 Mediates Persistent Inflammatory Responses in HIV-1 Infected Macrophages**
Sita Ramaswamy, Jacob Berrigan, Hisashi Akiyama, Andrés Quiñones, Alex Olson, Yunhan Chen, Yan Mei Liang, Rahm Gummuluru

452 **NIS Expression of Unspliced HIV-1 RNA Induces NLRP1 Inflammasome Activation in Myeloid Cells**
Ivy Hughes, Sallieu Jalloh, Andrés Quiñones, Hisashi Akiyama, Rahm Gummuluru

453 **NIS Type I Interferons Drive Sustained Dominance of CCR5-Tropic Variants During HIV Infection In Vitro**
Priya Pal, Sara Nicholson, Hongbo Gao, Liang Shan

454**NIS**

Crosstalk Between TLR-8 and RLR Enhanced Antiviral Immunity Against Acute HIV-1 and PWH

Killian Vlaming, John L. van Hamme, Pien M. van Paassen, Tanja M. Kaptein, Karel A. van Dort, Peter Reiss, Annelies Verbon, Casper Rokx, Monique Nijhuis, Jan M. Prins, Neeltje Kootstra, Godelieve J. de Bree, Teunis B. Geijtenbeek

455

The Effect of HIV Infection at Pre-ART Initiation on the Early Innate Immune System

Vinh B. Dinh, Lesley de Armas, Rajendra Pahwa, Suresh Pallikkuth, Christine Dang, Stefano Rinaldi, Nicola Cotugno, Paolo Palma, Nadia Sitoe, Paula Vaz, Maria Grazia Lain, Savita Pahwa

456

Inflammatory Monocytes Increase During HIV-1 Treatment Interruption Before Detectable Viremia

Natalia de la Force, Anna Farrell-Sherman, Renan Valieris, Steven G. Deeks, Israel Tojal Da Silva, Timothy J. Henrich, Lillian Cohn

Poster Session-D7 | Correlates of HIV Reservoir Size

2:30 PM - 4:00 PM • Poster Hall C-D

513

HIV-1 Reservoir Dynamics in Children With Early Treated, Perinatally-Acquired HIV: Does Sex Matter?

Kavidha Reddy, Chantal Molechan, Moira Spyer, Mathias Lichterfeld, Pablo Rojo, Paolo Rossi, Paolo Palma, Carlo Giaquinto, Afaaf Liberty, Mornay Isaacs, Loide Cardoso, Ligia Estevao, Alfredo Tagarro, Thumbi Ndung'u

514

Earlier Initiation of ART Reduces Intact Proviruses but Not Residual Viremia After 48 Weeks

Joshua C. Cytor, Joseph Puleo, Gregory M. Laird, Dianna Hoeth, Justin Ritz, Albine Martin, Gert U. van Zyl, Eric Daar, Trevor A. Crowell, Joseph J. Eron, Lu Zheng, John W. Mellors, for the ACTG A5354 Team

515

Host and Viral Factors Shape the Composition of the HIV-1 Viral Reservoir in the 2000HIV Cohort

Mareva Delporte, Kavita Mehta, Maxime Verschoore, Elizabeth R. Wonderlich, Wilhelm A. Vos, Albert L. Groenendijk, Louise E. van Eekeren, Marc Blaauw, Evy E. Blomme, Sofie Rutsaert, Sarah Gerlo, Wim Trypsteen, Mihai Netea, Andre J. van der Ven, **Linos Vandekerckhove**

516

Intact HIV DNA Decay During 15 Years of Suppressive ART: Comparisons by Timing of ART Initiation

Trevor A. Crowell, Mackensie Horn, Hsing-Chuan Hsieh, Xiuping Chu, Catherine M. Berjohn, Jason M. Blaylock, Joseph M. Yabes, Anuradha Ganesan, Timothy H. Burgess, Robert J. O'Connell, Gregory M. Laird, Lydie Trautmann, Brian K. Agan, for the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group

517**NIS**

Intact HIV Remains Similar in Early- and Late-Treated Patients With Comparable Immunological Status

Paula Suanzes, Judith Grau-Expósito, Jordi Navarro, Joan Rey Cano, Adrià Curran, Joaquín Burgos, Arnau Monforte, Meritxell Genescà, Vicenç Falcó, María Buzón

518

NIS

Tumor Suppressor and Innate/Inflammatory Pathways are Associated With the HIV Reservoir Size

German G. Gornalusse, Ashok K. Dwivedi, Rebecca Hoh, Jeffrey Martin, Frederick Hecht, Meei-Li Huang, Julieta Reppetti, Phuong M. Vo, Claire M. Levy, Pavitra Roychoudhury, Keith R. Jerome, Florian Hladik, Timothy J. Henrich, Steven G. Deeks, Sulggi A. Lee

519

NIS

Taming the Viral Reservoir Over 3 Decades of Advancements in HIV Treatment

Irene González-Navarro, Victor Urrea, Cristina Gálvez, Beatriz Mothe, Lucía Bailón, María Salgado, Javier Martínez-Picado

Poster Session-D8 | Strategies for an HIV Cure

2:30 PM - 4:00 PM • Poster Hall C-D

520

Vectored Delivery of Closer-to-Germline Antibodies Can Mediate Long-Term SHIV Suppression

Jose Martinez-Navio, Sebastian P. Fuchs, Desiree E. Mendes, Claudia Muniz, Paula G. Mondragon, Rachel Zabizhin, Eva Rakasz, Guangping Gao, Jeffrey Lifson, Ronald C. Desrosiers

521

Ruxolitinib-Mediated HIV-1 Reservoir Decay in A5336 Phase IIa Trial

Monica D. Reece, Vincent Marconi, Zhan Zhang, Susan P. Ribeiro, Rafick P. Sekaly, Deanna A. Kulpa, Christina Gavegnano

522

Short-Term BCL-2 Inhibition at ART Initiation Transiently Reduces SIV Reservoir in Rhesus Macaques

Tomas Raul Wiche Salinas, Justin L. Harper, Kevin Nguyen, James Auger, Laurence Raymond Marchand, Mackenzie Cottrell, Jason Brenchley, Jeffrey Lifson, Brandon Keele, Andrew Badley, Guido Silvestri, Deanna A. Kulpa, Mirko Paiardini

523

CD4-Targeted mRNA Delivery of Tat Reverses HIV-1 Latency

Edward Kreider, Vincent H. Wu, Jayme M. Nordin, Francesco Pennino, Amie Albertus, Tyler Papp, Obinna Uzosike, Khumoekae Richard, Carol Cheney, Karam Mounzer, Hamideh Parhiz, Michael R. Betts, Daniel T. Claiborne, Drew Weissman, Luis J. Montaner

524

NIS

Potent HIV Latency Reversal by Lipid Nanoparticles**Encapsulating HIV Tat mRNA**

Bridget M. Fisher, Paula M. Cevala, Stanislav Kan, Abdalla Ali, Abigail Tan, Rory Shepherd, Youry Kim, Marvin Holz, Damian Purcell, Frank Caruso, Sharon R. Lewin, Michael Roche

525

NIS

Nanoparticle Delivery of Tat Synergizes With Latency Reversal Agents to Express HIV Antigen

Shane D. Falcinelli, Samuel L. Raines, Jackson Peterson, Ellen Van Gulck, Jennifer Kirchherr, Isabel Najera, Jerel Vega, Daniel Boden, Nancie M. Archin, David M. Margolis

Poster Session-D9 | Novel HIV Cure Strategies

2:30 PM - 4:00 PM • Poster Hall C-D

526 Non-Neutralizing Antibody Therapeutics to Eliminate HIV-Infected Cells In Vitro and In Vivo via ADCC

Jonathan Richard, Dung N. Nguyen, William D. Tolbert, Derek Yang, Seung Tae Kim, Marco A. Diaz-Salinas, Jyothi K. Rajashekhar, Li Zhu, Catherine Bourassa, Halima Medjahed, Priti Kumar, James B. Munro, Amos B. Smith, Andrés Finzi, **Marzena Pazgier**

527 A New CD4mc Enables Fc-Mediated Reservoir Reduction for Durable Post-ART HIV-1 Control in Hu-Mice

Li Zhu, Sri Lakshmi T. Boodapati, Jonathan Richard, Christopher J. Fritschi, Derek Yang, Hongil Kim, Yaping Sun, Lorie Marchitto, Guillaume Beaudoin-Bussieres, Debashree Chatterjee, Catherine Bourassa, Joseph Sodroski, Amos B. Smith III, Andrés Finzi, **Priti Kumar**

528 Combination CAR T-Cell Therapy Restricts HIV Escape and Durably Suppresses HIV Replication In Vivo

Federica Severi, Alexandria Criswell, Dalia Bercow, Tyler Yang, Francesco Pennino, Reyes Acosta, Daniel T. Claiborne

529 Vaccination Combined With PD-1 Blockade Provides Sustained SIV Suppression in Mamu-A01(+) Macaques

Bhrugu Yagnik, Sheikh A. Rahman, Sailaja Gangadhara, Shan Liang, Gordon Freeman, Rafi Ahmed, Rama R. Amara

530 The Impact of HIV Cure-Related Study Drugs and Treatment Interruption on Viral Resuppression Rates

Ming J. Lee, Miles Eason, Antonella Castagna, Laura Galli, Marie-Angélique De Scheerder, James L. Riley, Pablo Tebas, Jesper D. Gunst, Ole S. Søgaard, Eric Florence, Eugene Kroon, Mark S. de Souza, Beatriz Mothe, Marina Caskey, Sarah Fidler

531 Blockade of IFN-beta Reactivates HIV Reservoir in ART-Suppressed HIV-Infected BLT Humanized Mice

Zhe Yuan, Emmanouil Papasavvas, Guorui Zu, Lily Lu, Matthew Fair, Samuel Keller, Luca Sardo, Guoxin Wu, Joel Cassel, Joseph Salvino, Pau Zuck, Bonnie Howell, Luis J. Monataner

532 Treatment With AZD5582 + hetIL-15 Disrupts the Reservoir Establishment in SIV-Infected Macaques

Maura Statzu, Cristina Micali, Tomas Raul Wiche Salinas, Catherine Gurley, Brandon Healy, Diane G. Carnathan, Brandon Keele, Jeffrey Lifson, Gregory M. Laird, David M. Margolis, Mirko Paiardini, Guido Silvestri

533 Drug-Controlled Anti-PD-1 CAR T-Cells to Target the Replication-Competent Reservoir in Tfh Cells

Karsten Eichholz, Yoshinori Fukazawa, Christopher W. Peterson, Francoise Haeseleer, Benjamin Varco-Merth, Sandra Dross, Haesun Park, Caralyn S. Labriola, Michael Axthelm, Jeremy Smedley, Hans-Peter Kiem, Louis Picker, Afam A. Okoye, Corey Larry

534 Refractoriness to SIV Reinfection Is Induced by Anti-IL-10/PD-1 Therapy in Rhesus Macaques

Susan P. Ribeiro, Felipe Ten Caten, Khader Ghneim, Zachary Strongin, Kevin Nguyen, Justin L. Harper, Robert Balderas, Luca Micci, Jeffrey Lifson, Daria Hazuda, Daniel Gorman, Bonnie Howell, Mirko Paiardini, Rafick P. Sekaly

535 Disrupting SIV Reservoir Seeding by Targeting Stemness Pathways in Rhesus Macaques

LB

Inna Ruiz-Salinas, Riri R. Hamid, Nils Schoof, Alice Lin, Jordan Goldy, Guido Silvestri, Ann Chahroudi, Maud Mavigner**536 Impact of Gender-Affirming Hormone Therapy on HIV Reservoirs and Inflammation in Transgender Women**

NIS

Elizabeth Hastie, Antoine Chaillon, Alan Wells, Christophe Vanpouille, Christy Anderson, Magali Porrachia, Kyra Forsyth, Vanessa Gomez-Moreno, Megha S. Srivatsa, Jill Blumenthal, Marvin Hanashiro, Eileen P. Scully, Jordan E. Lake, Jonathan Karn, Sara Gianella**537 Potent Indoline CD4 Mimetics Enable Anti-Coreceptor Binding Site Antibodies to Mediate ADCC**Jonathan Richard, Li Zhu, Lorie Marchitto, Catherine Bourassa, William D. Tolbert, Sri Lakshmi T. Boodapati, Derek Yang, Hongil Kim, Guillaume Beaudoin-Bussieres, Mehdi Benlarbi, Joseph Sodroski, Amos B. Smith III, Marzena Pazgier, Priti Kumar, **Andrés Finzi****538 Lipid Composition and CXCR4 Decoration Facilitate HIV-1 CRISPR Delivery and Viral Excision**

NIS

Sudipta Panja, **Lubaba A. Zaman**, Milankumar Patel, Howard E. Gendelman**539 The Humanized DRAGA Mouse as a Model for HIV Latency and Cure****Jiae Kim**, Nicholas Castrejon-Oropeza, Manuel Lopez, Barbara A. Force, Shahab Soltani, Phuong Nguyen, Kristina Peachman, Ahmad F. Karim, Teodor Brumeau, Sofia Casares, Francois J. Villinger, Chisu Song, Richard T. D'Aquila, Mangala Rao**540 Retinoids Enhance NK Natural and Antibody-Dependent Cell Cytotoxicity of HIV-Infected CD4 T-Cells**

NIS

Elyse K. McMahon, J. Natalie Howard, Rebecca M. Lynch, Alberto Bosque**541 Comparison of Anti-HIV ADC and Immunotoxin Shows Clinically Relevant Differences in Cytotoxic Effect****Seth H. Pincus**, Tami Peters, Megan Stackhouse, Kelli Ober, Frances Cole, Hans-Peter Kiem, Robert Harrington, Xinyi Wang, Anne-Sophie Kuhlmann, Valérie Copié**542 Type I IFN Signaling and Regulation in Vesatolimod-Treated Virally Suppressed Adults With HIV-1****Susie (Shih Yin) Huang**, Liao Zhang, Donovan Verrill, Christiaan R. de Vries, Elena Vendrame, Devi SenGupta, Jeff J. Wallin, Yanhui Cai**543 Evaluation of a Bispecific Antibody Targeting NK Cells for the Elimination of HIV Reservoirs**

NIS

Nerea Sanchez Gaona, David Perea, Adrià Curran, Joaquín Burgos, Jordi Navarro, Paula Suanzes, Vicenç Falcó, Enrique Martín Gayo, Meritxell Genescà, Jorge Carrillo, María Buzón**Poster Session-E7 | Neuroimaging in HIV****2:30 PM - 4:00 PM • Poster Hall C-D****583 Sociodemographics Were Stronger Classifiers of Cognitive Profiles Than Neuroimaging in HIV****Raha M. Dastgheyb**, **Sarah Cooley**, Alison Buchholz, Kalen J. Petersen, Beau Ances, Leah H. Rubin

- 584 MRI With T2 Maps and Spectroscopy Show Chronic Progressive Brain Damage Despite HIV Suppression**
David Jakabek, Kurt Lancaster, Lauriane Juge, Caroline D. Rae, Lucette A. Cysique, **Bruce J. Brew**
- 585 Functional Brain Network Changes Among People With HIV and Viral Suppression**
Jacob Van Doorn, Leah H. Rubin, Farah Naaz, Liuyi Chen, Seble Kassaye, Lakshmi Goparaju, Raha M. Dastgheyb, Asante Kamkwala, Hannah Lee, Arianna Konstantopoulos, Joan Severson, Olusola Ajilore, Alex Leow, Pauline Maki
- 586 HIV Status and APOE4 Differentially Impact White Matter Integrity in Adults With HIV**
Peyton Thomas, Hannah Walsh, Richard C. Gallagher, Kyle Shattuck, Princy Kumar, David J. Moore, Ronald J. Ellis, Xiong Jiang
- 587 HIV Clinical Factors and Cardiovascular Disease Risk Predict White Matter Hyperintensity Burden**
NIS Mikaley Bolden, Peyton Thomas, Richard C. Gallagher, Princy Kumar, David J. Moore, Ronald J. Ellis, Xiong Jiang
- 588 Neurite Orientation Dispersion and Density Imaging in People With HIV on Stable Treatment**
Phillip Chan, Nakul Raval, Praveen Honhar, Jennifer Chiarella, Allison Nelson, David Matuskey, Richard Carson, Ansel Hillmer, Serena Spudich
- 589 Associations Between a Polygenic Risk Score for Alzheimer's Disease and Brain Integrity in HIV**
Anna Curtis, Laura Ibanez, Carlos Cruchaga, Beau Ances, **Sarah Cooley**
- 590 Further Evidence of Hypertrophy in Acute Infection Identified Using Machine Learning**
Jacob Bolzenius, Napapon Sailasuta, Phillip Chan, Carlo P. Sacdalan, Julie Ake, Somchai Sriplienchan, Lydie Trautmann, Sandhya Vasan, Trevor A. Crowell, Ferron F. Ocampo, Serena Spudich, Victor Valcour, Kilian Pohl, Robert Paul, for the SEARCH010/RV254 Study Team
- 591 Beta-Amyloid PET Positivity Among Cognitively-Impaired People With HIV Over Age 60**
Samuel Wilson, Andjelika Milicic, Shireen Javandel, Claire Yballa, Benedetta Milanini, Kilian Pohl, Robert Paul, Victor Valcour

Poster Session-E8 | Omics Studies in NeuroHIV

2:30 PM - 4:00 PM • Poster Hall C-D

- 592 Differential Expression Analysis Reveals Pervasive Transcriptional Changes in the Brains of PWH**
NIS Kriti Agrawal, Jay S. Stanley, Junchen Yang, Nicholas C. Jacobs, Huawei Wang, Le Zhang, Mark Gerstein, Yuval Kluger, Serena Spudich, for Yale Single Cell Opioid Responses in the Context of HIV (Y-SCORCH)
- 593 Epigenetic Impact in CSF Cells From 48 Weeks of Adjunctive Telmisartan in Acute HIV**
Michael J. Corley, Phillip Chan, Eugene Kroon, Napapon Sailasuta, Alina Pang, Nittaya Phanuphak, Jennifer Chiarella, Sandhya Vasan, Robert Paul, Lydie Trautmann, Serena Spudich, Lishomwa Ndhlovu, for the SEARCH018/RV408 Study Group

594 Monocyte Epigenetic Age Relates to Non-Somatic Depressive Symptoms in Women With Undetectable HIV

Kalen J. Petersen, Nicole Perez, Ke Xu, Yanxun Xu, Lang Lang, Kathryn Anastos, Maria L. Alcaide, Mardge H. Cohen, Sadeep Shrestha, Andrew Edmonds, Jacquelyn Meyers, Seble Kassaye, Beau Ances, Brad Aouizerat, Leah H. Rubin

595 Epigenetic Age Advancement Is Associated With Cognition, Frailty, and Mortality in Older PWH

Carrie Johnston, Alina P. Pang, Eugenia Siegler, Chelsie Burchett, Charlene Thomas, Mia Crowley, Rochelle O'Brien, Lishomwa Ndhlovu, Marshall Glesby, Michael J. Corley

596 Plasma Proteomics Identifies Variable Patterns of Association With Neuropsychiatric Dimensions

Patricia K. Riggs, Ronald J. Ellis, Bin Tang, Jennifer E. Iudicello, Mattia Trunfio, Donald Franklin, Michael Potter, Melanie Crescini, Sara Gianella Weibel, Robert K. Heaton, Scott L. Letendre

Poster Session-E9 | Aging and NeuroHIV

2:30 PM - 4:00 PM • Poster Hall C-D

597 Clinical Profiles Predicting Cognitive Decline Over 10 Years Among Older Adults With HIV in Canada

Marie-Josée Brouillette, Marianne Harris, graham Smith, Réjean Thomas, Shariq Haider, Scott L. Letendre, Lesley K. Fellows, Nancy E. Mayo

598 High Plasma GFAP in Older PWH With Low Nadir CD4 Supports Legacy Brain Injury and Reactive Gliosis

Martina Strano, Federica Marmondi, Sara Diotallevi, Simona Bossolasco, Angelo Roberto Raccagni, Antonella Castagna, Gabriella Scarlatti, Matteo Bonato, Paola Cinque

599 Pattern of Age-Related Cognitive Decline in People With HIV Depends on Viral Suppression

James T. Kennedy, Sarah Cooley, Beau Ances

600 Hepcidin Modifies Effects of Age and Erythrocyte Indices on Cognitive Function in People With HIV

Azin Tavasoli, Oluwakemi K. Okwuegbuna, Jennifer E. Iudicello, Asha Kallianpur, Ronald J. Ellis, Scott L. Letendre

601 VACS 2.0 Shows Improved Discrimination of Neurocognitive Impairment and Frailty in People With HIV

Cynthia Yan, Sarah Cooley, Beau Ances

602 Latent Viral Infections Are Associated With Veterans Aging Cohort Study Index in People With HIV

Patricia K. Riggs, Gordon Honerkamp Smith, Milenka Meneses, Antoine Chaillon, Gemma Caballero, Donald Franklin, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre, Sara Gianella Weibel

603 Changes in HAND Prevalence Among Medicaid Enrollees From 2016-2021 in the US

Kashif Iqbal, Tiffany Williams, Jesse G. O'Shea, Kate Buchacz

Poster Session-F3 | Long-Acting Injectables, Broadly Neutralizing Antibodies, and New Drugs, Oh My!

2:30 PM - 4:00 PM • Poster Hall C-D

615 Preclinical to Human Scaling of Pharmacokinetics for Long-Acting Injectable Antiretrovirals

Henry Pertinez, Rajith Rajoli, Andrew Lloyd, Joanne Sharp, Joanne Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Megan Neary, Helen Cox, Chloe Bramwell, Anthony Valentijn, Usman Arshad, Paul Curley, Charles W. Flexner, Andrew Owen

616 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Elderly Using PBPK Modelling NIS

Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini

617 Model-Based Comparison of Cabotegravir Pharmacokinetics Following Thigh and Gluteal Injections

Kelong Han, Ronald D'Amico, William Spreen, **Susan Ford**

618 Effect of Broadly Neutralizing Antibody Exposure on HIV Rebound Following Combination Immunotherapy

Amelia N. Deitchman, Leonid Serebryannyy, Rowena Johnston, Lucio Gama, Marina Caskey, Elena Vendrame, Devi SenGupta, Romas Geleziunas, Jackie Reeves, Christos Petropoulos, Michel Nussenzweig, Rachel Rutishauser, Steven G. Deeks, Michael J. Peluso, for the UCSF-amfAR Study Team

619 A Randomized, Adaptive Phase I Study to Determine the Phase II Dose of VIR-7832: AGILE CST5

Richard J. Fitzgerald, Chris Edwards, Jimstan Periselneris, Geoff Saunders, Nicky Downs, Rebecca Lyon, Danny Pratt, Helen Reynolds, Lauren Walker, Gareth Griffiths, Saye Khoo, Thomas Fletcher, for AGILE CST5

Poster Session-G2 | Novel Antiretrovirals Development: More Than You Think!

2:30 PM - 4:00 PM • Poster Hall C-D

632 Discovery of Next-Generation CD4 Mimetic-Based Long-Acting Entry Inhibitors

Wei Li, Margaret G. Hines, Xiaojie Chu, Tianjian Liang, Cory Shetler, Kerri Penrose, Zhiwei Feng, Urvi M. Parikh, **Jana L. Jacobs**, John W. Mellors

633 The Preclinical Profile of Maturation Inhibitor VH3739937

Brian McAuliffe, Paul Falk, Ira Dicker, Susan Jenkins, Jean Simmermacher, Mark Krystal

634 Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance

Jerry L. Jeffrey, Tom White, Samit Joshi, Brian Wynne

635 Structure-Guided Optimization of InSTIs to Increase Antiviral Potencies Against HIV-1 IN Mutants

Steven Smith, Xue Zhi Zhao, Stephen Hughes, Terrence R. Burke

636 Preclinical Characterization of GS-5894, a Potent NNRTI With Once-Weekly Oral Dosing Potential

Eric Lansdon, Andrew Mulato, Petr Jansa, Gary Lee, George Stepan, Mike Matles, Kelly Wang, Carmen Ip, Julie Fogarty, Dan Soohoo, Bernard Murray, Stephen Yant, Zlatko Janeba, Richard L. Mackman, Tomas Cihlar

637 Discovery of GS-9770: A Novel Unboosted Once Daily Oral HIV Protease Inhibitor

Xiaochun Han, Ron Aoyama, Jacob Cha, Aesop Cho, Ana Z. Gonzalez, Salman Jabri, Michael Lee, Albert C. Liclican, Ryan McFadden, Andrew Mulato, Zach E. Newby, Jie Xu, Johannes Voigt, Lianhong Xu, Hong Yang

638 Discovery of MK-8527: A Long-Acting HIV-1 Nucleoside Reverse Transcriptase Translocation Inhibitor

Izzat Raheem, Kerry Fillgrove, Gregory O'Donnell, Jonathan Patteson, Shih Lin Goh, Carolyn Bahnck-Teets, Qian Huang, Ernest Asante-Appiah, Min Xu, Steve S. Carroll, Jay A. Grobler, Jeffrey Hale, Ming-Tain Lai, Vinay Girijavallabhan, **Tracy L. Diamond**

639 High-Dose VH3810109 (N6LS) ± Recombinant Human Hyaluronidase PH20: Phase I SPAN Study Safety Results

Beta Win, Peter Leone, Jan Losos, Paul Wannamaker, Riccardo D'Agostino, Michael Warwick-Sanders, Gabriela L. Ghita, Viviana Wilches, Max Lataillade

640 A Dose Escalation Study of Safety & PK of TMB-365 & TMB-380 in People With Suppressed HIV

Jacob P. Lalezari, Moti Ramgopal, Gary Richmond, Gordon Crofoot, Kuei-Ling Kuo, Yingan Lai, **Martin Markowitz**

Poster Session-G5 | New Formulations of Current Integrase Strand Transfer Inhibitors: Length Matters

2:30 PM - 4:00 PM • Poster Hall C-D

653 Preclinical Pharmacokinetics of a Novel Long-Acting Bictegravir Solid Injectable in Rats

Usman Arshad, Joanne Sharp, Megan Neary, Joanne Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Paul Curley, Helen Cox, Eleanor Barlow, James J. Hobson, Andrew B. Dwyer, Jonathan Massam, Steve Rannard, Andrew Owen

654 Shape-Shifting Tail Decay Is the Pharmacokinetic Profile of an Ultra-Long Acting Bictegravir Prodrug

Mohammad Ullah Nayan, Ivana Massud, Srijanee Das, Brady Sillman, Brandon Hanson, Arpan Acharya, Tiancheng Edwards, Richard Haaland, Siddappa N. Byrareddy, Gerardo Garcia-Lerma, Walid Heneine, Charles W. Dobard, Howard E. Gendelman, Benson Edagwa

655 A Third-Generation Long-Acting Dolutegravir Homodimer Prodrug

Bhoomika Suresh Gowda, Suyash Deodhar, Nam Thai Hoang Le, Mohammad Ullah Nayan, Brandon Hanson, Manish K. Sharma, Brady Sillman, Howard E. Gendelman, Benson Edagwa

656 Cabotegravir Stearate (XVIR-110), an InSTI Prodrug, Provides Ultra-Long Acting Cabotegravir Exposure

Brian P. Kearney, Brady Sillman, Howard E. Gendelman, Benson Edagwa, Leigh Ann Burns-Naas, Alborz Yazdi

Poster Session-H1 | Dolutegravir Treatment and Resistance in Resource-Limited Settings

2:30 PM - 4:00 PM • Poster Hall C-D

675 ACTG 5381: Virologic and Resistance Outcomes After Switch to TLD for Failing 1st- or 2nd-Line ART

LB Carole L. Wallis, **Caitlyn McCarthy**, Catherine Godfrey, Sarita Shah, Cissy Kityo, Urvi M. Parikh, Gary Maartens, Isaac Tsikhutsu, Fatma F. Some, Samuel Pierre, Yvetot Joseph, Charles W. Flexner, Michael D. Hughes, John W. Mellors, for the A5381 Team

676 Viremia and Drug Resistance 2 Years After Routine Switching to Dolutegravir-Based First-Line ART

Veronika Whitesell Skrivankova, Jacqueline Huwa, Guy Muula, Geldert D. Chiwaya, Esau Banda, Shameem Buleya, Belinda Chihota, Joseph Chintedza, Carolyn Bolton, Thokozani Kalua, Roger Kouyos, Gilles Wandeler, Matthias Egger, **Richard J. Lessells**

677 DTG Resistance in Patients with Previous ARV Experience and Viremia in Kenya Receiving DTG-Based ART

Leonard Kingwara, Vera M. Onwonga, Rukia S. Madada, Peter Lokamar, John N. Kiuru, James Wagude, Barbara Mambo, Caroline Mwangi, Rose Wafula, Kerri Penrose, Urvi M. Parikh, Bhavna Chohan

678 Emerging Dolutegravir Resistance in Lesotho

Nadine Tschumi, Blaise Lukau, Lipontšo Motaboli, Katleho Tlali, Mpho Kao, Mathebe Kopo, Moleboheng Mokebe, Klaudia Naegele, Irene Ayakaka, Karoline Leuzinger, Jennifer A. Brown, **Niklaus D. Labhardt**

679 Resistance to Second-Generation InSTIs in Mexican PLWH: Emergence of the R263K Mutant

Jannette A. Juárez-González, Emiliano Ivan Sanchez Cruz, Luis A. Angulo-Medina, Roberto A. Rodriguez-Díaz, Elsa Y. Vidal-Laurencio, Sofia Sierra Vásquez, **Luis Enrique Soto Ramírez**

680 Virologic Outcomes With Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure

Ying Zhao, Jacqueline Voget, Isaac Singini, Zaayid Omar, Vanessa Mudaly, Andrew Boulle, Gary Maartens, Graeme A. Meintjes

Poster Session-H4 | Archived Mutations and Sustained Suppression

2:30 PM - 4:00 PM • Poster Hall C-D

693 Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression

Rosa De Miguel Buckley, Mayra Sigcha, Maria de Lagarde, Jose Luis Blanco, Rocio Montejano, Angela Gutiérrez Liarte, Esperanza Cañas-Ruano, Arkaitz Imaz, Cristina Hernández, Antonio Ocampo Hermida, Pedro Gil, Rafael Delgado, Federico Pulido, Jose R. Arribas, for the VOLVER-GESIDA 11820 Study Group

694 Switching to Doravirine/Islatravir Maintains Viral Suppression Regardless of Archived Mutations

Ernest Asante-Appiah, Steffy Joseph, Jingwen Chai, Megan Green, Karen Eves, Prachi Nair, Mandy Su, Stephanie Olsen Klopfer, Todd Alan Correll, Jason Yun Kim, Michelle Candice Fox

695 Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch

Michelle L. D'Antoni, Kristen Andreatta, Silvia Chang, Jason Hindman, Laurie VanderVeen, Christian Callebaut

Poster Session-I5 | HIV and Steatotic Liver Disease

2:30 PM - 4:00 PM • Poster Hall C-D

742 Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living With HIV

Tinsay A. Woreta, Mark Sulkowski, Yuchen Xin, Laura Wilson, Eduardo Vilar-Gomez, Samer Gawrieh, Kathleen Corey, Jennifer Price, Susanna Naggie, Sonya Heath, Richard Sterling, James Tonascia, Rohit Loomba, Naga Chalasani, **Jordan E. Lake**

743 De Novo Liver Steatosis Among People With HIV On Contemporary Antiretroviral Therapy

NIS
Carlotta Riebensahm, Nicholas Giamboni, Julia Brocker, Bernard Surial, Huldrych F. Günthard, Philip E. Tarr, Hansjakob Furrer, Annalisa Berzigotti, Andri Rauch, Gilles Wandeler

744 A Gut Microbiome Signature for HIV and Non-Alcoholic Fatty Liver Disease

Javier Martínez-Sanz, **Alba Talavera-Rodríguez**, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez, Juan Miguel Rodríguez-Gómez, Claudio Sanz, María Luisa Montes, Rosa Martín-Mateos, Diego Burgos-Santamaría, Santiago Moreno, Sergio Serrano-Villar, Matilde Sánchez-Conde

745 Liver Steatosis Is Not Associated With Endothelial Function or Hormone Use in Transgender Women

Emilia M. Jalil, Rodrigo C. Moreira, Hugo Perazzo, Marcelo Cunha, Ronaldo Moreira, Laylla Monteiro, Monica D. Pedrosa, Biancka Fernandes, Valdilea Veloso, Beatriz Grinsztejn, Sandra W. Cardoso

746 Increased levels of FGF21 and GDF15 Are Associated With Severity of NAFLD in People With HIV

Paula Debroy, Francis Pike, Samer Gawrieh, Kathleen Corey, Ashok Balasubramanyam, Kate Ailstock, Nicholas Funderburg, Jordan E. Lake

747 Plasma Proteomics Signature of People Living With HIV, With NAFLD, With and Without Obesity

NIS
Louise E. van Eekeren, Nadira Vadaq, Vasiliki Matzaraki, Adriana Navas, Elise M. Meeder, Marc Blaauw, Wilhelm A. Vos, Albert L. Groenendijk, Gert Weijers, Jan van Lunzen, Mihai Netea, Andre J. van der Ven, Quirijn de Mast, Eric T. Tjwa, Leo Joosten

**Poster Session-J2 | HIV-Associated Malignancies:
Epidemiology, Incidence, and Demographics**
2:30 PM - 4:00 PM • Poster Hall C-D

- 753** Starting ART Early After HIV Acquisition Reduces Long-Term Non-AIDS-Defining Malignancy Risk
NIS Iris A. van der Wulp, Ferdinand Wit, Peter Reiss, Marc Van der Valk
- 754** Prevalence of Cancer Screening in People With HIV Utilizing a Symphony Health Data Linkage in Texas
NIS Jennifer K. McGee-Avila, Eric Engels, Cameron B. Haas, Qianlai Luo, Marie-Josephe Horner, Meredith Shiels
- 755** Racial Disparities in Cancer Incidence Among Men Who Have Sex With Men With HIV in the US, 2001-2019
NIS Benton G. Meldrum, Meredith Shiels, Jennifer K. McGee-Avila, Tyler Adamson, Qianlai Luo, Tabassum Insaf, Ruth Pfeiffer, Eric Engels, Cameron B. Haas
- 756** Prevalent and Incident Cancers in a Cohort of People With HIV in Latin America
NIS Valeria I. Fink, Carina Cesar, Shengxin Tu, Bryan E. Shepherd, Claudia P. Cortes, Guilherme Calvet, Juan Sierra-Madero, Eduardo Gotuzzo, Diana Varela, Jessica L. Castilho, for the Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
- 757** Increased Cancer Risk With Low CD4 Counts Persists Despite Over 2 Years of Virological Suppression
NIS Jennifer F. Hoy, for the RESPOND and D:A:D Study Groups
- 758** Incidence of Diffuse Large B-Cell Lymphoma in Relation to the HIV Epidemic in South Africa, 2011-2021
NIS Carole Metekoua, Mazvita Muchengeti, Yann Ruffieux, Patricia Kellett, Matthias Egger, Eliane Rohner, Tracey Wiggill

Poster Sessions • Wednesday

Poster Session-K4 | Heart Failure and Microvascular Health
2:30 PM - 4:00 PM • Poster Hall C-D

- 792** HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety Net Setting
NIS Matthew S. Durstenfeld, Anjali Thakkar, Yifei Ma, Priscilla Y. Hsue
- 793** Repeated Stimulant Use in the Context of Left Ventricular Dysfunction among Women Living with HIV
LB Elise D. Riley, Yifei Ma, Sanyog Shitole, Katherine C. Wu, Torsten Neilands, Adam W. Carrico, Claudia Martinez, Denise Vidot, Carlos Rodriguez, Aruna Chandran, Kathleen Weber, Jason Lazar, Antonina Foster, Phyllis Tien, Jorge R. Kizer
- 794** Proteomic Signature of HIV-Associated Myocardial Fibrosis and Incident Heart Failure
NIS Tess E. Peterson, Virginia S. Hahn, Ruin Moaddel, Sabina Haberlen, Frank Palella, Michael Plankey, Joao Lima, Robert Gerszten, Jerome Rotter, Stephen Rich, Damani Piggott, Joseph B. Margolick, Todd T. Brown, Wendy S. Post, Katherine C. Wu

795
NIS**Factors Linked to Reduced Myocardial Flow Reserve in HIV Using 82Rb Positron Emission Tomography****Samantha Sithole**, Serena Spudich, Mehran Sadeghi, Edward J. Miller, Attila Feher, Phillip Chan**796****Diastolic Dysfunction With Preserved Ejection Fraction in Humanized HIV-Female Mice on cART****Keshore R. Bidasee**, Prasanta Dash, Fadhel A. Alomar, Zachary L. Venn, Chen Zhang, Rongyue Tu, Lili Guo, Bryan T. Hackfort, Santhi Gorantla**Poster Session-L2 | Metabolic Outcomes**

2:30 PM - 4:00 PM • Poster Hall C-D

800**A Combination of Steatosis-Fibrosis Index Predict Major Cardiovascular Events in PLHIV****Maria Luisa Montes**, Carmen Busca, Antonio Olveira, **Jose I. Bernardino**, Luz Martín-Carbonero, Marta Abadia, Eulalia Valencia, Rafael Mican, Rocio Montejano, Rosa De Miguel Buckley, Jose R. Arribas, Juan González-García**801****T-Cell Subsets and Incidence of Diabetes in Persons With HIV in the ACTG Study A5001****Katherine Tassiopoulos**, Kunling Wu, Robert C. Kalayjian, Susan L. Koletar, **Frank Palella**, John Koethe, Alan Landay**802****Subcutaneous Adipose Tissue Myofibroblasts Are Associated With the Lipidome****Samuel Bailin**, Curtis L. Gabriel, Run Fan, Fei Ye, Mona Mashayekhi, Rama D. Gangula, LaToya Hannah, Jonathan A. Kropski, Spyros Kalams, Simon A. Mallal, Celestine Wanjalla, John Koethe**Poster Session-L8 | Mental Health Outcomes**

2:30 PM - 4:00 PM • Poster Hall C-D

833**Depressive Symptom Burden Predicts Diabetes Mellitus Control Among People Living With HIV****Aima A. Ahonkhai**, Aihua Bian, Paridhi Ranadive, Greer Burkholder, Richard D. Moore, Barbara M. Gripshover, Edward Cachay, Jennifer P. Jain, Kenneth H. Mayer, Deana Agil, April Pettit, Mari Kitahata, Heidi M. Crane, Bryan E. Shepherd, Jessica L. Castilho**834****Effectiveness of Electronic Screening for Substance Use, Depression, and Anxiety in HIV Primary Care****Michael J. Silverberg**, Tory Levine, Varada Sarovar, Alexandra Lea, Amy S. Leibowitz, Michael A. Horberg, Charles B. Hare, Mitchell N. Luu, Jason A. Flamm, Derek D. Satre**835****Group Therapy Reduces Depression Among People Newly-Enrolled in HIV Care in Kampala, Uganda****Sarah Lofgren**, Vanessa Akinyange, Anita Arinda, Raymond Sebuliba, David J. Bond, David R. Boulware, Noeline Nakasujja

Poster Session-L9 | Aging and Frailty

2:30 PM - 4:00 PM • Poster Hall C-D

836 Biomarkers of Microbial Translocation and Inflammation Associated With Frailty Among People With HIV

Stephanie A. Ruderman, Peter W. Hunt, Amanda Willig, Michael S. Saag, Sonia Napravnik, Edward Cachay, Laura Bamford, Lydia N. Drumright, Lyndsey S. Mixson, Bridget Whitney, Robin M. Nance, Mari Kitahata, Heidi M. Crane, Joseph A. Delaney, Andrew Hahn

837 Excess Inflammation Associated With AIDS and Non-AIDS Complications in Adults on ART

Kanal Singh, Shweta Sharma, Birgit Grund, Alejandro Arenas-Pinto, Nnakelu Eriobu, Edward Gardner, Win Min Han, Jose Hidalgo, Jennifer Hoy, Jakob Malin, Daniel Murray, Siegfried Schwarze, Alan Winston, Jason Baker, for the INSIGHT START Study Group

838 Optimizing Long-Term Exercise Benefits for Older Adults With HIV: The MOVING Study

Matilde Sánchez-Conde, Jorge Díaz-Álvarez, Rafael García-Molina, Jesus Fernández-Luna, Marta Martínez, Brian B. Vasquez-Brolen, Sara Martín-Colmenarejo, Pablo Ryan, Fernando Dronda, **Fatima Branas**

839 Clonal Hematopoiesis and HIV Infection Are Associated With Geriatric Outcomes: The ARCHIVE Study

Win Min Han, Mark Bloch, David A. Baker, Norman Roth, Jennifer F. Hoy, Ian Woolley, Robert Finlayson, Jane Costello, Mark Dawson, Sarah-Jane Dawson, Mark Polizzotto, Kathy Petoumenos, Paul Yeh, Nila J. Dharan, for the ARCHIVE Study Group

840 Frailty and Health-Related Quality of Life in an Aging Cohort of People With HIV, 2012-2022

Lydia N. Drumright, Bridget Whitney, Crystal Chapman Lambert, Amanda Willig, Robin M. Nance, Stephanie A. Ruderman, Sonia Napravnik, Katerina Christopoulos, Edward Cachay, Lara Haidar, Jimmy Ma, Mari Kitahata, Allison R. Webel, Heidi M. Crane

841 Dasatinib + Quercetin Drugs Reduced Senescent-Associated Secretory Phenotype (SASP) in PLWH PBMCs

Núria Climent, Víctor Casanova, Andrea Rodríguez Agustín, María José Maleno, Cristina Rovira, Josep Mallolas, Juan Ambrosioni, Sonsoles Sánchez-Palomino, José M. Miró, José Alcamí

842 Neighborhood Vulnerability Predicts Non-Communicable Disease Risk Among People With HIV

Aiwei Yan, Aihua Bian, Peter F. Rebeiro, Megan Turner, Paridhi Ranadive, Chandler Shaffernocker, Austin Katona, Noelle Best, Victor Tian, Leslie J. Pierce, Timothy R. Sterling, Bryan E. Shepherd, Jessica L. Castilho, Aima Ahonkhai

843 Application of STOPP Criteria in an Urban Cohort of People Aging With HIV

Lauren F. O'Connor, Jenna Resnik, Sam Simmens, Vinay Bhandaru, La'Marcus Wingate, Debra Benator, Amanda Castel, Anne Monroe, for the DC Cohort Executive Committee

Poster Session-N5 | Diagnostic Testing and Novel Biomarkers for Invasive Mycoses and Tuberculosis
2:30 PM - 4:00 PM • Poster Hall C-D

- 890** **Triple Screening for Invasive Mycoses in Patients With Advanced HIV Disease in Vietnam**
Vu Quoc Dat, Dieu Q. Nguyen, Hao T. Nguyen, Vo Trieu Ly, Thach N. Pham, Do Duy Cuong, Nam X. Ha, Tran Thi Hong Chau, Phuong L. Trinh, Khanh H. Dang, Phan Thi Hong Dao, Trinh Thi Men, Nguyen Thi Hoai Dung, H. Rogier van Doorn, Thuy Le, for the Talaromycosis Study Group
- 891** **Enhancing Advanced HIV Screening: Innovating With the 'Hub and Spoke' Testing Model in Tanzania**
Nelson M. Jonas, Alexander Christopher J. Christopher, Amos Scott, Julius Zelothe, John Roman, Aaron Tesha, Frederick Ndossi, Christopher Henjewele, Josephat Francis, Peter Mlacha, Hosea William, Andrea Mbunda, Eva Matiko, Redempta Mbatia
- 892** **Clinical Relevance of the CRAG Semiquantitative Scores in CRAG-Positive People with AIDS**
Thu T. M. Nguyen, Sruthi Venugopalan, Khanh H. Dang, Phuong L. Trinh, Heera N. Sambath, Matthew T. Burke, Vo Trieu Ly, H. Rogier van Doorn, Vu Quoc Dat, Thuy Le
- 893** **NIS** **Semi-Quantitative Cryptococcal Antigen Testing and Mortality in HIV-Related Cryptococcal Meningitis**
F. Kathryn Boyd, Olivia Maskill, Ronan Doyle, Kwana Lechiile, Cecilia Kanyama, Graeme A. Meintjes, David B. Meya, Mosepele Mosepele, Conrad Muzoora, Henry C. Mwandumba, Chiratidzo Ndhlovu, Thomas S. Harrison, David S. Lawrence, Joseph N. Jarvis, for the AMBITION Study Group
- 894** **NIS** **NSE and UCHL1 as Prognostic Biomarkers for Mortality From Cryptococcal Meningitis**
Mary Foley, F. Kathryn Boyd, Ronan Doyle, Kwana Lechiile, Conrad Muzoora, Cecilia Kanyama, Graeme A. Meintjes, David B. Meya, Mosepele Mosepele, Henry C. Mwandumba, Chiratidzo Ndhlovu, Thomas S. Harrison, David S. Lawrence, Joseph N. Jarvis, for the AMBITION Study Group
- 895** **Histoplasmosis in Advanced HIV Disease: A Multi-Center Prospective Diagnostic Validation Study**
Hao T. Nguyen, Dieu Q. Nguyen, Vo Trieu Ly, Khanh H. Dang, Phuong L. Trinh, Thach N. Pham, Nguyen Thanh Dung, Nguyen Thi Lan, Do Thi Le Na, Nguyen Thanh Vinh, Nguyen Phu Huong Lan, Vu Quoc Dat, H. Rogier van Doorn, Thuy Le, for the Talaromycosis Study Group
- 896** **Ultra Xpert in Blood and Urine and Myco/F Lytic Blood Culture in Patients With Advanced HIV Disease**
Dieu Q. Nguyen, Hao T. Nguyen, Thu D. Do, Quang L. Nguyen, Vu Quoc Dat, Phuong L. Trinh, Khanh H. Dang, Thach N. Pham, Nguyen Thanh Dung, Nguyen Phu Huong Lan, Vo Trieu Ly, Nguyen Thuy Thuong Thuong, H. Rogier van Doorn, **Thuy Le**, for the Talaromycosis Study Group
- 897** **Tuberculosis Drug Resistance Profiling by Targeted Next-Generation Sequencing in Sub-Saharan Africa**
Tiana C. Schwab, Lavania Joseph, Andrew Moono, Pauline Göller, Guy Muula, Denise Evans, Carolyn Bolton, Alban N. Ramette, Matthias Egger, Shaheed Omar, Lukas Fenner, for leDEA Southern Africa (leDEA-SA)

898 High Genetic Diversity of Rifampicin-Resistant *Mycobacterium tuberculosis* Strains in Botswana

Tuelo Mogashoa, Johannes Loubser, Anzaan Dippenaar, Ontlametse T. Bareng, Patience Motshosi, Kedumetse Seru, Tuduetsso Molefi, Maruping Maruping, Chawangwa Modongo, Dimpho Otukile, Mpaphi Mbulawa, Simani Gaseitiswe, Rob M. Warren, Sikhulile Moyo, Elizabeth M. Streicher

Poster Session-01 | Preventing HIV in Pregnancy and Breastfeeding

2:30 PM - 4:00 PM • Poster Hall C-D

899 Exposure to PrEP and Safety Monitoring in Pregnancy: Importance of Objective Exposure Measurement

Dvora L. Joseph Davey, Kalisha Bheemraj, Thokozile R. Malaba, Rufaro Mvududu, Linda-Gail Bekker, Thomas Coates, Landon Myer

900 Pharmacokinetic Study Comparing TAF and TDF as PrEP in Pregnant and Postpartum Women in South Africa

Dvora L. Joseph Davey, Sumaya Dadan, Saye Khoo, Lubbe Wiesner, Landon Myer, Peter L. Anderson, Catherine Orrell

901 Video Observed Therapy for Preexposure Prophylaxis Use in South African Pregnant/Postpartum Women

Sumaya Dadan, Catherine Orrell, Peter L. Anderson, Catriona Waitt, Saye Khoo, Landon Myer, **Dvora L. Joseph Davey**

902 PrEP Discontinuation and High HIV Incidence in South African Pregnant and Postpartum Women

Rufaro Mvududu, Kalisha Bheemraj, Aurelie Nelson, Linda-Gail Bekker, Thomas Coates, Landon Myer, Dvora L. Joseph Davey

903 The Role of Maternal Broadly Neutralizing Antibody Activity in Perinatal Transmission of HIV-1

Krithika P. Karthigeyan, Ashley Nelson, Dieter Mielke, Christian Binuya, Ria Goswami, John Isaac, Elena Giorgi, Justin Pollara, Joshua Eudailey, Megan Connors, Carolyn Weinbaum, Genevieve G. Fouda, Feng Gao, Manish Sagar, Sallie Permar

Poster Session-02 | Improving Maternal Outcomes on Antiretroviral Therapy

2:30 PM - 4:00 PM • Poster Hall C-D

904 Long-term Outcomes After Loss to Follow-Up From PMTCT Services for Women and Children in Kenya

John Humphrey, Bett Kipchumba, Edwin Sang, Marsha Alera, Beverly Musick, Lindah Muli, Justin Kipsang, Julia Songok, Constantin Yiannoutsos, Kara Wools-Kaloustian

905 ART Adherence And Elevated Viral Load in Pregnant & Postpartum Women Initiating DTG Versus EFV

Thokozile R. Malaba, Catherine Orrell, Laura Else, Duolao Wang, Catriona Waitt, Angela Colbers, Helen Reynolds, Nengjie He, Lucy Read, Mohammed Lamorde, Saye Khoo, Landon Myer, for the DolPHIN-2 Study Group

906 A Novel Risk Calculator to Predict Sub-Optimal Outcomes Among Pregnant and Postpartum Women With HV

Karen Hampanda, Kevin Owuor, Laura K. Beres, Emmah Ouma, Maricianah A. Onono, Anna Helova, Mercelline Onyando, Jeff Szychowski, I. L. Abuogi, Janet M. Turan

907 Mentor Mothers! Community Model to Attain Elimination of Mother-to-Child HIV Transmission, Tanzania

Neema E. Makya, Amani Maro, Agnes Kosia, Aaron Godwin, Donatha Kayoza, Amos Nyirenda

908 NIS Comparison of Models of Care to Promote Postpartum Viral Suppression in South African Women

Mustafa Shuaib, Tamsin Philips, Jasantha Odayar, Thokozile R. Malaba, Elaine J. Abrams, Landon Myer

909 Budget Impact Analysis of an Enhanced Retention Strategy for PMTCT Programs in Uganda

Elly Nuwamanya, Mohammed Lamorde, Ronald Galiwango, Tabitha Ayabo, Dianah Namuddu, **Benjamin Johnson**

Poster Session-P5 | Comorbidities and Complications in Children and Adolescents with HIV Infection

2:30 PM - 4:00 PM • Poster Hall C-D

967 Influence of Childhood Adversity on Cardiovascular Health in HIV Youth in Uganda

Sahera Dirajlal-Fargo, Shan Sun, Christine Karungi, Joy Gumikiriza-Onoria, Angel Nanteza, Nicholas Funderburg, Victor Musiime, Grace A. McComsey, Reuben Robbins

968 Changes in the Lipidome Are Associated With Immune Activation in Ugandan PHIV

Sahera Dirajlal-Fargo, Melica Nikahd, Kate Ailstock, Manjunath Manubolu, Victor Musiime, Grace A. McComsey, Nicholas Funderburg

969 NIS Activated Proinflammatory NK Cells Promote Atherogenesis in Adolescents With Perinatally Acquired HIV

Mario J. Alles, Manuja G. Gunasena, Victor Musiime, Cissy Kityo, Banumathi Tamilselvan, Brian Richardson, Wendy Ching-Wen Li, Cheryl Cameron, Mark Cameron, Sahera Dirajlal-Fargo, Nicholas Funderburg, Namal P. Liyanage

970 DNA Methylation Signatures of Inflammation in Youth Living With Perinatally-Acquired HIV

Stephanie Shiu, Sean Brummel, Jasmine Douglas, Francesca Zumpano, Michael J. Corley, Jennifer Jao, Murli Purwani, Kunjal Patel, Carmen Marsit, for Pediatric HIV/AIDS Cohort Study (PHACS)

971 Young CPHIV Have Low Proinsulin to C-Peptide Ratios That Inversely Correlate With T-Cell Exhaustion

Wei Li, Emily Sims, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

972 Metabolomic Signature in Youth With Perinatally Acquired HIV and Non-Alcoholic Fatty Liver Disease

Silvia Chafino, Laura Tarancón-Diez, Jara Hurtado-Gallego, Sonia Alcolea, Antonio Olveira, María Luisa Navarro, Salvador Fernández-Arroyo, Consuelo Viladés, María Luisa Montes, Francesc Vidal, Joaquim Peraire, Anna Rull, Talia Sainz

973 Low Bone Density Accrual and Increased Inflammation in Zimbabwean Adolescents With Perinatal HIV

Lisha Jeena, Victoria Simms, Rukuni Ruramayi, Andrea M. Rehman, Celia Gregson, Rashida A. Ferrand, **Sarah Rowland-Jones**, Anthony Hsieh

974 WITHDRAWN**975 Association Between HIV and Cytomegalovirus and Neuropsychological Outcomes Among Children With HIV**

NIS Jillian Neary, Daisy Chebet, Sarah Benki-Nugent, Hellen Moraa, Noah Cassidy, Carolyn Fish, Barbra Richardson, Irene Njuguna, Agnes Langat, Evelyn Ngugi, Dara Lehman, Jennifer Slyker, Dalton C. Wamalwa, Grace John-Stewart

976 Regional Brain Volume as Predictor of Cognitive and Mental Health Outcomes in Youth Living With HIV

Sedthapong Chunamchai, Anantaporn Sena, Akarin Hiransuthikul, Phillip Chan, Robert Paul, Somchai Sriplienchan, Thanyawee Puthanakit, Serena Spudich, Chaipat Chunharas

977 Neurocognitive Performance in Adolescents Living With HIV in Zimbabwe

NIS Nyasha V. Dzavakwa, Annalie Shears, Nicol Redzo, Tsitsi Bandason, Hilda A. Mujuru, Joseph Piper, Victoria Simms, Rashida A. Ferrand, for the VITALITY Mind Team

978 Development of Domain-General Cognition in Adolescents With HIV Is Slower Than Healthy Individuals

Anantaporn Sena, Sedthapong Chunamchai, Akarin Hiransuthikul, Phillip Chan, Robert Paul, Somchai Sriplienchan, Thanyawee Puthanakit, Serena Spudich, Chaipat Chunharas

979 Adult Outcomes Among Young People With Perinatal HIV Infection and Exposure in the United States

Elaine J. Abrams, Reuben Robbins, Afifa Ahmed, Curtis Dolezal, Luke Kluisza, Ohemaa Poku, Michael T. Yin, Andrew Wiznia, Claude Mellins

980 High Burden of HIV-Related Disease Among Adults With Perinatally-Acquired HIV in Argentina

NIS Violeta Z. Ortiz, **Julian Vega**, Maria L. Santos, Solange Arazi Caillaud, José A. Barletta, María J. Rolón

Poster Session-P7 | Interventions to Improve Identification and Care for Children and Adolescents

2:30 PM - 4:00 PM • Poster Hall C-D

989 Pediatric HIV Hotspots: Machine Learning and Geostatistical Analysis for Enhanced Case Finding

NIS

Amobi A. Onovo, Kathleen Handley, Gonza Omoro, Jonah Maswai, Reuben Ngumo, John Owuoth, Rosemary Mrina, Patricia Agaba

990 Pediatric Emergency Department-Based Opt-Out HIV Screening Identifies Adolescents Living With HIV

Sandy Francois, Mark A. Griffiths, Melissa N. Cameron, Jordan E. Daniel, Bridget A. Wynn, Sara P. Brown, Sarah Thompson, Rebekah G. Carter, Kelly DeNaples, Swaminathan Kandaswamy, Evan Orenstein, Andres Camacho-Gonzalez, Claudia R. Morris, **Lauren Middlebrooks**

991 Evaluation of Electronic Peer Navigation to Prevent Engagement Failure for Youth in Kenya

I. Lisa Abuogi, Lina M. Montoya, Edwin Nyagesoa, Jayne L. Lewis-Kulzer, Everlyne Nyandieka, Gladys Ontuga, Isaya Oondo, James Nyanga, Eliud Akama, Thomas Odeny, Elizabeth Bukusi, Elvin H. Geng

992 Effectiveness of the mHealth Intervention, InTSHA, Among Adolescents With HIV in South Africa

Brian C. Zanoni, Moherndran Archary, Thobekile Sibaya, Casiel T. Gethers, Madeleine Goldstein, Scarlett Bergam, Christina Psaros, Vincent Marconi, Jessica Haberer

993 Is HIV Outbreak Among Children in Larkana Over? Findings From a Large Test and Treat Initiative

LB

Muhammad S. Jamil, Muhammad S. Pasha, Shahida Memon, Atif Ali, Tanweer Hussain, Altaf A. Soomro, Saima Mushtaq, Sikandar Memon, Joumana Hermez

994 Data Informed Stepped Care (DiSC) to Improve HIV Care for Youth With HIV: A Cluster Randomized Trial

LB

Pamela Kohler, Wenwen Jiang, Jacinta Badia, James Kibugi, Jessica Dyer, Julie Kadima, Dorothy Oketch, Kristin Beima-Sofie, Sarah Hicks, Barbra Richardson, Irene Inwani, Seema Shah, Grace John-Stewart, Kawango Agot

Poster Session-Q6 | The HIV Care Cascade and Advanced HIV Disease

2:30 PM - 4:00 PM • Poster Hall C-D

1039 Progress Toward 95-95-95 and Viral Suppression Among FSW/CSEG in Unguja, Zanzibar, 2023

Mtoro J. Mtoro, Farhat J. Khalid, Christen A. Said, Thomas W. John, Joel Ndayongeje, Sarah Porter, Mohamed Dahoma, Tara Pinto, Asha Ussi, Ahmed Jahzumi, Augustino Msanga, Pili Khamisi, Ahmed Khatib

1040 Individual- and Community-Level Predictors of HIV Care Continuum Progression: Clark County, Nevada

Ravi Goyal, **Alan Wells**, Victoria Burris, Angel Stachnik, Preston Nguyen Tang, Lyell Collins, Sanjay R. Mehta, Susan J. Little

- 1041** **Multiple Care Disengagements and CD4 Restoration: A Comparative Analysis in People With HIV**
Giota Touloumi, Achilleas Stamoulopoulos, Christos Thomadakis, Vasilios Paparizos, Vasileios Papastamopoulos, Konstantinos Protopapas, Georgios Adamis, Maria Chini, M. Psichogiou, Georgios Chrysos, Nikos Pantazis, Helen Sambatakou
- 1042** **A Multistate Analysis of Longitudinal Care Outcomes Among People Newly-Linked to Care in Missouri**
Aditi Ramakrishnan, Aaloke Mody, Daniel Vo, Ernie-Paul Barrette, Rachel Presti, William G. Powderly, Anne Trolard, Catherine Schwarz, Elvin Geng, Lindsey M. Filiatreau
- 1043** **Rethinking the Definition of Late HIV Diagnosis Using Florida Surveillance Data, 2015-2021**
NIS
Christina E. Parisi, Robert Cook, Zhigang Li, Shantrel Canidate, Awewura Kwara, Zhi Zhou, Natalie Chichetto
- 1044** **Temporal Trends in CD4 Cell Count Soon After Seroconversion and HIV-RNA Viral Set-Point**
Nikos Pantazis, Dominique Costagliola, Ard van Sighem, Inma Jarrin, Laurence Meyer, Caroline Sabin, Christina Carlander, John Gill, Shema Tariq, Bruno Spire, Fiona Burns, Elisa Ruiz-Burga, Kholoud Porter, Giota Touloumi, for the CASCADE Collaboration
- 1045** **Advanced HIV Disease and the Care Cascade: Trends From 2015-2021**
NIS
David S. Lawrence, Melanie Moyo, Mark W. Tenforde, Kwana Lechiile, Charles Muthoga, Tshepo B. Leeme, Thomas S. Harrison, Madisa Mine, Joseph N. Jarvis, for the AMBITION Study Group
- 1046** **Global Trends in CD4 Count Measurement and Prevalence of CD4 <200 cells/ μ L at ART Initiation**
Renee De Waal, Kara Wools-Kaloustian, Ellen Brazier, Keri N. Althoff, Antoine Jacquet, Stephany Duda, Nagalingeswaran Kumarasamy, Helen Byakwaga, Gad Murenzi, Amy C. Justice, Didier Koumavi Ekouevi, Carina Cesar, Mark Pasayan, Reshma Kassanjee, for International Epidemiology Databases to Evaluate AIDS
- 1047** **Difficult-to-Treat HIV in Sweden: Describing the Current Landscape**
Olof Elvstam, Viktor Dahl, Anna Weibull Wärnberg, Susanne von Stockenström, **Aylin Yilmaz**
- Poster Session-Q7 | Mental Health, Morbidity, and Mortality among People Living with HIV**
2:30 PM - 4:00 PM • Poster Hall C-D
- 1048** **Life-Years Lost Associated With Mental Illness in People With HIV in South Africa and North America**
Yann Ruffieux, Keri N. Althoff, Brenna Hogan, Greg Kirk, Raynell Lang, Angela Parcesepe, Michael J. Silverberg, Chunyan Zheng, John Joska, Mpho Tlali, Naomi Folb, Gary Maartens, Mary-Ann Davies, Matthias Egger, Andreas Haas
- 1049** **Modeled Estimates of Disease Burden Attributable to Interactions Between HIV and Depression in Kenya**
Daniel T. Citron, Hae-Young Kim, Rosco Kasujja, Samuel Mwalili, Josiline Chemutai, Ingrida Platais, Frey Assefa, Anna Bershteyn

1050 Prevalence of Diagnosed and Undiagnosed Depression Among US Adults With HIV

Linda Beer, Linda J. Koenig, Yunfeng Tie, Xin A. Yuan, Jennifer Fagan, Kate Buchacz, **John Weiser**

1051 Trends in Suicide-Related Emergency Department Visits Among People With and Without HIV in Bronx, NY

LB Chloe Roske, **Caitlin Hills**, Wenzhu B. Mowrey, Yingchen Xu, Aaron S. Breslow, Atul K. Bhattiprolu, Ava Erulker, Grishma Patel, Joan W. Berman, Anjali Sharma, Vilma Gabbay, David B. Hanna

1052 Progress Toward Achieving National Goals for Improved Quality-of-Life Among Black Women With HIV

Jerris L. Raiford, Yunfeng Tie, Xin A. Yuan, Kathy Byrd, Kate Buchacz, Linda Beer

1053 Mind the Gap: Life Expectancy and Mortality in Males & Females With HIV in British Columbia, Canada**NIS**

Katherine Kooij, Wendy Zhang, Jason Trigg, Nance Cunningham, Michael Budu, Viviane Dias Lima, Kate Salters, Rolando Barrios, Julio Montaner, Robert Hogg

1054 Leading Causes of Death Among People With HIV in the US, 2001-2019**NIS**

Karena Volesky-Avellaneda, Eric Engels, Qianlai Luo, Meredith Shiels

1055 Age-Adjusted Mortality Rates Among Persons With HIV, by Race and Ethnicity and Cause of Death**LB**

Cameron Stainken, Cassandra O. Sember, Nannie Song, Deanna Sykes, Philip Peters, **Darpun Sachdev**

1056 Mortality Among People Living With HIV in India: Emergence of Noncommunicable Diseases

Manish Bamrotya, Neha Garg, Alice Marak, Jade Bell, Maria Salvat Ballester, Allison M. McFall, Shruti Mehta, Sunil Suhas Solomon, Bhawani Kushwaha, Chinmoyee Das, Purnima Parmar, Hekali Zhimomi, Nidhi Kesarwani

1057 Registered Causes of Death Remain Largely Unknown Among People With HIV in Latin America

Yanink Caro-Vega, Antonio Pacheco, Karu Jayathilake, Gabriela Carriquiry, Paula M. Luz, Daisy Machado, Jorge Pinto, Claudia Cortes, Carina Cesar, Marco T. Luque, Vanessa Rouzier, Stephany Duda, Peter F. Rebeiro, for the Caribbean, Central & South American Network for HIV epidemiology (CCASAnet)

1058 Predicting Cause-Specific Mortality With the VACS Index 2.0 Among Persons With HIV

Julie Ambia, **Suzanne M. Ingle**, John Gill, Sophie Abgrall, Mojgan Hessamfar, Peter Reiss, Christoph Wyen, Heidi M. Crane, Inma Jarrin, Michael J. Silverberg, Kathleen A. McGinnis, Amy C. Justice, Jonathan A. Sterne, Adam Trickey, for the Antiretroviral Therapy Cohort Collaboration (ART-CC)

- 1059 Care Interruptions and Mortality Among Adults on Antiretroviral Therapy in Europe and North America**
Adam Trickey, Christopher T. Rentsch, Nikos Pantazis, Rebeca Izquierdo, Andrea Antinori, Gisela Leirer, Greer Burkholder, John Gill, Marc Van der Valk, F. Bonnet, Heidi M. Crane, Michael J. Silverberg, Suzanne M. Ingle, Jonathan A. Sterne, for the Antiretroviral Therapy Cohort Collaboration (ART-CC)
- 1060 Impact of Accessing Care at an Advanced Stage on Mortality in PWH in France, 2002-2016**
Valérie Potard, Malamine Gassama, Emilie Lanoy, Sylvie Abel, Firouze Bani Sadr, Sylvie Bregigeon, Fabienne Caby, Blandine Denis, Pierre de Truchis, Guillaume Martin-Blondel, Lionel Piroth, Axel Ursenbach, Dominique Costagliola, Sophie Grabar, for the ANRS CO4 FHDH Late Presentation Study Group
- 1061 Trends in Hospital Readmission Among People With and Without HIV in the US, 2010-2020**
Xianming Zhu, Eshan U. Patel, Mary Kate Grabowski, Thomas C. Quinn, Stephen A. Berry, Kelly A. Gebo, Aaron A. R. Tobian
- Poster Session-Q8 | Insights from HIV Molecular Epidemiology**
2:30 PM - 4:00 PM • Poster Hall C-D
- 1062 Wastewater Monitoring of HIV-1: Feasibility and Comparison to Surveillance Data**
Marlene K. Wolfe, **Meri Varkila**, Julie Parsonnet, Alexandria B. Boehm
- 1063 Statewide Real-Time Integration of Molecular and Contact Tracing Data to Disrupt HIV Transmission**
Rami Kantor, Jon Steingrimsson, John Fulton, Vlad Novitsky, Mark Howison, Fizza Gillani, Lila Bhattacharai, Meghan MacAskill, Joel Hague, August Guang, Aditya Khanna, Casey Dunn, Joseph Hogan, Thomas Bertrand, Utapala Bandy
- 1064 Incident HIV Infection Drives Community HIV Cluster Growth**
Antoine Chaillon, Alan Wells, Tom Chen, Ravi Goyal, Samantha Tweeten, Sanjay R. Mehta, **Susan J. Little**
- 1065 Contribution of HIV Transmission Bursts to Future HIV Infections, United States**
Rachael Billock, Anne Marie France, Neeraja Saduvala, Nivedha Panneer, Alexandra M. Oster, Camden J. Hallmark, Joel O. Wertheim
- 1066 HIV Cases Averted in Phylogenetic Clusters via Preexposure Prophylaxis in British Columbia, Canada**
NIS
Angela McLaughlin, Junine Toy, Paul Sereda, Jason Trigg, Vincent Montoya, Richard H. Liang, Charlotte Beelen, Tim Tang, Alex LaBerge, Chanson J. Brumme, Rolando Barrios, Julio S. Montaner, Jeffrey B. Joy
- 1067 Geospatial and Phylogenetic Clustering of Acute HIV Infections in Lilongwe, Malawi**
NIS
Griffin J. Bell, Kimberly Powers, Oliver Ratmann, Ann M. Dennis, Pearson Mmodzi, Mitch Matoga, Edward Jere, David Bonsall, Sharon Weir, Michael Emch, Irving F. Hoffman, Myron S. Cohen, William Miller

- 1068 Increasing Intra- and Inter-Subtype HIV Diversity Despite Rapidly Declining HIV Incidence in Uganda**
Seungwon Kim, Michael A. Martin, Ronald M. Galiwango, Oliver Laeyendecker, Thomas C. Quinn, Godfrey Kigozi, Robert Sekubugu, David Bonsall, Steven J. Reynolds, Brian Foley, Lucie Abeler-Dörner, Christophe Fraser, Oliver Ratmann, Joseph Kagaayi, Mary Kate Grabowski
- 1069 HIV-1 A6 Variant Transmissions Poland Are Fuelled by War Refugees From Ukraine & Local MSM Clusters**
LB
Karol Serwin, Kaja Scheibe, Anna Urbańska, Bogusz Aksak-Wąs, Magdalena Witak-Jędra, Piotr Ząbek, Ewa Siwak, Iwona Cielniak, Paweł Jakubowski, Monika Bociąga-Jasik, Elżbieta Mularska, Bartosz Szetela, Aleksandra Szymczak, **Mirosz Parczewski**
- 1070 HIV Spread in Miami-Dade County**
Antoine Chaillon, Alan Wells, **Sanjay R. Mehta**, Susan J. Little
- 1071 Genetic Diversity From Proviral DNA as a Proxy for Time Since HIV-1 Infection**
Marius Zeeb, Paul Frischknecht, Karin Metzner, Michael Huber, Christine Leeman, Julia Notter, Andri Rauch, Marcel Stöckle, Alexandra Calmy, Matthias Cavassini, Enos Bernasconi, Dominique Braun, Huldrych F. Günthard, Roger Kouyos, for the Swiss HIV Cohort Study
- Poster Session-Q9 | COVID-19 Epidemiology and Impact on HIV Outcomes**
2:30 PM - 4:00 PM • Poster Hall C-D
- 1072 The Impact of COVID-19 on HIV Mortality Trends in United States Black, White, and Hispanic Adults**
Elizabeth B. Pathak, DaRel M. Barksdale, Mary Y. Masterson, Paul A. Burns
- 1073 COVID-19-Related Shutdowns and Viral Suppression in the US and Canada**
Keri N. Althoff, Brenna Hogan, Milton L. Wainberg, Kelly A. Gebo, Michael A. Horberg, John Gill, Peter F. Rebeiro, Mari Kitahata, Kathleen A. McGinnis, Jennifer Lee, Vincent Marconi, Michael J. Silverberg, Richard D. Moore, Angela Parcesepe, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA
- 1074 Impact of COVID-19 Pandemic on HIV Ambulatory Services and Viremia in a US HIV Cohort, 2019-2022**
Ellen M. Tedaldi, Qingjiang Hou, Carl Armon, Jonathan Mahnken, Frank Palella, Gina Simoncini, Jack Fuhrer, Cynthia Mayer, Alexander C. Ewing, Kalliope Chagaris, Kimberly Carlson, Jun Li, Kate Buchacz
- 1075 Variation in Viral Load Testing and Outcomes in Telehealth HIV Care During COVID-19**
Valerie Yelverton, Jan Ostermann, Michael E. Yarrington, Andrew K. Weinhold, Nabil Natafgi, Bankole Olatosi, Sharon Weissman, Nathan M. Thielman
- 1076 Differences in Country-Level COVID-19 Mortality Across the Western Hemisphere**
Katie Kerckaert, Adina Z. Zhang, Serena Koenig, Pierre Cremieux, Vanessa Rouzier

1077 What's in a Wave: Using COVID-19 Data to Explore the Definition of Epidemic Waves

NIS

Joshua Smith-Sreen, Jorge Ledesma, Mark Lurie

Poster Session-R1 | HIV, SARS-CoV-2, and Mpox Testing

2:30 PM - 4:00 PM • Poster Hall C-D

1078 National HIV Testing Trends and Sociodemographic Correlates in Black Cisgender or Transgender Women

NIS

Xinyi Li, Yijin Xiang, Jincong Q. Freeman, Yong G. Lee

1079 Seroprevalence of Mpox IgG Antibodies in a Cohort of PLWH in Rome During the 2022 Outbreak

Pierluigi Francesco Salvo, Rebecca Jo Steiner, Damiano Farinacci, Valentina Iannone, Francesco Lamanna, Rosa Anna Passerotto, Alberto Borghetti, Simona Di Giambenedetto, Francesca Lombardi

1080 Impact of COVID-19 Pandemic on HIV Testing Among MSM: An Interrupted Time Series Analysis

Emily J. Green, Lamia Khan, Jamieson T. Jann, Marjan Javanbakht, Risa Flynn

1081 Late HIV Diagnosis in CoRIS, 2012-2022, and Impact of a Formative Session in 20 Primary Care Centers

NIS

Alejandro G. García-Ruiz De Morales, Javier Martínez-Sanz, María Jesús Vivancos, Santos Del Campo Terrón, Beatriz Romero Hernández, Marta Montero Alonso, María Remedios Alemán Valls, Enrique Bernal, Félix Gutiérrez, Antonio Rivero Román, Miguel Cervero Jiménez, Gemma Navarro, David Dalmau Juanola, María Jesús Pérez Elías, for CoRIS

1082 Community-Based Sample Collection to Improve HIV Viral Load Coverage in Multiple States in Nigeria

Ughweroghene K. Omo-Emmanuel, Feyisayo E. Jegede, Pamela N. Gado, Blessing O. Airiagbonbu, Eloghosa Omorogbe, Usman B. Haliru, Laide K. Badmus

1083 Test-All Model for SARS-CoV-2 Testing Is More Cost-Effective Than Screen & Test in Kenya & Cameroon

Mario J.P. Songane, Boris Tchounga, Rose Masaba, Tatiana Djikeussi, James Ndimbii, Carolyn Mwancha-Kwasa, Emilienne Epée, Anne Bissek, Aida Yemaneberhan, Laura Guay, Rhoderick Machekano, Nilesh Bhatt, Appolinaire Tiam, Sushant Mukherjee

1084 Validation and Acceptability of SARS-CoV-2 Loop-Mediated Isothermal Amplification Test in Malawi

NIS

Maggie Nyirenda-Nyang'wa, Mercy Kamdolozi, Harry Meleke, David Chaima, Vincent S. Phiri, Thomas Waterfield, Nedson Bondera, Maganizo B. Chagomerana, James McKenna, Thandie Mwalukomo, Chisomo Msefula, Tonney Nyirenda, Derek Fairley, Mina Hosseinipour, for SARS LAMP Group

1085 Estimation of Recent HIV Infections in Japan Using a Novel Testing Algorithm With Chronological Tree

Teiichiro Shiino, Shuzo Matsushita, Tadashi Kikuchi, Machiko Otani, Kazuhisa Yoshimura, Wataru Sugiura, for Japanese Drug Resistance HIV-1 Surveillance Network

- 1086 HIV Testing Pre- and Post-COVID-19 Pandemic Among Persons Who Inject Drugs: 19 Cities, 2018-2022**
Rebecca B. Hershaw, Dita Broz, Lyssa Faucher, Johanna Chapin-Bardales, for National HIV Behavioral Surveillance Study Group
- 1087 Rapid Diagnosis of HIV Infection and Initiation of Antiretroviral Treatment**
Monica Mantilla Suarez, Leonardo Arevalo, Hector Mueses
- 1088 Targeted Outreach to Increase Linkage to Preventative Services for Patients Tested for Mpox**
Hannah Blanchard, Helen King, Kristin Alvarez, Ank Nijhawan, Virali Soni
- 1089 Detection of Diverse HIV Strains by the m-PIMA™ HIV-1/2 Detect Point-of-Care Assay**
Mark C. Anderson, Lara I. Teodoro, Fiona Harley, Eduardo Almaraz, Carolyn Strobel, Barbara Harris, Todd V. Meyer, Mary Rodgers, Gavin Cloherty
- 1090 HIV & HCV Screen Rates for Hospitalized PWUD Are Heterogeneous & Suboptimal Across 11 US Hospitals**
 Leo K. Westgard, **Taisuke Sato**, Finlay Pilcher, Emily D. Grussing, Jessica P. Ridgway, Ayesha Appa, Jaimie P. Meyer, Uriel R. Felsen, Luara Marks, Kinna Thakrar, Brian T. Montague, Ank Nijhawan, William S. Bradford, Ellen Eaton, Alysse G. Wurcel, for the PWUD Care Workgroup (PCW)
- 1091 Development and Evaluation of Tasso-M50 Method for Dried Blood Viral Load Detection**
Daniel S. Rosenbloom, Brad R. Evans, Brian Squadroni, Jennifer Nguyen, Livio Azzoni, Erin Coppola, Guoxin Wu, Jill W. Maxwell, Jessicamarie Morris, Kenneth Lynn, Paul Zuck, Pablo Tebas, Karam Mounzer, Luis J. Montaner, Bonnie Howell
- 1092 Declines in HIV Testing and Diagnoses: Unanticipated Consequences of Trump Adm 2019 Title X Policy**
Jennifer Sherwood, Elise Lankiewicz, Deborah Stenoien, Nathan Roberson, Brian Honermann, Greg Millett

Poster Session-S6 | Differentiated Service Delivery Models for PrEP and TasP

2:30 PM - 4:00 PM • Poster Hall C-D

- 1140 Enabling Mobility of Health Workers With Motorcycles to Improve PrEP Uptake Among Key Populations**
Mwedi Mohamedi, John Roman, Ola F. Jahaniour, Appolinary Bukuku, Japhet Daud, Damian Laki, Frederick Ndossi, Eva Matiko, Redempta Mbatia, Josephat Francis, Ramadhani Gongo, Nyagonde Nyagonde, Galal King'ori, Oscar Rwabyago
- 1141 Enhancing HIV PrEP Coverage Through Primary Care Initiation: A French Nationwide Study**
Sophie Bamouni, Sophie Billioti De Gage, David Desplas, Julie Valbousquet, Julie Lamant, Jean-Philippe Joseph, François Dabis, Agnès Viot, Salim Fakir, Rosemary Dray-Spira, Michel Carles

1142 Uptake of HIV prevention by Notified Seronegative Partners in HIV-Discordant Couples in Uganda

Edith Namulema, Elizabeth Mutambuze, Isaac Lwanga, Allan Simwogerere, Racheal Ankunda, Tonny Tumwesigye, Nelson Mugume, Arthur G. Fitzmaurice, Maria Bafumba

1143 NLPrEP Trial 24-Week Data: Nurse-Led PrEP Superior to Physician-Led PrEP Among Cis Women in Zambia

Lloyd B. Mulenga, Sombo Fwoloshi, Suilanji Sivile, Linah Mwango, Evelyn Mwamba, Chofwe Chola, Davies Kampamba, Lottie Hachaambwa, Aggrey Mweemba, C. William Wester, Mpanji Siwingwa, Pawel Ołowski, Lameck Chirwa, **Cassidy W. Claassen**

Poster Session-S7 | PrEP Drug-Drug Interactions and Complications

2:30 PM - 4:00 PM • Poster Hall C-D

1144 No Significant Interactions From Hormone Therapy on F/TAF-Based PrEP in Trans Women: iFACT3 Study

Akarin Hiransuthikul, **Narukjaporn Thammajaruk**, Stephen Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Peter L. Anderson, Nittaya Phanuphak, for the iFACT3 Study Team

1145 No Significant Interactions From Hormone Therapy Toward F/TDF-Based PrEP in Trans Men: iMACT Study

Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Peter L. Anderson, Nittaya Phanuphak, for the iMACT Study Team

1146 Potential Drug Interactions From Hormone Therapy Toward F/TAF-Based PrEP in Trans Men: iMACT Study

Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, Rena Janamnuaysook, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpiroon Tawon, Jakkrapatara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressey, Peter L. Anderson, Nittaya Phanuphak, for the iMACT Study Team

1147 One-Year Declines in Bone Mineral Density Among Young Women in Uganda Using TDF-Based PrEP and DMPA

Renee Heffron, Timothy Muwonge, Katherine K. Thomas, Kidist Zewdie, Timothy Ssebuliba, Gabrielle Stein, Susan Morrison, Josephine Badaru, Agnes Nakyanzi, Felix Bambia, Kenneth K. Mugwanya, Christina Wyatt, Michael T. Yin, Flavia Kiweewa Matovu, Andrew Mujugira

Poster Session-T1 | A Deep Dive Into DoxyPEP Implementation

2:30 PM - 4:00 PM • Poster Hall C-D

1148 Objective Assessment of Doxycycline PEP Use Among Cisgender Women in Kenya

Jenell Stewart, Kevin Oware, Deborah Donnell, Lauren R. Violette, Josephine Odoyo, Victor Omollo, Felix Mogaka, Matthew A. Spinelli, Hideaki Okochi, Monica Gandhi, Elizabeth Bukusi, Jared Baeten, for dPEP Kenya Study Team

1149 Doxycycline Postexposure Prophylaxis to Prevent *Trichomonas vaginalis* Among Cisgender Women

Fredericka Albertina Sesay, Kevin Oware, Lauren R. Violette, Deborah Donnell, Josephine Odoyo, Victor Omollo, Felix Mogaka, R. Scott McClelland, Jennifer E. Balkus, Elizabeth Bukusi, Jared Baeten, Jenell Stewart, for dPEP Kenya Study Team

1150 Bacterial STI Trends Associated With the October 2022 Doxy-Prophylaxis Recommendation, San Francisco

Andy Liu, Jiayuan Hao, Trevor A. Pickering, Jeffrey D. Klausner

1151 Doxy-PEP Effectiveness in Men Who Have Sex With Men (MSM) and Transgender Women (TGW) on HIV PrEP

LB
Oliver Bacon, Robert P. Kohn, David V. Glidden, Madeline Sankaran, Montica Levy, Trang Q. Nguyen, Stephanie E. Cohen

1152 Early Adopters: Implementation of Doxycycline Postexposure Prophylaxis in a Boston Health Center

Kenneth H. Mayer, Michael Traeger, Sy Gitin, Jessica Kraft, Taimur Khan

1153 National Survey on the Use of Antibiotics as Sexually Transmitted Infection Prophylaxis in the US

NIS
Michael W. Traeger, Douglas S. Krakower, Kenneth H. Mayer, Samuel M. Jenness, Julia L. Marcus

1154 Impact of Doxycycline as STI PEP on the Gut Microbiome and Antimicrobial Resistance Gene Expression

LB
Victoria T. Chu, Abigail Glascock, Deborah Donnell, Cole Grabow, Ryan Ward, Christina Love, Stephanie E. Cohen, Julia C. Dombrowski, Chase Cannon, Michael Woodworth, Colleen Kelley, Connie Celum, Annie Luetkemeyer, Charles Langelier

Poster Session-T2 | The Problem of the Persistent Pox: Global Syphilis Epidemiology

2:30 PM - 4:00 PM • Poster Hall C-D

1155 Increase in Syphilis Cases Diagnosed at a Tertiary IHS Facility Following Expanded Screening

Voichita Ianas, Heather Huentelman

1156 Prevalence of Syphilis and HIV/Syphilis Coinfection in an Inner-City Emergency Department

NIS
Joanne Hunt, Oliver Laeyendecker, Bhakti Hansoti, Reinaldo Fernandez, Richard E. Rothman, Thomas C. Quinn, Yu-Hsiang Hsieh

1157 Jarisch-Herxheimer Reaction in Patients With Syphilis With or Without Prior Antibiotic Prophylaxis

Samuel Lazzarin, Andrea Poloni, Giorgia Carrozzo, Giacomo Pozza, Chiara Fusetti, Francesco Caruso, Serena Reato, Maddalena Matone, Andrea Giacomelli, Maria Vittoria Cossu, Andrea Gori, Giuliano Rizzardini, Spinello Antinori, Davide Moschese

1158 Increasing Syphilis Prevalence Among MSM Across India Despite Improvements in the HIV Care Continuum

Matthew M. Hamill, Mihili P. Gunaratne, Allison M. McFall, Hussain Syed Iqbal, Canjeevaram K. Vasudevan, Santhanam Anand, Sunil Suhas Solomon, Shruti H. Mehta, Aylur K. Srikrishnan, David D. Celentano, Gregory M. Lucas

- 1159 Gaps in the Prevention of Mother-to-Child Transmission of Syphilis in South Africa, 2020-2022**
Alex de Voux, Wellington Maruma, Mabore Morifi, Modiehi Maduma, Joy Ebonwu, Sithembile Dlamini Nqeteko, Landon Myer, Tendesayi Kufa
- 1160 Routine Emergency Department Screening Increases Syphilis Diagnosis Among Pregnant Patients**
LB Kimberly A. Stanford, Eleanor Friedman, Joseph Mason, Aniruddha Hazra, John Schneider
- 1161 Syphilis Screening and Incident Infection Rates in HIV Treatment and HIV PrEP Programs in BC, Canada**
Junine Toy, Paul Sereda, Raquel M. Espinoza, Erin Ready, Viviane Dias Lima, Kate Salters, Peter Phillips, Rolando Barrios, Julio Montaner
- 1162 Altered Cellular Immune Response in the Context of Syphilis and Acute HIV Coinfection**
NIS Jasper Mundt, Lennart Nicksch, Carola Horn, Ute Sandaradura de Silva, Isabelle Suarez, **Max Augustin**, Clara Lehmann
- Poster Session-U08 | Long-Acting Antiretroviral Therapy and PrEP**
2:30 PM - 4:00 PM • Poster Hall C-D
- 1235 Implementing Long-Acting ART in a Community Health Center: Insights and Early Outcomes**
David Fessler, Erin Kelley, Rachel McLaughlin, Erin Loubier, Robert Bangert, Tasliym Adams, Amanda Fuchs, Lexeii Alves, Jessica Estrada, Jonathon Rendina, Sarah Henn
- 1236 Injectable Cabotegravir/Rilpivirine Reach and Effectiveness in a South Side Chicago HIV Clinic**
Geoffroy Liegeon, Chris Kaperak, Eleanor Friedman, Alicia Dawdani, Paul Djuricich, Kane Stafford, Jessica Schmitt, Aniruddha Hazra, Katerina Christopoulos, John Schneider, Moira McNulty
- 1237 Associations Between Interest in Oral vs Long-Acting Injectable ART Among US Women With HIV**
Morgan M. Philbin, Tara McCrimmon, Lauren F. Collins, Margaret Pereyra, Corbin Platamone, Anandi N. Sheth, Mardge H. Cohen, Tracey Wilson, Catalina Ramirez, David B. Hanna, Stephen J. Gange, Aadia Rana, Bani Tamraz, Lakshmi Goparaju, Maria L. Alcaide
- 1238 Uptake of Long-Acting Injectable Antiretroviral Therapy in Florida: An Assessment of EHR Data**
Yiyang Liu, Rebecca Fisk-Hoffman, Maitri Patel, Robert Cook, Mattia Prosperi
- 1239 Interest in Long-Acting Injectable PrEP Among Transgender Women in the United States**
NIS Erin E. Cooney, Sari Reisner, Tonia C. Poteat, Keri N. Althoff, Asa Radix, Meg Stevenson, Andrew J. Wawrzyniak, Christopher Cannon, Jason S. Schneider, Kenneth H. Mayer, Chris Beyer, Carolyn Brown, Vani Vannappagari, Annemiek de Ruiter, Andrea Wirtz

1240 Healthcare Staff Acceptability and Feasibility of Telehealth Delivery of Cabotegravir for PrEP

Albert Liu, Alvin Kingcade, Toyin Nwafor, Bo Li, Neelima Jain, Stephen Maher, Ray Hsieh, Alison Gaudion, Riya Moodley, Deanna Merrill, Lisa Petty, Piotr Budnik, Jean Van Wyk, Maggie Czarnogorski, Nanlesta Pilgrim

1241 Insurance Type Drives Cabotegravir Delays: Real-World Long-Acting PrEP Outcomes in the Midwest US

LB Aniruddha Hazra, John Schneider, Megan Murray, Jean Williams, Drew Halbur, Catherine Creticos

1242 Rapid Long-Acting Injectable PrEP Implementation in a Vulnerable Urban Safety Net Clinic Population

Ezra Bisom-Rapp, Christina Camp, Jon Oskarsson, Mary Shiels, Matthew A. Spinelli, Francis Mayorga-Munoz, Anthonia Chimezie, Monica Gandhi, **Sarah Puryear**

1243 High Acceptability of Long-Acting Injectable PrEP and ART Among MSM and PWID in India

Allison M. McFall, Talia A. Loeb, Jibon J. Baishya, Ashwini Kedar, Archit Sinha, Aylur K Srikrishnan, Sunil Suhas Solomon, Gregory M. Lucas, Shruti H. Mehta

1244 Gender Affirmation and Incentives for Long-Acting PrEP: Stated Preferences of Transgender Adults

LB Marta Wilson-Barthes, Arjee Restar, Emerson Dusic, Don Operario, Timothy Souza, Omar Galárraga

1245 Access to Long-Acting Injectable ART Through State AIDS Drug Assistance Programs

NIS Lauren C. Zalla, Tim Horn, Catherine Lesko

Poster Session-U09 | Differentiated Service Delivery

2:30 PM - 4:00 PM • Poster Hall C-D

1246 Effect of Changes in Script Renewal Period on HIV Viral Non-Suppression Among Insured South Africans

Gabriela E. Patten, **Mary-Ann Davies**, Gary Maartens, Naomi Folb, Andreas Haas

1247 High Viral Load Suppression Rates Among People Living With HIV Receiving Multi-Month Dispensing

Andrew Mugisa, Christopher Bwanika, Josephine Nakakande, Jane Nakaweesi, Peter Amutungire

1248 HIV Care Retention in 3 Multi-Month ART Dispensing: A Retrospective Cohort Study in Mozambique

NIS Anna Saura-Lázaro, Orvalho Augusto, Sheila Fernández-Luis, Elisa López-Varela, Laura Fuente-Soro, Dulce C. Bila, Milagre Tovela, Nello Macuacua, Paula Vaz, Aleny Couto, Carmen Bruno, Denise Naniche

1249 Using Best-Worst Scaling Experiments to Identify Profiles of Client & Provider Preferences in Zambia

Njekwa Mukamba, Musunge Mulabe, Marksman Foloko, Noelle Le Tourneau, Kombatende Sikombe, Sandra Simbeza, Anjali Sharma, Laura K. Beres, Jake M. Pry, Carolyn Bolton, Elvin H. Geng, Izukanji Sikazwe, **Aaloke Mody**

Poster Session-U10 | Novel Interventions

2:30 PM - 4:00 PM • Poster Hall C-D

1250 Automated Condom Distribution for HIV Prevention: Mwanza, Tanzania, 2021-2023

Aafke Kinemo, Julie Franks, Emmanuel Mihayo, Macdonald Mahiti, Joyce Thomas, Oreste Munishi, Omari Msumi, John Kahemele, Kokuhumbya Kazaura, Nyagonde Nyagonde, Mbaraka Amuri, Haruka Maruyama

1251 Cost-Effectiveness of an Agricultural Intervention Among Adults With HIV and Their Children in Kenya

Assurah W. Elly, Elly Weke, Pauline Wekesa, Rachel Burger, Lila Sheira, Mocello Adrienne, Edward Frongillo, Lisa Butler, Sheri Weiser, Craig Cohen, Jim Kahn, Elizabeth Bukusi, Starley Shade

1252 Integrated HIV+NCD Care in Community Microfinance Groups: Harambee Cluster Randomized Trial Results

LB

Becky Genberg, Jon Steingrimsson, Juddy Wachira, Catherine Kafu, Marta Wilson-Barthes, Sonak Pastakia, Dan N. Tran, Jamil A. Said, Rajesh Vedanthan, Suzanne Goodrich, Paula Braitstein, Youjin Lee, Joseph Hogan, Omar Galarraga

1253 Persistence on Contraception and PrEP in Hair Salons in South Africa

Ingrid V. Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile M. Ngcobo, Shruti Sagar, Jana Jarolimova, Dani Zions, Christina Psaros, Nduduzo Dube, Robert A. Parker

1254 Persistence in Care After PrEP Initiation Through a Community-Based Mobile Clinic

Susanne Doblecki-Lewis, Ariana L. Johnson, Katherine King, Katherine Klose, Gilianne Narcisse, Mario Stevenson

1255 Availability of Onsite Substance Use Disorder Services in HIV Facilities by Urbanicity in the US

Kashif Iqbal, Preetam A. Cholli, Yunfeng Tie, Stacy Crim, Jesse G. O'Shea, John Weiser, Sharoda Dasgupta

POSTER SESSIONS BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Posters should be displayed for the duration of the conference and are located in the Exhibit Hall.

A. Virology of HIV, SARS-CoV-2, or Mpox Virus

- P-A1 Virus Variation and Evasion of Antivirals and Restriction Factors (Tuesday)
- P-A2 Virus Replication in Host and Nonhuman Models (Wednesday)

B. Pathogenesis of HIV, SARS-CoV-2, or Mpox Virus: Human Studies and Animal Models

- P-B1 Correlates of HIV Transmission and Control (Monday)
- P-B2 HIV Immunopathogenesis (Monday)
- P-B3 HIV and the Gut Microbiome (Tuesday)
- P-B4 SARS-CoV-2 Pathogenesis (Tuesday)
- P-B5 Persistent Immune Activation and Inflammation During Antiretroviral Therapy (Tuesday)
- P-B6 Correlates of HIV Infection Outcome (Wednesday)
- P-B7 Animal Models of Viral Pathogenesis (Wednesday)

C. Host Immune Responses, Vaccines, and Immunotherapies: HIV, SARS-CoV-2, or Mpox Virus

- P-C1 HIV Neutralizing Antibodies (Monday)
- P-C2 HIV Vaccines (Monday)
- P-C3 COVID-19 Vaccines (Monday)
- P-C4 Immunity to SARS-CoV-2 Infection (Tuesday)
- P-C5 HIV Immunotherapy and Immunoprophylaxis (Tuesday)
- P-C6 Mpox Immunity, Therapy, and Transmission (Tuesday)
- P-C7 Mucosal Immunity to HIV (Wednesday)
- P-C8 NK and T-Cell Responses to HIV (Wednesday)
- P-C9 Inflammation and Innate Immunity to HIV/SIV (Wednesday)

D. HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy

- P-D1 Integration Sites and Proviral Landscape in the Reservoir (Tuesday)
- P-D2 Transcription in the HIV Reservoir (Tuesday)
- P-D3 HIV Latency and Latency Reversal (Tuesday)
- P-D4 Viral Rebound (Monday)
- P-D5 HIV Reservoirs in Cells and Tissues (Monday)
- P-D6 Immune Pressure on HIV Reservoirs (Monday)
- P-D7 Correlates of HIV Reservoir Size (Wednesday)
- P-D8 Strategies for an HIV Cure (Wednesday)
- P-D9 Novel HIV Cure Strategies (Wednesday)

E. Neuropathogenesis and Neurologic Complications of HIV and SARS-CoV-2 Infection and Neurologic Complications of HIV in Adults

- P-E1 Systemic Factors in NeuroHIV (Monday)
- P-E2 Antiretroviral Therapy Effects in NeuroHIV (Monday)
- P-E3 Pathogenesis of Central Nervous System Post-Acute Sequelae of COVID-19 (Monday)
- P-E4 Vascular Pathogenesis of NeuroHIV and NeuroCOVID-19 (Tuesday)
- P-E5 NeuroHIV in Global Settings (Tuesday)

E. Neuropathogenesis and Neurologic Complications of HIV and SARS-CoV-2 Infection and Neurologic Complications of HIV in Adults

- P-E6 Cerebrospinal Fluid, Blood Biomarkers, and Neurodegeneration in NeuroHIV (Tuesday)
- P-E7 Neuroimaging in HIV (Wednesday)
- P-E8 Omics Studies in NeuroHIV (Wednesday)
- P-E9 Aging and NeuroHIV (Wednesday)

F. Clinical Pharmacology in Adults

- P-F1 Understanding Drug-Drug Interactions and Sanctuary Site Pharmacology (Monday)
- P-F2 Important Antiretroviral Adherence and Pharmacokinetic Measures (Tuesday)
- P-F3 Long-Acting Injectables, Broadly Neutralizing Antibodies, and New Drugs, Oh My! (Wednesday)

G. Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 or Mpox Virus in Adults

- P-G1 Treatment With Currently Available Long-Acting Antiretroviral Therapy (Monday)
- P-G2 Novel Antiretrovirals Development: More Than You Think! (Wednesday)
- P-G3 Should I Stay or Should I Go: Switching Oral Antiretroviral Therapy (Tuesday)
- P-G4 Rollout of Integrase Strand Transfer Inhibitors in Low- and Middle-Income Countries (Monday)
- P-G5 New Formulations of Current Integrase Strand Transfer Inhibitors: Length Matters (Wednesday)
- P-G6 Treatment and Prevention of SARS-CoV-2 Infection (Tuesday)

H. Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults

- P-H1 Dolutegravir Treatment and Resistance in Resource-Limited Settings (Wednesday)
- P-H2 Resistance to Specific Drugs: Lenacapavir, Tecovirimat, and Dolutegravir (Monday)
- P-H3 Broadly Neutralizing Antibodies and Resistance (Tuesday)
- P-H4 Archived Mutations and Sustained Suppression (Wednesday)

I. Hepatitis Viruses and Liver Complications in Adults

- P-I1 Elimination of Hepatitis C (Monday)
- P-I2 Life After HCV Sustained Virologic Response (Monday)
- P-I3 HBV and HDV: Epidemiology, Natural History, and Pathogenesis (Tuesday)
- P-I4 HBV and HDV Treatment and Cure (Tuesday)
- P-I5 HIV and Steatotic Liver Disease (Wednesday)

J. HIV-Related Malignancies and Tumor Viruses

- P-J1 Cancer Pathogenesis and Natural History: Kaposi Sarcoma and General (Monday)
- P-J2 HIV-Associated Malignancies: Epidemiology, Incidence, and Demographics (Wednesday)
- P-J3 Anal and Cervical Cancer: Pathogenesis, Screening, and Treatment (Tuesday)
- P-J4 Other Cancers Complicating HIV Infection (Monday)

K. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy

- P-K1 Cardiovascular Disease Biomarkers (Monday)

- P-K2 Cardiovascular Disease Trends and Risk Factor Modification (Tuesday)
- P-K3 Hypertension: Risk Factors and Interventions (Tuesday)
- P-K4 Heart Failure and Microvascular Health (Wednesday)

L. Other Complications of HIV Infection and Antiretroviral Therapy in Adults

- P-L1 GLP-1 Receptor Agonists for Weight Loss in HIV (Monday)
- P-L2 Metabolic Outcomes (Wednesday)
- P-L3 Weight Gain and Metabolism (Monday)
- P-L4 Antiretroviral Therapy: Immunologic Effects (Tuesday)
- P-L5 Sex Differences in Comorbidities and Inflammation (Tuesday)
- P-L6 Pulmonary Outcomes (Monday)
- P-L7 Renal Outcomes (Tuesday)
- P-L8 Mental Health Outcomes (Wednesday)
- P-L9 Aging and Frailty (Wednesday)

M. Clinical Manifestations and Outcomes of SARS-CoV-2, Including Long COVID, and Mpox Infections

- P-M1 Post-Acute COVID-19 Syndrome: Predictors, Associations, and Clinical Manifestations (Monday)
- P-M2 Factors Affecting Outcome of Acute COVID-19 (Tuesday)

N. Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults

- P-N1 Pharmacologic and Other Programmatic Insights in Tuberculosis and Cryptococcal Meningitis (Monday)
- P-N2 Issues in Tuberculosis Preventive Therapy (Monday)
- P-N3 Immunologic Risk and Immune Activation in Tuberculosis and Other Opportunistic Infections (Monday)
- P-N4 Mortality Risk in Cryptococcal Meningitis and Other Invasive Mycoses (Tuesday)
- P-N5 Diagnostic Testing and Novel Biomarkers for Invasive Mycoses and Tuberculosis (Wednesday)

O. Maternal and Fetal HIV, SARS-CoV-2, and Mpox Virus

- P-01 Preventing HIV in Pregnancy and Breastfeeding (Wednesday)
- P-02 Improving Maternal Outcomes on Antiretroviral Therapy (Wednesday)
- P-03 Chronic Diseases, Pregnancy, and HIV (Tuesday)
- P-04 Maternal Mental Health and HIV (Monday)
- P-05 Understanding Breastmilk, HIV, and Antiretrovirals (Monday)
- P-06 HIV and Birth Outcomes (Tuesday)

P. Childhood and Adolescent HIV, SARS-CoV-2, or Mpox Virus

- P-P1 Health and Outcomes of Children Exposed to Antiretrovirals in Utero (Tuesday)
- P-P2 Pharmacokinetics, Dosing, and Safety of Antiretrovirals for Infants, Children, and Adolescents (Tuesday)
- P-P3 Exploring the Pediatric Reservoir (Monday)
- P-P4 Infants With HIV Infection: Diagnosis, Mortality, Morbidity, and Treatment Response (Tuesday)
- P-P5 Comorbidities and Complications in Children and Adolescents with HIV Infection (Wednesday)
- P-P6 Pediatric Antiretroviral Therapy Optimization: Dolutegravir in Action (Tuesday)
- P-P7 Intervention to Improve Testing and Care for Children and Adolescents (Wednesday)

Q. Epidemiology of HIV, COVID-19, and Mpox

- P-Q1 Hazards Ahead: The Intersection of HIV and Substance Use (Monday)
- P-Q2 HIV Transmission Among People Who Use Drugs (Monday)
- P-Q3 HIV Disparities and Social Determinants of Health (Tuesday)
- P-Q4 HIV Incidence, Prevalence, and Risk Factors (Tuesday)
- P-Q5 HIV Viremia and Viral Rebound (Tuesday)
- P-Q6 The HIV Care Cascade and Advanced HIV Disease (Wednesday)
- P-Q7 Mental Health, Morbidity, and Mortality among People Living with HIV (Wednesday)
- P-Q8 Insights from HIV Molecular Epidemiology (Wednesday)
- P-Q9 COVID-19 Epidemiology and Impact on HIV Outcomes (Wednesday)

R. Testing for HIV, COVID-19, and Mpox in Adults: New Tests, Population Studies, and Scale-Up

- P-R1 HIV, SARS-CoV-2, and Mpox Testing (Wednesday)
- P-R2 Partner Network Testing (Monday)
- P-R3 Self-Testing, Adherence, and Drug Resistance Monitoring (Tuesday)
- P-R4 Optimizing PrEP and Treatment (Tuesday)

S. Prevention of HIV, COVID-19, and Mpox in Adults

- P-S1 Long-Acting Injectable PrEP: Implementation and Clinical Insights (Monday)
- P-S2 Biomarkers and Other Assessments of PrEP Adherence (Tuesday)
- P-S3 PrEP Implementation Around the World: Successes, Challenges, and Disparities (Tuesday)
- P-S4 Nonoccupational Postexposure Prophylaxis: Everything Old is New Again: How, Who, Do's, and Don'ts (Monday)
- P-S5 PrEP: Novel Products, Strategies, and Delivery Systems (Tuesday)
- P-S6 Differentiated Service Delivery Models for PrEP and TasP (Wednesday)
- P-S7 PrEP Drug-Drug Interactions and Complications (Wednesday)

T. Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults

- P-T1 A Deep Dive Into DoxyPEP Implementation (Wednesday)
- P-T2 The Problem of the Persistent Pox: Global Syphilis Epidemiology (Wednesday)
- P-T3 Sexually Transmitted Infections in Women: Global Perspectives (Monday)
- P-T4 Sexually Transmitted Infections in Key Populations (Monday)
- P-T5 New Directions in Sexual and Reproductive Health and HIV Prevention (Tuesday)

U. Implementation and Scale-Up of Prevention and Treatment for HIV, and Impact of COVID-19 and Mpox on HIV-Related Programs

- P-U01 HIV Care (Monday)
- P-U02 PrEP, PEP, and Voluntary Medical Male Circumcision (Monday)
- P-U03 Viral Load Suppression (Tuesday)
- P-U04 COVID-19 Prevention (Tuesday)
- P-U05 Key and Vulnerable Populations (Tuesday)
- P-U06 Behavioral Predictors and Interventions (Tuesday)
- P-U07 Cost and Cost-Effectiveness (Tuesday)
- P-U08 Long-Acting Antiretroviral Therapy and PrEP (Wednesday)
- P-U09 Differentiated Service Delivery (Wednesday)
- P-U10 Novel Interventions (Wednesday)

INDEX OF PRESENTERS

The following index lists presenting authors as of January 31, 2024. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

-A-

- Abdi, Basma 683
- ★ Abelman, Rebecca 155, 821
- Abrams, Elaine J. 182, 979
- Abuogi, I. Lisa 991
- Abutidze, Akaki 720
- ★ Adams, Philipp 497
- Agot, Kawango 1120
- Agrawal, Parul 381
- Ahonkhai, Aima A. 833
- Ajibola, Gbolahan 959
- ★ Akiso, Matrona M. 317
- Akiyama, Matthew 1011
- Akolo, Christopher 1195
- ★ Al Burtamani, Nawal K.S. 477
- Aldred, Bruce 419
- ★ Aldredge, Amalia 822
- ★ Alles, Mario J. 969
- ★ Alrubayyi, Aljawharah 439
- Althoff, Keri N. 1073
- Amakulie, Patrick E. 1219
- Amorim, Gustavo 869
- Anderko, Renee R. 441
- Anderson, David 814
- ★ Anderson, Kim 961
- Anderson, Mark C. 1089
- Antar, Annukka A. R. 137
- ★ Apedaile, Dorothy 1126
- Appa, Ayesha 997, 998
- ★ Arca-Lafuente, Sonia 712, 723
- Arhel, Nathalie J. 303
- Arikatla, Mohith Reddy 301
- ★ Armani-Tourret, Marie 173
- ★ Arora, Juhi 372
- Arriaga, Maria B. 877
- Arshad, Usman 161, 653
- Asante-Appiah, Ernest 694
- Atieh, Ornina 865
- ★ Atkins, Kaitlyn 1005, 1119
- ★ Augello, Matteo 388
- ★ Augustin, Max 1162
- Avedissian, Sean N. 558, 607
- Avelino-Silva, Vivian I. 1104
- Avihingsanon, Anchalee 9, 732
- ★ Ávila Nieto, Carlos 392
- ★ Ayiekpo, James 1135
- Aziz, Mariam 686
- Azzoni, Livio 393, 1106

-B-

- ★ Bachmann, Niklas 414
- Bacon, Oliver 1151
- Bailin, Samuel 802
- ★ Balina, Queen M. 923
- Bamouni, Sophie 1141
- Bamrotiya, Manish 1056
- ★ Bana, Nicholas Brian 1130
- Banga, Jaspreet 958
- Bar, Katharine J. 179
- Barbehenn, Alton 508
- ★ Barnabas, Shaun L. 408
- Barrios-Tascon, Ana 963
- ★ Barry, Michael P. 999
- Bassett, Ingrid V. 1253
- ★ Basting, Christopher 331
- Bauermeister, José A. 10
- Baugher, Amy R. 1006
- ★ Beck-Friis, Josefine 866
- ★ Bégré, Lorin 733, 734
- Behar, Anna M. 191
- ★ Bekka, Soumia 954
- Bekker, Adrie 942
- Belinky, Frida 367
- ★ Bell, Griffin J. 1067
- Bello, George 187
- Benhabbour, S. Rahima 1137
- ★ Benlarbi, Mehdi 144, 146
- Bercot, Beatrice 36
- Berenguer, Juan 398, 717
- Bermejo Jambrina, Marta 340
- Bernardino, Jose I. 800
- Berry, Auburn R. 567
- Berry, Mark 657
- Berthaud, Vladmir 576
- ★ Bettonte, Sara 616
- ★ Bevers, Lisanne 946
- ★ Bhattachari, Shaurav 575
- Bidasee, Keshore R. 796
- Bikinesi, Leonard T. 652, 1198
- Billock, Rachael 1065
- ★ Biraro, Samuel 1206
- ★ Blaauw, Marc 770
- Blanchard, Hannah 1088
- ★ Blomme, Evy E. 646
- Boffito, Marta 785
- ★ Bolden, Mikaley 587
- Bolzenius, Jacob 564, 590
- Bomsel, Morgane 347
- ★ Bongomin, Pido 1036
- Bonner, Courtney P. 1221
- Bor, Jacob 1200
- Borges, Alvaro 210
- Bornstein, Sydney 1008
- Boudries, Malika A. 483
- Boulware, David R. 888
- ★ Boyd, F. Kathryn 893
- ★ Bradford, Layla E. 937
- Branas, Fatima 838
- Bravo, Enrico 147
- Brew, Bruce J. 584
- Brizzi, Andrea 195
- ★ Brooks, Kelsie 342
- Brouillette, Marie-Josée 597
- ★ Brown, Jennifer A. 185
- Browne, Sara 614
- Buchacz, Kate 786
- Bunge, Katherine E. 674
- Burchell, Ann N. 860
- Burgener, Adam 433
- Butt, Adeel A. 132, 559
- Bwakura-Dangarembizi, Mutsawashe 21
- C-**
- ★ Caballero, Ramon Edwin 307
- Cachay, Edward 759
- Cafardi, John 709
- Calvez, Vincent 684
- Cameron, Mark 778
- Camlin, Carol S. 1223
- Cannon, Chase 35
- Capoferri, Adam A. 313
- Cardinaud, Sylvain 382
- Caro-Vega, Yanink 1057
- ★ Carpino, Thomas 1169
- ★ Carrere, Leah 486
- ★ Carson, Joanne 699
- Carstens, Russ P. 115
- ★ Casadellà, Maria 819
- Cassidy, Adam R. 938
- Castillejo, Adam 1
- Castle, Alison C. 1122
- Cavallari, Eugenio Nelson 760
- ★ Ceriani, Cristina 365
- Chabata, Sungai 1027
- Chafino, Silvia 972
- Chaisson, Lelia H. 878
- Chan, Phillip 588

- Chandasana,
Hardik 944, 945
- ★ Chandiwana,
Nomathemba 810
- ★ Chandra, Christina 1190
Chapin-Bardales,
Johanna 1009
- Chappell, Catherine A. 710, 711
- Charpentier, Charlotte
761, 987
- Chee, Grace M. 726
- Chen, Guan-Jhou 701
- ★ Chenwi, Collins Ambe 713
Chew, Kara W. 669
- Chi, Benjamin H. 931
- ★ Choko, Augustine T. 202
- Chow, Felicia C. 565
- Chu, Victoria T. 1154
- ★ Chunamchai,
Sedthapong 976
- Churchill, Melissa J. 113
- Cingolani, Antonella 670
- Citron, Daniel T. 1049
- Claassen, Cassidy W.
1127, 1143, 1184, 1217
- Clark, Iain C. 5
- Clement, Meredith 131
- ★ Climent, Núria 841
Clipman, Steven J. 1012
- ★ Cockbain, Beatrice 927
- Coetzee, Nicola 1099
- Cohen, Stephanie E. 37
- Coiras, Mayte 440
- Colby, Donn J. 703
- ★ Collercandy, Nived 334
- Collins, Lauren F. 912
- Collins, Natalie 673
- Colson, Amy 208
- Connick, Elizabeth 1
- Conway, Brian 700
- Cooley, Sarah 581, 583, 589
- ★ Cooney, Erin E. 1239
- Corley, Michael J. 469, 593
- Corma-Gomez, Anais 715
- Cossarini, Francesca 325
- Coutinho, Carolina 1021
- Covington, Nia 606
- Coyle, Ryan P. 609
- Crabtree-Ramírez,
Brenda E. 649
- Crain, Charles R. 447
- Cressey, Tim R. 941
- Cromhout, Gabriela Z.L. 175
- Crowell, Trevor A. 470, 516
- Cusimano, Gina 378
- Cyktor, Joshua C. 514
- D-
- ★ Daama, Alex 1186
Dai, Mindy 1179
- Dailey, André 192
- Dalhuisen, Thomas 855
- ★ D'Anna, Stefano 162
D'Antoni, Michelle L. 695
- ★ Das, Srijanee 739
Dasgupta, Sharoda 1163
- ★ Dat, Vu Quoc 890
- ★ D'Auria, Alessandra 418
David, Hollie 1128
- Davies, Mary-Ann 1246
- de la Force, Natalia 456
- ★ De La Torre Tarazona,
Erick 481
- De Leon, Jacklynn 1007
- De Miguel Buckley, Rosa 693
- ★ de Voux, Alex 1159
- ★ De Waal, Renee 1046
Debroy, Paula 746
- Deitchman, Amelia N. 618
- ★ Delaney, Kayla E. 371
Delaney, Kevin P. 200
- ★ Delporte, Mareva 467
Demby, Suuba 1138
- Demirdjian, Sally 681
- Desmonde, Sophie 984
- Dharan, Nila J. 839
- Di Chiara, Costanza 861, 862
- Di Gennaro, Francesco 666
- Diamond, Tracy L. 42, 638
- Díaz-García, Claudio 330, 752
- Dinh, Vinh B. 455
- Dirajlal-Fargo, Sahera
23, 967, 968
- Diseko, Modiegi D. 929
- ★ Ditzenberger, Grace L. 799
Doblecki-Lewis,
Susanne 1254
- ★ Donaire, Maria Sophia B. 356
- ★ Doshi, Shraddha J. 772
- ★ Doyle, Ronan 885
- ★ Dragoni, Filippo 461
Drechsler, Henning J. 812
- ★ Dressel, Elise 879
Drumright, Lydia N. 840
- Du Preez, Jeantelle 157
- Dugas, Lara R. 919
- Durstenfeld, Matthew
S. 769, 792
- ★ Dzavakwa, Nyasha V. 977
- E-
- Ebrahim, Diako 310
- Eckard, Allison Ross 798
- Edén, Arvid 561
- Edmonds, Andrew 1004
- Egger, Matthias 873
- ★ Eichholz, Karsten 533
El Helou, Remie L. 570
- Elion, Richard A. 815
- ★ Ellis, Jayne P. 887
Ellis, Ronald J. 552
- ★ Elly, Assurah W. 1251
- ★ Epling, Brian P. 358
Erlandson, Kristine M. 152
- Erly, Steven 1213
- Eron, Joseph J. 120, 625
- Espinosa Da Silva,
Cristina 1002
- Espinosa Miranda,
Angelica 25
- Espinosa, Raquel M. 1188
- ★ Eustaquio, Patrick 1010
Evering, Teresa H. 580, 852
- ★ Ezeonwumelu, Ifeanyi J. 478
- F-
- ★ Falcinelli, Shane D. 525
Farhadian, Shelli 114, 562
- ★ Feng, Xinyi 1026
Ferrara, Micol 608
- Fessler, David 1235
- Fichtenbaum, Carl J. 116
- ★ Fink, Valeria I. 756
Finzi, Andrés 44, 537
- ★ Fisayo, Temitope 962
- ★ Fisher, Bridget M. 524
Fisher, Molly 831
- Fitzgerald, Richard J. 619
- Flexner, Charles W. 39
- ★ Flores-Piñas, Marina 357
- ★ Foley, Mary 894
Ford, Susan 617, 950
- ★ Foster, Emma G. 557
Fouad, Fouad M. 38
- ★ Fracella, Matteo 435
Fredericks, Megan N. 341
- Freed, Eric O. 27, 685
- Freeman, Michael L. 320
- ★ Freitas, Cassandra 396
Friedland, Barbara A. 1139
- Fromentin, Remi 474
- ★ Frouard, Julie 466
Fulcher, Jennifer A. 333
- Funderburg, Nicholas 818
- Fuster, Daniel 1003
- G-
- Gaito, Douglas K. 763
- Gallardo-Cartagena,
Jorge A. 1220
- ★ Gallego Cortes, Ana 495

- Gandhi, Malini M. 856
 Gandhi, Monica 629, 1097, 1113
 Gant Sumner, Zanetta 1019
 ★ Gao, Hongbo 489
 ★ Garcia, Mauro A. 482
 Garcia, Vinicius P. 777
 ★ Garcia-Ruiz De Morales, Alejandro G. 1081
 ★ Garcia-Vidal, Edurne 402
 Garrett, Nigel 399
 ★ Garziano, Micaela 403
 Gauduin, Marie-Claire 383
 Gaur, Aditya 188
 Gehring, Adam 33
 Genberg, Becky 1252
 Geng, Elvin H. 11
 ★ Gengiah, Tanuja N. 123
 Ghanem, Khalil G. 26
 ★ Ghosh, Sukanya 413
 Gianella Weibel, Sara 354, 490
 Giguere, Pierre 429
 Gillespie, Gillian 129
 Giron, Leila B. 359, 549
 ★ Glassey, Annemarie 488
 ★ Gluck, Joshua A. 457
 Golden, Matthew 1233
 ★ Gomez, Lauren A. 939
 Gómez-Ayerbe, Cristinia 1170
 ★ González-Navarro, Irene 519
 ★ González-Serna, Alejandro 719
 ★ Gornalusse, German G. 518
 ★ Goswami, Ria 499
 Gowda, Bhoomika Suresh 655
 Goyal, Ravi 1040
 Grabowski, Mary Kate 1028
 Graham, Barney S. 13
 ★ Grande-García, Sergio 718
 Green, Emily J. 1080
 Griffith, Gina L. 438
 Grinspoon, Steven 773, 781, 782, 864
 ★ Gu, Shuqin 406, 738
 Guggilla, Vijeeth 858
 ★ Gunst, Jesper D. 512
 Gupta, Samir K. 811
 -H-
 Haaland, Richard 611
 Hahn, Patricia A. 363
 Halvas, Elias K. 473
 Hamill, Matthew M. 1158
 Hampanda, Karen 906
 Hamzah, Lisa 205
 Han, Kelong 130
 ★ Han, Win Min 722
 Han, Xiaochun 637
 Hansen, Derek 304
 ★ Hastie, Elizabeth 536
 Haukoos, Jason 707
 Havens, Josh 604
 Hazra, Aniruddha 1241
 He, Buwei 1000
 ★ Heck, Craig J. 1136
 Hedberg, Pontus 863
 Heffron, Renee 169, 1147
 Heitner, Jesse A. 1166, 1230
 Hendricks, Simone L. 1212
 Henrich, Timothy J. 105
 Herate, Cecile 421
 Hernandez-Tamayo, Cassidy J. 705
 ★ Herrera, Alberto 505
 Hershow, Rebecca B. 1086
 ★ Hesselman, Maria C. 368
 Hickey, Matt 150, 628
 Hill, Andrew 790, 808, 1033
 Hill, Lucas 624
 Hills, Caitlin 1051
 Hiransuthikul, Akarin 1145, 1146
 Hoffman, Risa 183
 Hoover, Karen W. 1129
 Horberg, Michael A. 844, 845
 Hourani, Freya U. 404
 Howell, Pauline 872
 Hoy, Jennifer F. 757
 Hsu, Ricky K. 623
 Hsue, Priscilla Y. 46
 Hu, Wei-Shau 29
 Huaman, Moises A. 883, 884
 Huang, Susie S.Y. 542
 Huang, Wenting 1123
 Huang, Ya-Lin A. 1117
 Huang, Yunda 18
 Huang, Yu-Shan 725
 Huber, Amy N. 204
 ★ Hughes, Ivy 452
 Hultquist, Judd F. 300
 Humphrey, John 904
 Hung, Chien-Ching 729
 Hunsberger, Sally 12
 ★ Hunt, Joanne 1156
 Hwang, Y. Joseph 805
 Hyle, Emily P. 1232
 -I-
 Ianas, Voichita 1155
 Imamichi, Hiromi 498
 Ingle, Suzanne M. 1058
 Inzaule, Seth 199
 Iqbal, Kashif 603, 1255
 Irvine, Darrell 20
 Ishizaka, Aya 332
 Islam, Saiful 139
 ★ Isnard, Stephane 436
 ★ Iyer, Akshay 951
 ★ Izquierdo-Pujol, Jon 853
 -J-
 Jacobs, Jana L. 632
 Jacobson, Denise L. 910
 Jacobson, Evin 1228
 ★ Jacobson, Matilde P. 1175
 Jalil, Emilia M. 745
 Jamil, Muhammad S. 993, 1022
 Janssens, Julie 468
 Jao, Jennifer 1, 911
 ★ Jaschinski, Nadine 784
 ★ Jeena, Lisha 973
 Jeffrey, Jerry L. 634
 Jeffy, Jeffy 687, 688
 Jiang, Xun 448
 Jo, Youngji 1234
 Joel, Javies N. 1094
 ★ Johnson, Samuel D. 832
 Johnston, Carrie 595
 Jonas, Nelson M. 891
 Joseph Davey, Dvora L. 207, 899, 900, 901
 Joyce, M. Gordon 387
 Juelg, Boris D. 121
 ★ June, Lavender A. 1196
 Justman, Jessica E. 197
 -K-
 Kabami, Jane 920
 Kakkar, Fatima 955
 Kalayjian, Robert C. 578
 Kallianpur, Asha R. 582
 ★ Kamel, Ralph 750
 Kamya, Moses R. 172
 Kancheya, Nzali G. 1192
 Kang, Ezer 22
 Kantor, Rami 1063
 ★ Karthigeyan, Krithika P. 903
 Kauppinen, Kai J. 806
 Kearney, Brian P. 656
 Keene, Claire M. 1199
 ★ Kelly, Kristen E. 957
 Kennedy, James T. 599
 Kerckaert, Katie 1076
 Khaitan, Alka 548
 ★ Khetan, Priya R. 956
 Khoo, Saye 668
 ★ Kibuuka, Joseph 1189
 Kim, Arthur 696
 Kim, Jiae 539
 Kim, Sangwon F. 803
 Kim, Seungwon 1068
 Kim, Youry 480
 Kincer, Laura P. 112

- Kinemo, Aafke 1250
 ★ Kingston, Hanley 194
 Kingwara, Leonard 677
 ★ Kintu, Timothy 930
 ★ Kipkurui, Nicholas 1173
 Kirchhoff, Frank 1
 Kityo, Cissy 9, 122
 Kiweewa Matovu, Flavia 824
 Klein, Brandon 871
 Kmiec, Dorota J. 311
 Ko, Sung Hee 145
 Kohler, Pamela 994
 Kolossváry, Márton 151
 ★ Kooij, Katherine 1053
 Kosgei, Josphat 728
 Koss, Catherine A. 1107
 ★ Kostaki, Evangelia G. 1015
 Kreider, Edward 523
 Krishnan, Preethi 106
 Kumar, Priti 527
 Kvaratskhelia, Mamuka 30
 -L-
 Labhardt, Niklaus D. 678, 982
 ★ Laguía-Nueda, Fernando 305
 Lahiri, Cecile D. 823
 Lake, Jordan E. 159, 742
 Lam, Jennifer O. 825
 Landovitz, Raphael J. 128, 789
 ★ Langat, Robert 329
 Lansdon, Eric 636
 ★ Lara Aguilar, Violeta 348
 Latham, Christine 627
 Lau, Chuen-Yen 502
 ★ Lawrence, David S. 1045
 Lazzarin, Samuel 1157
 Le Hingrat, Quentin 682
 Le, Thuy 896
 Lee, Guinevere Q. 465
 ★ Lee, Ming J. 530
 ★ Lehloa, Amohelang 917
 Lei, Xiao 140
 Leister-Tebbe, Heidi 659
 Leonard, Colleen 430
 Lesi, Olufunmilayo 34
 Lessells, Richard J. 676
 Levy, Matthew E. 660
 Lewin, Sharon R. 108
 ★ Leyre, Louise 174
 Li, Feng 464
 Li, Wei 971
 Li, Xiaoyi 731
 ★ Li, Xinyi 850, 1078
 Li, Yijia 134
 Liegeon, Geoffroy 1236
 Lin, Qing 714
 ★ Linden, Noemi L. 460
 Little, Susan J. 1064
 Liu, Albert 1240
 Liu, Andy 1150
 Liu, Wang-Da 417
 Liu, Xiaosheng 352
 Liu, Yiyang 1238
 Liu, Ziang 1210
 Loeb, Talia A. 1013
 Lofgren, Sarah 835
 Lombardi, Francesca 820
 Longenecker, Chris T. 149
 Lopez Fernandez, Giselle 375
 Losos, Jan 117
 Lowenthal, Elizabeth D. 949
 Lozano, Ana Joy 551
 Luc, Casey M. 622
 Luetkemeyer, Annie 125
 ★ Lwin, Hay Mar Su 771
 -M-
 Ma, Jimmy 110, 698
 ★ Ma, Tongcui 484
 Macatangay, Bernard J. C. 351
 Machmach Leggat, Kawthar 315
 Mackie, Nicola 988
 MacLeod, Hannah J. 463
 ★ Madlala, Hlengiwe P. 914, 915
 Maguire, Christina 626
 Maison, David P. 400
 Makyao, Neema E. 907
 ★ Malaba, Thokozile R. 905, 918
 Malden, Deborah E. 847
 ★ Malgave, Devesh S. 766
 ★ Man, Shirley 476
 ★ Manning, Maegan R. 485
 Mansoor, Leila E. 49
 Mantilla Suarez, Monica 1087
 Marcelin, Anne-Genevieve 422
 Marconi, Vincent 355
 Marden, Grace 376
 Markowitz, Martin 640
 Marks, Kristen 209
 Marlowe, Elizabeth M. 724
 ★ Marmont, Ninon 854
 Marrazzo, Jeanne 1
 ★ Martin, Kevin 1167
 Martin, Mitchell 370
 Martin, Thomas 1037
 Martinez-Navio, Jose 520
 Martín-Gayo, Enrique 339
 Martin-Iguacel, Raquel 764
 ★ Martín-Pedraza, Laura 644
 Martins, Mauricio A. 177
 Mave, Vidya 28
 Mayer, Kenneth H. 1110, 1152
 Mazurov, Dmitriy 689
 Mazzitelli, Maria 826
 Mazzotta, Valentina 424, 661, 662
 Mbonye, Uri 479
 Mbori-Ngacha, Dorothy 14
 ★ McAlpine, Lindsay S. 560, 568
 McAuliffe, Brian 633
 McCarthy, Caitlyn 675
 McCluskey, Suzanne 648
 McElrath, Julianna 16
 McFall, Allison M. 1243
 ★ McGee-Avila, Jennifer K. 754
 McKenna, Michael 986
 ★ McLaughlin, Angela 1066
 ★ McMahon, Elyse K. 540
 ★ McMyn, Natalie F. 503
 Medland, Nicholas A. 166
 Mee, Paul 1024
 ★ Meeder, Elise M.G. 449
 ★ Mehta, Patrick 326
 Mehta, Sanjay R. 1070
 Mehta, Shruti H. 697
 ★ Meldrum, Benton G. 755
 ★ Mendum, Maanasa 762
 Mera, Jorge 704
 ★ Merad, Yanis 427
 Metcalf Pate, Kelly A. 366
 Metcalfe, John 164
 Metekoua, Carole 758
 ★ Mezzadri, Luca 736
 Mhlanga, Felix 168
 ★ Mickens, Kaylee 335
 Middlebrooks, Lauren 990
 Mihealsick, Erin 450
 ★ Milburn, James 572, 876
 Miller, Amanda P. 1001
 Mills, Anthony 631, 1109
 Mills, Anthony 1109
 ★ Miranda, Thamiris S. 308
 Mirembe, Brenda G. 167
 ★ Moabi, Kebaiphe 921
 ★ Moar, Preeti 353
 Moeser, Matthew 327
 ★ Mogashoa, Tuelo 898
 Mohamedi, Mwedi 1140
 Molina, Jean-Michel G. 124
 Molto, Jose 647
 Montano, Michalina 423
 Montenegro-Idrogo, Juan J. 1218
 Moore, David 1032
 ★ Moraes-Cardoso, Igor 416
 ★ Moraka, Natasha O. 328
 Morales, Ayana E. 748
 Morales, Juliet A. 1016

- Moreno, Elena 829
 Morris, Daniel J. 103
 Morsica, Giulia 737
 Moschese, Davide 426
 Mothe, Beatriz 506
 Mounzer, Karam 642, 807
 Mourad, Ahmad 868
 ★ Moyo, Melanie 886
 Mozaffari, Eddy
 663, 664, 665, 859
 Mtoro, Mtoro J. 1039
 ★ Mugisa, Andrew 1247
 Mugisha, Frank 15
 Mugo, Nelly R. 17
 Mugwanya, Kenneth K. 170
 Mujuru, Hilda A. 186
 Mukamba, Njekwa 1249
 Mukerji, Shibani S. 546
 Mukui, Irene 171
 Müller, Barbara 3
 Murphy, Teresa 692
 ★ Mvalo, Tisungane 966
 ★ Mvududu, Rufaro 902
 Mwanahapa, Patrick E. 1035
 ★ Mwangwa, Florence 189
 Myer, Landon 916
 -N-
 ★ Naicker, Vimla 377
 Naidoo, Anushka 211
 Nakasujja, Noeline 569
 ★ Nakawooya, Hadijja
 1197, 1205
 Namulema, Edith 1142
 Narayanasamy, Shanti 889
 Nayan, Mohammad
 Ullah 654
 ★ Neary, Jillian 975
 ★ Neer, Victoria 952
 Nelson, LaRon 1
 Nelson, Sydney G. 1174
 ★ Netttere, Danielle R. 323
 Ng, Teresa 411
 ★ Ngoufack Jagni Semengue,
 Ezechiel 395
 N'guessan, Kombo F. 316
 ★ Nguyen, Binh 302
 Nguyen, Hao T. 895
 Nguyen, Thu T.M. 892
 Nguyen, Thuy 462
 Nguyen, Tk 925
 Nightingale, Sam 553
 ★ Nka, Alex Durand 651
 Nogueira, Nicholas F. 1164
 Nordin, Jayme M.L. 496
 Noureddin, Mazen 8
 Novitsky, Vlad 983
 Ntsekhe, Mpiko 47
 Nuernberger, Eric 881
 Nuwamanya, Elly 909
 ★ Nyamari, Celestine K. 1165
 ★ Nyererere, Bernard 1222
 ★ Nyirenda-Nyang'wa,
 Maggie 1084
 Nyombi, Tamara N. 960
 ★ Nyoni, Ntombizodwa
 M. 1231
 -O-
 ★ Obeng-Nyarkoh,
 Peggy-Ita A. 830
 ★ Obosi, Abel C. 566
 ★ Ocampo, Ferron F. 846
 ★ O'Connor, Lauren F. 843
 Oh, Song Young 380
 Okango, Elphas 1023
 Okegbe, Tishina 985
 Okoye, Afam A. 1
 Olanrewaju, Ayokunle 1098
 Oldroyd, Alyssa R. 953
 Olivero, Rosemary M. 933
 Ollerton, Matthew 321
 ★ Oluoch, Lynda M. 1172
 ★ Ombajo, Loice A. 643
 Omo-Emmanuel,
 Ughwerothene K. 1082
 ★ Onovo, Amobi A. 989
 Onoya, Dorina 1178, 1201
 Opere, Philip 1208
 Orkin, Chloe M. 620, 621
 Orrell, Catherine 613
 Ortiz, Alexandra 364
 O'Shea, Jesse G. 1181
 ★ Ostrander, Emily I. 774
 Otte, Fabian 107
 Otten, Twan 783
 Owor, Maxensia 926
 Ozorowski, Gabriel 2
 -P-
 Padilla, Sergio 767, 867
 Pai, Nitika P. 40
 ★ Pal, Priya 453
 ★ Pal, Virender K. 459
 Palella, Frank 544, 801
 Pandit, Neha S. 1203
 Panfilova, Yana 38
 ★ Panjasawatwong,
 Navarat 943
 Pantazis, Nikos 804, 1044
 Papasavvas, Emmanouil 511
 Papathanasopoulos,
 Maria A. 493
 Paquin-Proulx, Dominic 360
 Parczewski, Milosz 38, 1069
 ★ Parisi, Christina E. 1043
 Park, Ina 24
 Park, Juwon 346
 ★ Parra-Rodriguez,
 Luis 554, 787
 Parsons, Matthew S. 412
 Patel, Deesha 1118
 Patel, Eshan U. 160
 Patel, Monita R. 1204
 Patel, Rena 605
 Patel, Rupa 48
 Pathak, Elizabeth B. 1072
 Paul, Robert 545, 555
 Pazgier, Marzena 526
 ★ Pearson, Rachel A. 882
 Peck, Robert 203
 Peluso, Michael J. 138
 Perazzolo, Simone 947
 ★ Perea, David 445
 ★ Pérez-Caballero, Raúl 390
 Persaud, Deborah 184
 Pertinez, Henry 615, 880
 Peters, M. Quinn 431
 Petersen, Kalen J. 594
 ★ Peterson, Tess E. 794
 Philbin, Morgan M. 1237
 ★ Phillips, Abimbola S. 1214
 Pierre, Marie Flore 1224
 Pierre, Samuel 641
 Pincus, Seth H. 541
 Piñeirúa-Menéndez,
 Alicia 650
 ★ Pinzone, Marilia R. 350
 Piske, Micah 1180
 Pollack, Todd 702
 ★ Pollock, James 1176
 Pool, Erica R.M. 1111
 Post, Frank A. 828
 Potard, Valérie 1060
 Pozniak, Anton 9
 ★ Prelli Bozzo, Caterina 142
 ★ Premazzi Papa, Michelle 384
 Price, Jennifer 6, 158
 Promsena, Pathariya 721
 Purpura, Lawrence 563
 Puryear, Sarah 1242
 ★ Pusnik, Jernej 389
 -Q-
 Qi, Hangfei 374
 -R-
 ★ Raccagni, Angelo
 Roberto 1171
 Rai, M. A. 690
 Raiford, Jerris L. 1052
 Raju, Sarath 153
 Rakhmanina, N 948
 Rallón, Norma 318
 Ramakrishnan, Aditi 1042
 ★ Ramani, Hardik 779

- ★ Ramaswamy, Sita 451
 Ramírez Mena,
 Adrià 727, 741
- ★ Rao, Amrita 1225
 Rascle, Philippe 104
- ★ Reddy, Kavidha 513
 Reece, Monica D. 521
- ★ Renborg, Linn 577
 Restar, Arjee 1244
 Ribeiro, Susan P. 534
- ★ Richard, Khumoekae 475
- ★ Richter, Enrico 349
- ★ Ridolfi, Felipe 870
- ★ Riebensahm, Carlotta 743
- ★ Riggs, Patricia K. 596, 602
 Riley, Elise D. 793
- ★ Rios-Vazquez, Victoria 817
- ★ Rittenhouse, Katelyn J. 913
 Roman, John 1209
 Romerio, Fabio 312
 Romo, Matthew 791
- ★ Rosen, Joseph G. 201
 Rosenberg, Nora E. 1029
 Rosenbloom, Daniel S. 1091
- ★ Rovito, Roberta 813
 Rowan, Sarah E. 708
- ★ Roy Paladhi, Unmeshia
 1093, 1102
 Rubin, Leah H. 109, 573
 Ruderman, Stephanie
 A. 797, 836
- Rudolph, Jacqueline E. 1185
 Ruffieux, Yann 1048
- ★ Ruijten, Suzanne 319
 Ruiz-Salinas, Inna 535
 Rungmaitree, Supattra 671
- ★ Russo, Antonio 706
 Rutstein, Sarah E. 1191
- S-
- Sachdev, Darpun 1055
- ★ Sakoi-Mosethi, Maureen 981
 Salvadori, Nicolas 667, 1101
 Salvo, Pierluigi
 Francesco 1079
- ★ Sanchez Gaona, Nerea 543
 Sánchez Menéndez,
 Clara 440
- ★ Sanchez, Alba 343
- ★ Sánchez, Ildefonso 443
 Sandel, Demi A. 446
 Sanders, Rogier W. 19
 Sankaran, Madeline 127
 Santelli, John S. 190
- ★ Santos Bravo, Marta 410
- ★ Santos, Jessica D. 442
- ★ Sardarni, Urvinder Kaur 337
- ★ Sarvadhanabhatla,
 Sannidhi 768
 Sato, Taisuke 1090
- ★ Saulle, Irma 401
- ★ Saura-Lázaro, Anna 1248
- ★ Sauter, Kristin 816
- ★ Schneider, Isaac 1211
- ★ Schnittman, Samuel R. 143
 Schnure, Melissa 1177
 Schrock, Joshua M. 547
 Schroeder, Ty 338
- ★ Schwab, Stefanie 610
 Schwab, Tiana C. 875, 897
 Sconza, Rebecca 932
 Scott, Hyman 126
 Scott, Rachel K. 928
 Scully, Eileen P. 405
- ★ Secco Torres da Silva,
 Mayara 198, 1121
 Segal-Maurer, Sorana 630
 Sena, Anantaporn 978
- ★ Serwanga, Jennifer 394
 Sesay, Fredericka
 Albertina 1149
 Severi, Federica 528
 Shan, Liang 41
 Shen, Yanhan 851
 Sherwood, Jennifer 1092
 Shiau, Stephanie 970, 995
 Shiino, Teiichiro 1085
- ★ Shongwe-Gama,
 Siphewe M. 1226
- ★ Shorer, Eran F. 579
- ★ Shrestha, Prerana 487
- ★ Shuaib, Mustafa 908
 Sigel, Keith 154, 751
 Silverberg, Michael J. 834
 Simons, Lacy M. 425
 Simpson, Jennifer 444
 Singh, Kanal 837
- ★ Singh, Shalini 336
 Singh, Sonia 193
- ★ Siqueira, Juliana D. 344
- ★ Sithole, Nsika N. 1202
- ★ Sithole, Samantha 795
 Skaathun, Britt 1014
 Smith, Jo 1020
 Smith, Steven 635
- ★ Smith-Sreen, Joshua
 1077, 1096
- ★ Soares, Fabiane 1215
 Song, Wei 1018
- ★ Songane, Mario J.P. 1083
- ★ Sop, Joel 391
- Sörstedt, Erik 645
- Soto Ramírez, Luis
 Enrique 679
 Spagnuolo, Vincenzo 691
 Spinelli, Matthew
 A. 996, 1114
- Spudich, Serena 1
 Srinivasan, Priya 1132
 Ssempejja, Victor 322
- ★ Ssuuna, Charles 1207
 Stanford, Kimberly A. 1160
- ★ Stanley, Jay S. 592
 Statzu, Maura 532
 Stelzle, Dominik 196
 Stewart, Jenell 50, 1148
- ★ Strano, Martina 598
 Su, Hang 178
- ★ Suanzes, Paula 517
 Sued, Omar M. 1182
 Sullivan, Patrick S. 165, 1116
- ★ Sun, Weiwei 504
 Szep, Zsófia 420
- T-
- Tagarro, Alfredo 964, 965
 Taiwo, Babafemi 119
 Takuva, Simbarashe 163
 Talavera-Rodríguez,
 Alba 744
- ★ Tamura, Trevor J. 135
 Tan, Darrell H.S. 1134
- ★ Tan, Toong Seng 176
 Tang, Weiming 1125, 1193
 Tang, Yuyang 494
 Tanner, Mary R. 1131
 Tao, Li 1124
 Tapley, Asa 133
 Tatham, Lee 672
- ★ Tavasoli, Azin 600
 Tayong, Ngwi 1183
 Tedaldi, Ellen M. 1074
 Teixeira, Sylvia L.M. 1031
 Tessema, Mesfin T. 38
- ★ Thammajaruk,
 Narukjaporn 1144
 Thomas, Peyton 586
 Thomas, Rasmi 43
 Thorne, Claire 935
 Tobin, Nicole H. 924
 Tomalka, Jeffrey A. 507
 Torres, Thiago S. 1115
 Touloumi, Giota 1041
 Towers, Gregory 31
 Toy, Junine 1161
- ★ Traeger, Michael W. 1153
- ★ Tram, Khai Hoan 1025
 Trejo, Mario J. 1017
 Trevillyan, Janine 9
- ★ Tribble, Jacob T. 765

- Trickey, Adam 1059
 ★ Trifone, César A. 492
 Trkola, Alexandra 102
 Tsao, Tasha 780
 Tsibris, Athé 118
 Turner, Christian 1108
 Tuttle, Dylan J. 385
 -U-
 ★ Udayakumar, Suji 1168
 ★ Ulfhammer, Gustaf 574
 ★ Umutoni, Victoria 1216
 -V-
 Vadaq, Nadira 361
 van Bremen, Kathrin 7
 ★ van der Straten, Karlijn 100, 379
 ★ van der Wekken-Pas, Lena 922
 ★ van der Wulp, Iris A.J. 753
 Van Doorn, Jacob 585
 ★ van Eekeren, Louise E. 747
 ★ van Paassen, Pien M. 510
 ★ van Santen, Daniela K. 716
 Vandekerckhove, Linos 515
 Vanderford, Thomas H. 1100
 ★ Vanetti, Claudia 314
 Varco-Merth, Benjamin 180
 Varkila, Meri 1062
 ★ Vega, Julian 980
 Velásquez, Gustavo E. 874
 Veler, Hana 306
 ★ Vellas, Camille 500, 501
 Velu, Vijayakumar 181
 Vetick, Michael 141
 Vick, Sarah C. 434
 Vita, Serena 345
 ★ Vlaming, Killian 454
- ★ Volesky-Avellaneda, Karena 1054
 ★ Vos, Wilhelm A. J. W. 324, 437
 -W-
 ★ Waalewijn, Hylke 940
 Wallace, Zoe 415, 509
 ★ Wallach, Sara 1194
 Walmsley, Sharon 857, 1227
 Wang, Hua 369
 Wang, Leyao 362
 ★ Wang, Melody 1105
 Wanjalla, Celestine 775, 776
 Wedrychowski, Adam 472
 Wei, Zixuan 428
 Weinstein, Edward 658
 Weiser, John 1050
 ★ Weissman, Sam 458
 Weld, Ethel D. 156
 ★ Wells, Alan 471
 Welsher, Kevin 4
 Wendt, Chris 827
 ★ Werner, Alexandra E. 432
 Whitlock, Gary 1133
 Wiche Salinas, Tomas Raul 522
 Williams, Paige L. 934
 Williamson, Anne 1187
 ★ Wilson, Meg 111
 Wilson, Samuel 571, 591
 Win, Beta 639
 Wise, Jenni 788
 ★ Witterholt, Matthew 749
 ★ Wong, Michelle E. 491
 Wu, En-Ling 1095
 Wyles, David L. 735
- X-
 Xiao, Jiayang 1038
 -Y-
 Yagnik, Bhrugu 529
 ★ Yan, Aiwei 842
 ★ Yan, Cynthia 601
 Yan, Lily D. 148
 Yang, Chin-An 809
 Yang, Eunmi 1034
 Yang, Xueying 397, 848, 849
 Yelverton, Valerie 1075
 Yendewa, George A. 730
 Yilmaz, Aylin 1047
 Yin, Li 936
 You, Shiying 1229
 Yu, Qigui 550
 Yuan, Zhe 531
 -Z-
 ★ Zalla, Lauren C. 1245
 ★ Zaman, Lubaba A. 538
 Zanni, Markella 45
 Zanoni, Brian C. 992
 ★ Zeballos Rivas, Diana Reyna 1030
 Zeeb, Marius 373
 Zeeb, Marius 1071
 ★ Zemelko, Lily 407
 ★ Zewdie, Kidist 1112
 Zhang, Y. Jason 101
 ★ Zhao, Ying 556, 680
 ★ Zheng, Ruohui 612
 Zhou, Shuntai 136
 Zhu, Weiming 206, 1103
 Zhu, Xianming 1061
 Zoulim, Fabien 32, 740

NOTES

NOTES

SUNDAY, MARCH 3, 2024

8:30 AM	Scott M. Hammer Workshop for New Investigators and Trainees 8:30 AM – 12:30 PM Mile High 1-2-3
9:00 AM	
9:30 AM	
10:00 AM	
10:30 AM	
11:00 AM	
11:30 AM	
12:00 PM	
12:30 PM	Lunch 12:30 PM – 1:30 PM Meet the Luminary *
1:00 PM	
1:30 PM	Concurrent Technical Workshops 1:30 – 3:30 PM Frontiers in Laboratory Technologies, Four Seasons 2-3
2:00 PM	Case-Based Workshop on the Liver and its Complications, Mile High 4 Case-Based Workshop on Antiretroviral Therapy: A Panel Discussion, Mile High 1-2-3
2:30 PM	Clinical Trial Design and Analysis, Four Seasons 1
3:00 PM	
3:30 PM	
4:00 PM	
4:30 PM	
5:00 PM	Opening Session 5:00 PM – 7:00 PM, Bellco Theatre Bernard Fields Lecture N'Galy-Mann Lecture Martin Delaney Presentation
5:30 PM	
6:00 PM	
6:30 PM	
7:00 PM	Opening Reception 7:00 PM – 9:30 PM, Upper Lobby D
7:30 PM	

MONDAY, MARCH 4, 2024

Plenary Session
8:30 AM – 9:30 AM, Bellco Theatre
What's New in HIV Vaccines: Vaccine-Induced Immune Responses
Shall We Reach HPV Elimination in the Face of Inequity?

Concurrent Oral Abstract Sessions
10:00 AM – 12:00 PM
O-01 HIV Immunology and Vaccines, Four Seasons 1
O-02 Neuropathogenesis of HIV, Four Seasons 2-3
O-03 Clinical Trials of Novel Antiretroviral Therapies, Mile High 1-2-3
O-04 Game Changers in Prevention of HIV and Sexually Transmitted Infections, Mile High 4

Lunch
12:00 PM – 1:30 PM
Meet the Luminary *

Concurrent Themed Discussions 1:30 PM – 2:30 PM
TD-01 Viral Rebound, Four Seasons 2-3
TD-02 Is the Weight Over: GLP-1 Receptor Agonists Are Here, Mile High 1-2-3
TD-03 PEP Prevention Toolbox: Do We Know How to Use It?, Four Seasons 1
TD-04 Hazards Ahead: The Intersection of HIV and Substance Use, Mile High 4

Poster Sessions
2:30 PM – 4:00 PM
Poster Walks *
ePoster Theaters

Concurrent Interactive Sessions and Symposia
4:00 PM – 5:30 PM
S-01 The HIV Vaccine Journey: Don't Stop Believin', Four Seasons 2-3
S-02 Living Into Young Adulthood With Perinatal HIV, Four Seasons 1
S-03 The Return of Syphilis, Mile High 1-2-3
Concurrent Oral Abstract Session
O-05 COVID-19: Epidemiologic and Clinical Insights, Mile High 4

TUESDAY, MARCH 5, 2024

Plenary Session
8:30 AM – 9:30 AM, Bellco Theatre
HIV Assembly, Maturation Inhibitors, and Drug Resistance
Accelerating Tuberculosis Elimination: Short-Course Prevention and Treatment

Concurrent Oral Abstract Sessions
10:00 AM – 12:00 PM
O-06 Virus at the Wheel: Regulation of Replication and Immunity, Four Seasons 2-3
O-07 Combating the Complications of HIV, Mile High 1-2-3
O-08 Hepatitis and Tuberculosis, Four Seasons 1
O-09 Leaning Into the Success of Biomedical HIV Prevention, Mile High 4

Lunch
12:00 PM – 1:30 PM
Meet the Luminary *

Concurrent Themed Discussions 1:30 PM – 2:30 PM
TD-05 Persistent Immune Activation and Inflammation During Antiretroviral Therapy, Four Seasons 1
TD-06 Hypertension and HIV: Pregnancy, Postpartum, and Beyond, Mile High 1-2-3
TD-07 Anal Cancer Screening and Pathogenesis, Four Seasons 2-3
TD-08 Violence, Displacement, and HIV, Mile High 4

Poster Sessions
2:30 PM – 4:00 PM
Poster Walks *
ePoster Theaters

Concurrent Interactive Sessions and Symposia
4:00 PM – 5:30 PM
S-04 Not Just A Pretty Shape: HIV Assembly to Disassembly, Four Seasons 1
S-05 New Frontiers in Hepatitis B, Mile High 4 (4:30 PM – 6:00 PM)
S-06 Roundtable on DoxyPEP: Ready or Not..., Mile High 1-2-3
S-07 Impact on HIV Care and Services Among Refugees, Displaced Persons, and Marginalized Populations, Four Seasons 2-3

WEDNESDAY, MARCH 6, 2024

Plenary Session
8:30 AM – 9:30 AM, Bellco Theatre
The End of Oral? How Long-Acting Formulations Are Changing the Management of Infectious Diseases
Diagnostics 4.0: The Future of Diagnostics for HIV and Related Infections

Concurrent Oral Abstract Sessions
10:00 AM – 12:00 PM
O-10 HIV Reservoir and Cure Strategies, Mile High 1-2-3
O-11 HIV Across the Continuum: Pregnant People, Infants, Children, and Adolescents, Four Seasons 1
O-12 Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpx, and COVID-19, Mile High 4
O-13 Strengthening Testing, Treatment, and Prevention of HIV and STIs, Four Seasons 2-3

Lunch
12:00 PM – 1:30 PM
Meet the Luminary *

Special Oral Abstract Session
12:15 PM – 1:15 PM
O-14 Clinical Late-Breaking Oral Abstracts, Mile High 1-2-3

Concurrent Themed Discussions 1:30 PM – 2:30 PM
TD-09 Mucosal Immunity to HIV, Four Seasons 1
TD-10 Strategies for HIV Cure, Four Seasons 2-3
TD-11 Dolutegravir Resistance in Resource-Limited Settings, Mile High 1-2-3
TD-12 Novel Interventions in HIV Programming, Mile High 4

Poster Sessions
2:30 PM – 4:00 PM
Poster Walks *
ePoster Theaters

Concurrent Interactive Sessions and Symposia
4:00 PM – 5:30 PM
S-08 Innovations in Intervention: Toward an HIV Cure, Four Seasons 1
S-09 Follow Your Heart: Managing Cardiovascular Disease in HIV, Mile High 4
S-10 Promise and Pitfalls of Biomedical Prevention: Beyond Phase III, Four Seasons 2-3

ADDITIONAL INFORMATION

Continental breakfast is available in the Bellco Lobby from 7:30 AM to 8:30 AM, Monday to Wednesday.

* Poster Walks and Meet the Luminaries sessions are limited to New Investigator Scholarship Awardees and Community Educator Scholarship Awardees. Sign-up in advance is required.

NEW TO CROI: ePoster Theaters will feature key science in the Poster Sessions each day, presented by CROI Program Committee members.

